US20050287165A1 - Meningococcal antigens - Google Patents
Meningococcal antigens Download PDFInfo
- Publication number
- US20050287165A1 US20050287165A1 US11/212,443 US21244305A US2005287165A1 US 20050287165 A1 US20050287165 A1 US 20050287165A1 US 21244305 A US21244305 A US 21244305A US 2005287165 A1 US2005287165 A1 US 2005287165A1
- Authority
- US
- United States
- Prior art keywords
- protein
- sequence
- expression
- gene
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title abstract description 43
- 108091007433 antigens Proteins 0.000 title abstract description 43
- 102000036639 antigens Human genes 0.000 title abstract description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 82
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 230000002163 immunogen Effects 0.000 claims abstract description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 111
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 110
- 229920001184 polypeptide Polymers 0.000 claims description 108
- 239000012634 fragment Substances 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 306
- 102000004169 proteins and genes Human genes 0.000 abstract description 208
- 230000014509 gene expression Effects 0.000 abstract description 115
- 241000588650 Neisseria meningitidis Species 0.000 abstract description 96
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 52
- 229960005486 vaccine Drugs 0.000 abstract description 42
- 230000000405 serological effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 194
- 210000004027 cell Anatomy 0.000 description 114
- 239000013598 vector Substances 0.000 description 107
- 108020004414 DNA Proteins 0.000 description 63
- 238000000034 method Methods 0.000 description 59
- 239000002773 nucleotide Substances 0.000 description 50
- 125000003729 nucleotide group Chemical group 0.000 description 50
- 150000007523 nucleic acids Chemical class 0.000 description 47
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 45
- 239000000872 buffer Substances 0.000 description 44
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 42
- 238000004458 analytical method Methods 0.000 description 41
- 102000039446 nucleic acids Human genes 0.000 description 40
- 108020004707 nucleic acids Proteins 0.000 description 40
- 239000000523 sample Substances 0.000 description 37
- 230000001580 bacterial effect Effects 0.000 description 35
- 241000894006 Bacteria Species 0.000 description 34
- 241000196324 Embryophyta Species 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 29
- 241000700605 Viruses Species 0.000 description 27
- 230000035897 transcription Effects 0.000 description 26
- 238000013518 transcription Methods 0.000 description 26
- 108091026890 Coding region Proteins 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 25
- 102000040430 polynucleotide Human genes 0.000 description 25
- 108091033319 polynucleotide Proteins 0.000 description 25
- 239000002157 polynucleotide Substances 0.000 description 25
- 241000701447 unidentified baculovirus Species 0.000 description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 241000588724 Escherichia coli Species 0.000 description 23
- 108010076504 Protein Sorting Signals Proteins 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 230000001105 regulatory effect Effects 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- 230000036961 partial effect Effects 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 21
- 239000002502 liposome Substances 0.000 description 21
- 108090001030 Lipoproteins Proteins 0.000 description 20
- 102000004895 Lipoproteins Human genes 0.000 description 20
- 241001212279 Neisseriales Species 0.000 description 20
- 238000010367 cloning Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000001415 gene therapy Methods 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 17
- 238000012546 transfer Methods 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 16
- 241000238631 Hexapoda Species 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 239000013615 primer Substances 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 230000009466 transformation Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 239000008188 pellet Substances 0.000 description 15
- 238000000746 purification Methods 0.000 description 14
- 230000010076 replication Effects 0.000 description 14
- 230000000890 antigenic effect Effects 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 210000004962 mammalian cell Anatomy 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 239000005017 polysaccharide Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000588653 Neisseria Species 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 108010083590 Apoproteins Proteins 0.000 description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 101150080370 pspA gene Proteins 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000005030 transcription termination Effects 0.000 description 10
- 102000006410 Apoproteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- -1 antibody Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003623 enhancer Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 230000001177 retroviral effect Effects 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 101710182846 Polyhedrin Proteins 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 210000001938 protoplast Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 241000710929 Alphavirus Species 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 101710116435 Outer membrane protein Proteins 0.000 description 7
- 241000831652 Salinivibrio sharmensis Species 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
- 239000002853 nucleic acid probe Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000005026 transcription initiation Effects 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 5
- 101000657456 Actinobacillus pleuropneumoniae Toxin RTX-I translocation ATP-binding protein Proteins 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 5
- 108700009124 Transcription Initiation Site Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 229960002086 dextran Drugs 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 108010060123 Conjugate Vaccines Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000007977 PBT buffer Substances 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000001261 affinity purification Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 229940031670 conjugate vaccine Drugs 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 101000956760 Arabidopsis thaliana Uncharacterized mitochondrial protein AtMg01000 Proteins 0.000 description 3
- 101100351191 Autographa californica nuclear polyhedrosis virus PCNA gene Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 3
- 108010004103 Chylomicrons Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 101100363961 Escherichia coli (strain K12) rseD gene Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 101100283436 Human herpesvirus 8 type P (isolate GK18) gM gene Proteins 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 101150016564 ORF39 gene Proteins 0.000 description 3
- 101150050790 ORF49 gene Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 101100378791 Paenarthrobacter nicotinovorans aldh gene Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 101000792499 Porphyra purpurea Uncharacterized protein ycf83 Proteins 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 101000748762 Trieres chinensis Uncharacterized 5.4 kDa protein in trnK-psbC intergenic region Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 210000004520 cell wall skeleton Anatomy 0.000 description 3
- 239000007330 chocolate agar Substances 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940048914 protamine Drugs 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101000812031 Anthoceros angustus Uncharacterized 5.9 kDa protein in rps16-psbA intergenic region Proteins 0.000 description 2
- 101001054928 Arabidopsis thaliana Uncharacterized mitochondrial protein AtMg00150 Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000713826 Avian leukosis virus Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101000786247 Bacillus subtilis (strain 168) Uncharacterized protein YqaT Proteins 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 108020004513 Bacterial RNA Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000208296 Datura Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 239000005980 Gibberellic acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101000748779 Marchantia polymorpha Uncharacterized 6.4 kDa protein in atpA-psbA intergenic region Proteins 0.000 description 2
- 101000788491 Marchantia polymorpha Uncharacterized mitochondrial protein ymf27 Proteins 0.000 description 2
- 241000219823 Medicago Species 0.000 description 2
- 206010027202 Meningitis bacterial Diseases 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101150054930 ORF112 gene Proteins 0.000 description 2
- 101150012394 PHO5 gene Proteins 0.000 description 2
- 241001442654 Percnon planissimum Species 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- UTPGJEROJZHISI-UHFFFAOYSA-N Pleniradin-acetat Natural products C1=C(C)C2C(OC(=O)C)CC(C)(O)C2CC2C(=C)C(=O)OC21 UTPGJEROJZHISI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000017033 Porins Human genes 0.000 description 2
- 108010013381 Porins Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101000708297 Pseudomonas stutzeri Uncharacterized 8.5 kDa protein in nirQ 3'region Proteins 0.000 description 2
- 101710089184 Putative uncharacterized protein ycf15 Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101000757825 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc01784 Proteins 0.000 description 2
- 101000814063 Salmonella phage P22 Uncharacterized 6.6 kDa protein in eae-abc2 intergenic region Proteins 0.000 description 2
- 101000953980 Salmonella phage P22 Uncharacterized 7.7 kDa protein in gp5-gp4 intergenic region Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 101000792450 Trieres chinensis Uncharacterized 4.7 kDa protein in ycf33-trnY intergenic region Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 101000736254 Zea mays Uncharacterized protein ycf70 Proteins 0.000 description 2
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 108010084541 asialoorosomucoid Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000003578 bacterial chromosome Anatomy 0.000 description 2
- 201000009904 bacterial meningitis Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108091006374 cAMP receptor proteins Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 2
- 229910001679 gibbsite Inorganic materials 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 101150095079 menB gene Proteins 0.000 description 2
- 229940124731 meningococcal vaccine Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 2
- 229960005225 mifamurtide Drugs 0.000 description 2
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 108010016264 ubiquitin-Nalpha-protein hydrolase Proteins 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- REAWNMHCBIUKLZ-ZYHUDNBSSA-N (3R,4R)-4-(hydroxymethyl)-3-(6-methylheptanoyl)oxolan-2-one Chemical compound CC(C)CCCCC(=O)[C@H]1[C@H](CO)COC1=O REAWNMHCBIUKLZ-ZYHUDNBSSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
- 244000179819 Aechmea magdalenae Species 0.000 description 1
- 235000001291 Aechmea magdalenae Nutrition 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000207875 Antirrhinum Species 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 101000956763 Arabidopsis thaliana Uncharacterized mitochondrial protein AtMg01010 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 241000178568 Aura virus Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000608319 Bebaru virus Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000209200 Bromus Species 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 241000868138 Cabassou virus Species 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000723343 Cichorium Species 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 244000024469 Cucumis prophetarum Species 0.000 description 1
- 235000010071 Cucumis prophetarum Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000208175 Daucus Species 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100173936 Escherichia coli (strain K12) flmA gene Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000231322 Fort Morgan virus Species 0.000 description 1
- 241000220223 Fragaria Species 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 101000588929 Heteractis crispa Delta-stichotoxin-Hcr1e Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 101000743767 Homo sapiens Coiled-coil domain-containing protein R3HCC1L Proteins 0.000 description 1
- 101001071515 Homo sapiens Gastrin-releasing peptide Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101001033034 Homo sapiens UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Proteins 0.000 description 1
- 101150100310 Hsf gene Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000208278 Hyoscyamus Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241000231318 Kyzylagach virus Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 101000820218 Lactococcus phage LL-H Uncharacterized protein ORF5 Proteins 0.000 description 1
- 241000208822 Lactuca Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000208204 Linum Species 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 101000803530 Loxosceles intermedia Astacin-like metalloprotease toxin 1 Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000121629 Majorana Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 101000788489 Marchantia polymorpha Uncharacterized mitochondrial protein ymf26 Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical group COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- 241000868135 Mucambo virus Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 1
- 101100100125 Mus musculus Traip gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 229910021204 NaH2 PO4 Inorganic materials 0.000 description 1
- 241000608287 Ndumu virus Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001162910 Nemesia <spider> Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 1
- 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000036364 Normal newborn Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 101150104094 ORF52 gene Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241000219830 Onobrychis Species 0.000 description 1
- 101100389785 Orgyia pseudotsugata multicapsid polyhedrosis virus ETM gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
- 241000209117 Panicum Species 0.000 description 1
- 235000006443 Panicum miliaceum subsp. miliaceum Nutrition 0.000 description 1
- 235000009037 Panicum miliaceum subsp. ruderale Nutrition 0.000 description 1
- 241000208181 Pelargonium Species 0.000 description 1
- 241000209046 Pennisetum Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010090127 Periplasmic Proteins Proteins 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 102100026123 Pirin Human genes 0.000 description 1
- 241000868134 Pixuna virus Species 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 101100481711 Pneumococcus phage Dp-1 TMP gene Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102100029796 Protein S100-A10 Human genes 0.000 description 1
- 101710110950 Protein S100-A10 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 108010019653 Pwo polymerase Proteins 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 241001106018 Salpiglossis Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000780602 Senecio Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000193687 Serra do Navio virus Species 0.000 description 1
- 241000220261 Sinapis Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 101000814062 Streptomyces lividans Uncharacterized 6.0 kDa protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102100040296 TATA-box-binding protein Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 241000868137 Tonate virus Species 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100022972 Transcription factor AP-2-alpha Human genes 0.000 description 1
- 101710189834 Transcription factor AP-2-alpha Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 1
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 241001312519 Trigonella Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 102100038413 UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Human genes 0.000 description 1
- 241000608278 Una virus Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 241000231320 Whataroa virus Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 108010022164 acetyl-LDL Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010050181 aleurone Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000658 anti-neisserial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 101150042295 arfA gene Proteins 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000005739 manihot Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 229940035102 meningococcal group b vaccine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000000819 phase cycle Methods 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- 210000000745 plant chromosome Anatomy 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to antigens from the bacterium Neisseria meningitidis.
- Neisseria meningitidis is a non-motile, gram negative diplococcus human pathogen. It colonises the pharynx, causing meningitis and, occasionally, septicaemia in the absence of meningitis. It is closely related to N. gonorrhoeae , although one feature that clearly differentiates meningococcus from gonococcus is the presence of a polysaccharide capsule that is present in all pathogenic meningococci.
- N. meningitidis causes both endemic and epidemic disease.
- the attack rate is 0.6-1 per 100,000 persons per year, and it can be much greater during outbreaks (see Lieberman el al. (1996) Safety and Immunogenicity of a Serogroups A/C Neisseria meningitidis Oligosaccharide-Protein Conjugate Vaccine in Young Children. JAMA 275(19):1499-1503; Schuchat et al (1997) Bacterial Meningitis in the United States in 1995. N Engl J Med 337(14):970-976). In developing countries, endemic disease rates are much higher and during epidemics incidence rates can reach 500 cases per 100,000 persons per year.
- the meningococcal vaccine currently in use is a tetravalent polysaccharide vaccine composed of serogroups A, C, Y and W135. Although efficacious in adolescents and adults, it induces a poor immune response and short duration of protection, and cannot be used in infants [eg. Morbidity and Mortality weekly report, Vol.
- Meningococcus B remains a problem, however. This serotype currently is responsible for approximately 50% of total meningitis in the United States, Europe, and South America.
- the polysaccharide approach cannot be used because the menB capsular polysaccharide is a polymer of ⁇ (2-8)-linked N-acetyl neuraminic acid that is also present in mammalian tissue. This results in tolerance to the antigen; indeed, if an immune response were elicited, it would be anti-self, and therefore undesirable.
- the capsular polysaccharide has, for instance, been chemically modified substituting the N-acetyl groups with N-propionyl groups, leaving the specific antigenicity unaltered (Romero & Outschoorn (1994) Current status of Meningococcal group B vaccine candidates: capsular or non-capsular? Clin Microbiol Rev 7(4):559-575).
- OMPs outer membrane proteins
- the invention provides proteins comprising the N. meningitidis amino acid sequences disclosed in the examples.
- proteins comprising sequences homologous (ie. having sequence identity) to the N. meningitidis amino acid sequences disclosed in the examples.
- the degree of sequence identity is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more).
- These homologous proteins include mutants and allelic variants of the sequences disclosed in the examples.
- 50% identity or more between two proteins is considered to be an indication of functional equivalence.
- the invention further provides proteins comprising fragments of the N. meningitidis amino acid sequences disclosed in the examples.
- the fragments should comprise at least n consecutive amino acids from the sequences and, depending on the particular sequence, n is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20 or more).
- n is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20 or more).
- the fragments comprise an epitope from the sequence.
- the proteins of the invention can, of course, be prepared by various means (eg. recombinant expression, purification from cell culture, chemical synthesis etc.) and in various forms (eg. native, fusions etc.). They are preferably prepared in substantially pure form (ie. substantially free from other N. meningitidis or host cell proteins).
- the invention provides antibodies which bind to these proteins. These may be polyclonal or monoclonal and may be produced by any suitable means.
- the invention provides nucleic acid comprising the N. meningitidis nucleotide sequences disclosed in the examples.
- the invention provides nucleic acid comprising sequences homologous (ie. having sequence identity) to the N. meningitidis nucleotide sequences disclosed in the examples.
- the invention provides nucleic acid which can hybridise to the N. meningitidis nucleic acid disclosed in the examples, preferably under “high stringency” conditions (eg. 65° C. in a 0.1 ⁇ SSC, 0.5% SDS solution).
- “high stringency” conditions eg. 65° C. in a 0.1 ⁇ SSC, 0.5% SDS solution.
- Nucleic acid comprising fragments of these sequences are also provided. These should comprise at least n consecutive nucleotides from the N. meningitidis sequences and, depending on the particular sequence, n is 10 or more (eg 12, 14, 15, 18, 20, 25, 30, 35, 40 or more).
- the invention provides nucleic acid encoding the proteins and protein fragments of the invention.
- nucleic acid comprising sequences complementary to those described above (eg. for antisense or probing purposes).
- Nucleic acid according to the invention can, of course, be prepared in many ways (eg. by chemical synthesis, from genomic or cDNA libraries, from the organism itself etc.) and can take various forms (eg. single stranded, double stranded, vectors, probes etc.).
- nucleic acid includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) etc.
- PNA peptide nucleic acids
- the invention provides vectors comprising nucleotide sequences of the invention (eg. expression vectors) and host cells transformed with such vectors.
- compositions comprising protein, antibody, and/or nucleic acid according to the invention.
- These compositions may be suitable as vaccines, for instance, or as diagnostic reagents, or as immunogenic compositions.
- the invention also provides nucleic acid, protein, or antibody according to the invention for use as medicaments (eg. as vaccines) or as diagnostic reagents. It also provides the use of nucleic acid, protein, or antibody according to the invention in the manufacture of: (i) a medicament for treating or preventing infection due to Neisserial bacteria; (ii) a diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisserial bacteria; and/or (iii) a reagent which can raise antibodies against Neisserial bacteria Said Neisserial bacteria may be any species or strain (such as N. gonorrhoeae ) but are preferably N. meningitidis , especially strain A, strain B or strain C.
- the invention also provides a method of treating a patient, comprising administering to the patient a therapeutically effective amount of nucleic acid, protein, and/or antibody according to the invention.
- the invention provides various processes.
- a process for producing proteins of the invention comprising the step of culturing a host cell according to the invention under conditions which induce protein expression.
- a process for producing protein or nucleic acid of the invention wherein the protein or nucleic acid is synthesised in part or in whole using chemical means.
- a process for detecting polynucleotides of the invention comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting said duplexes.
- a process for detecting proteins of the invention comprising the steps of: (a) contacting an antibody according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.
- sequences disclosed in the present application are believed not to have any significant homologs in N. gonorrhoeae . Accordingly, the sequences of the present invention also find use in the preparation of reagents for distinguishing between N. meningitidis and N. gonorrhoeae.
- a composition containing X is “substantially free of” Y when at least 85% by weight of the total X+Y in the composition is X.
- X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95% or even 99% by weight.
- composition “comprising” means “including” as well as “consisting” eg. a composition “comprising” X may consist exclusively of X or may include something additional to X, such as X+Y.
- a “conserved” Neisseria amino acid fragment or protein is one that is present in a particular Neisserial protein in at least x % of Neisseria .
- the value of x may be 50% or more, e.g., 66%, 75%, 80%, 90%, 95% or even 100% (i.e. the amino acid is found in the protein in question in all Neisseria ).
- a reference population may include a number of different Neisseria species or may include a single species.
- the reference population may include a number of different serogroups of a particular species or a single serogroup.
- a preferred reference population consists of the 5 most common Neisseria.
- heterologous refers to two biological components that are not found together in nature.
- the components may be host cells, genes, or regulatory regions, such as promoters.
- heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a gene is operably linked to the gene.
- Another example is where a Neisserial sequence is heterologous to a mouse host cell.
- a further examples would be two epitopes from the same or different proteins which have been assembled in a single protein in an arrangement not found in nature.
- An “origin of replication” is a polynucleotide sequence that initiates and regulates replication of polynucleotides, such as an expression vector.
- the origin of replication behaves as an autonomous unit of polynucleotide replication within a cell, capable of replication under its own control.
- An origin of replication may be needed for a vector to replicate in a particular host cell. With certain origins of replication, an expression vector can be reproduced at a high copy number in the presence of the appropriate proteins within the cell. Examples of origins are the autonomously replicating sequences, which are effective in yeast; and the viral T-antigen, effective in COS-7 cells.
- a “mutant” sequence is defined as DNA, RNA or amino acid sequence differing from but having sequence identity with the native or disclosed sequence. Depending on the particular sequence, the degree of sequence identity between the native or disclosed sequence and the mutant sequence is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more, calculated using the Smith-Waterman algorithm as described above).
- an “allelic variant” of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a nucleic acid molecule, or region, that occurs essentially at the same locus in the genome of another or second isolate, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence.
- allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared.
- allelic variant can also comprise an alteration in the 5′ or 3′ untranslated regions of the gene, such as in regulatory control regions (eg. see U.S. Pat. No. 5,753,235).
- Neisserial nucleotide sequences can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, plants, bacteria, and yeast.
- a mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3′) transcription of a coding sequence (eg. structural gene) into mRNA.
- a promoter will have a transcription initiating region, which is usually placed proximal to the 5′ end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site.
- a mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box.
- An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) “Expression of Cloned Genes in Mammalian Cells.” In Molecular Cloning: A Laboratory Manual, 2nd ed.]
- Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallotheionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.
- Enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of the Cell, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range.
- Examples include the SV40 early gene enhancer [Dijkema et al (1985) EMBO J. 4:761] and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) Proc. Natl. Acad. Sci. 79:6777] and from human cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237].
- an inducer such as a hormone or metal ion
- a DNA molecule may be expressed intracellularly in mammalian cells.
- a promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.
- foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells.
- a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells.
- processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro.
- the leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.
- the adenovirus triparite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.
- transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3′ to the translation stop codon and thus, together with the promoter elements, flank the coding sequence.
- the 3′ terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) “Termination and 3′ end processing of eukaryotic RNA. In Transcription and splicing (ed. B. D. Hames and D. M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105].
- transcription terminater/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) “Expression of cloned genes in cultured mammalian cells.” In Molecular Cloning: A Laboratory Manual].
- Enhancers introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired.
- Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria.
- Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate.
- plasmids containing the replication systems of papovaviruses such as SV40 [Gluzman (1981) Cell 23:175] or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen.
- mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus.
- the replicon may have two replicaton systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a prokaryotic host for cloning and amplification.
- mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) Mol. Cell. Biol. 9:946] and pHEBO [Shimizu et al. (1986) Mol. Cell. Biol. 6:1074].
- the transformation procedure used depends upon the host to be transformed.
- Methods for introduction of heterologous polynucleotides into mammalian cells include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
- Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (eg. Hep G2), and a number of other cell lines.
- ATCC American Type Culture Collection
- CHO Chinese hamster ovary
- HeLa cells HeLa cells
- BHK baby hamster kidney cells
- COS monkey kidney cells
- human hepatocellular carcinoma cells eg. Hep G2
- the polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector.
- Vector construction employs techniques which are known in the art.
- the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.
- the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine.
- the packaged recombinant-virus is expressed and recombinant plaques are identified and purified.
- Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego Calif. (“MaxBac” kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter “Summers and Smith”).
- an intermediate transplacement construct Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector).
- This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements.
- Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as a bacterium.
- the replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.
- pAc373 the most commonly used transfer vector for introducing foreign genes into AcNPV.
- Many other vectors known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.
- the plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a prokaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in E. coli.
- polyhedrin polyadenylation signal iller et al. (1988) Ann. Rev. Microbiol., 42:177
- amp prokaryotic ampicillin-resistance
- Baculovirus transfer vectors usually contain a baculovirus promoter.
- a baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5′ to 3) transcription of a coding sequence (eg. structural gene) into mRNA.
- a promoter will have a transcription initiation region which is usually placed proximal to the 5′ end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site.
- a baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.
- Structural genes abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) “The Regulation of Baculovirus Gene Expression,” in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlak et al., (1988), J. Gen. Virol. 69:765.
- DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409).
- the signals for mammalian cell posttranslational modifications such as signal peptide cleavage, proteolytic cleavage, and phosphorylation
- the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells
- leaders of non-insect origin such as those derived from genes encoding human ⁇ -interferon, Maeda et al., (1985), Nature 315:592; human gastrin-releasing peptide, Lebacq-Verheyden et al., (1988), Molec.
- a recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted.
- Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by in vitro incubation with cyanogen bromide.
- recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects.
- the leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.
- an insect cell host After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus—usually by co-transfection.
- the promoter and transcription termination sequence of the construct will usually comprise a 2-5 kb section of the baculovirus genome.
- the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), Bioessays 4:91
- the DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5′ and 3′ by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.
- the newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses.
- An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished.
- the polyhedrin protein which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles.
- occlusion bodies up to 15 ⁇ m in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope.
- Cells infected with recombinant viruses lack occlusion bodies.
- the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. “Current Protocols in Microbiology” Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, supra; Miller et al. (1989).
- Recombinant baculovirus expression vectors have been developed for infection into several insect cells.
- recombinant baculoviruses have been developed for, inter alia: Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda , and Trichoplusia ni (WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al., (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225).
- Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, eg. Summers and Smith supra.
- the modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host.
- the expression product gene is under inducible control, the host may be grown to high density, and expression induced.
- the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients.
- the product may be purified by such techniques as chromatography, eg. HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like.
- the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, eg. proteins, lipids and polysaccharides.
- host debris eg. proteins, lipids and polysaccharides.
- recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.
- a desired polynucleotide sequence is inserted into an expression cassette comprising genetic regulatory elements designed for operation in plants.
- the expression cassette is inserted into a desired expression vector with companion sequences upstream and downstream from the expression cassette suitable for expression in a plant host.
- the companion sequences will be of plasmid or viral origin and provide necessary characteristics to the vector to permit the vectors to move DNA from an original cloning host, such as bacteria, to the desired plant host.
- the basic bacterial/plant vector construct will preferably provide a broad host range prokaryote replication origin; a prokaryote selectable marker, and, for Agrobacterium transformations, T DNA sequences for Agrobacterium -mediated transfer to plant chromosomes.
- the construct will preferably also have a selectable marker gene suitable for determining if a plant cell has been transformed.
- a selectable marker gene suitable for determining if a plant cell has been transformed is found in Wilmink and Dons, 1993, Plant Mol. Biol. Reptr, 11(2):165-185.
- Sequences suitable for permitting integration of the heterologous sequence into the plant genome are also recommended. These might include transposon sequences and the like for homologous recombination as well as Ti sequences which permit random insertion of a heterologous expression cassette into a plant genome. Suitable prokaryote selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions may also be present in the vector, as is known in the art.
- the nucleic acid molecules of the subject invention may be included into an expression cassette for expression of the protein(s) of interest.
- the recombinant expression cassette will contain in addition to the heterologous protein encoding sequence the following elements, a promoter region, plant 5′ untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and a transcription and translation termination sequence.
- Unique restriction enzyme sites at the 5′ and 3′ ends of the cassette allow for easy insertion into a pre-existing vector.
- a heterologous coding sequence may be for any protein relating to the present invention.
- the sequence encoding the protein of interest will encode a signal peptide which allows processing and translocation of the protein, as appropriate, and will usually lack any sequence which might result in the binding of the desired protein of the invention to a membrane. Since, for the most part, the transcriptional initiation region will be for a gene which is expressed and translocated during germination, by employing the signal peptide which provides for translocation, one may also provide for translocation of the protein of interest. In this way, the protein(s) of interest will be translocated from the cells in which they are expressed and may be efficiently harvested.
- the ultimate expression of the desired gene product will be in a eucaryotic cell it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's splicosome machinery. If so, site-directed mutagenesis of the “intron” region may be conducted to prevent losing a portion of the genetic message as a false intron code, Reed and Maniatis, Cell 41:95-105, 1985.
- the vector can be microinjected directly into plant cells by use of micropipettes to mechanically transfer the recombinant DNA. Crossway, Mol. Gen. Genet, 202:179-185, 1985.
- the genetic material may also be transferred into the plant cell by using polyethylene glycol, Krens, et al., Nature, 296, 72-74, 1982.
- Another method of introduction of nucleic acid segments is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface, Klein, et al., Nature, 327, 70-73, 1987 and Knudsen and Muller, 1991, Planta, 185:330-336 teaching particle bombardment of barley endosperm to create transgenic barley.
- Yet another method of introduction would be fusion of protoplasts with other entities, either minicells, cells, lysosomes or other fusible lipid-surfaced bodies, Fraley, et al., Proc. Natl. Acad. Sci. USA, 79, 1859-1863, 1982.
- the vector may also be introduced into the plant cells by electroporation. (Fromm et al., Proc. Natl Acad. Sci. USA 82:5824, 1985).
- plant protoplasts are electroporated in the presence of plasmids containing the gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form plant callus.
- All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred gene. It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugarcane, sugar beet, cotton, fruit and other trees, legumes and vegetables.
- Some suitable plants include, for example, species from the genera Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Lycopersion, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Cichorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Hererocallis, Nemesia, Pelargonium, Panicum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Lolium, Zea, Triticum, Sorghum , and Datura.
- Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced from the protoplast suspension. These embryos germinate as natural embryos to form plants.
- the culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.
- the desired protein of the invention may be excreted or alternatively, the protein may be extracted from the whole plant. Where the desired protein of the invention is secreted into the medium, it may be collected. Alternatively, the embryos and embryoless-half seeds or other plant tissue may be mechanically disrupted to release any secreted protein between cells and tissues. The mixture may be suspended in a buffer solution to retrieve soluble proteins. Conventional protein isolation and purification methods will be then used to purify the recombinant protein. Parameters of time, temperature pH, oxygen, and volumes will be adjusted through routine methods to optimize expression and recovery of heterologous protein.
- a bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3′) transcription of a coding sequence (eg. structural gene) into mRNA.
- a promoter will have a transcription initiation region which is usually placed proximal to the 5′ end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site.
- a bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene.
- Constitutive expression may occur in the absence of negative regulatory elements, such as the operator.
- positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5′) to the RNA polymerase binding sequence.
- An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli ( E. coli ) [Raibaud et al. (1984) Annu. Rev. Genet. 18:173].
- Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.
- Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) [Chang et al. (1977) Nature 198:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp) [Goeddel et al. (1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. Pat. No. 4,738,921; EP-A-0036776 and EP-A-0121775].
- sugar metabolizing enzymes such as galactose, lactose (lac) [Chang et al. (1977) Nature 198:1056]
- maltose additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (
- g-laotamase (bla) promoter system [Weissmann (1981) “The cloning of interferon and other mistates.” In Interferon 3 (ed I. Gresser)], bacteriophage lambda PL [Shimatake et al. (1981) Nature 292:128] and T5 [U.S. Pat. No. 4,689,406] promoter systems also provide useful promoter sequences.
- synthetic promoters which do not occur in nature also function as bacterial promoters.
- transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [U.S. Pat. No. 4,551,433].
- the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repressor [Amann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21].
- a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription.
- a naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes.
- the bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074].
- a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (EPO-A-0 267 851).
- an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes.
- the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine et al. (1975) Nature 254:34).
- SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3′ and of E. coli 16S rRNA [Steitz et al.
- a DNA molecule may be expressed intracellularly.
- a promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo on in vitro incubation with a bacterial methionine N-terminal peptidase (EPO-A-0 219 237).
- Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5′ end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences.
- the bacteriophage lambda cell gene can be linked at the 5′ terminus of a foreign gene and expressed in bacteria The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins can also be made with sequences from the lacZ [Jia et al.
- the DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site.
- a ubiquitin fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (eg. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein.
- a processing enzyme eg. ubiquitin specific processing-protease
- foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [U.S. Pat. No. 4,336,336].
- the signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.
- the protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria).
- processing sites which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.
- DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (ompA) [Masui et al. (1983), in: Experimental Manipulation of Gene Expression ; Ghrayeb et al. (1984) EMBO J. 3:2437] and the E. coli alkaline phosphatase signal sequence (phoA) [Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212].
- the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from B. subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EP-A-0 244 042].
- transcription termination sequences recognized by bacteria are regulatory regions located 3′ to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the trip gene in E. coli as well as other biosynthetic genes.
- expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as bacteria
- a replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification.
- a replicon may be either a high or low copy number plasmid.
- a high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150.
- a host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.
- the expression constructs can be integrated into the bacterial genome with an integrating vector.
- Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome.
- integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EP-A-0 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.
- extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed.
- Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies et al. (1978) Annu. Rev. Microbiol. 32:469].
- Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.
- Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.
- Expression and transformation vectors have been developed for transformation into many bacteria
- expression vectors have been developed for, inter alia, the following bacteria: Bacillus subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541], Escherichia coli [Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol.
- Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl 2 or other agents, such as divalent cations and DMSO.
- DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See eg. [Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci USA 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541, Bacillus ], [Miller et al. (1988) Proc. Natl. Acad. Sci.
- a yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3′) transcription of a coding sequence (eg. structural gene) into mRNA.
- a promoter will have a transcription initiation region which is usually placed proximal to the 5′ end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the “TATA Box”) and a transcription initiation site.
- a yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene.
- the UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.
- Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EP-A-0 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO-A-0 329 203).
- the yeast PHO5 gene encoding acid phosphatase, also provides useful promoter sequences [Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].
- synthetic promoters which do not occur in nature also function as yeast promoters.
- UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter.
- hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Pat. Nos. 4,876,197 and 4,880,734).
- Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EP-A-0 164 556).
- a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) “The Expression of Bacterial Antibiotic Resistance Genes in the Yeast Saccharomyces cerevisiae ,” in: Plasmids of Medical, Environmental and Commercial Importance (eds. K. N. Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109;].
- a DNA molecule may be expressed intracellularly in yeast.
- a promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.
- Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems.
- a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein is fused to the 5′ end of heterologous coding sequences.
- this construct will provide a fusion of the two amino acid sequences.
- the yeast or human superoxide dismutase (SOD) gene can be linked at the 5′ terminus of a foreign gene and expressed in yeast.
- the DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See eg. EP-A-0 196 056.
- a ubiquitin fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (eg. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein.
- a processing enzyme eg. ubiquitin-specific processing protease
- native foreign protein can be isolated (eg. WO88/024066).
- foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein.
- a leader sequence fragment that provide for secretion in yeast of the foreign protein.
- processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro.
- the leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.
- DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EP-A-0 012 873; JPO. 62,096,086) and the A-factor gene (U.S. Pat. No. 4,588,684).
- leaders of non-yeast origin such as an interferon leader, exist that also provide for secretion in yeast (EP-A-0 060 057).
- a preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a “pre” signal sequence, and a “pro” region.
- the types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Pat. Nos. 4,546,083 and 4,870,008; EP-A-0 324 274).
- Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (eg. see WO 89/02463.)
- transcription termination sequences recognized by yeast are regulatory regions located 3′ to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.
- Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as yeast or bacteria.
- the replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification.
- yeast-bacteria shuttle vectors include YEp24 [Botstein et al. (1979) Gene 8:17-24], pCl/1 [Brake et al. (1984) Proc. Natl. Acad.
- a replicon may be either a high or low copy number plasmid.
- a high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150.
- a host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See eg. Brake et al., supra.
- the expression constructs can be integrated into the yeast genome with an integrating vector.
- Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver et al. (1983) Methods in Enzymol. 101:228-245].
- An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver et al., supra.
- One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine et al.
- the chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.
- extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed.
- Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively.
- a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal.
- the presence of CUP1 allows yeast to grow in the presence of copper ions [Butt et al. (1987) Microbiol, Rev. 51:351].
- Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.
- Expression and transformation vectors have been developed for transformation into many yeasts.
- expression vectors have been developed for, inter alia, the following yeasts: Candida albicans [Kurtz, et al. (1986) Mol. Cell. Biol. 6:142], Candida maltosa [Kunze, et al. (1985) J. Basic Microbiol. 25:141]. Hansenula polymorpha [Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302], Kluyveromyces fragilis [Das, et al. (1984) J.
- Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See eg. [Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141; Candida ]; [Gleeson et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; Hansenula ]; [Das et al. (1984) J. Bacteriol.
- antibody refers to a polypeptide or group of polypeptides composed of at least one antibody combining site.
- An “antibody combining site” is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen.
- Antibody includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, altered antibodies, univalent antibodies, Fab proteins, and single domain antibodies. Antibodies against the proteins of the invention are useful for affinity chromatography, immunoassays, and distinguishing/identifying Neisserial proteins.
- Antibodies to the proteins of the invention may be prepared by conventional methods.
- the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies.
- Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 ⁇ g/injection is typically sufficient.
- Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using Freund's incomplete adjuvant.
- Polyclonal antisera is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25° C. for one hour, followed by incubating at 4° C. for 2-18 hours. The serum is recovered by centrifugation (eg. 1,000 g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.
- Monoclonal antibodies are prepared using the standard method of Kohler & Milstein [ Nature (1975) 256:495-96], or a modification thereof.
- a mouse or rat is immunized as described above.
- the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells.
- the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen.
- B-cells expressing membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension.
- Resulting B-cells, or all dissociated spleen cells are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (eg. hypoxanthine, aminopterin, thymidine medium, “HAT”).
- a selective medium eg. hypoxanthine, aminopterin, thymidine medium, “HAT”.
- the resulting hybridomas are plated by limiting dilution, and are assayed for the production of antibodies which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens).
- the selected MAb-secreting hybridomas are then cultured either in vitro (eg. in tissue culture bottles or hollow fiber reactors), or in vivo (as ascites in mice).
- the antibodies may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly 32 P and 125 I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3′,5,5′-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. “Specific binding partner” refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor.
- 125 I may serve as a radioactive label or as an electron-dense reagent.
- HRP may serve as enzyme or as antigen for a MAb.
- MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with 125 I, or with an anti-biotin MAb labeled with HRP.
- Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.
- compositions can comprise either polypeptides, antibodies, or nucleic acid of the invention.
- the pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.
- therapeutically effective amount refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect.
- the effect can be detected by, for example, chemical markers or antigen levels.
- Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature.
- the precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of the clinician.
- an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.
- a pharmaceutical composition can also contain a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents.
- the term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
- Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.
- Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
- mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like
- organic acids such as acetates, propionates, malonates, benzoates, and the like.
- compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.
- the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.
- compositions of the invention can be administered directly to the subject.
- the subjects to be treated can be animals; in particular, human subjects can be treated.
- Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue.
- the compositions can also be administered into a lesion.
- Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays.
- Dosage treatment may be a single dose schedule or a multiple dose schedule.
- Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection).
- Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with “pharmaceutically acceptable carriers,” which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition.
- Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles.
- Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents (“adjuvants”).
- the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori , etc. pathogens.
- a bacterial toxoid such as a toxoid from diphtheria, tetanus, cholera, H. pylori , etc. pathogens.
- Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59TM (WO 90/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds.
- aluminum salts alum
- oil-in-water emulsion formulations with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components
- MF59TM WO 90/14837
- Span 85 containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RibiTM adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (MPL), trehalose dimycolate (TDM), and cell wall skeleton (MPL), trehalose dimycol
- interferons eg. gamma interferon
- M-CSF macrophage colony stimulating factor
- TNF tumor necrosis factor
- other substances that act as immunostimulating agents to enhance the effectiveness of the composition.
- Alum and MF59TM are preferred.
- muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl- L -alanyl- D -isoglutamine (nor-MDP), N-acetylmuramyl- L -alanyl- D -isoglutaminyl- L -alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamine (MTP-PE), etc.
- thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
- nor-MDP N-acetyl-normuramyl- L -alanyl- D -isoglutaminyl- L -alanine-2-(1′-2′-dipal
- the immunogenic compositions typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.
- the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
- the preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.
- Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed.
- immunologically effective amount it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (eg. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctors assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
- the immunogenic compositions are conventionally administered parenterally, eg. by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously (eg. WO98/20734). Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- the vaccine may be administered in conjunction with other immunoregulatory agents.
- DNA vaccination may be employed [eg. Robinson & Torres (1997) Seminars in Immunology 9:271-283; Donnelly et al. (1997) Annu Rev Immunol 15:617-648; see later herein].
- Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention, to be delivered to the mammal for expression in the mammal can be administered either locally or systemically.
- constructs can utilize viral or non-viral vector approaches in in vivo or ex vivo modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constitutive or regulated.
- the invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences.
- the gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector.
- the viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picomavirus, poxvirus, or togavirus viral vector. See generally, Jolly (1994) Cancer Gene Therapy 1:51-64; Kimura (1994) Human Gene Therapy 5:845-852; Connelly (1995) Human Gene Therapy 6:185-193; and Kaplitt (1994) Nature Genetics 6:148-153.
- Retroviral vectors are well known in the art and we contemplate that any retroviral gene therapy vector is employable in the invention, including B, C and D type retroviruses, xenotropic retroviruses (for example, NZB-X1, NZB-X2 and NZB9-1 (see O'Neill (1985) J. Virol. 53:160) polytropic retrovirus eg. MCF and MCF-MLV (see Kelly (1983) J. Virol. 45:291), spumaviruses and lentiviruses. See RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985.
- xenotropic retroviruses for example, NZB-X1, NZB-X2 and NZB9-1 (see O'Neill (1985) J. Virol. 53:160) polytropic retrovirus eg. MCF and MCF-MLV (see Kelly (1983) J. Virol. 45:291)
- RNA Tumor Viruses Second Edition, Cold Spring Harbor Laboratory, 1985
- retroviral gene therapy vector may be derived from different retroviruses.
- retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.
- Retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see U.S. Pat. No. 5,591,624).
- Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle (see WO96/37626). It is preferable that the recombinant viral vector is a replication defective recombinant virus.
- Packaging cell lines suitable for use with the above-described retrovirus vectors are well known in the art, are readily prepared (see WO95/30763 and WO92/05266), and can be used to create producer cell lines (also termed vector cell lines or “VCLs”) for the production of recombinant vector particles.
- the packaging cell lines are made from human parent cells (eg. HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.
- Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia, Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus.
- Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe (1976) J Virol 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC Nol VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No.
- Retroviruses may be obtained from depositories or collections such as the American Type Culture Collection (“ATCC”) in Rockville, Md. or isolated from known sources using commonly available techniques.
- ATCC American Type Culture Collection
- Exemplary known retroviral gene therapy vectors employable in this invention include those described in patent applications GB2200651, EP0415731, EP0345242, EP0334301, WO89/02468; WO89/05349, WO89/09271, WO90/02806, WO90/07936, WO94/03622, WO93/25698, WO93/25234, WO93/11230, WO93/10218, WO91/02805, WO91/02825, WO95/07994, U.S. Pat. No. 5,219,740, U.S. Pat. No. 4,405,712, U.S. Pat. No. 4,861,719, U.S. Pat. No.
- Human adenoviral gene therapy vectors are also known in the art and employable in this invention. See, for example, Berkner (1988) Biotechniques 6:616 and Rosenfeld (1991) Science 252:431, and WO93/07283, WO93/06223, and WO93/07282.
- Exemplary known adenoviral gene therapy vectors employable in this invention include those described in the above referenced documents and in WO94/12649, WO93/03769, WO93/19191, WO94/28938, WO95/11984, WO95/00655, WO95/27071, WO95/29993, WO95/34671, WO96/05320, WO94/08026, WO94/11506, WO93/06223, WO94/24299, WO95/14102, WO95/24297, WO95/02697, WO94/28152, WO94/24299, WO95/09241, WO95/25807, WO95/05835, WO94/18922 and WO95/09654.
- the gene delivery vehicles of the invention also include adenovirus associated virus (AAV) vectors.
- AAV adenovirus associated virus
- Leading and preferred examples of such vectors for use in this invention are the AAV-2 based vectors disclosed in Srivastava, WO93/09239.
- Most preferred AAV vectors comprise the two AAV inverted terminal repeats in which the native D-sequences are modified by substitution of nucleotides, such that at least 5 native nucleotides and up to 18 native nucleotides, preferably at least 10 native nucleotides up to 18 native nucleotides, most preferably 10 native nucleotides are retained and the remaining nucleotides of the D-sequence are deleted or replaced with non-native nucleotides.
- the native D-sequences of the AAV inverted terminal repeats are sequences of 20 consecutive nucleotides in each AAV inverted terminal repeat (ie. there is one sequence at each end) which are not involved in HP formation.
- the non-native replacement nucleotide may be any nucleotide other than the nucleotide found in the native D-sequence in the same position.
- Other employable exemplary AAV vectors are pWP-19, pWN-1, both of which are disclosed in Nahreini (1993) Gene 124:257-262.
- Another example of such an AAV vector is psub201 (see Samulski (1987) J. Virol. 61:3096).
- Another exemplary AAV vector is the Double-D ITR vector. Construction of the Double-D ITR vector is disclosed in U.S. Pat. No. 5,478,745. Still other vectors are those disclosed in Carter U.S. Pat. No. 4,797,368 and Muzyczka U.S. Pat. No.
- AAV vector employable in this invention is SSV9AFABTKneo, which contains the AFP enhancer and albumin promoter and directs expression predominantly in the liver. Its structure and construction are disclosed in Su (1996) Human Gene Therapy 7:463-470. Additional AAV gene therapy vectors are described in U.S. Pat. No. 5,354,678, U.S. Pat. No. 5,173,414, U.S. Pat. No. 5,139,941, and U.S. Pat. No. 5,252,479.
- the gene therapy vectors of the invention also include herpes vectors.
- Leading and preferred examples are herpes simplex virus vectors containing a sequence encoding a thymidine kinase polypeptide such as those disclosed in U.S. Pat. No. 5,288,641 and EP0176170 (Roizman).
- herpes simplex virus vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar Institute), pHSVlac described in Geller (1988) Science 241:1667-1669 and in WO90/09441 and WO92/07945, HSV Us3::pgC-lacZ described in Fink (1992) Human Gene Therapy 3:11-19 and HSV 7134, 2 RH 105 and GAL4 described in EP 0453242 (Breakefield), and those deposited with the ATCC as accession numbers ATCC VR-977 and ATCC VR-260.
- alpha virus gene therapy vectors that can be employed in this invention.
- Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in U.S. Pat. Nos. 5,091,309, 5,217,879, and WO92/10578. More particularly, those alpha virus vectors described in U.S. Ser. No. 08/405,627, filed Mar.
- alpha viruses may be obtained from depositories or collections such as the ATCC in Rockville, Md. or isolated from known sources using commonly available techniques. Preferably, alphavirus vectors with reduced cytotoxicity are used (see U.S. Ser. No. 08/679,640).
- DNA vector systems such as eukaryotic layered expression systems are also useful for expressing the nucleic acids of the invention. See WO95/07994 for a detailed description of eukaryotic layered expression systems.
- the eukaryotic layered expression systems of the invention are derived from alphavirus vectors and most preferably from Sindbis viral vectors.
- viral vectors suitable for use in the present invention include those derived from poliovirus, for example ATCC VR-58 and those described in Evans, Nature 339 (1989) 385 and Sabin (1973) J. Biol. Standardization 1:115; rhinovirus, for example ATCC VR-1110 and those described in Arnold (1990) J Cell Biochem L 401; pox viruses such as canary pox virus or vaccinia virus, for example ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch (1989) Proc Natl Acad Sci 86:317; Flexner (1989) Ann NY Acad Sci 569:86, Flexner (1990) Vaccine 8:17; in U.S. Pat. No. 4,603,112 and U.S. Pat. No.
- SV40 virus for example ATCC VR-305 and those described in Mulligan (1979) Nature 277:108 and Madzak (1992) J Gen Virol 73:1533
- influenza virus for example ATCC VR-797 and recombinant influenza viruses made employing reverse genetics techniques as described in U.S. Pat. No.
- measles virus for example ATCC VR-67 and VR-1247 and those described in EP-0440219; Aura virus, for example ATCC VR-368; Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou virus, for example ATCC VR-922; Chikungunya virus, for example ATCC VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC VR-924; Getah virus, for example ATCC VR-369 and ATCC VR-1243; Kyzylagach virus, for example ATCC VR-927; Mayaro virus, for example ATCC VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244; Ndumu virus, for example ATCC VR-371; Pixuna virus, for example ATCC VR-372 and ATCC VR-1245; Tonate virus, for example ATCC VR-925; Triniti virus, for example ATCC VR-469; Una virus, for example ATCC VR-374; Whataroa
- compositions of this invention into cells is not limited to the above mentioned viral vectors.
- Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see U.S. Ser. No. 08/366,787, filed Dec. 30, 1994 and Curiel (1992) Hum Gene Ther 3:147-154 ligand linked DNA, for example see Wu (1989) J Biol Chem 264:16985-16987, eucaryotic cell delivery vehicles cells, for example see U.S. Ser. No. 08/240,030, filed May 9, 1994, and U.S. Ser. No.
- Particle mediated gene transfer may be employed, for example see U.S. Ser. No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu & Wu (1987) J. Biol. Chem. 262:4429-4432, insulin as described in Hucked (1990) Biochem Pharmacol 40:253-263, galactose as described in Plank (1992) Bioconjugate Chem 3:533-539, lactose or transferrin.
- synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu & Wu (1987) J. Biol
- Naked DNA may also be employed.
- Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Pat. No. 5,580,859. Uptake efficiency may be improved using biodegradable latex beads.
- DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.
- Liposomes that can act as gene delivery vehicles are described in U.S. Pat. No. 5,422,120, WO95/13796, WO94/23697, WO91/14445 and EP-524,968.
- the nucleic acid sequences encoding a polypeptide can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, insulin, galactose, lactose, or transferrin.
- Non-viral delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously-active promoters.
- Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al (1994) Proc. Natl. Acad. Sci. USA 91(24):11581-11585.
- the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials.
- Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. Pat. No. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. Pat. No. 5,206,152 and WO92/11033
- Exemplary liposome and polycationic gene delivery vehicles are those described in U.S. Pat. Nos. 5,422,120 and 4,762,915; in WO 95/13796; WO94/23697, and WO91/14445; in EP-0524968; and in Stryer, Biochemistry, pages 236-240 (1975) W.H. Freeman, San Francisco; Szoka (1980) Biochem Biophys Acta 600:1; Bayer (1979) Biochem Biophys Acta 550:464; Rivnay (1987) Meth Enzymol 149:119; Wang (1987) Proc Natl Acad Sci 84:7851; Plant (1989) Anal Biochem 176:420.
- a polynucleotide composition can comprises therapeutically effective amount of a gene therapy vehicle, as the term is defined above.
- an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.
- the polynucleotide compositions of the invention can be administered (1) directly to the subject; (2) delivered ex vivo, to cells derived from the subject; or (3) in vitro for expression of recombinant proteins.
- the subjects to be treated can be mammals or birds. Also, human subjects can be treated.
- Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue.
- the compositions can also be administered into a lesion.
- Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays.
- Dosage treatment may be a single dose schedule or a multiple dose schedule.
- cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells.
- nucleic acids for both ex vivo and in vitro applications can be accomplished by the following procedures, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.
- polypeptides which include, without limitation: asioloorosomucoid (ASOR); transferrin; asialoglycoproteins; antibodies; antibody fragments; ferritin; interleukins; interferons, granulocyte, macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor and erythropoietin.
- Viral antigens such as envelope proteins, can also be used.
- proteins from other invasive organisms such as the 17 amino acid peptide from the circumsporozoite protein of plasmodium falciparum known as RII.
- hormones for example: hormones, steroids, androgens, estrogens, thyroid hormone, or vitamins, folic acid.
- polyalkylene glycol can be included with the desired polynucleotides/polypeptides.
- the polyalkylene glycol is polyethlylene glycol.
- mono-, di-, or polysaccharides can be included.
- the polysaccharide is dextran or DEAE-dextran.
- the desired polynucleotide/polypeptide can also be encapsulated in lipids or packaged in liposomes prior to delivery to the subject or to cells derived therefrom.
- Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid.
- the ratio of condensed polynucleotide to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid.
- Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations.
- Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner (1987) Proc. Natl. Acad. Sci. USA 84:7413-7416); mRNA (Malone (1989) Proc. Natl. Acad. Sci. USA 86:6077-6081); and purified transcription factors (Debs (1990) J. Biol. Chem. 265:10189-10192), in functional form.
- Cationic liposomes are readily available.
- N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner supra).
- Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boerhinger).
- Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, eg. Szoka (1978) Proc. Nail. Acad. Sci. USA 75:41944198; WO90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.
- anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials.
- Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others.
- DOPC dioleoylphosphatidyl choline
- DOPG dioleoylphosphatidyl glycerol
- DOPE dioleoylphoshatidyl ethanolamine
- the liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs).
- MLVs multilammelar vesicles
- SUVs small unilamellar vesicles
- LUVs large unilamellar vesicles
- the various liposome-nucleic acid complexes are prepared using methods known in the art See eg. Straubinger (1983) Meth. Immunol. 101:512-527; Szoka (1978) Proc. Natl. Acad. Sci. USA 75:4194-4198; Papahadjopoulos (1975) Biochim. Biophys. Acta 394:483; Wilson (1979) Cell 17:77); Deamer & Bangham (1976) Biochim. Biophys.
- lipoproteins can be included with the polynucleotide/polypeptide to be delivered.
- lipoproteins to be utilized include: chylomicrons, HDL, DL, LDL, and VLDL. Mutants, fragments, or fusions of these proteins can also be used. Also, modifications of naturally occurring lipoproteins can be used, such as acetylated LDL. These lipoproteins can target the delivery of polynucleotides to cells expressing lipoprotein receptors. Preferably, if lipoproteins are including with the polynucleotide to be delivered, no other targeting ligand is included in the composition.
- Naturally occurring lipoproteins comprise a lipid and a protein portion.
- the protein portion are known as apoproteins.
- apoproteins A, B, C, D, and E have been isolated and identified. At least two of these contain several proteins, designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.
- a lipoprotein can comprise more than one apoprotein.
- naturally occurring chylomicrons comprises of A, B, C, and E, over time these lipoproteins lose A and acquire C and E apoproteins.
- VLDL comprises A, B, C, and E apoproteins
- LDL comprises apoprotein B; and HDL comprises apoproteins A, C, and E.
- Lipoproteins contain a variety of lipids including, triglycerides, cholesterol (free and esters), and phospholipids.
- the composition of the lipids varies in naturally occurring lipoproteins.
- chylomicrons comprise mainly triglycerides.
- a more detailed description of the lipid content of naturally occurring lipoproteins can be found, for example, in Meth. Enzymol. 128 (1986).
- the composition of the lipids are chosen to aid in conformation of the apoprotein for receptor binding activity.
- the composition of lipids can also be chosen to facilitate hydrophobic interaction and association with the polynucleotide binding molecule.
- Naturally occurring lipoproteins can be isolated from serum by ultracentrifugation, for instance. Such methods are described in Meth. Enzymol . (supra); Pitas (1980) J. Biochem. 255:5454-5460 and Mahey (1979) J. Clin. Invest 64:743-750. Lipoproteins can also be produced by in vitro or recombinant methods by expression of the apoprotein genes in a desired host cell. See, for example, Atkinson (1986) Annu Rev Biophys Chem 15:403 and Radding (1958) Biochim Biophys Acia 30: 443. Lipoproteins can also be purchased from commercial suppliers, such as Biomedical Techniologies, Inc., Stoughton, Mass., USA. Further description of lipoproteins can be found in Zuckermann et al. PCT/US97/14465.
- Polycationic agents can be included, with or without lipoprotein, in a composition with the desired polynucleotide/polypeptide to be delivered.
- Polycationic agents typically, exhibit a net positive charge at physiological relevant pH and are capable of neutralizing the electrical charge of nucleic acids to facilitate delivery to a desired location. These agents have both in vitro, ex vivo, and in vivo applications. Polycationic agents can be used to deliver nucleic acids to a living subject either intramuscularly, subcutaneously, etc.
- polypeptides as polycationic agents: polylysine, polyarginine, polyornithine, and protamine.
- Other examples include histones, protamines, human serum albumin, DNA binding proteins, non-histone chromosomal proteins, coat proteins from DNA viruses, such as (X174, transcriptional factors also contain domains that bind DNA and therefore may be useful as nucleic aid condensing agents.
- transcriptional factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF, Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains that bind DNA sequences.
- Organic polycationic agents include: spermine, spermidine, and purtrescine.
- polycationic agent The dimensions and of the physical properties of a polycationic agent can be extrapolated from the list above, to construct other polypeptide polycationic agents or to produce synthetic polycationic agents.
- Synthetic polycationic agents which are useful include, for example, DEAE-dextran, polybrene.
- LipofectinTM, and lipofectAMINETM are monomers that form polycationic complexes when combined with polynucleotides/polypeptides.
- Neisserial antigens of the invention can be used in immunoassays to detect antibody levels (or, conversely, anti-Neisserial antibodies can be used to detect antigen levels). Immunoassays based on well defined, recombinant antigens can be developed to replace invasive diagnostics methods. Antibodies to Neisserial proteins within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation.
- assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules.
- Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.
- Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the invention, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutions, etc.) required for the conduct of the assay, as well as suitable set of assay instructions.
- Hybridization refers to the association of two nucleic acid sequences to one another by hydrogen bonding. Typically, one sequence will be fixed to a solid support and the other will be free in solution. Then, the two sequences will be placed in contact with one another under conditions that favor hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase sequence to the solid support (Denhardt's reagent or BLOTTO); concentration of the sequences; use of compounds to increase the rate of association of sequences (dextran sulfate or polyethylene glycol); and the stringency of the washing conditions following hybridization. See Sambrook et al. [supra] Volume 2, chapter 9, pages 9.47 to 9.57.
- “Stringency” refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ.
- the combination of temperature and salt concentration should be chosen that is approximately 120 to 200° C. below the calculated Tm of the hybrid under study.
- the temperature and salt conditions can often be determined empirically in preliminary experiments in which samples of genomic DNA immobilized on filters are hybridized to the sequence of interest and then washed under conditions of different stringencies. See Sambrook et al. at page 9.50.
- Variables to consider when performing, for example, a Southern blot are (1) the complexity of the DNA being blotted and (2) the homology between the probe and the sequences being detected.
- the total amount of the fragment(s) to be studied can vary a magnitude of 10, from 0.1 to 1 g for a plasmid or phage digest to 10 ⁇ 9 to 10 ⁇ 8 g for a single copy gene in a highly complex eukaryotic genome.
- substantially shorter blotting, hybridization, and exposure times a smaller amount of starting polynucleotides, and lower specific activity of probes can be used.
- a single-copy yeast gene can be detected with an exposure time of only 1 hour starting with 1 ⁇ g of yeast DNA, blotting for two hours, and hybridizing for 4-8 hours with a probe of 10 8 cpm/ ⁇ g.
- a conservative approach would start with 10 ⁇ g of DNA, blot overnight, and hybridize overnight in the presence of 10% dextran sulfate using a probe of greater than 10 8 cpm/ ⁇ g, resulting in an exposure time of 24 hours.
- Tm melting temperature
- the temperature of the hybridization and washes and the salt concentration during the washes are the simplest to adjust. As the temperature of the hybridization increases (ie. stringency), it becomes less likely for hybridization to occur between strands that are nonhomologous, and as a result, background decreases. If the radiolabeled probe is not completely homologous with the immobilized fragment (as is frequently the case in gene family and interspecies hybridization experiments), the hybridization temperature must be reduced, and background will increase. The temperature of the washes affects the intensity of the hybridizing band and the degree of background in a similar manner. The stringency of the washes is also increased with decreasing salt concentrations.
- Methods such as PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes according to the invention can determine the presence of cDNA or mRNA.
- a probe is said to “hybridize” with a sequence of the invention if it can form a duplex or double stranded complex, which is stable enough to be detected.
- the nucleic acid probes will hybridize to the Neisserial nucleotide sequences of the invention (including both sense and antisense strands). Though many different nucleotide sequences will encode the amino acid sequence, the native Neisserial sequence is preferred because it is the actual sequence present in cells.
- mRNA represents a coding sequence and so a probe should be complementary to the coding sequence; single-stranded cDNA is complementary to mRNA, and so a cDNA probe should be complementary to the non-coding sequence.
- the probe sequence need not be identical to the Neisserial sequence (or its complement)—some variation in the sequence and length can lead to increased assay sensitivity if the nucleic acid probe can form a duplex with target nucleotides, which can be detected.
- the nucleic acid probe can include additional nucleotides to stabilize the formed duplex. Additional Neisserial sequence may also be helpful as a label to detect the formed duplex.
- a non-complementary nucleotide sequence may be attached to the 5′ end of the probe, with the remainder of the probe sequence being complementary to a Neisserial sequence.
- non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the a Neisserial sequence in order to hybridize therewith and thereby form a duplex which can be detected.
- the exact length and sequence of the probe will depend on the hybridization conditions, such as temperature, salt condition and the like.
- the nucleic acid probe typically contains at least 10-20 nucleotides, preferably 15-25, and more preferably at least 30 nucleotides, although it may be shorter than this. Short primers generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.
- Probes may be produced by synthetic procedures, such as the triester method of Matteucci et al. [ J. Am. Chem. Soc . (1981) 103:3185], or according to Urdea et al. [ Proc. Natl. Acad. Sci. USA (1983) 80: 7461], or using commercially available automated oligonucleotide synthesizers.
- the chemical nature of the probe can be selected according to preference. For certain applications, DNA or RNA are appropriate. For other applications, modifications may be incorporated eg. backbone modifications, such as phosphorothioates or methylphosphonates, can be used to increase in vivo half-life, alter RNA affinity, increase nuclease resistance etc. [eg. see Agrawal & Iyer (1995) Curr Opin Biotechnol 6:12-19; Agrawal (1996) TIBTECH 14:376-387]; analogues such as peptide nucleic acids may also be used [eg. see Corey (1997) TIBTECH 15:224-229; Buchardt et al. (1993) TIBTECH 11:384-386].
- backbone modifications such as phosphorothioates or methylphosphonates
- PCR polymerase chain reaction
- the assay is described in: Mullis et al. [ Meth. Enzymol . (1987) 155: 335-350]; U.S. Pat. Nos. 4,683,195 and 4,683,202.
- Two “primer” nucleotides hybridize with the target nucleic acids and are used to prime the reaction.
- the primers can comprise sequence that does not hybridize to the sequence of the amplification target (or its complement) to aid with duplex stability or, for example, to incorporate a convenient restriction site. Typically, such sequence will flank the desired Neisserial sequence.
- thermostable polymerase creases copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a threshold amount of target nucleic acids are generated by the polymerase, they can be detected by more traditional methods, such as Southern blots. When using the Southern blot method, the labelled probe will hybridize to the Neisserial sequence (or its complement).
- mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook et al [supra].
- mRNA, or cDNA generated from mRNA using a polymerase enzyme can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The solid support is exposed to a labelled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labeled probe are detected. Typically, the probe is labelled with a radioactive moiety.
- FIGS. 1-7 show biochemical data and sequence analysis pertaining to Examples 1, 2, 3, 7, 13, 16 and 19, respectively, with ORFs 40, 38, 44, 52, 114, 41 and 124.
- M1 and M2 are molecular weight markers. Arrows indicate the position of the main recombinant product or, in Western blots, the position of the main N. meningitidis immunoreactive band.
- TP indicates N. meningitidis total protein extract;
- OMV indicates N. meningitidis outer membrane vesicle preparation.
- FIG. 8 shows an alignment comparison of amino acid sequences for ORF 40 for several strains of Neisseria . Dark shading indicates regions of homology, and gray shading indicates the conservation of amino acids with similar characteristics. The Figure demonstrates a high degree of conservation among the various strains, further confirming its utility as an antigen for both vaccines and diagnostics.
- nucleic acid sequences which have been identified in N. meningitidis , along with their putative translation products. Not all of the nucleic acid sequences are complete ie. they encode less than the full-length wild-type protein. It is believed at present that none of the DNA sequences described herein have significant homologs in N. gonorrhoeae.
- the examples typically include details of sequence homology between species and strains. Proteins that are similar in sequence are generally similar in both structure and function, and the homology often indicates a common evolutionary origin. Comparison with sequences of proteins of known function is widely used as a guide for the assignment of putative protein function to a new sequence and has proved particularly useful in whole-genome analyses.
- nucleotide sequences eg. position 288 in Example 12
- Dots within nucleotide sequences represent nucleotides which have been arbitrarily introduced in order to maintain a reading frame. In the same way, double-underlined nucleotides were removed. Lower case letters (eg. position 589 in Example 12) represent ambiguities which arose during alignment of independent sequencing reactions (some of the nucleotide sequences in the examples are derived from combining the results of two or more experiments).
- Nucleotide sequences were scanned in all six reading frames to predict the presence of hydrophobic domains using an algorithm based on the statistical studies of Esposti et al. [Critical evaluation of the hydropathy of membrane proteins (1990) Eur J Biochem 190:207-219]. These domains represent potential transmembrane regions or hydrophobic leader sequences.
- Open reading frames were predicted from fragmented nucleotide sequences using the program ORFFINDER (NCBI).
- the proteins can be expressed recombinantly and used to screen patient sera by immunoblot A positive reaction between the protein and patient serum indicates that the patient has previously mounted an immune response to the protein in question ie. the protein is an immunogen. This method can also be used to identify immunodominant proteins.
- the recombinant protein can also be conveniently used to prepare antibodies eg. in a mouse. These can be used for direct confirmation that a protein is located on the cell-surface. Labelled antibody (eg. fluorescent labelling for FACS) can be incubated with intact bacteria and the presence of label on the bacterial surface confirms the location of the protein.
- Labelled antibody eg. fluorescent labelling for FACS
- N. meningitidis strain 2996 was grown to exponential phase in 100 ml of GC medium, harvested by centrifugation, and resuspended in 5 ml buffer (20% Sucrose, 50 mM Tris-HCl, 50 mM EDTA, pH8). After 10 minutes incubation on ice, the bacteria were lysed by adding 10 ml lysis solution (50 mM NaCl, 1% Na-Sarkosyl, 50 ⁇ g/ml Proteinase K), and the suspension was incubated at 37° C. for 2 hours. Two phenol extractions (equilibrated to pH 8) and one ChCl 3 /isoamylalcohol (24:1) extraction were performed.
- DNA was precipitated by addition of 0.3M sodium acetate and 2 volumes ethanol, and was collected by centrifugation. The pellet was washed once with 70% ethanol and redissolved in 4 ml buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The DNA concentration was measured by reading the OD at 260 nm.
- Synthetic oligonucleotide primers were designed on the basis of the coding sequence of each ORF, using (a) the meningococcus B sequence when available, or (b) the gonococcus/meningococcus A sequence, adapted to the codon preference usage of meningococcus as necessary. Any predicted signal peptides were omitted, by deducing the 5′-end amplification primer sequence immediately downstream from the predicted leader sequence.
- the 5′ primers included two restriction enzyme recognition sites (BamHI-NdeI, BamHI-NheI, or EcoRI-NheI, depending on the gene's own restriction pattern); the 3′ primers included a XhoI restriction site. This procedure was established in order to direct the cloning of each amplification product (corresponding to each ORF) into two different expression systems: pGEX-KG (using either BamHI-XhoI or EcoRI-XhoI), and pET21b+ (using either NdeI-XhoI or NheI-XhoI).
- 5′end primer tail CGC GGATCCCATATG (BamHI-NdeI) CGC GGATCCGCTAGC (BamHI-NheI) CCG GAATTC TA GCTAGC (EcoRI-NheI) 3′-end primer tail: CCCG CTCGAG (XhoI)
- the primers included nucleotides which hybridised to the sequence to be amplified.
- the average melting temperature of the selected oligos were 65-70° C. for the whole oligo and 50-55° C. for the hybridising region alone.
- Table I shows the forward and reverse primers used for each amplification. Oligos were synthesized by a Perkin Elmer 394 DNA/RNA Synthesizer, eluted from the columns in 2 ml NH 4 OH, and deprotected by 5 hours incubation at 56° C. The oligos were precipitated by addition of 0.3M Na-Acetate and 2 volumes ethanol. The samples were then centrifuged and the pellets resuspended in either 100 ⁇ l or 1 ml of water. OD 260 was determined using a Perkin Elmer Lambda Bio spectrophotometer and the concentration was determined and adjusted to 2-10 pmol/ ⁇ l.
- the standard PCR protocol was as follows: 50-200 ng of genomic DNA were used as a template in the presence of 20-40 ⁇ M of each oligo, 400-8004M dNTs solution, 1 ⁇ PCR buffer (including 1.5 mM MgCl 2 ), 2.5 units TaqI DNA polymerase (using Perkin-Elmer AmpliTaQ, GIBCO Platinum, Pwo DNA polymerase, or Tahara Shuzo Taq polymerase).
- PCR was optimised by the addition of 10 ⁇ l DMSO or 50 ⁇ l 2M betaine.
- each sample underwent a double-step amplification: the first 5 cycles were performed using as the hybridization temperature the one of the oligos excluding the restriction enzymes tail, followed by 30 cycles performed according to the hybridization temperature of the whole length oligos. The cycles were followed by a final 10 minute extension step at 72° C.
- the standard cycles were as follows: Denaturation Hybridisation Elongation First 5 cycles 30 seconds 30 seconds 30-60 seconds 95° C. 50-55° C. 72° C. Last 30 cycles 30 seconds 30 seconds 30-60 seconds 95° C. 65-70° C. 72° C.
- the elongation time varied according to the length of the ORF to be amplified.
- the amplifications were performed using either a 9600 or a 2400 Perkin Elmer GeneAmp PCR System. To check the results, 1/10 of the amplification volume was loaded onto a 1-1.5% agarose gel and the size of each amplified fragment compared with a DNA molecular weight marker.
- the amplified DNA was either loaded directly on a 1% agarose gel or first precipitated with ethanol and resuspended in a suitable volume to be loaded on a 1% agarose gel.
- the DNA fragment corresponding to the right size band was then eluted and purified from gel, using the Qiagen Gel Extraction Kit, following the instructions of the manufacturer.
- the final volume of the DNA fragment was 30 ⁇ l or 500 of either water or 10 mM Tris, pH 8.5.
- the purified DNA corresponding to the amplified fragment was split into 2 aliquots and double-digested with:
- Each purified DNA fragment was incubated (37° C. for 3 hours to overnight) with 20 units of each restriction enzyme (New England Biolabs) in a either 30 or 40 ⁇ l final volume in the presence of the appropriate buffer.
- the digestion product was then purified using the QIAquick PCR purification kit, following the manufacturer's instructions, and eluted in a final volume of 30 or 50 ⁇ l of either water or 10 mM Tris-HCl, pH 8.5.
- the final DNA concentration was determined by 1% agarose gel electrophoresis in the presence of titrated molecular weight marker.
- 10 ⁇ g plasmid was double-digested with 50 units of each restriction enzyme in 200 ⁇ l reaction volume in the presence of appropriate buffer by overnight incubation at 37° C. After loading the whole digestion on a 1% agarose gel, the band corresponding to the digested vector was purified from the gel using the Qiagen QIAquick-Gel Extraction Kit and the DNA was eluted in 50 ⁇ l of 10 mM Tris-HCl, pH 8.5. The DNA concentration was evaluated by measuring OD 260 of the sample, and adjusted to 50 ⁇ g/ ⁇ l. 1 ⁇ l of plasmid was used for each cloning procedure.
- the vector pGEX-His is a modified pGEX-2T vector carrying a region encoding six histidine residues upstream to the thrombin cleavage site and containing the multiple cloning site of the vector pTRC99 (Pharmacia).
- a molar ratio of 3:1 fragment/vector was ligated using 0.5 ⁇ l of NEB T4 DNA ligase (400 units/ ⁇ l), in the presence of the buffer supplied by the manufacturer. The reaction was incubated at room temperature for 3 hours. In some experiments, ligation was performed using the Boehringer “Rapid Ligation Kit”, following the manufacturer's instructions.
- E. coli DH5 competent cells were incubated with the ligase reaction solution for 40 minutes on ice, then at 37° C. for 3 minutes, then, after adding 800 ⁇ l LB broth, again at 37° C. for 20 minutes. The cells were then centrifuged at maximum speed in an Eppendorf microfuge and resuspended in approximately 200 ⁇ l of the supernatant. The suspension was then plated on LB ampicillin (100 mg/ml).
- the screening of the recombinant clones was performed by growing 5 randomly-chosen colonies overnight at 37° C. in either 2 ml (pGEX or pTC clones) or 5 ml (pET clones) LB broth+100 ⁇ g/ml ampicillin. The cells were then pelletted and the DNA extracted using the Qiagen QIAprep Spin Miniprep Kit, following the manufacturer's instructions, to a final volume of 30 ⁇ l.
- each individual miniprep (approximately 1 g) were digested with either NdeI/XhoI or BamHI/XhoI and the whole digestion loaded onto a 1-1.5% agarose gel (depending on the expected insert size), in parallel with the molecular weight marker (1 Kb DNA Ladder, GIBCO). The screening of the positive clones was made on the base of the correct insert size.
- Each ORF cloned into the expression vector was transformed into the strain suitable for expression of the recombinant protein product. 1 ⁇ l of each construct was used to transform 30 ⁇ l of E. coli BL21 (pGEX vector), E. coli TOP 10 (pTRC vector) or E. coli BL21-DE3 (pET vector), as described above. In the case of the pGEX-His vector, the same E. coli strain (W3110) was used for initial cloning and expression. Single recombinant colonies were inoculated into 2 ml LB+Amp (100 ⁇ g/ml), incubated at 37° C.
- a single colony was grown overnight at 37° C. on LB+Amp agar plate.
- the bacteria were inoculated into 20 ml of LB+Amp liquid culture in a water bath shaker and grown overnight.
- Bacteria were diluted 1:30 into 600 ml of fresh medium and allowed to grow at the optimal temperature (20-37° C.) to OD 550 0.8-1.
- Protein expression was induced with 0.2 mM IPTG followed by three hours incubation.
- the culture was centrifuged at 800 rpm at 4° C. The supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml cold PBS.
- the cells were disrupted by sonication on ice for 30 sec at 40 W using a Branson sonifier B-15, frozen and thawed twice and centrifuged again.
- the supernatant was collected and mixed with 150 ⁇ l Glutatione-Sepharose 4B resin (Pharmacia) (previously washed with PBS) and incubated at room temperature for 30 minutes.
- the sample was centrifuged at 700 g for 5 minutes at 4° C.
- the resin was washed twice with 10 ml cold PBS for 10 minutes, resuspended in 1 ml cold PBS, and loaded on a disposable column.
- the resin was washed twice with 2 ml cold PBS until the flow-through reached OD 280 of 0.02-0.06.
- the GST-fusion protein was eluted by addition of 70011 cold Glutathione elution buffer (10 mM reduced glutathione, 50 mM Tris-HCl) and fractions collected until the OD 280 was 0.1. 21 ⁇ l of each fraction were loaded on a 12% SDS gel using either Biorad SDS-PAGE Molecular weight standard broad range (M1) (200, 116.25, 97.4, 66.2, 45, 31, 21.5, 14.4, 6.5 kDa) or Amersham Rainbow Marker (M2) (220, 66, 46, 30, 21.5, 14.3 kDa) as standards. As the MW of GST is 26 kDa, this value must be added to the MW of each GST-fusion protein.
- M1 Biorad SDS-PAGE Molecular weight standard broad range
- M2 Amersham Rainbow Marker
- pellets of 3 ml cultures were resuspended in buffer M1 [500 ⁇ l PBS pH 7.2]. 25 ⁇ l lysozyme (10 mg/ml) was added and the bacteria were incubated for 15 min at 4° C. The pellets were sonicated for 30 sec at 40 W using a Branson sonifier B-15, frozen and thawed twice and then separated again into pellet and supernatant by a centrifugation step.
- the supernatant was collected and the pellet was resuspended in buffer M2 [8M urea, 0.5M NaCl, 20 mM imidazole and 0.1M NaH 2 PO 4 ] and incubated for 3 to 4 hours at 4° C. After centrifugation, the supernatant was collected and the pellet was resuspended in buffer M3 [6M guanidinium-HCl, 0.5M NaCl, 20 mM imidazole and 0.1M NaH 2 PO 4 ] overnight at 4° C. The supernatants from all steps were analysed by SDS-PAGE.
- a single colony was grown overnight at 37° C. on a LB+Amp agar plate.
- the bacteria were inoculated into 20 ml of LB+Amp liquid culture and incubated overnight in a water bath shaker. Bacteria were diluted 1:30 into 600 ml fresh medium and allowed to grow at the optimal temperature (20-37° C.) to OD 550 0.6-0.8. Protein expression was induced by addition of 1 mM IPTG and the culture further incubated for three hours.
- the culture was centrifuged at 8000 rpm at 4° C., the supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml of either (i) cold buffer A (300 mM NaCl, 50 mM phosphate buffer, 10 mM imidazole, pH 8) for soluble proteins or (ii) buffer B (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 8.8) for insoluble proteins.
- cold buffer A 300 mM NaCl, 50 mM phosphate buffer, 10 mM imidazole, pH 8) for soluble proteins
- buffer B urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 8.8 for insoluble proteins.
- the cells were disrupted by sonication on ice for 30 sec at 40 W using a Branson sonifier B-15, frozen and thawed two times and centrifuged again.
- the supernatant was stored at ⁇ 20° C., while the pellets were resuspended in 2 ml buffer C (6M guanidine hydrochloride, 100 mM phosphate buffer, 10 mM Tris-HCl, pH 7.5) and treated in a homogenizer for 10 cycles. The product was centrifuged at 13000 rpm for 40 minutes.
- the resin was washed with either (i) 2 ml cold 20 mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 20 mM imidazole, pH 8) or (ii) buffer D (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 6.3) until the flow-through reached the O.D 280 of 0.02-0.06.
- the His-fusion protein was eluted by addition of 700 ⁇ l of either (i) cold elution buffer A (300 mM NaCl, 50 mM phosphate buffer, 250 mM imidazole, pH 8) or (ii) elution buffer B (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 4.5) and fractions collected until the O.D 280 was 0.1. 21 ⁇ l of each fraction were loaded on a 12% SDS gel.
- cold elution buffer A 300 mM NaCl, 50 mM phosphate buffer, 250 mM imidazole, pH 8
- elution buffer B urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 4.5
- the acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37° C. Bacterial colonies were collected from the agar plates using a sterile dracon swab and inoculated into 7 ml of Mueller-Hinton Broth (Difco) containing 0.25% Glucose. Bacterial growth was monitored every 30 minutes by following OD 620 . The bacteria were let to grow until the OD reached the value of 0.3-0.4. The culture was centrifuged for 10 minutes at 10000 rpm.
- the acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37° C. Bacterial colonies were collected from the agar plates using a sterile dracon swab and inoculated into 4 tubes containing 8 ml each Mueller-Hinton Broth (Difco) containing 0.25% glucose. Bacterial growth was monitored every 30 minutes by following OD 620 . The bacteria were let to grow until the OD reached the value of 0.35-0.5. The culture was centrifuged for 10 minutes at 4000 rpm. The supernatant was discarded and the pellet was resuspended in blocking buffer (1% BSA, 0.4% NaN 3 ) and centrifuged for 5 minutes at 4000 rpm.
- blocking buffer 1% BSA, 0.4% NaN 3
- Bacteria were grown overnight on 5 GC plates, harvested with a loop and resuspended in 10 ml 20 mM Tris-HCl. Heat inactivation was performed at 56° C. for 30 minutes and the bacteria disrupted by sonication for 10 minutes on ice (50% duty cycle, 50% output). Unbroken cells were removed by centrifugation at 5000 g for 10 minutes and the total cell envelope fraction recovered by centrifugation at 50000 g at 4° C. for 75 minutes. To extract cytoplasmic membrane proteins from the crude outer membranes, the whole fraction was resuspended in 2% sarkosyl (Sigma) and incubated at room temperature for 20 minutes.
- 2% sarkosyl Sigma
- the suspension was centrifuged at 10000 g for 10 minutes to remove aggregates, and the supernatant further ultracentrifuged at 50000 g for 75 minutes to pellet the outer membranes.
- the outer membranes were resuspended in 10 mM Tris-HCl, pH8 and the protein concentration measured by the Bio-Rad Protein assay, using BSA as a standard.
- Bacteria were grown overnight on a GC plate, harvested with a loop and resuspended in 1 ml of 20 mM Tris-HCl. Heat inactivation was performed at 56° C. for 30 minutes.
- Purified proteins 500 ng/lane
- outer membrane vesicles 5 ⁇ g
- total cell extracts 25 ⁇ g derived from MenB strain 2996 were loaded on 15% SDS-PAGE and transferred to a nitrocellulose membrane.
- the transfer was performed for 2 hours at 150 mA at 4° C., in transferring buffer (0.3% Tris base, 1.44% glycine, 20% methanol).
- the membrane was saturated by overnight incubation at 4° C. in saturation buffer (10% skimmed milk, 0.1% Triton X100 in PBS).
- the membrane was washed twice with washing buffer (3% skimmed milk, 0.1% Triton X100 in PBS) and incubated for 2 hours at 37° C. with mice sera diluted 1:200 in washing buffer.
- the membrane was washed twice and incubated for 90 minutes with a 1:2000 dilution of horseradish peroxidase labelled anti-mouse Ig.
- the membrane was washed twice with 0.1% Triton X100 in PBS and developed with the Opti-4CN Substrate Kit (Bio-Rad). The reaction was stopped by adding water.
- MC58 strain was grown overnight at 37° C. on chocolate agar plates. 5-7 colonies were collected and used to inoculate 7 ml Mueller-Hinton broth. The suspension was incubated at 37° C. on a nutator and let to grow until OD 620 was 0.5-0.8. The culture was aliquoted into sterile 1.5 ml Eppendorf tubes and centrifuged for 20 minutes at maximum speed in a microfuge. The pellet was washed once in Gey's buffer (Gibco) and resuspended in the same buffer to an OD 620 of 0.5, diluted 1:20000 in Gey's buffer and stored at 25° C.
- Gey's buffer Gibco
- mice sera 50 ⁇ l of Gey's buffer/1% BSA was added to each well of a 96-well tissue culture plate.
- 25 ⁇ l of the previously described bacterial suspension were added to each well.
- 25 ⁇ l of either heat-inactivated (56° C. waterbath for 30 minutes) or normal baby rabbit complement were added to each well.
- 22 ⁇ l of each sample/well were plated on Mueller-Hinton agar plates (time 0).
- the 96-well plate was incubated for 1 hour at 37° C. with rotation and then 22 ⁇ l of each sample/well were plated on Mueller-Hinton agar plates (time 1). After overnight incubation the colonies corresponding to time 0 and time 1 hour were counted.
- Table II gives a summary of the cloning, expression and purification results. TABLE II Cloning, expression and purification His-fusion GST-fusion ORF PCR/cloning expression expression Purification orf 38 + + + His-fusion orf 40 + + + His-fusion orf 41 + n.d. n.d. orf 44 + + + His-fusion orf 51 + n.d. n.d. orf 52 + n.d. + GST-fusion orf 56 + n.d. n.d. orf 69 + n.d. n.d. orf 82 + n.d. n.d. orf 114 + n.d. + GST-fusion orf 124 + n.d. n.d.
- ORF40 and Hsf protein show 54% aa identity in 251 aa overlap: Orf40 1 TLLFATVQASANQEEQEEDLYLDPVQRTVAVLVINSDXXXXXXXXXNSDWAVYFNEK 60 TLLFATVQA+A E++E LDPV RT VL +SD NS+W +YF+ K Hsf 41 TLLFATVQANATDEDEE----LDPVVRTAPVLSFHSDKEGTGEKEVTE-NSNWGIYFDNK 95 Orf40 61 GVLTAREITXKAGDNLKIKQN------GTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVN 114 GVL A IT KAGDNLKIKQN ++FTYSLKKDLTDLTSV TEKLSF ANG+KV+ Hsf 96 GVLKAGAITLKAGDNLKIKQNTDESTNASSFTYSLKKDLTDLTSVATEKLSFGANGDKVD 155 Orf40
- ORF40a also shows homology to Hsf: gi
- ORF40-1 (61 kDa) was cloned in pET and pGex vectors and expressed in E. coli , as described above. The products of protein expression and purification were analyzed by SDS-PAGE.
- FIG. 1A shows the results of affinity purification of the His-fusion protein
- FIG. 1B shows the results of expression of the GST-fusion in E. coli .
- Purified His-fusion protein was used to immunise mice, whose sera were used for FACS analysis ( FIG. 1C ), a bactericidal assay ( FIG. 1D ), and ELISA (positive result). These experiments confirm that ORF40-1 is a surface-exposed protein, and that it is a useful immunogen.
- FIG. 1E shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF40-1.
- ORF38 and lipo show 38% aa identity in 96 aa overlap: Orf38: 40 EGASVTVKTARGDVQIPQNPERIAVYDLGMLDTLSKLGVKTGLS-VKDNRLPYLEEYFKT 98 EG S VK + G+ + P+NP ++ + DLG+LDT L + ++ V LP + FK Lipo: 51 EGDSFLVKDSLGENKTPKNPSKVVILDLGILDTFDALKLNDKVAGVPAKNLPKYLQQFKN 110 Orf38: 99 TKPAGTLFEPDYETLNAYKPQLIIIGSRAAKAFDKL 134 G + + D+E +NA KP LIII R +K +DKL Lipo: 111 KPSVGGVQQVDFEAINALKPDLIIISGRQSKFYDKL 146
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF38-1 (32 kDa) was cloned in pET and pGex vectors and expressed in E. coli , as described above. The products of protein expression and purification were analyzed by SDS-PAGE.
- FIG. 2A shows the results of affinity purification of the His-fusion protein
- FIG. 2B shows the results of expression of the GST-fusion in E. coli .
- Purified His-fusion protein was used to immunise mice, whose sera were used for Western blot analysis ( FIG. 2C ) and FACS analysis ( FIG. 2D ). These experiments confirm that ORF38-1 is a surface-exposed protein, and that it is a useful immunogen.
- FIG. 2E shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF38-1.
- N. meningitidis DNA sequence was identified ⁇ SEQ ID 13>: 1 ATGAAACTTC TGACCACCGC AATCCTGTCT TCCGCAATCG CGCTCAGCAG 51 TATGGCTGCC GCCGCTGGCA CGGACAACCC CACTGTTGCA AAAAAAACCG 101 TCAGCTACGT CTGCCAGCAA GGTAAAAAAG TCAAAGTAAC CTACGGCTTC 151 AACAAACAGG GTCTGACCAC ATACGCTTCC GCCGTCATCA ACGGCAAACG 201 CGTGCAAATG CCTGTCAATT TGGACAAATC CGACAATGTG GAAACATTCT 251 ACGGCAAAGA AGGCGGTTAT GTTTTGGGTA CCGGCGTGAT GGATGGCAAA 301 TCCTACCGCA AACAGCCCAT TATGATTACC GCACCTGACA ACCAAATCGT 351 CTTCAAAGAC TGTTCCCCAC GTTAA
- strain B sequence shows 99.2% identity over a 124 aa overlap with ORF44a: 10 20 30 40 50 60 orf44.
- ORF44 and LecA protein show 45% aa identity in 91 aa overlap: Orf44 33 TVSYVCQQGKKVKVTYGFNKQGLTTYASAVINGKRVQMPVNLDKSDNVETFYGKEGGYVL 92 +V+YVCQQG+++ V Y FN G+ T A +N + +++P NL SDNV+T + GY L LecA 135 SVAYVCQQGRRLNVNYRFNSAGVPTSAELRVNNRNLRLPYNLSASDNVDTVF-SANGYRL 193 Orf44 93 GTGVHDGKSYRKQPIHITAPDNQIVFKDCSP 123 T MD +YR Q I+++AP+ Q+++KDCSP LecA 194 TTNAMDSANYRSQDIIVSAPNGQNLYKDCSP 224
- this protein from N. meningitidis , and its epitopes, could be useful antigens for vaccines or diagnostics.
- ORF44-1 (11.2 kDa) was cloned in pET and pGex vectors and expressed in E. coli , as described above. The products of protein expression and purification were analyzed by SDS-PAGE. FIG. 3A shows the results of affinity purification of the His-fusion protein, and FIG. 3B shows the results of expression of the GST-fusion in E-coli. Purified His-fusion protein was used to immunise mice, whose sera were used for ELISA, which gave positive results, and for a bactericidal assay ( FIG. 3C ). These experiments confirm that ORF44-1 is a surface-exposed protein, and that it is a useful immunogen.
- FIG. 3D shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF44-1.
- ORF49 shows 86.1% identity over a 173 aa overlap with an ORF (ORF49a) from strain A of N. meningitidis : 10 20 30 orf49.pep GTEFKTTLSGADIQAGVGEKARADAKIILK
- orf49a SKNELNETKLPVRVVAQXAATRSGWDTVLEGTEFKTTLAGADIQAGVXEKARVDAKIILK 40 50 60 70 80 90 40 50 60 70 80 90 orf49.pep GIVNRIQTEEKLESNSTVWQKQAGSGSTVETLKLPSFEGPALPKLTAPGGYIADIPKGNL
- ORF49-1 and ORF49a show 83.2% identity in 457 aa overlap: orf49a.pep XQLLAEEGIHKHELDVQKSRRFIGIKVGXSNYSKNELNETKLPVRVVAQXAATRSGWDTV
- ORF49a nucleotide sequence ⁇ SEQ ID 21> is: 1 NTGCAACTGC TGGCAGAAGA AGGCATCCAC AAGCACGAGT TGGATGTCCA 51 AAAAAGCCGC CGCTTTATCG GCATCAAGGT AGGTNAGAGC AATTACAGTA 101 AAAACGAACT GAACGAAACC AAATTGCCTG TCCGCGTCGT CGCCCAAANT 151 GCAGCCACCC GTTCAGGCTG GGATACCGTG CTCGAAGGTA CCGAATTCAA 201 AACCACGCTG GCCGGTGCCG ACATTCAGGC AGGTGTANGC GAAAAAGCCC 251 GTGTCGATGC GAAAATTATC CTCAAAGGCA TTGTGAACCG TATCCAGTCG 301 GAAGAAAAAT TAGAAACCAA CTCAACCGTA TGGCAGAAAC AGGCCGGACG 351 CGGCAGCACT ATCGAAACGC TAAAACTGCC CAGCTTCGAA AGCCCTACTC 401 CGCCCAAATT GT
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF39 shows 100% identity over a 165 aa overlap with an ORF (ORF39a) from strain A of N. meningitidis : 10 20 30 orf39.
- orf39a AVLSFAEFSNRYSGKLILVASRASVLGSLAKFDFTWFIPAVIKYRRLFFEVLVVSVVLQL 110 120 130 140 150 160 40 50 60 70 80 90 orf39.
- ORF39-1 and ORF39a show 99.4% identity in 710 aa overlap: orf39-1.pep MSIVSAPLPALSALIILAHYHGIAANPADIQHEFCTSAQSDLNETQWLLAAKSLGLKAKV
- ORF39a nucleotide sequence ⁇ SEQ ID 29> is: 1 ATGTCTATCG TATCCGCACC GCTCCCCGCC CTTTCCGCCC TCATCATCCT 51 CGCCCATYAC CACGGCATTG CCGCCAATCC TGCCGATATA CAGCATGAAT 101 TTTGTACTTC CGCACAGAGC GATTTAAATG AAACGCAATG GCTGTTAGCC 151 GCCAAATCTT TGGGATTGAA GGCAAAGGTA GTCCGCCAGC CTATTAAACG 201 TTTGGCTATG GCGACTTTAC CCGCATTGGT ATGGTGTGAT GACGGCAACC 251 ATTTTATTTT GGCTAAAACA GACGGTGGGG GTGAGCATGC CCAATATCTA 301 ATACAGGATT TAACTACGAA TAAGTCTGCG GTATTGTCTT TTGCCGAATT 351 TTCTAACAGA TATTCGGGCA AACTGATATT GGTTGCTTCC CGCGCTTCGG 401 TATTGGGCAG TTCC
- ORF39a is homologous to a cytolysin from A. pleuropneumoniae : sp
- ORF39 and HlyB protein show 71% and 69% amino acid identity in 167 and 55 overlap at the N- and C-terminal regions, respectively: Orf39 1 KFDFTWFIPAVIKYRRXXXXXXXXXXXXXXXITPLFFQVVMDKVLVHRGFXXXXXXX 60 KFDFTWFIPAVIKYR+ ITPLFFQVVMDKVLVHRGF HlyB 137 KFDFTWFIPAVIKYRKIFIETLIVSIFLQIFALITPLFFQVVMDKVLVHRGFSTLNVITV 196 Orf39 61 XXXXXXXFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLSLPLSYFEHRRVGDTVARVR 120 FEI+LGGLRTY+FAH+TSRIDVELGARLFMLL+LP+SYFE RRVGDTVARVR HlyB 197 ALAIVVLFEIILGGLRTYVFAHSTSRIDVELGARLFR
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF52-1 (7 kDa) was cloned in the pGex vectors and expressed in E. coli , as described above. The products of protein expression and purification were analyzed by SDS-PAGE.
- FIG. 4A shows the results of affinity purification of the GST-fusion.
- FIG. 4B shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF52-1.
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF56 might be a membrane or periplasmic protein.
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF69 shows 96.2% identity over a 78 aa overlap with an ORF (ORF69a) from strain A of N. meningitidis : 10 20 30 40 50 60 orf69.pep VRTWLVFWLQRLKYP LLLWIADMLLYRLLGGA EIECGRCPVPPMTDWQHFLPA MGTVSAW
- the ORF69a nucleotide sequence ⁇ SEQ ID 43> is: 1 GTGCGGACGT GGTTGGTTTT TTGGTTGCAG CGTTTGAAAT ACCCGTTGTT 51 GCTTTGTATT GCGGATATGC TGCTGTACCG GTTGTTGGGC GGCGCGGAAA 101 TCGAATGCGG CCGTTGCCCT GTACCGCCGA TGACGGATTG GCAGCATTTT 151 TTGCCGACGA TGGGAACGGT GGCGGCTTGG GTGGCGGTGA TTTGGGCATA 201 CCTGATGATT GAAAGTGAAA AAAACGGAAG ATATTGA
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF77 shows 96.5% identity over a 173 aa overlap with an ORF (ORF77a) from strain A of N. meningitidis: 10 20 30 40 50 60 ort77.pep MFQNFDLGVFLLAVLPVLPSITVSHVARGYTARYWGDNTAEQYGR LTLNPLPHIDLVGTI
- ORF77-1 and ORF77a show 96.8% identity in 185 aa overlap: 10 20 30 40 50 60 orf77-1.pep MFQNFDLGVFLLAVLPVLLSITVREVARGYTARYWGDNTAEQYGRLTLNPLPHIDLVGTI
- a partial ORF77a nucleotide sequence ⁇ SEQ ID 49> was identified: 1 ..CGCGGCTATA CAGCGCTA CTGGGGTGAC AACACTGCCG AACAATACGG 51 CAGGCTGACA CTGAACCCCC TGCCCCATAT CGATTTGGTC GGCACAATCA 101 TCGTACCGCT GCTTACTTTG ATGTTTACGC CCTTCCTGTT CGGCTGGGCG 151 CGTCCGATTC CTATCGATTC GCGCAACTTC CGCAACCCGC GCCTTGCCTG 201 GCGTTGCGTT GCCGCGTCCG GCCCGCTGTC GAATCTGGCG ATGGCTGTTC 251 TGTGGGGCGT GGTTTTGGTG CTGACTCCGT ATGTCGGTGG GGCGTATCAG 301 ATGCCGTTGG CNCAAATGGC AAACTACNNN ATTCTGATCA ATGCGATTCT 351 GTNCGCGCTC AACATCATCC CCATCCTGCC TTGGGACGGC GGCATTTTCA
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF112 shows 96.4% identity over a 166 aa overlap with an ORF (ORF112a) from strain A of N. meningitidis : 10 20 30 40 50 60 orf112.pep MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMLGYTALKMPAR
- a partial ORF112a nucleotide sequence ⁇ SEQ ID 55> was identified: 1 ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT 51 TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT 101 ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAAATGNTG 151 GGNTACACCG CCCTCAAAAT GNCCGCCCGC GCCTACGAAC TGATGCCCCT 201 CGCCGTCCTT ATCGGCGGAC TGGTCTCTNT CAGCCAGCTT GCCGCCGGCA 251 GCGAACTGAN CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG 301 TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCT 351 CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAAAGCCGAA AACATCAAAG
- ORF112a and ORF112-1 show 96.3% identity in 326 aa overlap: orf112a.pep MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMXGYTALKMXAR
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF114 shows 91.9% identity over a 284 aa overlap with an ORF (ORF114a) from strain A of N. meningitidis : 10 20 30 40 orf114.pep AVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTTLKTLVC
- ORF114a nucleotide sequence ⁇ SEQ ID 61> is: 1 ATGAATAAAG GTTTACATCG CATTATCTTT AGTAAAAAGC ACAGCACCAT 51 GGTTGCAGTA GCCGAAACTG CCAACAGCCA GGGCAAAGGT AAACAGGCAG 101 GCAGTTCGGT TTCTGTTTCA CTGAAAACTT CAGGCGACCT TTGCGGCAAA 151 CTCAAAACCA CCCTTAAAAC CTTGGTCTGC TCTTTGGTTT CCCTGAGTAT 201 GGNATTNCNN NNCNNTNCCC AAATTACCAC CGACAAATCA GCACCTAAAA 251 ACCANCAGGT CGTTATCCTT AAAACCAACA CTGGTGCCCC CTTGGTGAAT 301 ATCCAAACTC CGAATGGACG CGGATTGAGC CACAACCGCT ATACGCAGTT 351 TGATGTTGAC AACAAAGGGG CAGTGTTAAA CAACGACCGT AACAATAATC 401 CGTTTC
- ORF114-1 and ORF114a show 89.8% identity in 1564 aa overlap orf114a.pep MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTTLKTLVC
- ORF114 and pspA protein show 36% aa identity in 302 aa overlap: Orf114: 1 AVAETANSQGKGKQAGSSVSVSL----KTSGDXXXXXXXXXXXXXXXXXPAHAQ 56 AVAE + GK Q + SV + S PA A pspA: 19 AVAENVHRDGKSMQDSEAASVRVTGAASVSSARAAFGFRMAAFSVMLALGVAAFSPAPAS 78 Orf114: 57 -ITTDKSAPKNQQVVILKTNTGAPLVNIQTPNGRGLSHNRXYAFDVDNKGAVLNNDRNN- 114 I DKSAPKNQQ VIL+T G P VNIQTP+ +G+S NR FDVD KG +LNN R+N pspA: 79 GIIADKSAPKNQQAVILQTANGLPQVNIQTPSSQGVSVNRFKQFDVDEKGVILNN
- ORF116 and pspA protein show 38% aa identity in 502 aa overlap: Orf116: 6 EAVGSNIGGGKMIVAAGQDINVRGXSLISDKGIVLKAGHDIDISTAHNRYTGNEYHESXX 65 +AV + G ++I+ +G+DI V G ++I+D +L A ++I + A R E ++ PspA: 1235 QAVSGTLDGKEIILVSGRDITVTGSNIIADNHTILSAKNNIVLKAAETRSRSAEMNKKEK 1294 Orf116: 66 XXXXXXXXXXXXXNRKXXXXXXRTNIVHTGSIIGSLNGDTVTVAGNRYRQTGSTVSSPE 125 ++K + HT S++GSLNG+T+ AG Y QTGST+SSP+ PspA: 1295 SGLMGSGGIGFTAGSKKDTQTNRSETVSHTESVVGSLNGNTLISAGKHYTQTGSTISSP
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF41 shows 92.8% identity over a 279 aa overlap with an ORF (ORF41a) from strain A of N. meningitidis: 10 20 30 40 50 60 69 orf41.pep YRRHLLCKYIYRFPIYCPXACVAEDTPYACYLXQLQVTKDVNWNQVXLAYDKWDYKQEGL 11 1111:1::11111 1111:11111111 orf41a YLKQLQVAXNINWNQVQLAYDRWDYKQEGL 10 20 30 70 80 90 100 110 120 129 orf41.pep TG AGAAIIALAVTVVTAGA GAGAALGLNGAAAAATDAAFASLASQASVSLINNKGNIGNT
- a partial ORF41a nucleotide sequence ⁇ SEQ ID 71> is: 1 TATCTGAAAC AGCTCCAAGT AGCGAAAAAC ATCAACTGGA ATCAGGTGCA 51 GCTTGCTTAC GACAGATGGG ACTACAAACA GGAGGGCTTA ACCGAAGCAG 101 GTGCGGCGAT TATCGCACTG GCCGTTACCG TGGTCACCTC AGGCAGGA 151 ACCGGAGCCG TATTGGGATT AAACGGTGCG NCCGCCGCCG CAACCGATGC 201 AGCATTCGCC TCTTTGGCCA GCCAGGCTTC CGTATCGTTC ATCAACAACA 251 AAGGCGATGT CGGCAAAACC CTGAAAGAGC TGGGCAGAAG CAGCACGGTG 301 AAAAATCTGG TGGTTGCCGC CGCTACCGCA GGCGTAGCCG ACAAAATCGG 351 CGCTTCGGCA CTGANCAATG TCAGCGATAA GCAGTGGATC AACAACCTGA 401
- ORF41a and ORF41-1 show 94.8% identity in 595 aa overlap: 10 20 30 orf41a.pep YLKQLQVAKNINWNQVQLAYDRWDYKQEGLTEAGAA
- orf41-1 MQVNIQIPYILPRCVRAEDTPYACYLKQLQVTKDVNWNQVQLAYDKWDYKQEGLTGAGAA 10 20 30 40 50 60 40 50 60 70 80 90 orf41a.pep IIALAVTVVTSGAGTGAVLGLNGAXAAATDAAFASLASQASVSFINNKGDVGKTLKELGR
- FIG. 6 shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF41-1.
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF51 shows 96.7% identity over a 150 aa overlap with an ORF (ORF51a) from strain A of N. meningitidis : 10 20 30 orf51.
- ORF51a an ORF from strain A of N. meningitidis : 10 20 30 orf51.
- pep MAII TLYYSVNGILNVCAKAKNIQVVANNK
- orf51a YKLLAIGSVVGSILGVK LLLILPVSWLLLLMAII TLYYSVNGILNVCAKAKNIQVVANNK 80 90 100 110 120 130 40 50 60 70 80 90 orf51.
- ORF51-1 and ORF51a show 99.2% identity in 255 aa overlap: orf51a.pep MQEIMQSIVFVAAAILHGITGMGFPMLGTTALAFIMPLSKVVALVALPSLLMSLLVLCSN
- ORF51a nucleotide sequence SEQ D 77> is: 1 ATGCAAGAAA TAATGCAATC TATCGTTTTT GTTGCTGCCG CAATACTGCA 51 CGGAATTACA GGCATGGGAT TTCCGATGCT CGGTACAACC GCATTGGCTT 101 TTATCATGCC ATTGTCTAAG GTTGTTGCCT TGGTGGCATT ACCAAGCCTG 151 TTAATGAGCT TGTTGGTTCT ATGCAGCAAT AACAAAAAGG GTTTTTGGCA 201 AGAGATTGTT TATTATTTAA AAACCTATAA ATTGCTTGCT ATCGGCAGCG 251 TCGTTGGCAG CATTTTGGGG GTGAAGTTGC TTTTGATACT TCCAGTGTCT 301 TGGCTGCTTT TACTGATGGC AATCATTACA TTGTATTATT CTGTCAATGG 351 TATTTTAAAT GTATGTGCAA AAAAAA TATTCAAGTA GTTGCCAATA 401 ATAAGAATA
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF82 shows 97.1% identity over a 172 aa overlap with an ORF (ORF82a) from strain A of N. meningitidis : 10 20 30 40 50 60 orf82 pep MRHMKIQNYLLVFIVLHIALIVINIVFGYFVFLFDFFAFLFFANVFLA VNLLFLEKNIKN
- ORF82a and ORF82-1 show 99.2% identity in 242 aa overlap: orf82a.pep MRHMKNKNYLLVFIVLHITLIVINIVFGYGVFLFDFFAFLFFANVFLAVNLLFLEKNIKN
- ORF82a nucleotide sequence ⁇ SEQ D 83> is: 1 ATGAGACATA TGAAAAATAA AAATTATTTA CTAGTATTTA TAGTTTTACA 51 TATAACCTTG ATAGTAATTA ATATAGTGTT TGGTTATTTT GTTTTTCTAT 101 TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTTCT TGCTGTAAAT 151 TTATTATTTT TAGAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC 201 GATTTCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA 251 AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT 301 ACTGGGGTGA TAAAACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA 351 TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAGG GTAATTACAG 401 AAACACCTTA TATTGATGTA
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- ORF124 shows 87.5% identity over a 152 aa overlap with an ORF (ORF124a) from strain A of N. meningitidis : 10 20 30 40 50 60 orf124.pep TPNSVTVLPSFGGFGRTGATINAAGGVGMTAFSTTLISVAEGAVVELQAVRAKAVNATAA
- orf124a MTAFSTTLISVAEGALVELQAVMAKAVNTTAA 10 20 30 70 80 90 100 110 120 orf124.pep CIFTVLSKDIFDFLFIFRFQTADFRLYFRQSHADSVRLDFIFKSFRACQFQFARIVLSRQ
- ORF124a and ORF124-1 show 89.5% identity in 152 aa overlap: orf124-1.pep MTAFSTTLISVAEGAVVELQAVRAKAVNATAACIFTVLSKDIFDFLFIFRFQTADFRLFF
- ORF124a nucleotide sequence ⁇ SEQ ID 89> is: 1 ATGACCGCCT TTTCGACAAC CTTAATTTCC GTAGCCGAGG GCGCTTGT 51 AGAGCTGCAA GCCGTGATGG CCAAAGCCGT CAATACAACC GCCGCCTGCA 101 TTTTTACGGT CTTGAGTAAG GACATTTTCG ATTTCCTTTT TATTTTCCGT 151 TTTCAGACGG CTGACTTCCG CCTGTTTTTT CGCCAAAGCC ATGCCGACGG 201 CGTGCGCCTT GACTTCATAT TTTTTAGCTT CCGCACGC CTGTTCCAGT 251 TCGCGGGCGT AGTTTTGAGC CGACAACAGC AGGGCTTGCG CCTTGTCGCG 301 CTTCATTTTC TCAATGACCG CCTGCTGCTT CGCAAAAGCC GACTTGTAGC 351 CTTGATGGTG CGACACCGCC AAACCCGTGC CGACAAGCGC GATGATGGCA 401
- ORF124-1 was amplified as described above.
- FIG. 7 shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF124-1.
- this protein from N. meningitidis could be useful antigens for vaccines or diagnostics.
- Table III lists several Neisseria strains which were used to assess the conservation of the sequence of ORF 40 among different strains. TABLE III List of Neisseria Strains Used for Gene Variability Study of ORF 40 Identification number Strains Source/reference Group B zn02_1 BZ198 R. Moxon/Seiler et al., 1996 zn03_1 NG3/88 R. Moxon/Seiler et al., 1996 zn04_1 297-0 R. Moxon/Seiler et al., 1996 zn06_1 BZ147 R. Moxon/Seiler et al., 1996 zn07_1 BZ169 R.
- amino acid sequences for each listed strain are as follows: >Z2491 ⁇ SEQ ID 91> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNVSPSKADEM
- FIG. 8 shows the results of aligning the sequences of each of these strains. Dark shading indicates regions of homology, and gray shading indicates the conservation of amino acids with similar characteristics. As is readily discernible, there is significant conservation among the various strains of ORF 40, further confirming its utility as an antigen for both vaccines and diagnostics.
- An isolated polypeptide comprising 1. An isolated polypeptide comprising a a member selected from the group consisting of member selected from the group consisting of (a) the amino acid sequence of SEQ ID (a) the amino acid sequence of SEQ ID NO: 4; and NO: 2; (b) an immunogenic fragment of at (b) an immunogenic fragment of at least least 15 contiguous amino acids of SEQ ID 15 contiguous amino acids of SEQ ID NO: 2; NO: 4, wherein the immunogenic fragment, wherein the immunogenic fragment, when when administered to a subject in a suitable administered to a subject in a suitable composition which can include an adjuvant, or composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, a suitable carrier coupled to the polypeptide, induces an antibody or T-cell meditated induces an antibody or T
Abstract
Description
- This application is a continuation-in-part of international patent application PCT/IB99/00103, filed Jan. 14, 1999, from which priority is claimed under 35 U.S.C. § 119.
- This invention relates to antigens from the bacterium Neisseria meningitidis.
- Neisseria meningitidis is a non-motile, gram negative diplococcus human pathogen. It colonises the pharynx, causing meningitis and, occasionally, septicaemia in the absence of meningitis. It is closely related to N. gonorrhoeae, although one feature that clearly differentiates meningococcus from gonococcus is the presence of a polysaccharide capsule that is present in all pathogenic meningococci.
- N. meningitidis causes both endemic and epidemic disease. In the United States the attack rate is 0.6-1 per 100,000 persons per year, and it can be much greater during outbreaks (see Lieberman el al. (1996) Safety and Immunogenicity of a Serogroups A/C Neisseria meningitidis Oligosaccharide-Protein Conjugate Vaccine in Young Children. JAMA 275(19):1499-1503; Schuchat et al (1997) Bacterial Meningitis in the United States in 1995. N Engl J Med 337(14):970-976). In developing countries, endemic disease rates are much higher and during epidemics incidence rates can reach 500 cases per 100,000 persons per year. Mortality is extremely high, at 10-20% in the United States, and much higher in developing countries. Following the introduction of the conjugate vaccine against Haemophilus influenzae, N. meningitidis is the major cause of bacterial meningitis at all ages in the United States (Schuchat et al (1997) supra).
- Based on the organism's capsular polysaccharide, 12 serogroups of N. meningitidis have been identified. Group A is the pathogen most often implicated in epidemic disease in sub-Saharan Africa. Serogroups B and C are responsible for the vast majority of cases in the United States and in most developed countries. Serogroups W135 and Y are responsible for the rest of the cases in the United States and developed countries. The meningococcal vaccine currently in use is a tetravalent polysaccharide vaccine composed of serogroups A, C, Y and W135. Although efficacious in adolescents and adults, it induces a poor immune response and short duration of protection, and cannot be used in infants [eg. Morbidity and Mortality weekly report, Vol. 46, No. RR-5 (1997)]. This is because polysaccharides are T-cell independent antigens that induce a weak immune response that cannot be boosted by repeated immunization. Following the success of the vaccination against H. influenzae, conjugate vaccines against serogroups A and C have been developed and are at the final stage of clinical testing (Zollinger W D “New and Improved Vaccines Against Meningococcal Disease” in: New Generation Vaccines, supra, pp. 469-488; Lieberman et al (1996) supra; Costantino et al (1992) Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10:691-698).
- Meningococcus B remains a problem, however. This serotype currently is responsible for approximately 50% of total meningitis in the United States, Europe, and South America. The polysaccharide approach cannot be used because the menB capsular polysaccharide is a polymer of α(2-8)-linked N-acetyl neuraminic acid that is also present in mammalian tissue. This results in tolerance to the antigen; indeed, if an immune response were elicited, it would be anti-self, and therefore undesirable. In order to avoid induction of autoimmunity and to induce a protective immune response, the capsular polysaccharide has, for instance, been chemically modified substituting the N-acetyl groups with N-propionyl groups, leaving the specific antigenicity unaltered (Romero & Outschoorn (1994) Current status of Meningococcal group B vaccine candidates: capsular or non-capsular? Clin Microbiol Rev 7(4):559-575).
- Alternative approaches to menB vaccines have used complex mixtures of outer membrane proteins (OMPs), containing either the OMPs alone, or OMPs enriched in porins, or deleted of the class 4 OMPs that are believed to induce antibodies that block bactericidal activity. This approach produces vaccines that are not well characterized. They are able to protect against the homologous strain, but are not effective at large where there are many antigenic variants of the outer membrane proteins. To overcome the antigenic variability, multivalent vaccines containing up to nine different porins have been constructed (eg. Poolman J T (1992) Development of a meningococcal vaccine. Infect. Agents Dis. 4:13-28). Additional proteins to be used in outer membrane vaccines have been the opa and opc proteins, but none of these approaches have been able to overcome the antigenic variability (eg. Ala'Aldeen & Borriello (1996) The meningococcal transferrin-binding
proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine 14(1):49-53). - A certain amount of sequence data is available for meningococcal and gonococcal genes and proteins (eg. EP-A-0467714, WO96/29412), but this is by no means complete. The provision of further sequences could provide an opportunity to identify secreted or surface-exposed proteins that are presumed targets for the immune system and which are not antigenically variable. For instance, some of the identified proteins could be components of efficacious vaccines against meningococcus B, some could be components of vaccines against all meningococcal serotypes, and others could be components of vaccines against all pathogenic Neisseriae.
- The Invention
- The invention provides proteins comprising the N. meningitidis amino acid sequences disclosed in the examples.
- It also provides proteins comprising sequences homologous (ie. having sequence identity) to the N. meningitidis amino acid sequences disclosed in the examples. Depending on the particular sequence, the degree of sequence identity is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more). These homologous proteins include mutants and allelic variants of the sequences disclosed in the examples. Typically, 50% identity or more between two proteins is considered to be an indication of functional equivalence. Identity between the proteins is preferably determined by the Smith-Waterman homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters gap open penalty=12 and gap extension penalty=1.
- The invention further provides proteins comprising fragments of the N. meningitidis amino acid sequences disclosed in the examples. The fragments should comprise at least n consecutive amino acids from the sequences and, depending on the particular sequence, n is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20 or more). Preferably the fragments comprise an epitope from the sequence.
- The proteins of the invention can, of course, be prepared by various means (eg. recombinant expression, purification from cell culture, chemical synthesis etc.) and in various forms (eg. native, fusions etc.). They are preferably prepared in substantially pure form (ie. substantially free from other N. meningitidis or host cell proteins).
- According to a further aspect, the invention provides antibodies which bind to these proteins. These may be polyclonal or monoclonal and may be produced by any suitable means.
- According to a further aspect, the invention provides nucleic acid comprising the N. meningitidis nucleotide sequences disclosed in the examples. In addition, the invention provides nucleic acid comprising sequences homologous (ie. having sequence identity) to the N. meningitidis nucleotide sequences disclosed in the examples.
- Furthermore, the invention provides nucleic acid which can hybridise to the N. meningitidis nucleic acid disclosed in the examples, preferably under “high stringency” conditions (eg. 65° C. in a 0.1×SSC, 0.5% SDS solution).
- Nucleic acid comprising fragments of these sequences are also provided. These should comprise at least n consecutive nucleotides from the N. meningitidis sequences and, depending on the particular sequence, n is 10 or more (
eg - According to a further aspect, the invention provides nucleic acid encoding the proteins and protein fragments of the invention.
- It should also be appreciated that the invention provides nucleic acid comprising sequences complementary to those described above (eg. for antisense or probing purposes).
- Nucleic acid according to the invention can, of course, be prepared in many ways (eg. by chemical synthesis, from genomic or cDNA libraries, from the organism itself etc.) and can take various forms (eg. single stranded, double stranded, vectors, probes etc.).
- In addition, the term “nucleic acid” includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) etc.
- According to a further aspect, the invention provides vectors comprising nucleotide sequences of the invention (eg. expression vectors) and host cells transformed with such vectors.
- According to a further aspect, the invention provides compositions comprising protein, antibody, and/or nucleic acid according to the invention. These compositions may be suitable as vaccines, for instance, or as diagnostic reagents, or as immunogenic compositions.
- The invention also provides nucleic acid, protein, or antibody according to the invention for use as medicaments (eg. as vaccines) or as diagnostic reagents. It also provides the use of nucleic acid, protein, or antibody according to the invention in the manufacture of: (i) a medicament for treating or preventing infection due to Neisserial bacteria; (ii) a diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisserial bacteria; and/or (iii) a reagent which can raise antibodies against Neisserial bacteria Said Neisserial bacteria may be any species or strain (such as N. gonorrhoeae) but are preferably N. meningitidis, especially strain A, strain B or strain C.
- The invention also provides a method of treating a patient, comprising administering to the patient a therapeutically effective amount of nucleic acid, protein, and/or antibody according to the invention.
- According to further aspects, the invention provides various processes.
- A process for producing proteins of the invention is provided, comprising the step of culturing a host cell according to the invention under conditions which induce protein expression.
- A process for producing protein or nucleic acid of the invention is provided, wherein the protein or nucleic acid is synthesised in part or in whole using chemical means.
- A process for detecting polynucleotides of the invention is provided, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting said duplexes.
- A process for detecting proteins of the invention is provided, comprising the steps of: (a) contacting an antibody according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.
- Unlike the sequences disclosed in PCT/IB98/01665, the sequences disclosed in the present application are believed not to have any significant homologs in N. gonorrhoeae. Accordingly, the sequences of the present invention also find use in the preparation of reagents for distinguishing between N. meningitidis and N. gonorrhoeae.
- A summary of standard techniques and procedures which may be employed in order to perform the invention (eg. to utilise the disclosed sequences for vaccination or diagnostic purposes) follows. This summary is not a limitation on the invention but, rather, gives examples that may be used, but are not required.
- General
- The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature eg. Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and ii (D. N Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed, 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription and Translation (B. D. Hames & S. J. Higgins eds. 1984); Animal Cell Culture (R. I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J. H. Miller and M. P. Calos eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds. (1987), Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer-Verlag, N.Y.), and Handbook of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell eds 1986).
- Standard abbreviations for nucleotides and amino acids are used in this specification.
- All publications, patents, and patent applications cited herein are incorporated in full by reference. In particular, the contents of UK patent applications 9800760.2, 9819015.0 and 9822143.5 are incorporated herein.
- Definitions
- A composition containing X is “substantially free of” Y when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95% or even 99% by weight.
- The term “comprising” means “including” as well as “consisting” eg. a composition “comprising” X may consist exclusively of X or may include something additional to X, such as X+Y.
- A “conserved” Neisseria amino acid fragment or protein is one that is present in a particular Neisserial protein in at least x % of Neisseria. The value of x may be 50% or more, e.g., 66%, 75%, 80%, 90%, 95% or even 100% (i.e. the amino acid is found in the protein in question in all Neisseria). In order to determine whether an animo acid is “conserved” in a particular Neisserial protein, it is necessary to compare that amino acid residue in the sequences of the protein in question from a plurality of different Neisseria (a reference population). The reference population may include a number of different Neisseria species or may include a single species. The reference population may include a number of different serogroups of a particular species or a single serogroup. A preferred reference population consists of the 5 most common Neisseria.
- The term “heterologous” refers to two biological components that are not found together in nature. The components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a gene is operably linked to the gene. Another example is where a Neisserial sequence is heterologous to a mouse host cell. A further examples would be two epitopes from the same or different proteins which have been assembled in a single protein in an arrangement not found in nature.
- An “origin of replication” is a polynucleotide sequence that initiates and regulates replication of polynucleotides, such as an expression vector. The origin of replication behaves as an autonomous unit of polynucleotide replication within a cell, capable of replication under its own control. An origin of replication may be needed for a vector to replicate in a particular host cell. With certain origins of replication, an expression vector can be reproduced at a high copy number in the presence of the appropriate proteins within the cell. Examples of origins are the autonomously replicating sequences, which are effective in yeast; and the viral T-antigen, effective in COS-7 cells.
- A “mutant” sequence is defined as DNA, RNA or amino acid sequence differing from but having sequence identity with the native or disclosed sequence. Depending on the particular sequence, the degree of sequence identity between the native or disclosed sequence and the mutant sequence is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more, calculated using the Smith-Waterman algorithm as described above). As used herein, an “allelic variant” of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a nucleic acid molecule, or region, that occurs essentially at the same locus in the genome of another or second isolate, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence. A coding region allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared. An allelic variant can also comprise an alteration in the 5′ or 3′ untranslated regions of the gene, such as in regulatory control regions (eg. see U.S. Pat. No. 5,753,235).
- Expression Systems
- The Neisserial nucleotide sequences can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, plants, bacteria, and yeast.
- i. Mammalian Systems
- Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3′) transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5′ end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) “Expression of Cloned Genes in Mammalian Cells.” In Molecular Cloning: A Laboratory Manual, 2nd ed.]
- Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallotheionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.
- The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of the Cell, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al (1985) EMBO J. 4:761] and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) Proc. Natl. Acad. Sci. 79:6777] and from human cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237].
- A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.
- Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus triparite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.
- Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3′ to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3′ terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) “Termination and 3′ end processing of eukaryotic RNA. In Transcription and splicing (ed. B. D. Hames and D. M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105]. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminater/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) “Expression of cloned genes in cultured mammalian cells.” In Molecular Cloning: A Laboratory Manual].
- Usually, the above described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers; introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 [Gluzman (1981) Cell 23:175] or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replicaton systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a prokaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) Mol. Cell. Biol. 9:946] and pHEBO [Shimizu et al. (1986) Mol. Cell. Biol. 6:1074].
- The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
- Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (eg. Hep G2), and a number of other cell lines.
- ii. Baculovirus Systems
- The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.
- After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant-virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego Calif. (“MaxBac” kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter “Summers and Smith”).
- Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.
- Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.
- The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a prokaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in E. coli.
- Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5′ to 3) transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5′ end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.
- Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) “The Regulation of Baculovirus Gene Expression,” in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlak et al., (1988), J. Gen. Virol. 69:765.
- DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human α-interferon, Maeda et al., (1985), Nature 315:592; human gastrin-releasing peptide, Lebacq-Verheyden et al., (1988), Molec. Cell. Biol. 8:3129; human IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404; mouse IL-3, (Miyajima et al., (1987) Gene 58:273; and human glucocerebrosidase, Martin et al. (1988) DNA, 7:99, can also be used to provide for secretion in insects.
- A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by in vitro incubation with cyanogen bromide.
- Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.
- After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus—usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5 kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art (See Summers and Smith supra; Ju et al. (1987); Smith et al., Mol. Cell. Biol. (1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), Bioessays 4:91 The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5′ and 3′ by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.
- The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15 μm in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. “Current Protocols in Microbiology” Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, supra; Miller et al. (1989).
- Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, inter alia: Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni (WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al., (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225).
- Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, eg. Summers and Smith supra.
- The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, eg. HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, eg. proteins, lipids and polysaccharides.
- In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.
- iii. Plant Systems
- There are many plant cell culture and whole plant genetic expression systems known in the art. Exemplary plant cellular genetic expression systems include those described in patents, such as: U.S. Pat. No. 5,693,506; U.S. Pat. No. 5,659,122; and U.S. Pat. No. 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, Phytochemistry 30:3861-3863 (1991). Descriptions of plant protein signal peptides may be found in addition to the references described above in Vaulcombe et al., Mol. Gen. Genet. 209:33-40 (1987); Chandler et al., Plant Molecular Biology 3:407-418 (1984); Rogers, J. Biol. Chem. 260:3731-3738 (1985); Rothstein et al., Gene 55:353-356 (1987); Whittier et al., Nucleic Acids Research 15:2515-2535 (1987); Wirsel et al., Molecular Microbiology 3:3-14 (1989); Yu et al., Gene 122:247-253 (1992). A description of the regulation of plant gene expression by the phytohormone, gibberellic acid and secreted enzymes induced by gibberellic acid can be found in R. L. Jones and J. MacMillin, Gibberellins: in: Advanced Plant Physiology, Malcolm B. Wilkins, ed., 1984 Pitman Publishing Limited, London, pp. 21-52. References that describe other metabolically-regulated genes: Sheen, Plant Cell, 2:1027-1038 (1990); Maas et al., EMBO J. 9:3447-3452 (1990); Benkel and Hickey, Proc. Natl. Acad. Sci 84:1337-1339 (1987)
- Typically, using techniques known in the art, a desired polynucleotide sequence is inserted into an expression cassette comprising genetic regulatory elements designed for operation in plants. The expression cassette is inserted into a desired expression vector with companion sequences upstream and downstream from the expression cassette suitable for expression in a plant host. The companion sequences will be of plasmid or viral origin and provide necessary characteristics to the vector to permit the vectors to move DNA from an original cloning host, such as bacteria, to the desired plant host. The basic bacterial/plant vector construct will preferably provide a broad host range prokaryote replication origin; a prokaryote selectable marker, and, for Agrobacterium transformations, T DNA sequences for Agrobacterium-mediated transfer to plant chromosomes. Where the heterologous gene is not readily amenable to detection, the construct will preferably also have a selectable marker gene suitable for determining if a plant cell has been transformed. A general review of suitable markers, for example for the members of the grass family, is found in Wilmink and Dons, 1993, Plant Mol. Biol. Reptr, 11(2):165-185.
- Sequences suitable for permitting integration of the heterologous sequence into the plant genome are also recommended. These might include transposon sequences and the like for homologous recombination as well as Ti sequences which permit random insertion of a heterologous expression cassette into a plant genome. Suitable prokaryote selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions may also be present in the vector, as is known in the art.
- The nucleic acid molecules of the subject invention may be included into an expression cassette for expression of the protein(s) of interest. Usually, there will be only one expression cassette, although two or more are feasible. The recombinant expression cassette will contain in addition to the heterologous protein encoding sequence the following elements, a promoter region,
plant 5′ untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and a transcription and translation termination sequence. Unique restriction enzyme sites at the 5′ and 3′ ends of the cassette allow for easy insertion into a pre-existing vector. - A heterologous coding sequence may be for any protein relating to the present invention. The sequence encoding the protein of interest will encode a signal peptide which allows processing and translocation of the protein, as appropriate, and will usually lack any sequence which might result in the binding of the desired protein of the invention to a membrane. Since, for the most part, the transcriptional initiation region will be for a gene which is expressed and translocated during germination, by employing the signal peptide which provides for translocation, one may also provide for translocation of the protein of interest. In this way, the protein(s) of interest will be translocated from the cells in which they are expressed and may be efficiently harvested. Typically secretion in seeds are across the aleurone or scutellar epithelium layer into the endosperm of the seed. While it is not required that the protein be secreted from the cells in which the protein is produced, this facilitates the isolation and purification of the recombinant protein.
- Since the ultimate expression of the desired gene product will be in a eucaryotic cell it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's splicosome machinery. If so, site-directed mutagenesis of the “intron” region may be conducted to prevent losing a portion of the genetic message as a false intron code, Reed and Maniatis, Cell 41:95-105, 1985.
- The vector can be microinjected directly into plant cells by use of micropipettes to mechanically transfer the recombinant DNA. Crossway, Mol. Gen. Genet, 202:179-185, 1985. The genetic material may also be transferred into the plant cell by using polyethylene glycol, Krens, et al., Nature, 296, 72-74, 1982. Another method of introduction of nucleic acid segments is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface, Klein, et al., Nature, 327, 70-73, 1987 and Knudsen and Muller, 1991, Planta, 185:330-336 teaching particle bombardment of barley endosperm to create transgenic barley. Yet another method of introduction would be fusion of protoplasts with other entities, either minicells, cells, lysosomes or other fusible lipid-surfaced bodies, Fraley, et al., Proc. Natl. Acad. Sci. USA, 79, 1859-1863, 1982.
- The vector may also be introduced into the plant cells by electroporation. (Fromm et al., Proc. Natl Acad. Sci. USA 82:5824, 1985). In this technique, plant protoplasts are electroporated in the presence of plasmids containing the gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form plant callus.
- All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred gene. It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugarcane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Some suitable plants include, for example, species from the genera Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Lycopersion, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Cichorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Hererocallis, Nemesia, Pelargonium, Panicum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Lolium, Zea, Triticum, Sorghum, and Datura.
- Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced from the protoplast suspension. These embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.
- In some plant cell culture systems, the desired protein of the invention may be excreted or alternatively, the protein may be extracted from the whole plant. Where the desired protein of the invention is secreted into the medium, it may be collected. Alternatively, the embryos and embryoless-half seeds or other plant tissue may be mechanically disrupted to release any secreted protein between cells and tissues. The mixture may be suspended in a buffer solution to retrieve soluble proteins. Conventional protein isolation and purification methods will be then used to purify the recombinant protein. Parameters of time, temperature pH, oxygen, and volumes will be adjusted through routine methods to optimize expression and recovery of heterologous protein.
- iv. Bacterial Systems
- Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3′) transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5′ end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5′) to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli (E. coli) [Raibaud et al. (1984) Annu. Rev. Genet. 18:173]. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.
- Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) [Chang et al. (1977) Nature 198:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp) [Goeddel et al. (1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. Pat. No. 4,738,921; EP-A-0036776 and EP-A-0121775]. The g-laotamase (bla) promoter system [Weissmann (1981) “The cloning of interferon and other mistates.” In Interferon 3 (ed I. Gresser)], bacteriophage lambda PL [Shimatake et al. (1981) Nature 292:128] and T5 [U.S. Pat. No. 4,689,406] promoter systems also provide useful promoter sequences.
- In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [U.S. Pat. No. 4,551,433]. For example, the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repressor [Amann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074]. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (EPO-A-0 267 851).
- In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In E. coli, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine et al. (1975) Nature 254:34). The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3′ and of E. coli 16S rRNA [Steitz et al. (1979) “Genetic signals and nucleotide sequences in messenger RNA.” In Biological Regulation and Development: Gene Expression (ed. R. F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site [Sambrook et al. (1989) “Expression of cloned genes in Escherichia coli.” In Molecular Cloning: A Laboratory Manual].
- A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo on in vitro incubation with a bacterial methionine N-terminal peptidase (EPO-A-0 219 237).
- Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5′ end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5′ terminus of a foreign gene and expressed in bacteria The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins can also be made with sequences from the lacZ [Jia et al. (1987) Gene 60:197], trpE (Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11], and Chey [EP-A-0 324 647] genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (eg. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated [Miller et al. (1989) Bio/Technology 7:698].
- Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [U.S. Pat. No. 4,336,336]. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.
- DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (ompA) [Masui et al. (1983), in: Experimental Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J. 3:2437] and the E. coli alkaline phosphatase signal sequence (phoA) [Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212]. As an additional example, the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from B. subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EP-A-0 244 042].
- Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3′ to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the trip gene in E. coli as well as other biosynthetic genes.
- Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as bacteria The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.
- Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EP-A-0 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.
- Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies et al. (1978) Annu. Rev. Microbiol. 32:469]. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.
- Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.
- Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria For example, expression vectors have been developed for, inter alia, the following bacteria: Bacillus subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541], Escherichia coli [Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol. 189:113; EP-A-0 036 776, EP-A-0 136 829 and EP-A-0 136 907], Streptococcus cremoris [Powell et al. (1988) Appl. Environ. Microbiol. 54:655]; Streptococcus lividans [Powell et al. (1988) Appl. Environ. Microbiol. 54:655], Streptomyces lividans [U.S. Pat. No. 4,745,056].
- Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl2 or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See eg. [Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci USA 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541, Bacillus], [Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, Campylobacter], [Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res. 16:6127; Kushner (1978) “An improved method for transformation of Escherichia coli with ColE1-derived plasmids. In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H. W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159; Taketo (1988) Biochim Biophys. Acta 949:318; Escherichia], [Chassy et al. (1987) FEMS Microbiol. Lett. 44:173 Lactobacillus]; [Fiedler et al. (1988) Anal. Biochem 170:38, Pseudomonas]; [Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, Staphylococcus], [Barany et al. (1980) J. Bacteriol. 144:698; Harlander (1987) “Transformation of Streptococcus lactis by electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981) Infect Immun. 32:1295; Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Evr. Cong. Biotechnology 1:412, Streptococcus].
- v. Yeast Expression
- Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3′) transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5′ end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the “TATA Box”) and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.
- Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EP-A-0 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO-A-0 329 203). The yeast PHO5 gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].
- In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Pat. Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EP-A-0 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) “The Expression of Bacterial Antibiotic Resistance Genes in the Yeast Saccharomyces cerevisiae,” in: Plasmids of Medical, Environmental and Commercial Importance (eds. K. N. Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109;].
- A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.
- Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5′ end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5′ terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See eg. EP-A-0 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (eg. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (eg. WO88/024066).
- Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.
- DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EP-A-0 012 873; JPO. 62,096,086) and the A-factor gene (U.S. Pat. No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EP-A-0 060 057).
- A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a “pre” signal sequence, and a “pro” region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Pat. Nos. 4,546,083 and 4,870,008; EP-A-0 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (eg. see WO 89/02463.)
- Usually, transcription termination sequences recognized by yeast are regulatory regions located 3′ to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.
- Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein et al. (1979) Gene 8:17-24], pCl/1 [Brake et al. (1984) Proc. Natl. Acad. Sci USA 81:4642-4646], and YRp17 [Stinchcomb et al. (1982) J. Mol. Biol. 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See eg. Brake et al., supra.
- Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver et al. (1983) Methods in Enzymol. 101:228-245]. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver et al., supra. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.
- Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions [Butt et al. (1987) Microbiol, Rev. 51:351].
- Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.
- Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: Candida albicans [Kurtz, et al. (1986) Mol. Cell. Biol. 6:142], Candida maltosa [Kunze, et al. (1985) J. Basic Microbiol. 25:141]. Hansenula polymorpha [Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302], Kluyveromyces fragilis [Das, et al. (1984) J. Bacteriol. 158:1165], Kluyveromyces lactis [De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology 8:135], Pichia guillerimondii [Kunze et al. (1985) J. Basic Microbiol. 25:141], Pichia pastoris [Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; U.S. Pat. Nos. 4,837,148 and 4,929,555], Saccharomyces cerevisiae [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163], Schizosaccharomyces pombe [Beach and Nurse (1981) Nature 300:706], and Yarrowia lipolytica [Davidow, et al. (1985) Curr. Genet. 10:380471 Gaillardin, et al (1985) Curr. Genet. 10:49].
- Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See eg. [Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141; Candida]; [Gleeson et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; Hansenula]; [Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et al. (1990) Bio/Technology 8:135; Kluyveromyces]; [Cregg et al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic Microbiol. 25:141; U.S. Pat. Nos. 4,837,148 and 4,929,555; Pichia]; [Hinnen et al. (1978) Proc. Natl.
Acad. Sci. USA 75;1929; Ito et al. (1983) J. Bacteriol. 153:163 Saccharomyces]; [Beach and Nurse (1981) Nature 300:706; Schizosaccharomyces]; [Davidow et al. (1985) Curr. Genet. 10:39; Gaillardin et al. (1985) Curr. Genet. 10:49; Yarrowia]. - Antibodies
- As used herein, the term “antibody” refers to a polypeptide or group of polypeptides composed of at least one antibody combining site. An “antibody combining site” is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen. “Antibody” includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, altered antibodies, univalent antibodies, Fab proteins, and single domain antibodies. Antibodies against the proteins of the invention are useful for affinity chromatography, immunoassays, and distinguishing/identifying Neisserial proteins.
- Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods. In general, the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies. Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 μg/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using Freund's incomplete adjuvant. One may alternatively generate antibodies by in vitro immunization using methods known in the adt, which for the purposes of this invention is considered equivalent to in vivo immunization. Polyclonal antisera is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25° C. for one hour, followed by incubating at 4° C. for 2-18 hours. The serum is recovered by centrifugation (eg. 1,000 g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.
- Monoclonal antibodies are prepared using the standard method of Kohler & Milstein [Nature (1975) 256:495-96], or a modification thereof. Typically, a mouse or rat is immunized as described above. However, rather than bleeding the animal to extract serum, the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen. B-cells expressing membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated spleen cells, are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (eg. hypoxanthine, aminopterin, thymidine medium, “HAT”). The resulting hybridomas are plated by limiting dilution, and are assayed for the production of antibodies which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens). The selected MAb-secreting hybridomas are then cultured either in vitro (eg. in tissue culture bottles or hollow fiber reactors), or in vivo (as ascites in mice).
- If desired, the antibodies (whether polyclonal or monoclonal) may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly 32P and 125I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3′,5,5′-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. “Specific binding partner” refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example, 125I may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with 125I, or with an anti-biotin MAb labeled with HRP. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.
- Pharmaceutical Compositions
- Pharmaceutical compositions can comprise either polypeptides, antibodies, or nucleic acid of the invention. The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.
- The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of the clinician.
- For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.
- A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.
- Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).
- Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.
- Delivery Methods
- Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.
- Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- Vaccines
- Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection).
- Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with “pharmaceutically acceptable carriers,” which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents (“adjuvants”). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, etc. pathogens.
- Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59™ (WO 90/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (Detox™); (3) saponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, Mass.) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (eg. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59™ are preferred.
- As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-
L -alanyl-D -isoglutamine (nor-MDP), N-acetylmuramyl-L -alanyl-D -isoglutaminyl-L -alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamine (MTP-PE), etc. - The immunogenic compositions (eg. the immunising antigen/immunogen/polypeptide/protein/nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.
- Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.
- Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By “immunologically effective amount”, it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (eg. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctors assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
- The immunogenic compositions are conventionally administered parenterally, eg. by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously (eg. WO98/20734). Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.
- As an alternative to protein-based vaccines, DNA vaccination may be employed [eg. Robinson & Torres (1997) Seminars in Immunology 9:271-283; Donnelly et al. (1997) Annu Rev Immunol 15:617-648; see later herein].
- Gene Delivery Vehicles
- Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention, to be delivered to the mammal for expression in the mammal, can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in in vivo or ex vivo modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constitutive or regulated.
- The invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picomavirus, poxvirus, or togavirus viral vector. See generally, Jolly (1994) Cancer Gene Therapy 1:51-64; Kimura (1994) Human Gene Therapy 5:845-852; Connelly (1995) Human Gene Therapy 6:185-193; and Kaplitt (1994) Nature Genetics 6:148-153.
- Retroviral vectors are well known in the art and we contemplate that any retroviral gene therapy vector is employable in the invention, including B, C and D type retroviruses, xenotropic retroviruses (for example, NZB-X1, NZB-X2 and NZB9-1 (see O'Neill (1985) J. Virol. 53:160) polytropic retrovirus eg. MCF and MCF-MLV (see Kelly (1983) J. Virol. 45:291), spumaviruses and lentiviruses. See RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985.
- Portions of the retroviral gene therapy vector may be derived from different retroviruses. For example, retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.
- These recombinant retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see U.S. Pat. No. 5,591,624). Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle (see WO96/37626). It is preferable that the recombinant viral vector is a replication defective recombinant virus.
- Packaging cell lines suitable for use with the above-described retrovirus vectors are well known in the art, are readily prepared (see WO95/30763 and WO92/05266), and can be used to create producer cell lines (also termed vector cell lines or “VCLs”) for the production of recombinant vector particles. Preferably, the packaging cell lines are made from human parent cells (eg. HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.
- Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia, Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe (1976) J Virol 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC Nol VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No. VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190). Such retroviruses may be obtained from depositories or collections such as the American Type Culture Collection (“ATCC”) in Rockville, Md. or isolated from known sources using commonly available techniques.
- Exemplary known retroviral gene therapy vectors employable in this invention include those described in patent applications GB2200651, EP0415731, EP0345242, EP0334301, WO89/02468; WO89/05349, WO89/09271, WO90/02806, WO90/07936, WO94/03622, WO93/25698, WO93/25234, WO93/11230, WO93/10218, WO91/02805, WO91/02825, WO95/07994, U.S. Pat. No. 5,219,740, U.S. Pat. No. 4,405,712, U.S. Pat. No. 4,861,719, U.S. Pat. No. 4,980,289, U.S. Pat. No. 4,777,127, U.S. Pat. No. 5,591,624. See also Vile (1993) Cancer Res 53:3860-3864; Vile (1993) Cancer Res 53:962-967; Rain (1993) Cancer Res 53 (1993) 83-88; Takamiya (1992) J Neurosci Res 33:493-503; Baba (1993) J Neurosurg 79:729-735; Mann (1983) Cell 33:153; Cane (1984) Proc Natl Acad Sci 81:6349; and Miller (1990)
Human Gene Therapy 1. - Human adenoviral gene therapy vectors are also known in the art and employable in this invention. See, for example, Berkner (1988) Biotechniques 6:616 and Rosenfeld (1991) Science 252:431, and WO93/07283, WO93/06223, and WO93/07282. Exemplary known adenoviral gene therapy vectors employable in this invention include those described in the above referenced documents and in WO94/12649, WO93/03769, WO93/19191, WO94/28938, WO95/11984, WO95/00655, WO95/27071, WO95/29993, WO95/34671, WO96/05320, WO94/08026, WO94/11506, WO93/06223, WO94/24299, WO95/14102, WO95/24297, WO95/02697, WO94/28152, WO94/24299, WO95/09241, WO95/25807, WO95/05835, WO94/18922 and WO95/09654. Alternatively, administration of DNA linked to killed adenovirus as described in Curiel (1992) Hum. Gene Ther. 3:147-154 may be employed. The gene delivery vehicles of the invention also include adenovirus associated virus (AAV) vectors. Leading and preferred examples of such vectors for use in this invention are the AAV-2 based vectors disclosed in Srivastava, WO93/09239. Most preferred AAV vectors comprise the two AAV inverted terminal repeats in which the native D-sequences are modified by substitution of nucleotides, such that at least 5 native nucleotides and up to 18 native nucleotides, preferably at least 10 native nucleotides up to 18 native nucleotides, most preferably 10 native nucleotides are retained and the remaining nucleotides of the D-sequence are deleted or replaced with non-native nucleotides. The native D-sequences of the AAV inverted terminal repeats are sequences of 20 consecutive nucleotides in each AAV inverted terminal repeat (ie. there is one sequence at each end) which are not involved in HP formation. The non-native replacement nucleotide may be any nucleotide other than the nucleotide found in the native D-sequence in the same position. Other employable exemplary AAV vectors are pWP-19, pWN-1, both of which are disclosed in Nahreini (1993) Gene 124:257-262. Another example of such an AAV vector is psub201 (see Samulski (1987) J. Virol. 61:3096). Another exemplary AAV vector is the Double-D ITR vector. Construction of the Double-D ITR vector is disclosed in U.S. Pat. No. 5,478,745. Still other vectors are those disclosed in Carter U.S. Pat. No. 4,797,368 and Muzyczka U.S. Pat. No. 5,139,941, Chartejee U.S. Pat. No. 5,474,935, and Kotin WO94/288157. Yet a further example of an AAV vector employable in this invention is SSV9AFABTKneo, which contains the AFP enhancer and albumin promoter and directs expression predominantly in the liver. Its structure and construction are disclosed in Su (1996) Human Gene Therapy 7:463-470. Additional AAV gene therapy vectors are described in U.S. Pat. No. 5,354,678, U.S. Pat. No. 5,173,414, U.S. Pat. No. 5,139,941, and U.S. Pat. No. 5,252,479.
- The gene therapy vectors of the invention also include herpes vectors. Leading and preferred examples are herpes simplex virus vectors containing a sequence encoding a thymidine kinase polypeptide such as those disclosed in U.S. Pat. No. 5,288,641 and EP0176170 (Roizman). Additional exemplary herpes simplex virus vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar Institute), pHSVlac described in Geller (1988) Science 241:1667-1669 and in WO90/09441 and WO92/07945, HSV Us3::pgC-lacZ described in Fink (1992) Human Gene Therapy 3:11-19 and HSV 7134, 2
RH 105 and GAL4 described in EP 0453242 (Breakefield), and those deposited with the ATCC as accession numbers ATCC VR-977 and ATCC VR-260. - Also contemplated are alpha virus gene therapy vectors that can be employed in this invention. Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in U.S. Pat. Nos. 5,091,309, 5,217,879, and WO92/10578. More particularly, those alpha virus vectors described in U.S. Ser. No. 08/405,627, filed Mar. 15, 1995, WO94/21792, WO92/10578, WO95/07994, U.S. Pat. No. 5,091,309 and U.S. Pat. No. 5,217,879 are employable. Such alpha viruses may be obtained from depositories or collections such as the ATCC in Rockville, Md. or isolated from known sources using commonly available techniques. Preferably, alphavirus vectors with reduced cytotoxicity are used (see U.S. Ser. No. 08/679,640).
- DNA vector systems such as eukaryotic layered expression systems are also useful for expressing the nucleic acids of the invention. See WO95/07994 for a detailed description of eukaryotic layered expression systems. Preferably, the eukaryotic layered expression systems of the invention are derived from alphavirus vectors and most preferably from Sindbis viral vectors.
- Other viral vectors suitable for use in the present invention include those derived from poliovirus, for example ATCC VR-58 and those described in Evans, Nature 339 (1989) 385 and Sabin (1973) J. Biol. Standardization 1:115; rhinovirus, for example ATCC VR-1110 and those described in Arnold (1990) J Cell Biochem L401; pox viruses such as canary pox virus or vaccinia virus, for example ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch (1989) Proc Natl Acad Sci 86:317; Flexner (1989) Ann NY Acad Sci 569:86, Flexner (1990) Vaccine 8:17; in U.S. Pat. No. 4,603,112 and U.S. Pat. No. 4,769,330 and WO89/01973; SV40 virus, for example ATCC VR-305 and those described in Mulligan (1979) Nature 277:108 and Madzak (1992) J Gen Virol 73:1533; influenza virus, for example ATCC VR-797 and recombinant influenza viruses made employing reverse genetics techniques as described in U.S. Pat. No. 5,166,057 and in Enami (1990) Proc Nail Acad Sci 87:3802-3805; Enami & Palese (1991) J Virol 65:2711-2713 and Luytjes (1989) Cell 59:110, (see also McMichael (1983) NEJ Med 309:13, and Yap (1978) Nature 273:238 and Nature (1979) 277:108); human immunodeficiency virus as described in EP-0386882 and in Buchschacher (1992) J. Virol. 66:2731; measles virus, for example ATCC VR-67 and VR-1247 and those described in EP-0440219; Aura virus, for example ATCC VR-368; Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou virus, for example ATCC VR-922; Chikungunya virus, for example ATCC VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC VR-924; Getah virus, for example ATCC VR-369 and ATCC VR-1243; Kyzylagach virus, for example ATCC VR-927; Mayaro virus, for example ATCC VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244; Ndumu virus, for example ATCC VR-371; Pixuna virus, for example ATCC VR-372 and ATCC VR-1245; Tonate virus, for example ATCC VR-925; Triniti virus, for example ATCC VR-469; Una virus, for example ATCC VR-374; Whataroa virus, for example ATCC VR-926; Y-62-33 virus, for example ATCC VR-375; O'Nyong virus, Eastern encephalitis virus, for example ATCC VR-65 and ATCC VR-1242; Western encephalitis virus, for example ATCC VR-70, ATCC VR-1251, ATCC VR-622 and ATCC VR-1252; and coronavirus, for example ATCC VR-740 and those described in Hamre (1966) Proc Soc Exp Biol Med 121:190.
- Delivery of the compositions of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see U.S. Ser. No. 08/366,787, filed Dec. 30, 1994 and Curiel (1992) Hum Gene Ther 3:147-154 ligand linked DNA, for example see Wu (1989) J Biol Chem 264:16985-16987, eucaryotic cell delivery vehicles cells, for example see U.S. Ser. No. 08/240,030, filed May 9, 1994, and U.S. Ser. No. 08/404,796, deposition of photopolymerized hydrogel materials, hand-held gene transfer particle gun, as described in U.S. Pat. No. 5,149,655, ionizing radiation as described in U.S. Pat. No. 5,206,152 and in WO92/11033, nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip (1994) Mol Cell Biol 14:2411-2418 and in Woffendin (1994) Proc Natl Acad Sci 91:1581-1585.
- Particle mediated gene transfer may be employed, for example see U.S. Ser. No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu & Wu (1987) J. Biol. Chem. 262:4429-4432, insulin as described in Hucked (1990) Biochem Pharmacol 40:253-263, galactose as described in Plank (1992) Bioconjugate Chem 3:533-539, lactose or transferrin.
- Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Pat. No. 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.
- Liposomes that can act as gene delivery vehicles are described in U.S. Pat. No. 5,422,120, WO95/13796, WO94/23697, WO91/14445 and EP-524,968. As described in U.S. S No. 60/023,867, on non-viral delivery, the nucleic acid sequences encoding a polypeptide can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, insulin, galactose, lactose, or transferrin. Other delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously-active promoters. Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al (1994) Proc. Natl. Acad. Sci. USA 91(24):11581-11585. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. Pat. No. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. Pat. No. 5,206,152 and WO92/11033
- Exemplary liposome and polycationic gene delivery vehicles are those described in U.S. Pat. Nos. 5,422,120 and 4,762,915; in WO 95/13796; WO94/23697, and WO91/14445; in EP-0524968; and in Stryer, Biochemistry, pages 236-240 (1975) W.H. Freeman, San Francisco; Szoka (1980) Biochem Biophys Acta 600:1; Bayer (1979) Biochem Biophys Acta 550:464; Rivnay (1987) Meth Enzymol 149:119; Wang (1987) Proc Natl Acad Sci 84:7851; Plant (1989) Anal Biochem 176:420.
- A polynucleotide composition can comprises therapeutically effective amount of a gene therapy vehicle, as the term is defined above. For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.
- Delivery Methods
- Once formulated, the polynucleotide compositions of the invention can be administered (1) directly to the subject; (2) delivered ex vivo, to cells derived from the subject; or (3) in vitro for expression of recombinant proteins. The subjects to be treated can be mammals or birds. Also, human subjects can be treated.
- Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- Methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and described in eg. WO93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells.
- Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by the following procedures, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.
- Polynucleotide and Polypeptide Pharmaceutical Compositions
- In addition to the pharmaceutically acceptable carriers and salts described above, the following additional agents can be used with polynucleotide and/or polypeptide compositions.
- A. Polypeptides
- One example are polypeptides which include, without limitation: asioloorosomucoid (ASOR); transferrin; asialoglycoproteins; antibodies; antibody fragments; ferritin; interleukins; interferons, granulocyte, macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor and erythropoietin. Viral antigens, such as envelope proteins, can also be used. Also, proteins from other invasive organisms, such as the 17 amino acid peptide from the circumsporozoite protein of plasmodium falciparum known as RII.
- B. Hormones, Vitamins, etc.
- Other groups that can be included are, for example: hormones, steroids, androgens, estrogens, thyroid hormone, or vitamins, folic acid.
- C. Polyalkylenes, Polysaccharides, etc.
- Also, polyalkylene glycol can be included with the desired polynucleotides/polypeptides. In a preferred embodiment, the polyalkylene glycol is polyethlylene glycol. In addition, mono-, di-, or polysaccharides can be included. In a preferred embodiment of this aspect, the polysaccharide is dextran or DEAE-dextran. Also, chitosan and poly(lactide-co-glycolide)
- D. Lipids, and Liposomes
- The desired polynucleotide/polypeptide can also be encapsulated in lipids or packaged in liposomes prior to delivery to the subject or to cells derived therefrom.
- Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid. The ratio of condensed polynucleotide to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight (1991) Biochim. Biophys. Acta. 1097:1-17; Straubinger (1983) Meth. Enzymol. 101:512-527.
- Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner (1987) Proc. Natl. Acad. Sci. USA 84:7413-7416); mRNA (Malone (1989) Proc. Natl. Acad. Sci. USA 86:6077-6081); and purified transcription factors (Debs (1990) J. Biol. Chem. 265:10189-10192), in functional form.
- Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner supra). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boerhinger). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, eg. Szoka (1978) Proc. Nail. Acad. Sci. USA 75:41944198; WO90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.
- Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.
- The liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art See eg. Straubinger (1983) Meth. Immunol. 101:512-527; Szoka (1978) Proc. Natl. Acad. Sci. USA 75:4194-4198; Papahadjopoulos (1975) Biochim. Biophys. Acta 394:483; Wilson (1979) Cell 17:77); Deamer & Bangham (1976) Biochim. Biophys. Acia 443:629; Ostro (1977) Biochem. Biophys. Res. Commun. 76:836; Fraley (1979) Proc. Natl. Acad. Sci. USA 76:3348); Enoch & Strittmatter (1979) Proc. Natl. Acad. Sci. USA 76:145; Fraley (1980) J. Biol. Chem. (1980) 255:10431; Szoka & Papahadjopoulos (1978) Proc. Natl. Acad. Sci. USA 75:145; and Schaefer-Ridder (1982) Science 215:166.
- E. Lipoproteins
- In addition, lipoproteins can be included with the polynucleotide/polypeptide to be delivered. Examples of lipoproteins to be utilized include: chylomicrons, HDL, DL, LDL, and VLDL. Mutants, fragments, or fusions of these proteins can also be used. Also, modifications of naturally occurring lipoproteins can be used, such as acetylated LDL. These lipoproteins can target the delivery of polynucleotides to cells expressing lipoprotein receptors. Preferably, if lipoproteins are including with the polynucleotide to be delivered, no other targeting ligand is included in the composition.
- Naturally occurring lipoproteins comprise a lipid and a protein portion. The protein portion are known as apoproteins. At the present, apoproteins A, B, C, D, and E have been isolated and identified. At least two of these contain several proteins, designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.
- A lipoprotein can comprise more than one apoprotein. For example, naturally occurring chylomicrons comprises of A, B, C, and E, over time these lipoproteins lose A and acquire C and E apoproteins. VLDL comprises A, B, C, and E apoproteins, LDL comprises apoprotein B; and HDL comprises apoproteins A, C, and E.
- The amino acid of these apoproteins are known and are described in, for example, Breslow (1985) Annu Rev. Biochem 54:699; Law (1986) Adv. Exp Med. Biol. 151:162; Chen (1986) J Biol Chem 261:12918; Kane (1980) Proc Natl Acad Sci USA 77:2465; and Utermann (1984) Hum Genet 65:232.
- Lipoproteins contain a variety of lipids including, triglycerides, cholesterol (free and esters), and phospholipids. The composition of the lipids varies in naturally occurring lipoproteins. For example, chylomicrons comprise mainly triglycerides. A more detailed description of the lipid content of naturally occurring lipoproteins can be found, for example, in Meth. Enzymol. 128 (1986). The composition of the lipids are chosen to aid in conformation of the apoprotein for receptor binding activity. The composition of lipids can also be chosen to facilitate hydrophobic interaction and association with the polynucleotide binding molecule.
- Naturally occurring lipoproteins can be isolated from serum by ultracentrifugation, for instance. Such methods are described in Meth. Enzymol. (supra); Pitas (1980) J. Biochem. 255:5454-5460 and Mahey (1979) J. Clin. Invest 64:743-750. Lipoproteins can also be produced by in vitro or recombinant methods by expression of the apoprotein genes in a desired host cell. See, for example, Atkinson (1986) Annu Rev Biophys Chem 15:403 and Radding (1958) Biochim Biophys Acia 30: 443. Lipoproteins can also be purchased from commercial suppliers, such as Biomedical Techniologies, Inc., Stoughton, Mass., USA. Further description of lipoproteins can be found in Zuckermann et al. PCT/US97/14465.
- F. Polycationic Agents
- Polycationic agents can be included, with or without lipoprotein, in a composition with the desired polynucleotide/polypeptide to be delivered.
- Polycationic agents, typically, exhibit a net positive charge at physiological relevant pH and are capable of neutralizing the electrical charge of nucleic acids to facilitate delivery to a desired location. These agents have both in vitro, ex vivo, and in vivo applications. Polycationic agents can be used to deliver nucleic acids to a living subject either intramuscularly, subcutaneously, etc.
- The following are examples of useful polypeptides as polycationic agents: polylysine, polyarginine, polyornithine, and protamine. Other examples include histones, protamines, human serum albumin, DNA binding proteins, non-histone chromosomal proteins, coat proteins from DNA viruses, such as (X174, transcriptional factors also contain domains that bind DNA and therefore may be useful as nucleic aid condensing agents. Briefly, transcriptional factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF, Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains that bind DNA sequences.
- Organic polycationic agents include: spermine, spermidine, and purtrescine.
- The dimensions and of the physical properties of a polycationic agent can be extrapolated from the list above, to construct other polypeptide polycationic agents or to produce synthetic polycationic agents.
- Synthetic polycationic agents which are useful include, for example, DEAE-dextran, polybrene. Lipofectin™, and lipofectAMINE™ are monomers that form polycationic complexes when combined with polynucleotides/polypeptides.
- Immunodiagnostic Assays
- Neisserial antigens of the invention can be used in immunoassays to detect antibody levels (or, conversely, anti-Neisserial antibodies can be used to detect antigen levels). Immunoassays based on well defined, recombinant antigens can be developed to replace invasive diagnostics methods. Antibodies to Neisserial proteins within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.
- Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the invention, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutions, etc.) required for the conduct of the assay, as well as suitable set of assay instructions.
- Nucleic Acid Hybridisation
- “Hybridization” refers to the association of two nucleic acid sequences to one another by hydrogen bonding. Typically, one sequence will be fixed to a solid support and the other will be free in solution. Then, the two sequences will be placed in contact with one another under conditions that favor hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase sequence to the solid support (Denhardt's reagent or BLOTTO); concentration of the sequences; use of compounds to increase the rate of association of sequences (dextran sulfate or polyethylene glycol); and the stringency of the washing conditions following hybridization. See Sambrook et al. [supra] Volume 2, chapter 9, pages 9.47 to 9.57.
- “Stringency” refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ. For example, the combination of temperature and salt concentration should be chosen that is approximately 120 to 200° C. below the calculated Tm of the hybrid under study. The temperature and salt conditions can often be determined empirically in preliminary experiments in which samples of genomic DNA immobilized on filters are hybridized to the sequence of interest and then washed under conditions of different stringencies. See Sambrook et al. at page 9.50.
- Variables to consider when performing, for example, a Southern blot are (1) the complexity of the DNA being blotted and (2) the homology between the probe and the sequences being detected. The total amount of the fragment(s) to be studied can vary a magnitude of 10, from 0.1 to 1 g for a plasmid or phage digest to 10−9 to 10−8 g for a single copy gene in a highly complex eukaryotic genome. For lower complexity polynucleotides, substantially shorter blotting, hybridization, and exposure times, a smaller amount of starting polynucleotides, and lower specific activity of probes can be used. For example, a single-copy yeast gene can be detected with an exposure time of only 1 hour starting with 1 μg of yeast DNA, blotting for two hours, and hybridizing for 4-8 hours with a probe of 108 cpm/μg. For a single-copy mammalian gene a conservative approach would start with 10 μg of DNA, blot overnight, and hybridize overnight in the presence of 10% dextran sulfate using a probe of greater than 108 cpm/μg, resulting in an exposure time of 24 hours.
- Several factors can affect the melting temperature (Tm) of a DNA-DNA hybrid between the probe and the fragment of interest, and consequently, the appropriate conditions for hybridization and washing. In many cases the probe is not 100% homologous to the fragment. Other commonly encountered variables include the length and total G+C content of the hybridizing sequences and the ionic strength and formamide content of the hybridization buffer. The effects of all of these factors can be approximated by a single equation:
Tm—81+16.6(log10 Ci)+0.4[% (G+C)]−0.6(% formamide)-600/n−1.5(% mismatch).
where Ci is the salt concentration (monovalent ions) and n is the length of the hybrid in base pairs (slightly modified from Meinkoth & Wahl (1984) Anal. Biochem. 138: 267-284). - In designing a hybridization experiment, some factors affecting nucleic acid hybridization can be conveniently altered. The temperature of the hybridization and washes and the salt concentration during the washes are the simplest to adjust. As the temperature of the hybridization increases (ie. stringency), it becomes less likely for hybridization to occur between strands that are nonhomologous, and as a result, background decreases. If the radiolabeled probe is not completely homologous with the immobilized fragment (as is frequently the case in gene family and interspecies hybridization experiments), the hybridization temperature must be reduced, and background will increase. The temperature of the washes affects the intensity of the hybridizing band and the degree of background in a similar manner. The stringency of the washes is also increased with decreasing salt concentrations.
- In general, convenient hybridization temperatures in the presence of 50% formamide are 42° C. for a probe with is 95% to 100% homologous to the target fragment, 37° C. for 90% to 95% homology, and 32° C. for 85% to 90% homology. For lower homologies, formamide content should be lowered and temperature adjusted accordingly, using the equation above. If the homology between the probe and the target fragment are not known, the simplest approach is to start with both hybridization and wash conditions which are nonstringent. If non-specific bands or high background are observed after autoradiography, the filter can be washed at high stringency and reexposed. If the time required for exposure makes this approach impractical, several hybridization and/or washing stringencies should be tested in parallel.
- Nucleic Acid Probe Assays
- Methods such as PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes according to the invention can determine the presence of cDNA or mRNA. A probe is said to “hybridize” with a sequence of the invention if it can form a duplex or double stranded complex, which is stable enough to be detected.
- The nucleic acid probes will hybridize to the Neisserial nucleotide sequences of the invention (including both sense and antisense strands). Though many different nucleotide sequences will encode the amino acid sequence, the native Neisserial sequence is preferred because it is the actual sequence present in cells. mRNA represents a coding sequence and so a probe should be complementary to the coding sequence; single-stranded cDNA is complementary to mRNA, and so a cDNA probe should be complementary to the non-coding sequence.
- The probe sequence need not be identical to the Neisserial sequence (or its complement)—some variation in the sequence and length can lead to increased assay sensitivity if the nucleic acid probe can form a duplex with target nucleotides, which can be detected. Also, the nucleic acid probe can include additional nucleotides to stabilize the formed duplex. Additional Neisserial sequence may also be helpful as a label to detect the formed duplex. For example, a non-complementary nucleotide sequence may be attached to the 5′ end of the probe, with the remainder of the probe sequence being complementary to a Neisserial sequence. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the a Neisserial sequence in order to hybridize therewith and thereby form a duplex which can be detected.
- The exact length and sequence of the probe will depend on the hybridization conditions, such as temperature, salt condition and the like. For example, for diagnostic applications, depending on the complexity of the analyte sequence, the nucleic acid probe typically contains at least 10-20 nucleotides, preferably 15-25, and more preferably at least 30 nucleotides, although it may be shorter than this. Short primers generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.
- Probes may be produced by synthetic procedures, such as the triester method of Matteucci et al. [J. Am. Chem. Soc. (1981) 103:3185], or according to Urdea et al. [Proc. Natl. Acad. Sci. USA (1983) 80: 7461], or using commercially available automated oligonucleotide synthesizers.
- The chemical nature of the probe can be selected according to preference. For certain applications, DNA or RNA are appropriate. For other applications, modifications may be incorporated eg. backbone modifications, such as phosphorothioates or methylphosphonates, can be used to increase in vivo half-life, alter RNA affinity, increase nuclease resistance etc. [eg. see Agrawal & Iyer (1995) Curr Opin Biotechnol 6:12-19; Agrawal (1996) TIBTECH 14:376-387]; analogues such as peptide nucleic acids may also be used [eg. see Corey (1997) TIBTECH 15:224-229; Buchardt et al. (1993) TIBTECH 11:384-386].
- Alternatively, the polymerase chain reaction (PCR) is another well-known means for detecting small amounts of target nucleic acids. The assay is described in: Mullis et al. [Meth. Enzymol. (1987) 155: 335-350]; U.S. Pat. Nos. 4,683,195 and 4,683,202. Two “primer” nucleotides hybridize with the target nucleic acids and are used to prime the reaction. The primers can comprise sequence that does not hybridize to the sequence of the amplification target (or its complement) to aid with duplex stability or, for example, to incorporate a convenient restriction site. Typically, such sequence will flank the desired Neisserial sequence.
- A thermostable polymerase creases copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a threshold amount of target nucleic acids are generated by the polymerase, they can be detected by more traditional methods, such as Southern blots. When using the Southern blot method, the labelled probe will hybridize to the Neisserial sequence (or its complement).
- Also, mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook et al [supra]. mRNA, or cDNA generated from mRNA using a polymerase enzyme, can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The solid support is exposed to a labelled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labeled probe are detected. Typically, the probe is labelled with a radioactive moiety.
-
FIGS. 1-7 show biochemical data and sequence analysis pertaining to Examples 1, 2, 3, 7, 13, 16 and 19, respectively, withORFs 40, 38, 44, 52, 114, 41 and 124. M1 and M2 are molecular weight markers. Arrows indicate the position of the main recombinant product or, in Western blots, the position of the main N. meningitidis immunoreactive band. TP indicates N. meningitidis total protein extract; OMV indicates N. meningitidis outer membrane vesicle preparation. In bactericidal assay results: a diamond (♦) shows preimmune data; a triangle (▴) shows GST control data; a circle (●) shows data with recombinant N. meningitidis protein. Computer analyses show a hydrophilicity plot (upper), an antigenic index plot (middle), and an AMPHI analysis (lower). The AMPHI program has been used to predict T-cell epitopes [Gao et al. (1989) J. Immunol. 143:3007; Roberts et al. (1996) AIDS Res Hum Retrovir 12:593; Quakyi et al. (1992) Scand J Immunol suppl. 11:9) and is available in the Protean package of DNASTAR, Inc. (1228 South Park Street, Madison, Wis. 53715 USA). -
FIG. 8 shows an alignment comparison of amino acid sequences forORF 40 for several strains of Neisseria. Dark shading indicates regions of homology, and gray shading indicates the conservation of amino acids with similar characteristics. The Figure demonstrates a high degree of conservation among the various strains, further confirming its utility as an antigen for both vaccines and diagnostics. - The examples describe nucleic acid sequences which have been identified in N. meningitidis, along with their putative translation products. Not all of the nucleic acid sequences are complete ie. they encode less than the full-length wild-type protein. It is believed at present that none of the DNA sequences described herein have significant homologs in N. gonorrhoeae.
- The examples are generally in the following format:
-
- a nucleotide sequence which has been identified in N. meningitidis (strain B)
- the putative translation product of this sequence
- a computer analysis of the translation product based on database comparisons
- a corresponding gene and protein sequence identified in N. meningitidis (strain A)
- a description of the characteristics of the proteins which indicates that they might be suitably antigenic
- results of biochemical analysis (expression, purification, ELISA, FACS etc.)
- The examples typically include details of sequence homology between species and strains. Proteins that are similar in sequence are generally similar in both structure and function, and the homology often indicates a common evolutionary origin. Comparison with sequences of proteins of known function is widely used as a guide for the assignment of putative protein function to a new sequence and has proved particularly useful in whole-genome analyses.
- Sequence comparisons were performed at NCBI (http://www.ncbi.nlm.nih.gov) using the algorithms BLAST, BLAST2, BLASTn, BLASTp, tBLASTn, BLASTx, & tBLASTx [eg. see also Altschul et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research 25:2289-3402]. Searches were performed against the following databases: non-redundant GenBank+EMBL+DDBJ+PDB sequences and non-redundant GenBank CDS translations+PDB+SwissProt+SPupdate+PIR sequences.
- Dots within nucleotide sequences (eg. position 288 in Example 12) represent nucleotides which have been arbitrarily introduced in order to maintain a reading frame. In the same way, double-underlined nucleotides were removed. Lower case letters (eg.
position 589 in Example 12) represent ambiguities which arose during alignment of independent sequencing reactions (some of the nucleotide sequences in the examples are derived from combining the results of two or more experiments). - Nucleotide sequences were scanned in all six reading frames to predict the presence of hydrophobic domains using an algorithm based on the statistical studies of Esposti et al. [Critical evaluation of the hydropathy of membrane proteins (1990) Eur J Biochem 190:207-219]. These domains represent potential transmembrane regions or hydrophobic leader sequences.
- Open reading frames were predicted from fragmented nucleotide sequences using the program ORFFINDER (NCBI).
- Underlined amino acid sequences indicate possible transmembrane domains or leader sequences in the ORFs, as predicted by the PSORT algorithm (http://www.psort.nibb.ac.jp). Functional domains were also predicted using the MOTIFS program (GCG Wisconsin & PROSITE).
- Various tests can be used to assess the in vivo immunogenicity of the proteins identified in the examples. For example, the proteins can be expressed recombinantly and used to screen patient sera by immunoblot A positive reaction between the protein and patient serum indicates that the patient has previously mounted an immune response to the protein in question ie. the protein is an immunogen. This method can also be used to identify immunodominant proteins.
- The recombinant protein can also be conveniently used to prepare antibodies eg. in a mouse. These can be used for direct confirmation that a protein is located on the cell-surface. Labelled antibody (eg. fluorescent labelling for FACS) can be incubated with intact bacteria and the presence of label on the bacterial surface confirms the location of the protein.
- In particular, the following methods (A) to (S) were used to express, purify and biochemically characterise the proteins of the invention:
- A) Chromosomal DNA Preparation
- N. meningitidis strain 2996 was grown to exponential phase in 100 ml of GC medium, harvested by centrifugation, and resuspended in 5 ml buffer (20% Sucrose, 50 mM Tris-HCl, 50 mM EDTA, pH8). After 10 minutes incubation on ice, the bacteria were lysed by adding 10 ml lysis solution (50 mM NaCl, 1% Na-Sarkosyl, 50 μg/ml Proteinase K), and the suspension was incubated at 37° C. for 2 hours. Two phenol extractions (equilibrated to pH 8) and one ChCl3/isoamylalcohol (24:1) extraction were performed. DNA was precipitated by addition of 0.3M sodium acetate and 2 volumes ethanol, and was collected by centrifugation. The pellet was washed once with 70% ethanol and redissolved in 4 ml buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The DNA concentration was measured by reading the OD at 260 nm.
- B) Oligonucleotide Design
- Synthetic oligonucleotide primers were designed on the basis of the coding sequence of each ORF, using (a) the meningococcus B sequence when available, or (b) the gonococcus/meningococcus A sequence, adapted to the codon preference usage of meningococcus as necessary. Any predicted signal peptides were omitted, by deducing the 5′-end amplification primer sequence immediately downstream from the predicted leader sequence.
- The 5′ primers included two restriction enzyme recognition sites (BamHI-NdeI, BamHI-NheI, or EcoRI-NheI, depending on the gene's own restriction pattern); the 3′ primers included a XhoI restriction site. This procedure was established in order to direct the cloning of each amplification product (corresponding to each ORF) into two different expression systems: pGEX-KG (using either BamHI-XhoI or EcoRI-XhoI), and pET21b+ (using either NdeI-XhoI or NheI-XhoI).
5′end primer tail: CGCGGATCCCATATG (BamHI-NdeI) CGCGGATCCGCTAGC (BamHI-NheI) CCGGAATTCTAGCTAGC (EcoRI-NheI) 3′-end primer tail: CCCGCTCGAG (XhoI) - As well as containing the restriction enzyme recognition sequences, the primers included nucleotides which hybridised to the sequence to be amplified. The number of hybridizing nucleotides depended on the melting temperature of the whole primer, and was determined for each primer using the formulae:
T m=4 (G+C)+2 (A+T) (tail excluded)
T m=64.9+0.41 (% GC)−600/N (whole primer) - The average melting temperature of the selected oligos were 65-70° C. for the whole oligo and 50-55° C. for the hybridising region alone.
- Table I shows the forward and reverse primers used for each amplification. Oligos were synthesized by a Perkin Elmer 394 DNA/RNA Synthesizer, eluted from the columns in 2 ml NH4OH, and deprotected by 5 hours incubation at 56° C. The oligos were precipitated by addition of 0.3M Na-Acetate and 2 volumes ethanol. The samples were then centrifuged and the pellets resuspended in either 100 μl or 1 ml of water. OD260 was determined using a Perkin Elmer Lambda Bio spectrophotometer and the concentration was determined and adjusted to 2-10 pmol/μl.
TABLE I PCR primers ORF Primer Sequence Restriction sites ORF 38 Forward CGCGGATCCCATATG-TCGCCGCAAAATTCCGA BamHI-NdeI <SEQ ID 112> Reverse CCCGCTCGAG-TTTTGCCGCGTTAAAAGC XhoI <SEQ ID 113> ORF 40 Forward CGCGGATCCCATATG-ACCGTGAAGACCGCC BamHI-NdeI <SEQ ID 114> Reverse CCCGCTCGAG-CCACTGATAACCGACAGA XhoI <SEQ ID 115> ORF 41 Forward CGCGGATCCCATATG-TATTTGAAACAGCTCCAAG BamHI-NdeI <SEQ ID 116> Reverse CCCGCTCGAG-TTCTGGGTGAATGTTA XhoI <SEQ ID 117> ORF 44 Forward GCGGATCCCATATG-GGCACGGACAACCCC BamHI-NdeI <SEQ ID 118> Reverse CCCGCTCGAG-ACGTGGGGAACAGTCT XhoI <SEQ ID 119> ORF 51 Forward GCGGATCCCATATG-AAAAATATTCAAGTAGTTGC BamHI-NdeI <SEQ ID 120> Reverse CCCGCTCGAG-AAGTTTGATTAAACCCG XhoI <SEQ ID 121> ORF 52 Forward CGCGGATCCCATATG-TGCCAACCGCAATCCG BamHI-NdeI <SEQ ID 122> Reverse CCCGCTCGAG-TTTTTCCAGCTCCGGCA XhoI <SEQ ID 123> ORF 56 Forward GCGGATCCCATATG-GTTATCGGAATATTACTCG BamHI-NdeI <SEQ ID 124> Reverse CCCGCTCGAG-GGCTGCAGAAGCTGG XhoI <SEQ ID 125> ORF 69 Forward CGCGGATCCCATATG-CGGACGTGGTTGGTTTT BamHI-NdeI <SEQ ID 126> Reverse CCCGCTCGAG-ATATCTTCCGTTTTTTTCAC XhoI <SEQ ID 127> ORF 82 Forward CGCGGATCCGCTAGC-GTAAATTTATTATTTTTAGAA BamHI-NheI <SEQ ID 128> Reverse CCCGCTCGAG-TCCAACTCATTGAAGTA XhoI <SEQ ID 129> ORF 114 Forward CGCGGATCCCATATG-AATAAAGGTTTACATCGCAT BamHI-NheI <SEQ ID 130> Reverse CCCGCTCGAG-AATCGCTGCACCGGCT XhoI <SEQ ID 131> ORF 124 Forward CGCGGATCCCATATG-ACTGCCTTTTCGACA BamHI-NheI <SEQ ID 132> Reverse CCCGCTCGAG-GCGTGAAGCGTCAGGA XhoI <SEQ ID 133>
C) Amplification - The standard PCR protocol was as follows: 50-200 ng of genomic DNA were used as a template in the presence of 20-40 μM of each oligo, 400-8004M dNTs solution, 1×PCR buffer (including 1.5 mM MgCl2), 2.5 units TaqI DNA polymerase (using Perkin-Elmer AmpliTaQ, GIBCO Platinum, Pwo DNA polymerase, or Tahara Shuzo Taq polymerase).
- In some cases, PCR was optimised by the addition of 10 μl DMSO or 50 μl 2M betaine.
- After a hot start (adding the polymerase during a preliminary 3 minute incubation of the whole mix at 95° C.), each sample underwent a double-step amplification: the first 5 cycles were performed using as the hybridization temperature the one of the oligos excluding the restriction enzymes tail, followed by 30 cycles performed according to the hybridization temperature of the whole length oligos. The cycles were followed by a final 10 minute extension step at 72° C.
- The standard cycles were as follows:
Denaturation Hybridisation Elongation First 5 cycles 30 seconds 30 seconds 30-60 seconds 95° C. 50-55° C. 72° C. Last 30 cycles 30 seconds 30 seconds 30-60 seconds 95° C. 65-70° C. 72° C. - The elongation time varied according to the length of the ORF to be amplified.
- The amplifications were performed using either a 9600 or a 2400 Perkin Elmer GeneAmp PCR System. To check the results, 1/10 of the amplification volume was loaded onto a 1-1.5% agarose gel and the size of each amplified fragment compared with a DNA molecular weight marker.
- The amplified DNA was either loaded directly on a 1% agarose gel or first precipitated with ethanol and resuspended in a suitable volume to be loaded on a 1% agarose gel. The DNA fragment corresponding to the right size band was then eluted and purified from gel, using the Qiagen Gel Extraction Kit, following the instructions of the manufacturer. The final volume of the DNA fragment was 30 μl or 500 of either water or 10 mM Tris, pH 8.5.
- D) Digestion of PCR Fragments
- The purified DNA corresponding to the amplified fragment was split into 2 aliquots and double-digested with:
-
- NdeI/XhoI or NheI/XhoI for cloning into pET-21b+ and further expression of the protein as a C-terminus His-tag fusion
- BamHI/XhoI or EcoRI/XhoI for cloning into pGEX-KG and further expression of the protein as N-terminus GST fusion.
- EcoRI/PstI, EcoRI/SalI, SalI/PstI for cloning into pGex-His and further expression of the protein as N-terminus His-tag fusion
- Each purified DNA fragment was incubated (37° C. for 3 hours to overnight) with 20 units of each restriction enzyme (New England Biolabs) in a either 30 or 40 μl final volume in the presence of the appropriate buffer. The digestion product was then purified using the QIAquick PCR purification kit, following the manufacturer's instructions, and eluted in a final volume of 30 or 50 μl of either water or 10 mM Tris-HCl, pH 8.5. The final DNA concentration was determined by 1% agarose gel electrophoresis in the presence of titrated molecular weight marker.
- E) Digestion of the Cloning Vectors (pET22B, pGEX-KG, pTRC-His A, and pGex-His)
- 10 μg plasmid was double-digested with 50 units of each restriction enzyme in 200 μl reaction volume in the presence of appropriate buffer by overnight incubation at 37° C. After loading the whole digestion on a 1% agarose gel, the band corresponding to the digested vector was purified from the gel using the Qiagen QIAquick-Gel Extraction Kit and the DNA was eluted in 50 μl of 10 mM Tris-HCl, pH 8.5. The DNA concentration was evaluated by measuring OD260 of the sample, and adjusted to 50 μg/μl. 1 μl of plasmid was used for each cloning procedure.
- The vector pGEX-His is a modified pGEX-2T vector carrying a region encoding six histidine residues upstream to the thrombin cleavage site and containing the multiple cloning site of the vector pTRC99 (Pharmacia).
- F) Cloning
- The fragments corresponding to each ORF, previously digested and purified, were ligated in both pET22b and pGEX-KG. In a final volume of 20 μl, a molar ratio of 3:1 fragment/vector was ligated using 0.5 μl of NEB T4 DNA ligase (400 units/μl), in the presence of the buffer supplied by the manufacturer. The reaction was incubated at room temperature for 3 hours. In some experiments, ligation was performed using the Boehringer “Rapid Ligation Kit”, following the manufacturer's instructions.
- In order to introduce the recombinant plasmid in a suitable strain, 100 μl E. coli DH5 competent cells were incubated with the ligase reaction solution for 40 minutes on ice, then at 37° C. for 3 minutes, then, after adding 800 μl LB broth, again at 37° C. for 20 minutes. The cells were then centrifuged at maximum speed in an Eppendorf microfuge and resuspended in approximately 200 μl of the supernatant. The suspension was then plated on LB ampicillin (100 mg/ml).
- The screening of the recombinant clones was performed by growing 5 randomly-chosen colonies overnight at 37° C. in either 2 ml (pGEX or pTC clones) or 5 ml (pET clones) LB broth+100 μg/ml ampicillin. The cells were then pelletted and the DNA extracted using the Qiagen QIAprep Spin Miniprep Kit, following the manufacturer's instructions, to a final volume of 30 μl. 5 μl of each individual miniprep (approximately 1 g) were digested with either NdeI/XhoI or BamHI/XhoI and the whole digestion loaded onto a 1-1.5% agarose gel (depending on the expected insert size), in parallel with the molecular weight marker (1 Kb DNA Ladder, GIBCO). The screening of the positive clones was made on the base of the correct insert size.
- G) Expression
- Each ORF cloned into the expression vector was transformed into the strain suitable for expression of the recombinant protein product. 1 μl of each construct was used to transform 30 μl of E. coli BL21 (pGEX vector), E. coli TOP 10 (pTRC vector) or E. coli BL21-DE3 (pET vector), as described above. In the case of the pGEX-His vector, the same E. coli strain (W3110) was used for initial cloning and expression. Single recombinant colonies were inoculated into 2 ml LB+Amp (100 μg/ml), incubated at 37° C. overnight, then diluted 1:30 in 20 ml of LB+Amp (100 μg/ml) in 100 ml flasks, making sure that the OD600 ranged between 0.1 and 0.15. The flasks were incubated at 30° C. into gyratory water bath shakers until OD indicated exponential growth suitable for induction of expression (0.4-0.8 OD for pET and pTRC vectors; 0.8-1 OD for pGEX and pGEX-His vectors). For the pET, pTRC and pGEX-His vectors, the protein expression was induced by addition of 1 mM IPTG, whereas in the case of pGEX system the final concentration of IPTG was 0.2 mM. After 3 hours incubation at 30° C., the final concentration of the sample was checked by OD. In order to check expression, 1 ml of each sample was removed, centrifuged in a microfuge, the pellet resuspended in PBS, and analysed by 12% SDS-PAGE with Coomassie Blue staining. The whole sample was centrifuged at 6000 g and the pellet resuspended in PBS for further use.
- H) GST-Fusion Proteins Large-Scale Purification.
- A single colony was grown overnight at 37° C. on LB+Amp agar plate. The bacteria were inoculated into 20 ml of LB+Amp liquid culture in a water bath shaker and grown overnight. Bacteria were diluted 1:30 into 600 ml of fresh medium and allowed to grow at the optimal temperature (20-37° C.) to OD550 0.8-1. Protein expression was induced with 0.2 mM IPTG followed by three hours incubation. The culture was centrifuged at 800 rpm at 4° C. The supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml cold PBS. The cells were disrupted by sonication on ice for 30 sec at 40 W using a Branson sonifier B-15, frozen and thawed twice and centrifuged again. The supernatant was collected and mixed with 150 μl Glutatione-Sepharose 4B resin (Pharmacia) (previously washed with PBS) and incubated at room temperature for 30 minutes. The sample was centrifuged at 700 g for 5 minutes at 4° C. The resin was washed twice with 10 ml cold PBS for 10 minutes, resuspended in 1 ml cold PBS, and loaded on a disposable column. The resin was washed twice with 2 ml cold PBS until the flow-through reached OD280 of 0.02-0.06. The GST-fusion protein was eluted by addition of 70011 cold Glutathione elution buffer (10 mM reduced glutathione, 50 mM Tris-HCl) and fractions collected until the OD280 was 0.1. 21 μl of each fraction were loaded on a 12% SDS gel using either Biorad SDS-PAGE Molecular weight standard broad range (M1) (200, 116.25, 97.4, 66.2, 45, 31, 21.5, 14.4, 6.5 kDa) or Amersham Rainbow Marker (M2) (220, 66, 46, 30, 21.5, 14.3 kDa) as standards. As the MW of GST is 26 kDa, this value must be added to the MW of each GST-fusion protein.
- I) His-Fusion Solubility Analysis
- To analyse the solubility of the His-fusion expression products, pellets of 3 ml cultures were resuspended in buffer M1 [500 μl PBS pH 7.2]. 25 μl lysozyme (10 mg/ml) was added and the bacteria were incubated for 15 min at 4° C. The pellets were sonicated for 30 sec at 40 W using a Branson sonifier B-15, frozen and thawed twice and then separated again into pellet and supernatant by a centrifugation step. The supernatant was collected and the pellet was resuspended in buffer M2 [8M urea, 0.5M NaCl, 20 mM imidazole and 0.1M NaH2 PO4] and incubated for 3 to 4 hours at 4° C. After centrifugation, the supernatant was collected and the pellet was resuspended in buffer M3 [6M guanidinium-HCl, 0.5M NaCl, 20 mM imidazole and 0.1M NaH2PO4] overnight at 4° C. The supernatants from all steps were analysed by SDS-PAGE.
- J) His-Fusion Large-Scale Purification.
- A single colony was grown overnight at 37° C. on a LB+Amp agar plate. The bacteria were inoculated into 20 ml of LB+Amp liquid culture and incubated overnight in a water bath shaker. Bacteria were diluted 1:30 into 600 ml fresh medium and allowed to grow at the optimal temperature (20-37° C.) to OD550 0.6-0.8. Protein expression was induced by addition of 1 mM IPTG and the culture further incubated for three hours. The culture was centrifuged at 8000 rpm at 4° C., the supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml of either (i) cold buffer A (300 mM NaCl, 50 mM phosphate buffer, 10 mM imidazole, pH 8) for soluble proteins or (ii) buffer B (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 8.8) for insoluble proteins.
- The cells were disrupted by sonication on ice for 30 sec at 40 W using a Branson sonifier B-15, frozen and thawed two times and centrifuged again.
- For insoluble proteins, the supernatant was stored at −20° C., while the pellets were resuspended in 2 ml buffer C (6M guanidine hydrochloride, 100 mM phosphate buffer, 10 mM Tris-HCl, pH 7.5) and treated in a homogenizer for 10 cycles. The product was centrifuged at 13000 rpm for 40 minutes.
- Supernatants were collected and mixed with 150 μl Ni2+-resin (Pharmacia) (previously washed with either buffer A or buffer B, as appropriate) and incubated at room temperature with gentle agitation for 30 minutes. The sample was centrifuged at 700 g for 5 minutes at 4° C. The resin was washed twice with 10 ml buffer A or B for 10 minutes, resuspended in 1 ml buffer A or B and loaded on a disposable column. The resin was washed at either (i) 4° C. with 2 ml cold buffer A or (ii) room temperature with 2 ml buffer B, until the flow-through reached OD280 of 0.02-0.06.
- The resin was washed with either (i) 2 ml cold 20 mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 20 mM imidazole, pH 8) or (ii) buffer D (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 6.3) until the flow-through reached the O.D280 of 0.02-0.06. The His-fusion protein was eluted by addition of 700 μl of either (i) cold elution buffer A (300 mM NaCl, 50 mM phosphate buffer, 250 mM imidazole, pH 8) or (ii) elution buffer B (urea 8M, 10 mM Tris-HCl, 100 mM phosphate buffer, pH 4.5) and fractions collected until the O.D280 was 0.1. 21 μl of each fraction were loaded on a 12% SDS gel.
- K) His-Fusion Proteins Renaturation
- 10% glycerol was added to the denatured proteins. The proteins were then diluted to 20 μg/ml using dialysis buffer I (10% glycerol, 0.5M arginine, 50 mM phosphate buffer, 5 mM reduced glutathione, 0.5 mM oxidised glutathione, 2M urea, pH 8.8) and dialysed against the same buffer at 4° C. for 12-14 hours. The protein was further dialysed against dialysis buffer II (10% glycerol, 0.5M arginine, 50 mM phosphate buffer, 5 mM reduced glutathione, 0.5 mM oxidised glutathione, pH 8.8) for 12-14 hours at 4° C. Protein concentration was evaluated using the formula:
Protein (mg/ml)=(1.55×OD 280)−(0.76×OD 260)
L) His-Fusion Large-Scale Purification - 500 ml of bacterial cultures were induced and the fusion proteins were obtained soluble in buffer M1, M2 or M3 using the procedure described above. The crude extract of the bacteria was loaded onto a Ni-NTA superflow column (Qiagen) equilibrated with buffer M1, M2 or M3 depending on the solubilization buffer of the fusion proteins. Unbound material was eluted by washing the column with the same buffer. The specific protein was eluted with the corresponding buffer containing 500 mM imidazole and dialysed against the corresponding buffer without imidazole. After each run the columns were sanitized by washing with at least two column volumes of 0.5 M sodium hydroxide and reequilibrated before the next use.
- M) Mice Immunisations
- 20 μg of each purified protein were used to immunise mice intraperitoneally. In the case of ORF 44, CD1 mice were immunised with Al(OH)3 as adjuvant on
days 1, 21 and 42, and immune response was monitored in samples taken on day 56. ForORF 40, CD1 mice were immunised using Freund's adjuvant, rather than Al(OH)3, and the same immunisation protocol was used, except that the immune response was measured on day 42, rather than 56. Similarly, for ORF 38, CD1 mice were immunised with Freund's adjuvant, but the immune response was measured on day 49. - N) ELISA Assay (Sera Analysis)
- The acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37° C. Bacterial colonies were collected from the agar plates using a sterile dracon swab and inoculated into 7 ml of Mueller-Hinton Broth (Difco) containing 0.25% Glucose. Bacterial growth was monitored every 30 minutes by following OD620. The bacteria were let to grow until the OD reached the value of 0.3-0.4. The culture was centrifuged for 10 minutes at 10000 rpm. The supernatant was discarded and bacteria were washed once with PBS, resuspended in PBS containing 0.025% formaldehyde, and incubated for 2 hours at room temperature and then overnight at 4° C. with stirring. 100 μl bacterial cells were added to each well of a 96 well Greiner plate and incubated overnight at 4° C. The wells were then washed three times with PBT washing buffer (0.1% Tween-20 in PBS). 200 μl of saturation buffer (2.7
% Polyvinylpyrrolidone 10 in water) was added to each well and the plates incubated for 2 hours at 37° C. Wells were washed three times with PBT. 200 μl of diluted sera (Dilution buffer: 1% BSA, 0.1% Tween-20, 0.1% NaN3 in PBS) were added to each well and the plates incubated for 90 minutes at 37° C. Wells were washed three times with PBT. 100 μl of HRP-conjugated rabbit anti-mouse (Dako) serum diluted 1:2000 in dilution buffer were added to each well and the plates were incubated for 90 minutes at 37° C. Wells were washed three times with PBT buffer. 100 μl of substrate buffer for HRP (25 ml of citrate buffer pH5, 10 mg of O-phenildiamine and 10 μl of H2O) were added to each well and the plates were left at room temperature for 20 minutes. 100 μl H2SO4 was added to each well and OD490 was followed. The ELISA was considered positive when OD490 was 2.5 times the respective pre-immune sera. - O) FACScan Bacteria Binding Assay Procedure.
- The acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37° C. Bacterial colonies were collected from the agar plates using a sterile dracon swab and inoculated into 4 tubes containing 8 ml each Mueller-Hinton Broth (Difco) containing 0.25% glucose. Bacterial growth was monitored every 30 minutes by following OD620. The bacteria were let to grow until the OD reached the value of 0.35-0.5. The culture was centrifuged for 10 minutes at 4000 rpm. The supernatant was discarded and the pellet was resuspended in blocking buffer (1% BSA, 0.4% NaN3) and centrifuged for 5 minutes at 4000 rpm. Cells were resuspended in blocking buffer to reach OD620 of 0.07. 100 μl bacterial cells were added to each well of a Costar 96 well plate. 100 μl of diluted (1:200) sera (in blocking buffer) were added to each well and plates incubated for 2 hours at 4° C. Cells were centrifuged for 5 minutes at 4000 rpm, the supernatant aspirated and cells washed by addition of 200 μl/well of blocking buffer in each well. 100 μl of R-Phicoerytin conjugated F(ab)2 goat anti-mouse, diluted 1:100, was added to each well and plates incubated for 1 hour at 4° C. Cells were spun down by centrifugation at 4000 rpm for 5 minutes and washed by addition of 200 μl/well of blocking buffer. The supernatant was aspirated and cells resuspended in 200 μl/well of PBS, 0.25% formaldehyde. Samples were transferred to FACScan tubes and read. The condition for FACScan setting were: FL1 on, FL2 and FL3 off; FSC-H threshold: 92; FSC PMT Voltage: E 02; SSC PMT: 474; Amp. Gains 7.1; FL-2 PMT: 539; compensation values: 0.
- P) OMV Preparations
- Bacteria were grown overnight on 5 GC plates, harvested with a loop and resuspended in 10
ml 20 mM Tris-HCl. Heat inactivation was performed at 56° C. for 30 minutes and the bacteria disrupted by sonication for 10 minutes on ice (50% duty cycle, 50% output). Unbroken cells were removed by centrifugation at 5000 g for 10 minutes and the total cell envelope fraction recovered by centrifugation at 50000 g at 4° C. for 75 minutes. To extract cytoplasmic membrane proteins from the crude outer membranes, the whole fraction was resuspended in 2% sarkosyl (Sigma) and incubated at room temperature for 20 minutes. The suspension was centrifuged at 10000 g for 10 minutes to remove aggregates, and the supernatant further ultracentrifuged at 50000 g for 75 minutes to pellet the outer membranes. The outer membranes were resuspended in 10 mM Tris-HCl, pH8 and the protein concentration measured by the Bio-Rad Protein assay, using BSA as a standard. - Q) Whole Extracts Preparation
- Bacteria were grown overnight on a GC plate, harvested with a loop and resuspended in 1 ml of 20 mM Tris-HCl. Heat inactivation was performed at 56° C. for 30 minutes.
- R) Western Blotting
- Purified proteins (500 ng/lane), outer membrane vesicles (5 μg) and total cell extracts (25 μg) derived from MenB strain 2996 were loaded on 15% SDS-PAGE and transferred to a nitrocellulose membrane. The transfer was performed for 2 hours at 150 mA at 4° C., in transferring buffer (0.3% Tris base, 1.44% glycine, 20% methanol). The membrane was saturated by overnight incubation at 4° C. in saturation buffer (10% skimmed milk, 0.1% Triton X100 in PBS). The membrane was washed twice with washing buffer (3% skimmed milk, 0.1% Triton X100 in PBS) and incubated for 2 hours at 37° C. with mice sera diluted 1:200 in washing buffer. The membrane was washed twice and incubated for 90 minutes with a 1:2000 dilution of horseradish peroxidase labelled anti-mouse Ig. The membrane was washed twice with 0.1% Triton X100 in PBS and developed with the Opti-4CN Substrate Kit (Bio-Rad). The reaction was stopped by adding water.
- S) Bactericidal Assay
- MC58 strain was grown overnight at 37° C. on chocolate agar plates. 5-7 colonies were collected and used to inoculate 7 ml Mueller-Hinton broth. The suspension was incubated at 37° C. on a nutator and let to grow until OD620 was 0.5-0.8. The culture was aliquoted into sterile 1.5 ml Eppendorf tubes and centrifuged for 20 minutes at maximum speed in a microfuge. The pellet was washed once in Gey's buffer (Gibco) and resuspended in the same buffer to an OD620 of 0.5, diluted 1:20000 in Gey's buffer and stored at 25° C.
- 50 μl of Gey's buffer/1% BSA was added to each well of a 96-well tissue culture plate. 25 μl of diluted mice sera (1:100 in Gey's buffer/0.2% BSA) were added to each well and the plate incubated at 4° C. 25 μl of the previously described bacterial suspension were added to each well. 25 μl of either heat-inactivated (56° C. waterbath for 30 minutes) or normal baby rabbit complement were added to each well. Immediately after the addition of the baby rabbit complement, 22 μl of each sample/well were plated on Mueller-Hinton agar plates (time 0). The 96-well plate was incubated for 1 hour at 37° C. with rotation and then 22 μl of each sample/well were plated on Mueller-Hinton agar plates (time 1). After overnight incubation the colonies corresponding to
time 0 andtime 1 hour were counted. - Table II gives a summary of the cloning, expression and purification results.
TABLE II Cloning, expression and purification His-fusion GST-fusion ORF PCR/cloning expression expression Purification orf 38 + + + His- fusion orf 40 + + + His-fusion orf 41 + n.d. n.d. orf 44 + + + His-fusion orf 51 + n.d. n.d. orf 52 + n.d. + GST-fusion orf 56 + n.d. n.d. orf 69 + n.d. n.d. orf 82 + n.d. n.d. orf 114 + n.d. + GST-fusion orf 124 + n.d. n.d. - The following partial DNA sequence was identified in N. meningitidis <
SEQ ID 1>:1 ACACTGTTGT TTGCAACGGT TCAGGCAAGT GCTAACCAAT GAAGAGCAAG 51 AAGAAGATTT ATATTTAGAC CCCGTACAAC GCACTGTTGC CGTGTTGATA 101 GTCAATTCCG ATAAAGAAGG CACGGGAGAA AAAGAAAAAG TAGAAGAAAA 151 TTCAGATTGG GCAGTATATT TCAACGAGAA AGGAGTACTA ACAGCCAGAG 201 AAATCACCyT CAAAGCCGGC GACAACCTGA AAATCAAACA AAACGGCACA 251 AACTTCACCT ACTCGCTGAA AAALGACCTC ACAGATCTGA CCAGTGTTGG 301 AACTGAAAAA TTATCGTTTA GCGCAAACGG CAATAAAGTC AACATCACAA 351 GCGACACCAA AGGCTTGAAT TTTGCGAAAG AAACGGCTGG sACGAACGgC 401 GACACCACGG TTCATCTGAA CGGTATTGGT TCGACTTTGA CCGATACGCT 451 GCTGAATACC GGAGCGACCA CAAACGTAAC CAACGACAAC GTTACCGATG 501 ACGAGAAAAA ACGTGCGGCA AGCGTTAAAG ACGTATTAAA CGCTGGCTGG 551 AACATTAAAG GCGTTAAACC CGGTACAACA GCTTCCGATA ACGTTGATTT 601 CGTCCGCACT TACGACACAG TCGAGTTCTT GAGCGCAGAT ACGAAAACAA 651 CGACTGTTAA TGTGGAAAGC AAAGACAACG GCAAGAAAAC CGAAGTTAAA 701 ATCGGTGCGA AGACTTCTGT TATTAAAGAA AAAGAC... - This corresponds to the amino acid sequence <SEQ ID 2; ORF40>:
1 ..TLLFATVQAS ANQEEQEEDL YLDPVQRTVA VLIVNSDKEG TGEKEKVEEN 51 SDWAVYFNEK GVLTAREITX KAGDNLKIKQ NGTNFTYSLK KDLTDLTSVG 101 TEKLSFSANG NKVNITSDTK GLNFAKETAG TNGDTTVHLN GIGSTLTDTL 151 LNTGATTNVT NDNVTDDEKK RAASVKDVLN AGWNIKGVKP GTTASDNVDF 201 VRTYDTVEFL SADTKTITVN VESKDNGKKT EVKIGAXTSV IKEKD... - Further work revealed the complete DNA sequence <SEQ ID 3>:
1 ATGAACAAAA TATACCGCAT CATTTGGAAT AGTGCCCTCA ATGCCTGGGT 51 CGTCGTATCC GAGCTCACAC GCAACCACAC CAAACGCGCC TCCGCAACCG 101 TGAAGACCGC CGTATTGGCG ACACTGTTGT TTGCAACGGT TCAGGCAAGT 151 GCTAACAATG AAGAGCAAGA AGAAGATTTA TATTTAGACC CCGTACAACG 201 CACTGTTGCC GTGTTGATAG TCAATTCCGA TAAAGAAGGC ACGGGAGAAA 251 AAGAAAAAGT AGAAGAAAAT TCAGATTGGG CAGTATATTT CAACGAGAAA 301 GGAGTACTAA CAGCCAGAGA AATCACCCTC AAAGCCGGCG ACAACCTGAA 351 AATCAAACAA AACGGCACAA ACTTCACCTA CTCGCTGAAA AAAGACCTCA 401 CAGATCTGAC CAGTGTTGGA ACTGAAAAAT TATCGTTTAG CGCAAACGGC 451 AATAAAGTCA ACATCACAAG CGACACCAAA GGCTTGAATT TTGCGAAAGA 501 AACGGCTGGG ACGAACGGCG ACACCACGGT TCATCTGAAC GGTATTGGTT 551 CGACTTTGAC CGATACGCTG CTGAATACCG GAGCGACCAC AAACGTAACC 601 AACGACAACG TTACCGATGA CGAGAAAAAA CGTGCGGCAA GCGTTAAAGA 651 CGTATTAAAC GCTGGCTGGA ACATTAAAGG CGTTAAACCC GGTACAACAG 701 CTTCCGATAA CGTTGATTTC GTCCGCACTT ACGACACAGT CGAGTTCTTG 751 AGCGCAGATA CGAAAACAAC GACTGTTAAT GTGGAAAGCA AAGACAACGG 801 CAAGAAAACC GAAGTTAAAA TCGGTGCGAA GACTTCTGTT ATTAAAGAAA 851 AAGACGGTAA GTTGGTTACT GGTAAAGACA AAGGCGAGAA TGGTTCTTCT 901 ACAGACGAAG GCGAAGGCTT AGTGACTGCA AAAGAAGTGA TTGATGCAGT 951 AAACAAGGCT GGTTGGAGAA TGAAAACAAC AACCGCTAAT GGTCAAACAG 1001 GTCAAGCTGA CAAGTTTGAA ACCGTTACAT CAGGCACAAA TGTAACCTTT 1051 GCTAGTGGTA AAGGTACAAC TGCGACTGTA AGTAAAGATG ATCAAGGCAA 1101 CATCACTGTT ATGTATGATG TAAATGTCGG CGATGCCCTA AACGTCAATC 1151 AGCTGCAAAA CAGCGGTTGG AATTTGGATT CCAAAGCGGT TGCAGGTTCT 1201 TCGGGCAAAG TCATCAGCGG CAATGTTTCG CCGAGCAAGG GAAAGATGGA 1251 TGAAACCGTC AACATTAATG CCGGCAACAA CATCGAGATT ACCCGCAACG 1301 GTAAAAATAT CGACATCGCC ACTTCGATGA CCCCGCAGTT TTCCAGCGTT 1351 TCGCTCGGCG CGGGGGCGGA TGCGCCCACT TTGAGCGTGG ATGGGGACGC 1401 ATTGAATGTC GGCAGCAAGA AGGACAACAA ACCCGTCCGC ATTACCAATG 1451 TCGCCCCGGG CGTTAAAGAG GGGGATGTTA CAAACGTCGC ACAACTTAAA 1501 GGCGTGGCGC AAAACTTGAA CAACCGCATC GACAATGTGG ACGGCAACGC 1551 GCGTGCGGGC ATCGCCCAAG CGATTGCAAC CGCAGGTCTG GTTCAGGCGT 1601 ATTTGCCCGG CAAGAGTATG ATGGCGATCG GCGGCGGCAC TTATCGCGGC 1651 GAAGCCGGTT ACGCCATCGG CTACTCCAGT ATTTCCGACG GCGGAAATTG 1701 GATTATCAAA GGCACGGCTT CCGGCAATTC GCGCGGCCAT TTCGGTGCTT 1751 CCGCATCTGT CGGTTATCAG TGGTAA - This corresponds to the amino acid sequence <SEQ ID 4; ORF40-1>:
1 MNKIYRIIWN SALNAWVVVS ELTRNHTKRA SATVKTAVLA TLLFATVQAS 51 ANNEEQEEDL YLDFVQRTVA VLIVNSDKEG TGEKEKVEEN SDWAVYFNEK 101 GVLTAREITL KAGDNLKIKQ NGTNFTYSLK KDLTDLTSVG TEKLSFSMIG 151 NKVNITSDTK GLNFAKETAG TNGDTTVHLN GIGSTLTDTL LNTGATTNVT 201 NDNVTDDEKK RAASVKDVLN AGWNIKGVKP GTTASDNVDF VRTYDTVEFL 251 SADTKTTTVN VESKDNGKKT EVKIGAKTSV IKEKDGKLVT GKDKGENGSS 301 TDEGEGLVTA KEVIDAYNKA GWRMKTTTAN GQTGQADKFE TVTSGTNVTF 351 ASGKGTTATV SKDDQGNITV NYDVNVGDAL NVNQLQNSGW NLDSKAVAGS 401 SGKVISGNVS PSKGKMDETV NINAGNNIEI TRNGKNIDIA TSHTPQFSSV 451 SLGAGADAPT LSVDGDALNV GSKKDNKPVR ITNVAPGVKE GOVTNVAQLK 501 GVAQNLNNRI DNVDGNARAG ZAQAIATAGL VQAYLPGKSM MAIGGGTYRG 551 EAGYAIGYSS ISDGGNWIIK GTASGNSRGH FGASASVGYQ W* - Further work identified the corresponding gene in strain A of N. meningitidis <
SEQ ID 5>:1 ATGAACAAAA TATACCGCAT CATTTGGAAT AGTGCCCTCA ATGCCTGNGT 51 CGCCGTATCC GAGCTCACAC GCAACCACAC CAAACGCGCC TCCGCAACCG 101 TGAAGACCGC CGTATTGGCG ACACTGTTGT TTGCAACGGT TCAGGCGAAT 151 GCTACCGATG AAGATGAAGA AGAAGAGTTA GAATCCGTAC AACGCTCTGT 201 CGTAGGGAGC ATTCAAGCCA GTATGGAAGG CAGCGGCGAA TTGGAAACGA 251 TATCATTATC AATGACTAAC GACAGCAAGG AATTTGTAGA CCCATACATA 301 GTAGTTACCC TCAAAGCCGG CGACAACCTG AAAATCAAAC AAAACACCAA 351 TGAAAACACC AATGCCAGTA GCTTCACCTA CTCGCTGAAA AAAGACCTCA 401 CAGGCCTGAT CAATGTTGAN ACTGAAAAAT TATCGTTTGG CGCAAACGGC 451 AAGAAAGTCA ACATCATAAG CGACACCAAA GGCTTGAATT TCGCGAAAGA 501 AACGGCTGGG ACGAACGGCG ACACCACGGT TCATCTGAAC GGTATCGGTT 551 CGACTTTGAC CGATACGCTT GCGGGTTCTT CTGCTTCTCA CGTTGATGCG 601 GGTAACCNAA GTACACATTA CACTCGTGCA GCAAGTATTA AGGATGTGTT 651 GAATGCGGGT TGGAATATTA AGGGTGTTAA ANNNGGCTCA ACAACTGGTC 701 AATCAGAAAA TGTCGATTTC GTCCGCACTT ACGACACAGT CGAGTTCTTG 751 AGCGCAGATA CGNAAACAAC GACNGTTAAT GTGGAAAGCA AAGACAACGG 801 CAAGAGAACC GAAGTTAAAA TCGGTGCGAA GACTTCTGTT ATTAAAGAAA 851 AAGACGGTAA GTTGGTTACT GGTAAAGGCA AAGGCGAGAA TGGTTCTTCT 901 ACAGACGAAG GCGAAGGCTT AGTGACTGCA AAAGAAGTGA TTGATGCAGT 951 AAACAAGGCT GGTTGGAGAA TGAAAACAAC AACCGCTAAT GGTCAAACAG 1001 GTCAAGCTGA CAAGTTTGAA ACCGTTACAT CAGGCACAAA TGTAACCTTT 1051 GCTAGTGGTA AAGGTACAAC TGCGACTGTA AGTAAAGATG ATCAAGGCAA 1101 CATCACTGTT ATGTATGATG TAAATGTCGG CGATGCCCTA AACGTCAATC 1151 AGCTGCAAAA CAGCGGTTGG AATTTGGATT CCAAAGCGGT TGCAGGTTCT 1201 TCGGGCAAAG TCATCAGCGG CAATGTTTCG CCGAGCAAGG GAAAGATGGA 1251 TGAAACCGTC AACATTAATG CCGGCAACAA CATCGACATT AGCCGCAACG 1301 GTAAAAATAT CGACATCGCC ACTTCGATGG CGCCGCAGTT TTCCAGCGTT 1351 TCGCTCGGCG CGGGGGCAGA TGCGCCCACT TTAAGCGTGG ATGACGAGGG 1401 CGCGTTGAAT GTCGGCAGCA AGGATGCCAA CAAACCCGTC CGCATTACCA 1451 ATGTCGCCCC GGGCGTTAAA GANGGGGATG TTACAAACGT CNCACAACTT 1501 AAAGGCGTGG CGCAAAACTT GAACAACCGC ATCGACAATG TGGACGGCAA 1551 CGCGCGTGCN GGCATCGCCC AAGCGATTGC AACCGCAGGT CTGGTTCAGG 1601 CGTATCTGCC CGGCAAGAGT ATGATGGCGA TCGGCGGCGG CACTTATCGC 1651 GGCGAAGCCG GTTACGCCAT CGGCTACTCC AGTATTTCCG ACGGCGGAAA 1701 TTGGATTATC AAAGGCACGG CTTCCGGCAA TTCGCGCGGC CATTTCGGTG 1751 CTTCCGCATC TGTCGGTTAT CAGTGGTAA - This encodes a protein having amino acid sequence <SEQ ID 6; ORF40a>:
1 MNKIYRIIWN SALNPXVAVS ELTRNHTKRA SATVKTAVLA TLLFATVQAN 51 ATDEDEKEEL ESVQRSVVGS IQASMEGSGE LETISLSHTN DSKEFVDPYI 101 VVTLKAGDNL KIKONTHENT NASSFTYSLK KDLTGLINVX TEKLSFGANG 151 KKVNIISDTK GLNFAXETAG TNGDTTVHLN GIGSTLTDTL AGSSASHVDA 201 GNXSTHYTRA ASIKDVLNAG WNIKGVKXGS TTGQSENVDF VRTYDTVEFL 251 SADTXTTTVN VESKDNGKRT EVXIGAXTSV IKEKDGKLVT GKGKGENGSS 301 TDEGEGLVTA KEVIDAVNKA GWRMKTTTAN GQTGQADKFE TVTSGTNVTF 351 ASGKGTTATV SXDDQGNITV MYDVNVGDAL NVNQLONSGW NLDSKAVAGS 401 SGKVISGNVS PSKGKMDETV NINAGNNIEI SRNGKNIDIA TSMAPQFSSV 451 SLGAGADAPT LSVDDEGALN VGSKDANKPV RITNVAPGVK XGDVTNVXQL 501 KGVAQNLNNR IDNYOGNARA GIAQAIATAG LVQAYLPGKS NNAIGGGTYR 551 GEAGYAIGYS SISDGGNWII KGTASGNSRG HFGASASVGY QW - The originally-identified partial strain B sequence (ORF40) shows 65.7% identity over a 254 aa overlap with ORF40a:
10 20 30 orf40.pep TLLFATVQASANQEEQEEDLYLDPVQRTVA |||||||||:|::|::||:| : |||:| orf40a SALNAXVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL--ESVQRSV- 20 30 40 50 60 40 50 60 70 80 orf40.pep VLIVNSDKEGTGEKEKVEEN-SDWAVYFNEKGVLTAREITXKAGDNLKIKQN------GT | :::: ||:|| | : : :: : | : :: :| ||||||||||| :: orf40a VGSIQASMEGSGELETISLSMTNDSKEFVDPYIV----VTLKAGDNLKIKQNTNENTNAS 70 80 90 100 110 120 90 100 110 120 130 140 orf40.pep NFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKETAGTNGDTTVHLNGIG :|||||||||| | :| ||||||:|||:|||| ||||||||||||||||||||||||||| orf40a SFTYSLKKDLTGLINVXTEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLNGIG 130 140 150 160 170 180 150 160 170 180 190 200 orf40.pep STLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTA--SDNVDFV ||||||| :::|: :| | : : ||||:|||||||||||||| |:|: |:||||| orf40a STLTDTLAGSSAS-HVDAGNXST-HYTRAASIKDVLNAGWNIKGVKXGSTTGQSENVDFV 190 200 210 220 230 240 210 220 230 240 orf40.pep RTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKD ||||||||||||| |||||||||||||:|||||||||||||||| orf40a RTYDTVEFLSADTXTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSST 250 260 270 280 290 300 - The complete strain B sequence (ORF44-1) and ORF40a show 83.7% identity in 601 aa overlap:
10 20 30 40 50 60 orf40-1.pep MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKTAVLATLLFATVQASANNEEQEEDL ||||||||||||||| |:|||||||||||||||||||||||||||||||:|::|::||:| orf40a MNKIYRIIWNSALNAXVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL 10 20 30 40 50 60 70 80 90 100 110 119 orf40-1.pep YLDPVQRTVAVLIVNSDKEGTGEKEKVEEN-SDWAVYFNEKGVLTAREITLKAGDNLKIK : |||:| | :::: ||:|| | : : :: : | : :: :||||||||||| orf40a --ESVQRSV-VGSIQASMEGSGELETISLSMTNDSKEFVDPYIV----VTLKAGDNLKIK 70 80 90 100 110 120 130 140 150 160 170 orf40-1.pep QN------GTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKETAGTNG || :::||||||||| | :| ||||||:|||:|||| ||||||||||||||||| orf40a QNTNENTNASSFTYSLKKDLTGLINVXTEKLSFGANGKKVNIISDTKGLNFAKETAGTNG 120 130 140 150 160 170 180 190 200 210 220 230 orf40-1.pep DTTVHLNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTT ||||||||||||||||| :::|: :| | : : ||||:|||||||||||||| |:| orf40a DTTVHLNGIGSTLTDTLAGSSAS-HVDAGNXST-HYTRAASIKDVLNAGWNIKGVKXGST 180 190 200 210 220 230 240 250 260 270 280 290 orf40-1.pep A--SDNVDFVRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTG : |:|||||||||||||||||| |||||||||||||:|||||||||||||||||||||| orf40a TGQSENVDFVRTYDTVEFLSADTXTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTG 240 250 260 270 280 290 300 310 320 330 340 350 orf40-1.pep KDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf40a KGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFA 300 310 320 330 340 350 360 370 360 390 400 410 orf40-1.pep SGKGTTATVSKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSP |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf40a SGKGTTATVSKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSP 360 370 360 390 400 410 420 430 440 450 460 470 orf40-1.pep SKGKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGD-ALNV |||||||||||||||||||:||||||||||||:|||||||||||||||||||| : |||| orf40a SKGKMDETVNINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNV 420 430 440 450 460 470 480 490 500 510 520 530 orf40-1.pep GSKKDNKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGL ||| |||||||||||||| |||||| ||||||||||||||||||||||||||||||||| orf40a GSKDANKPVRITNVAPGVKXGDVTNVXQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGL 480 490 500 510 520 530 540 550 560 570 580 590 orf40-1.pep VQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQ |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf40a VQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQ 540 550 560 570 580 590 orf40-1.pep WX || orf40a WX - Computer analysis of these amino acid sequences gave the following results:
- Homology with Hsf Protein Encoded by the Type b Surface Fibrils Locus of H. influenzae (Accession Number U41852)
- ORF40 and Hsf protein show 54% aa identity in 251 aa overlap:
Orf40 1 TLLFATVQASANQEEQEEDLYLDPVQRTVAVLVINSDXXXXXXXXXXXXNSDWAVYFNEK 60TLLFATVQA+A E++E LDPV RT VL +SD NS+W +YF+ K Hsf 41 TLLFATVQANATDEDEE----LDPVVRTAPVLSFHSDKEGTGEKEVTE- NSNWGIYFDNK 95Orf40 61 GVLTAREITXKAGDNLKIKQN------GTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVN 114 GVL A IT KAGDNLKIKQN ++FTYSLKKDLTDLTSV TEKLSF ANG+KV+ Hsf 96 GVLKAGAITLKAGDNLKIKQNTDESTNASSFTYSLKKDLTDLTSVATEKLSFGANGDKVD 155 Orf40 115 ITSDTKGLNFAKETAGTNGDTTVhLNGIGSTLTDTLLNTGAXXXXXXXXXXXXEKKRAAS 174 ITSD GL AK G+ VHLNG+ STL D + NTG EK RAA+ Hsf 156 ITSDANGLKLAK-----TGNGNVHLNGLDSTLPDAVTNTGVLSSSSFTPNDV-EKTRAAT 209 Orf40 175 VKDVLNAGWNIKGVKPGTTASDNVDFVRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKI 234 VKDVLNAGWNIKG K ++VD V Y+ VEF++ D T V ++K+NGK TEVK Hsf 210 VKDVLNAGWNIKGAKTAGGNVESVDLVSAYNNVEFITGDKNTLDVVLTAKENGKTTEVKF 269 Orf40 235 GAKTSVIKEKD 245 KTSVIKEKD Hsf 270 TPKTSVIKEKD 280 - ORF40a also shows homology to Hsf:
gi|1666683 (U41852) hsf gene product [Haemophilus influenzae] Length = 2353 Score = 153 (67.7 bits), Expect = 1.5−116, Sum P(11) = 1.5e−116 Identities = 33/36 (91%), Positives = 34/36 (94%) Query: 16 VAVSELTRNHTKRASATVKTAVLATLLFATVQANAT 51 V VSELTR HTKRASATV+TAVLATLLFATVQNAT Sbjct: 17 VVVSELTRTHTKRASATVETAVLATLLFATVQANAT 52 Score = 161 (71.2 bits), Expect = 1.5e−116, Sum P(11) 1.5e−116 Identities = 32/38 (84%), Positives = 36/38 (94%) Query: 101 VTLKAGDNLKIKQNTNENTNASSFTYSLKKDLTGLINV 138 +TLAGDNLKIKQNT+E+TNASSFTYSLKKDLT L +V Sbjct: 103 ITLKAGDNLKIKQNTDESTNASSFFYSLKKDLTDLTSV 140 Score = 110 (48.7 bits), Expect = 1.5e−116, Sum P(11) = 1.5e−116 Identities = 21/29 (72%), Positives = 25/29 (86%) Query: 138 VTEKLSFGANGKKVNIISDTKGLNFAKET 166 V++KLS G NG KVNI SDTKGLNFAK++ Sbjct: 1439 VSDKLSLGTNGNKVNITSDTXGLNFAKDS 1467 Score = 85 (37.6 bits), Expect = 1.5e−116, Sum P(11) = 1.5e−116 Identities = 18/32 (56%), Positives = 20/32 (62%) Query: 169 TNGDTTVHLNGIGSTLTDTLAGSSASHVDAGN 200 T D +HLNGI STLTDTL S A+ GN Sbjct: 1469 TGDDANIHLNGIASTLTDTLLNSGATTNLGGN 1500 Score = 92 (40.7 bits), Expect = 1.5e−116, Sum P(11) = 1.5e−116 Identities = 16/19 (84%), Positives = 19/19 (100%) Query: 206 RAASIKOVLNAGWNIKGVK 224 RAAS+KDVLNAGWN++GVK Sbjct: 1509 RAASVKDVLNAGWNVRGVK 1527 Score = 90 (39.8 bits), Expect = 1.5e−116, Sum P(11) = 1.5e−116 Identities = 17/28 (60%), Positives 20/28 (71%) Query: 226 STTGQSENVDFVRTYDTVEFLSADTTTT 253 S Q EN+DFV TYDTV+F+S D TT Sbjct: 1530 SANNQVENIDFVATYDTVDFVSGDKDTT 1557 - Based on homology with Hsf, it was predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- ORF40-1 (61 kDa) was cloned in pET and pGex vectors and expressed in E. coli, as described above. The products of protein expression and purification were analyzed by SDS-PAGE.
FIG. 1A shows the results of affinity purification of the His-fusion protein, andFIG. 1B shows the results of expression of the GST-fusion in E. coli. Purified His-fusion protein was used to immunise mice, whose sera were used for FACS analysis (FIG. 1C ), a bactericidal assay (FIG. 1D ), and ELISA (positive result). These experiments confirm that ORF40-1 is a surface-exposed protein, and that it is a useful immunogen. -
FIG. 1E shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF40-1. - The following partial DNA sequence was identified in N. meningitidis <SEQ ID 7>
1 ATGTFACGTt TGACTGCtTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC 51 GTGTT~GCCG CAAAATTCCG ACTCTGCCCC ACAAGCCAAA GaACAGGCGG 101 TTTCCGCCGC ACAAACCGAA GgCGCGTCCG TTACCGTCAA AACCGCGCGC 151 GGCGACGTTC AAATACCGCA AAACCCCGAA CGCATCGCCG TTTACGATTT 201 GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGAAAACC GGTTTGTCCG 251 TCGATAAAAA CCGCCTGCCG TATTTAGAGG AATATTTCAA AACGACAAAA 301 CCTGCcGGCA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGCTTACAA 351 ACCGCAGCTC ATCATCATCG GCAGCCGCGC CgCCAAGGCG TTTGACAAAT 401 TGAAcGAAAT CGCGCCGACC ATCGrmwTGA CCGCCGATAC CGCCAACCTC 451 AAAGAAAGTG CCAArGAGGC ATCGACGCTG GCGCAAATCT TC.. - This corresponds to the amino acid sequence <SEQ ID 8; ORF38>:
1 MLRLTALAVC TALALGACSP QNSDSAPOAK EQAVSAAQTE GASVTVKTAR 51 GDVQIPQNPE RIAVYDLGHL DTLSKLGVKT GLSVDKNRLP YLEEYFKTTK 101 PAGTLFEPDY ETLNAYKPQL IIIGSRAAKA FDKLNEIAPT IXXTADTANL 151 KESAKEASTL AQIF.. - Further work revealed the complete nucleotide sequence <SEQ ID 9>:
1 ATGTTACGTT TGACTGCTTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC 51 GTGTTCGCCG CAAAATTCCG ACTCTGCCCC ACAAGCCAAA GAACAGGCGG 101 TTTCCGCCGC ACAAACCGAA GGCGCGTCCG TTACCGTCAA AACCGCGCGC 151 GGCGACGTTC AAATACCGCA AAACCCCGAA CGCATCGCCG TTTACGATTT 201 GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGAAAACC GGTTTGTCCG 251 TCGATAAAAA CCGCCTGCCG TATTTAGAGG AATATTTCAA AACGACAAAA 301 CCTGCCGGCA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGCTTACAA 351 ACCGCAGCTC ATCATCATCG GCAGCCGCGC CGCCAAGGCG TTTGACAAAT 401 TGAACGAAAT CGCGCCGACC ATCGAAATGA CCGCCGATAC CGCCAACCTC 451 AAAGAAAGTG CCAAAGAGCG CATCGACGCG CTGGCGCAAA TCTTCGGCAA 501 ACAGGCGGAA GCCGACAAGC TGAAGGCGGA AATCGACGCG TCTTTTGAAG 551 CCGCGAAAAC TGCCGCACAA GGTAAGGGCA AAGGTTTGGT GATTTTGGTC 601 AACGGCGGCA AGATGTCGGC TTTCGGCCCG TCTTCACGCT TGGGCGGCTG 651 GCTGCACAAA GACATCGGCG TTCCCGCTGT CGATGAATCA ATTAAAGAAG 701 GCAGCCACGG TCAGCCTATC AGCTTTGAAT ACCTGAAAGA GAAAAATCCC 751 GACTGGCTGT TTGTCCTTGA CCGAAGCGCG GCCATCGGCG AAGAGGGTCA 801 GGCGGCGAAA GACGTGTTGG ATAATCCGCT GGTTGCCGAA ACAACCGCTT 851 GGAAAAAAGG ACAGGTCGTG TACCTCGTTC CTGAAACTTA TTTGGCAGCC 901 GGTGGCGCGC AAGAGCTGCT GAATGCAAGC AAACAGGTTG CCGACGCTTT 951 TAACGCGGCA AAATAA - This corresponds to the amino acid sequence <
SEQ ID 10; ORF38-1>:1 MLRLTALAVC TALALGACSP QNSDSAPQAK EQAVSAAQTE GASVTVKTAR 51 GDVQIPQNPE RIAVYDLQIL DTLSXLGVKT GLSVDKNRLP YLEEYFKTTK 101 PAGTLFEPDY ETLNAYKPQL IIIGSRAAKA FDKLNEIAPT IENTADTANL 151 KESAKERIDA LAQIFGKQAE ADKLKAEIDA SFEAAKTAAQ GKGKGLVILV 201 NGGKMSAFGP SSRLGGWLKK DIGVPAVDES IKEGSHGQPI SFEYLKEKNP 251 DWLFVLDRSA AIGEEGQAAK DVLDNPLVAE TTAWKKGQVV YLVPETYLAA 301 GGAQELLNAS KQVADAFNAA K* - Computer analysis of this amino acid sequence reveals a putative prokaryotic membrane lipoprotein lipid attachment site (underlined).
- Further work identified the corresponding gene in strain A of N. meningitidis <SEQ ID 11>:
1 ATGTTACGTT TGACTGCTTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC 51 GTGTTCGCCG CAAAATTCCG ACTCTGCCCC ACAAGCCAAA GAACAGGCGG 101 TTTCCGCCGC ACAATCCGAA GGCGTGTCCG TTACCGTCAA AACGGCGCGC 151 GGCGATGTTC AAATACCGCA AAACCCCGAA CGTATCGCCG TTTACGATTT 201 GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGAAAACC GGTTTGTCCG 251 TCGATAAAAA CCGCCTGCCG TATTTAGAGG AATATTTCAA AACGACAAAA 301 CCTGCCGGAA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGCTTACAA 351 ACCGCAGCTC ATCATCATCG GCAGCCGCGC AGCCAAAGCG TTTGACAAAT 401 TGAACGAAAT CGCGCCGACC ATCGAAATGA CCGCCGATAC CGCCAACCTC 451 AAAGAAAGTG CCAAAGAGCG TATCGACGCG CTGGCGCAAA TCTTCGGCAA 501 AAAGGCGGAA GCCGACAAGC TGAAGGCGGA AATCGACGCG TCTTTTGAAG 551 CCGCGAAAAC TGCCGCGCAA GGCAAAGGCA AGGGTTTGGT GATTTTGGTC 601 AAcGGCGGCA AGATGTCCGC CTTCGGCCCG TCTTCACGAC TGGGCGGCTG 651 GCTGCACAAA GACATCGGCG TTCCCGCTGT TGACGAAGCC ATCAAAGAAG 701 GCAGCCACGG TCAGCCTATC AGCTTTGAAT ACCTGAAAGA GAAAAATCCC 751 GACTGGCTGT TTGTCCTTGA CCGCAGCGCG GCCATCGGCG AAAAGGGTCA 601 GGCGGCGAAA GACGTGTTGA ACAATCCGCT GGTTGCCGAA ACAACCGCTT 851 GGAAAAATGG ACAAGTCGTT TACCTTGTTC CTGAAACTTA TTTGGCAGCC 901 GGTGGCGCGC AAGAGCTACT GAATGCAAGC AAACAGGTTG CCGACGCTTT 951 TAACGCGGCA AAATAA - This encodes a protein having amino acid sequence <SEQ ID 12; ORF38a>:
1 MLRLTALAVC TALALGACSP QNSDSAPOAK EQAVSAAQSE GVSVTVKTAR 51 GDVQIPQNPE RIAVYDLGHL DTLSKLGVKT GLSVDKNRLP YLEEYFKTTK 101 PAGTLFEPDY ETLNAYKPQL IIIGSRAAKA FDKLNEIAPT IENTADTANL 151 KESAKERIDA LAOIFGKKAE ADKLKAEIDA SFEAAKTAAQ GKGKGLVILV 201 NGGKMSAFGP SSRLGGWLHK DIGVPAVDEA IKEGSHGQPI SFEYLKEKNP 251 DWLFVLDRSA AIGEEGQAAK DVLNNPLVAE TTAWKKGQVV YLVPETYLAA 301 GGAQELLNAS KQVAOAFWAA K* - The originally-identified partial strain B sequence (ORF38) shows 95.2% identity over a 165 aa overlap with ORF38a:
10 20 30 40 50 60 orf38.pep MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQTEGASVTVKTARGDVQIPQNPE ||||||||||||||||||||||||||||||||||||||:||:|||||||||||||||||| orf38a MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQSEGVSVTVKTARGDVQIPQNPE 10 20 30 40 50 60 70 80 90 100 110 120 orf38.pep RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEEYFKTTKPAGTLFEPDYETLNAYKPQL |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf38a RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEEYFKTTKPAGTLFEPDYETLNAYKPQL 70 80 90 100 110 120 130 140 150 160 orf38.pep IIIGSRAAKAFDKLNEIAPTIXXTADTANLKESAKE-ASTLAQIF ||||||||||||||||||||| ||||||||||||| ::||||| orf39a IIIGSRAAKAFDKLNEIAPTIEMTADTANLKESAKERIDALAQIFGKKAEADKLKAEIDA 130 140 150 160 orf38a SFEAAKTAAQGKGKGLVILVNGGKMSAFGPSSRLGGWLHKDIGVPAVDEAIKEGSHGQPI 190 200 210 220 230 240 - The complete strain B sequence (ORF38-1) and ORF38a show 98.4% identity in 321 aa overlap:
orf38a.pep MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQSEGVSVTVKTARGDVQIPQNPE ||||||||||||||||||||||||||||||||||||||:||:|||||||||||||||||| orf38-1 MLRLTALAVCTALALGACSPQNSDSAPQAKEQAVSAAQTEGASVTVKTARGDVQIPQNPE orf38a.pep RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEEYFKTTKPAGTLFEPDYETLNAYKPQL |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf38-1 RIAVYDLGMLDTLSKLGVKTGLSVDKNRLPYLEEYFKTTKPAGTLFEPDYETLNAYKPQL orf38a.pep IIIGSRAAKAFDKLNEIAPTIEMTADTANLKESAKERIDALAQIFGKKAEADKLKAEIDA |||||||||||||||||||||||||||||||||||||||||||||||:|||||||||||| orf38-1 IIIGSRAAKAFDKLNEIAPTIEMTADTANLKESAKERIDALAQIFGKQAEADKLKAEIDA orf38a.pep SFEAAKTAAQGKGKGLVILVNGGKMSAFGPSSRLGGWLHKDIGVPAVDEAIKEGSHGQPI |||||||||||||||||||||||||||||||||||||||||||||||||:|||||||||| orf38-1 SFEAAKTAAQGKGKGLVILVNGGKMSAFGPSSRLGGWLHKDIGVPAVDESIKEGSHGQPI orf38a.pep SFEYLKEKNPDWLFVLDRSAAIGEEGQAAKDVLNNPLVAETTAWKKGQVVYLVPETYLAA |||||||||||||||||||||||||||||||||:|||||||||||||||||||||||||| orf38-1 SFEYLKEKNPDWLFVLDRSAAIGEEGQAAKDVLDNPLVAETTAWKKGQVVYLVPETYLAA orf38a.pep GGAQELLNASKQVADAFNAAK ||||||||||||||||||||| orf38-1 GGAQELLNASKQVADAFNAAK - Computer analysis of these sequences revealed the following:
- Homology with a Lipoprotein (lipo) of C. jejuni (Accession Number X82427)
- ORF38 and lipo show 38% aa identity in 96 aa overlap:
Orf38: 40 EGASVTVKTARGDVQIPQNPERIAVYDLGMLDTLSKLGVKTGLS-VKDNRLPYLEEYFKT 98 EG S VK + G+ + P+NP ++ + DLG+LDT L + ++ V LP + FK Lipo: 51 EGDSFLVKDSLGENKTPKNPSKVVILDLGILDTFDALKLNDKVAGVPAKNLPKYLQQFKN 110Orf38: 99 TKPAGTLFEPDYETLNAYKPQLIIIGSRAAKAFDKL 134 G + + D+E +NA KP LIII R +K +DKL Lipo: 111 KPSVGGVQQVDFEAINALKPDLIIISGRQSKFYDKL 146 - Based on this analysis, it was predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- ORF38-1 (32 kDa) was cloned in pET and pGex vectors and expressed in E. coli, as described above. The products of protein expression and purification were analyzed by SDS-PAGE.
FIG. 2A shows the results of affinity purification of the His-fusion protein, andFIG. 2B shows the results of expression of the GST-fusion in E. coli. Purified His-fusion protein was used to immunise mice, whose sera were used for Western blot analysis (FIG. 2C ) and FACS analysis (FIG. 2D ). These experiments confirm that ORF38-1 is a surface-exposed protein, and that it is a useful immunogen. -
FIG. 2E shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF38-1. - The following N. meningitidis DNA sequence was identified <SEQ ID 13>:
1 ATGAAACTTC TGACCACCGC AATCCTGTCT TCCGCAATCG CGCTCAGCAG 51 TATGGCTGCC GCCGCTGGCA CGGACAACCC CACTGTTGCA AAAAAAACCG 101 TCAGCTACGT CTGCCAGCAA GGTAAAAAAG TCAAAGTAAC CTACGGCTTC 151 AACAAACAGG GTCTGACCAC ATACGCTTCC GCCGTCATCA ACGGCAAACG 201 CGTGCAAATG CCTGTCAATT TGGACAAATC CGACAATGTG GAAACATTCT 251 ACGGCAAAGA AGGCGGTTAT GTTTTGGGTA CCGGCGTGAT GGATGGCAAA 301 TCCTACCGCA AACAGCCCAT TATGATTACC GCACCTGACA ACCAAATCGT 351 CTTCAAAGAC TGTTCCCCAC GTTAA - This corresponds to the amino acid sequence <SEQ ID 14; ORF44>:
1 MKLLTTAILS SAIALSSMAA AAGTDWPTVA KKTVSYVCQQ GKKVKVTYGF 51 NKQGLTTYAS AVINGKRVQH PVNLDKSDNV ETFYGKEGGY VLGTGVMDGK 101 SYRKQPIHIT APDNQIVFKD CSPR* - Computer analysis of this amino acid sequence predicted the leader peptide shown underlined.
- Further work identified the corresponding gene in strain A of N. meningitidis <
SEQ ID 15>:1 ATGAAACTTC TGACCACCGC AATCCTGTCT TCCGCAATCG CGCTCAGCAG 51 TATGGCTGCT GCTGCCGGCA CGAACAACCC CACCGTTGCC AAAAAAACCG 101 TCAGCTACGT CTGCCAGCAA GGTAAAAAAG TCAAAGTAAC CTACGGCTTT 151 AACAAACAGG GCCTGACCAC ATACGCTTCC GCCGTCATCA ACGGCAAACG 201 TGTGCAAATG CCTGTCAATT TGGACAAATC CGACAATGTG GAAACATTCT 251 ACGGCAAAGA AGGCGGTTAT GTTTTGGGTA CCGGCGTGAT GGATGGCAAA 301 TCCTATCGCA AACAGCCTAT TATGATTACC GCACCTGACA ACCAAATCGT 351 CTTCAAAGAC TGTTCCCCAC GTTAA - This encodes a protein having amino acid sequence <SEQ ID 16; ORF44a>:
1 MKLLTTAILS SAIALSSMAA AAGTNNPTVA KKTVSYVCQQ GKKVKVTYGF 51 NKQGLTTYAS AVINGKRVQM PVNLDKSDNV ETFYGKEGGY VLGTGVMDGK 101 SYRKQPIMIT APDNQIVFKD CSPR* - The strain B sequence (ORF44) shows 99.2% identity over a 124 aa overlap with ORF44a:
10 20 30 40 50 60 orf44.pep MKLLTTAILSSAIALSSMAAAAGTDNPTVAKKTVSYVCQQGKKVKVTYGFNKQGLTTYAS ||||||||||||||||||||||||:||||||||||||||||||||||||||||||||||| orf44a MKLLTTAILSSAIALSSMAAAAGTNNPTVAKKTVSYVCQQGKKVKVTYGFNKQGLTTYAS 10 20 30 40 50 60 70 80 90 100 110 120 orf44.pep AVINGKRVQMPVNLDKSDNVETFYGKEGGYVLGTGVMDGKSYRKQPIMITAPDNQIVFKD |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf44a AVINGKRVQMPVNLDKSDNVETFYGKEGGYVLGTGVMDGKSYRKQPIMITAPDNQIVFKD 70 80 90 100 110 120 orf44.pep CSPRX ||||| orf44a CSPRX - Computer analysis gave the following results:
- Homology with the LecA Adhesin of Eikenella corrodens (Accession Number D78153)
- ORF44 and LecA protein show 45% aa identity in 91 aa overlap:
Orf44 33 TVSYVCQQGKKVKVTYGFNKQGLTTYASAVINGKRVQMPVNLDKSDNVETFYGKEGGYVL 92 +V+YVCQQG+++ V Y FN G+ T A +N + +++P NL SDNV+T + GY L LecA 135 SVAYVCQQGRRLNVNYRFNSAGVPTSAELRVNNRNLRLPYNLSASDNVDTVF-SANGYRL 193 Orf44 93 GTGVHDGKSYRKQPIHITAPDNQIVFKDCSP 123 T MD +YR Q I+++AP+ Q+++KDCSP LecA 194 TTNAMDSANYRSQDIIVSAPNGQNLYKDCSP 224 - Based on homology with the adhesin, it was predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- ORF44-1 (11.2 kDa) was cloned in pET and pGex vectors and expressed in E. coli, as described above. The products of protein expression and purification were analyzed by SDS-PAGE.
FIG. 3A shows the results of affinity purification of the His-fusion protein, andFIG. 3B shows the results of expression of the GST-fusion in E-coli. Purified His-fusion protein was used to immunise mice, whose sera were used for ELISA, which gave positive results, and for a bactericidal assay (FIG. 3C ). These experiments confirm that ORF44-1 is a surface-exposed protein, and that it is a useful immunogen. -
FIG. 3D shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF44-1. - The following partial DNA sequence was identified in N. meningitidis <SEQ ID 17>
1 GGCACCGAAT TCAAAACCAC CCTTTCCGGA GCCGACATAC AGGCAGGGGT 51 GGGTGAAAAA GCCCGAGCCG ATGCGAAAAT TATCCTAAAA GGCATCGTTA 101 ACCGCATCCA AACCGAAGAA AAGCTGGAAT CCAACTCGAC CGTATGGCAA 151 AAGCAGGCCG GAAGCGGCAG CACGGTTGAA ACGCTGAAGC TACCGAGCTT 201 TGAAGGGCCG GCACTGCCTA AGCTGACCGC TCCCGGCGGC TATATCGCCG 251 ACATCCCCAA AGGCAACCTC AAAACCGAAA TCGAAAAGCT GGCCAAACAG 301 CCCGAATATG CCTATCTGAA ACAGCTTCAG ACGGTCAAGG ACGTGAACTG 351 GAACCAAGTA CAGCTCGCTT ACGACAAATG GGACTATAAA CAGGAAGGCC 401 TAACCGGAGC CGGAGCCGCA ATTANCGCAC TGGCCGTTAC CGTGGTCACC 451 TCAGGCGCAG GAACCGGAGC CGTATTGGGA TTAANACGNG TGGCCGCCGC 501 CGCAACCGAT GCAGCATTT... - This corresponds to the amino acid sequence <SEQ ID 18; ORF49>:
1 GTEFKTTLSG ADIQAGVGEK ARADPKIILK GIVNRIQTEE KLESNSTVWQ 51 KQAGSGSTVE TLKLPSFEGP ALPKLTAPGG YIADIPKGNL KTEIEKLAKQ 101 PEYAYLKQLQ TVKDVNWNQV QLAYDKWDYK QEGLTCAGAA IXALAVTVVT 151 SGAGTGAVLG LXRVAAAATD AAF.. - Further work revealed the complete nucleotide sequence <SEQ ID 19>:
1 ATGCAACTGC TGGCAGCCGA AGGCATTCAC CAACACCAAT TGAATGTTCA 51 GAAAAGTACC CGTTTCATCG GCATCAAAGT GGGTAAAAGC AATTACAGCA 101 AAAACGAGCT GAACGAAACC AAACTGCCCG TACGCGTTAT CGCCCAAACA 151 GCCAAAACCC GTTCCGGCTG GGATACCGTA CTCGAAGGCA CCGAATTCAA 201 AACCACCCTT TCCGGAGCCG ACATACAGGC AGGGGTGGGT GAAAAAGCCC 251 GAGCCGATGC GAAAATTATC CTAAAAGGCA TCGTTAACCG CATCCAAACC 301 GAAGAAAAGC TGGAATCCAA CTCGACCGTA TGGCAAAAGC AGGCCGGAAG 351 CGGCAGCACG GTTGAAACGC TGAAGCTACC GAGCTTTGAA GGGCCGGCAC 401 TGCCTAAGCT GACCGCTCCC GGCGGCTATA TCGCCGACAT CCCCAAAGGC 451 AACCTCAAAA CCGAAATCGA AAAGCTGGCC AAACAGCCCG AATATGCCTA 501 TCTGAAACAG CTTCAGACGG TCAAGGACGT GAACTGGAAC CAAGTACAGC 551 TCGCTTACGA CAAATGGGAC TATAAACAGG AAGGCCTAAC CGGAGCCGGA 601 GCCGCAATTA TCGCACTGGC CGTTACCGTG GTCACCTCAG GCGCAGGAAC 651 CGGAGCCGTA TTGGGATTAA ACGGTGCGGC CGCCGCCGCA ACCGATGCAG 701 CATTTGCCTC TTTGGCCAGC CAGGCTTCCG TATCGTFCAT CAACAACAAA 751 CGCAATATCG GTAACACCCT GAAAGAGCTG GGCAGAAGCA GCACGGTGAA 801 AAATCTGATG GTTGCCGTCG CTACCGCAGG CGTAGCCGAC AAAATCGGTG 851 CTTCGGCACT GAACAATGTC AGCGATAAGC AGTGGATCAA CAACCTGACC 901 GTCAACCTGG CCAATGCGGG CAGTGCCGCA CTGATTAATA CCGCTGTCAA 951 CGGCGGCAGC CTGAAAGACA ATCTGGAAGC GAATATCCTT GCGGCTTTGG 1001 TGAATACTGC GCATGGAGAG GCAGCAAGTA AAATCAAACA GTTGGATCAG 1051 CACTACATTG CCCATAAGAT TGCCCATGCC ATAGCGGGCT GTGCGGCAGC 1101 GGCGGCGAAT AAGGGCAAGT GTCAAGATGG TGCGATCGGT GCGGCGGTCG 1151 GTGAAATCCT TGGCGAAACC CTACTGGACG GCAGAGACCC TGGCAGCCTG 1201 AATGTGAAGG ACAGGGCAAA AATCATTGCT AAGGCGAAGC TGGCAGCAGG 1251 GGCGGTTGCG GCGTTGAGTA AGGGGGATGT GAGTACGGCG GCGAATGCGG 1301 CTGCTGTGGC GGTAGAGAAT AATTCTTTAA ATOATATACA GGATCGTTTG 1351 TTGAGTGGAA ATTATGCTTT ATGTATGAGT GCAGGAGGAG CAGAAAGCTT 1401 TTGTGAGTCT TATCGACCAC TGGGCTTGCC ACACTTTGTA AGTGTTTCAG 1451 GAGAAATGAA ATTACCTAAT AAATTCGGGA ATCGTATGGT TAATGGAAAA 1531 TTAATTATTA ACACTAGAAA TGGCAATGTA TATTTCTCTG TAGGTAAAAT 1551 ATGGAGTACT GTAAAATCAA CAAAATCAAA TATAAGTGGG GTATCTGTCG 1601 GTTGGGTTTT AAATGTTTCC CCTAATGATT ATTTAAAAGA AGCATTTATG 1651 AATGATTTCA GAAATAGTAA TCAAAATAAA GCCTATGCAG AAATGATTTC 1701 CCAGACTTTG GTAGGTGAGA GTGTTGGTGG TAGTCTTTGT CTGACAAGAG 1751 CCTGCTTTTC GGTAAGTTCA ACAATATCTA AATCTAAATC TCCTTTTAAA 1801 GATTCAAAAA TTATTGGGGA AATCGGTTTG GGAAGTGGTG TTGCTGCAGG 1851 AGTAGAAAAA ACAATATACA TAGGTAACAT AAAAGATATT GATAAATTTA 1901 TTAGTGCAAA CATAAAAAAA TAG - This corresponds to the amino acid sequence <
SEQ ID 20; ORF49-1>:1 MQLLAAEGIH QHQLNVQKST RFIGIKVGKS NYSKNELNET KLPVRVIAQT 51 AKTRSGWDTV LEGTEFKTTL SGADIQAGVG EKARADAKII LKGIVNRIQT 101 EEKLESNSTV WQKQAGSGST VETLKLPSFE GPALPKLTAP GGYIADIPKG 151 NLKTEIEKLA KQPEYAYLKQ LQTVKDVNWN QVQLAYDKWD YKQEGLTGAG 201 AAIIALAVTV VTSGAGTGAV LGLNGAAAAA TDAAFASLAS QASVSFINNK 251 GNIGNTLKEL GRSSTVKNLM VAVATAGVAD KIGASALNNV SDKQWINNLT 301 VNLANAGSAA LINTAVNGGS LKDNLEANIL AALVNTAHGE AASKIKQLDQ 351 HYIAHKIAHA IAGCAAAAAN KGKCQDGAIG AAVGEILGET LLDGRDPGSL 401 NVKDRAKIIA KAKLAAGAVA ALSKGDVSTA ANAAAVAVEN NSLNDIQDRL 451 LSGNYALCNS AGGAESFCES YRPLGLPHFV SVSGENKLPN KFGNRNVNGK 501 LIINTRNGNV YFSVGKIWST VKSTKSNISG VSVGWVLNVS PNDYLKEASM 551 NDFRNSNQNK AYAEMISQTL VGESVGGSLC LTRACFSVSS TISKSKSPFK 601 DSKIIGEIGL GSGVAAGVEK TIYIGNIKDI DKFISANIKK * - Computer analysis predicts a transmembrane domain and also indicates that ORF49 has no significant amino acid homology with known proteins. A corresponding ORF from N. meningitidis strain A was, however, identified:
- ORF49 shows 86.1% identity over a 173 aa overlap with an ORF (ORF49a) from strain A of N. meningitidis:
10 20 30 orf49.pep GTEFKTTLSGADIQAGVGEKARADAKIILK ||||||||:|||||||| ||||:||||||| orf49a SKNELNETKLPVRVVAQXAATRSGWDTVLEGTEFKTTLAGADIQAGVXEKARVDAKIILK 40 50 60 70 80 90 40 50 60 70 80 90 orf49.pep GIVNRIQTEEKLESNSTVWQKQAGSGSTVETLKLPSFEGPALPKLTAPGGYIADIPKGNL |||||||:|||||:|||||||||| |||:|||||||||:|: |||:||||||:||||||| orf49a GIVNRIQSEEKLETNSTVWQKQAGRGSTIETLKLPSFESPTPPKLSAPGGYIVDIPKGNL 100 110 120 130 140 150 100 110 120 130 140 150 orf49.pep KTEIEKLAKQPEYAYLKQLQTVKDVNWNQVQLAYDKWDYKQEGLTGAGAAIXALAVTVVT |||||||:||||||||||||::|::||||||||||:||||||||| ||||| |||||||| orf49a KTEIEKLSKQPEYAYLKQLQVAKNINWNQVQLAYDRWDYKQEGLTEAGAAIIALAVTVVT 160 170 180 190 200 210 160 170 orf49.pep SGAGTGAVLGLXRVAAAATDAAF ||||||||||| : |||||||| orf49a SGAGTGAVLGLNGAXAAATDAAFASLASQASVSFINNKGDVGKTLKELGRSSTVKNLVVA 220 230 240 250 260 270 - ORF49-1 and ORF49a show 83.2% identity in 457 aa overlap:
orf49a.pep XQLLAEEGIHKHELDVQKSRRFIGIKVGXSNYSKNELNETKLPVRVVAQXAATRSGWDTV |||| ||||:|:|:|||| |||||||| |||||||||||||||||:||:| |||||||| orf49-1 MQLLAAEGIHQHQLNVQKSTRFIGIKVGKSNYSKNELNETKLPVRVIAQTAKTRSGWDTV orf49a.pep LEGTEFKTTLAGADIQAGVXEKARVDAKIILKGIVNRIQSEEKLETNSTVWQKQAGRGST ||||||||||:|||||||| ||||:||||||||||||||:|||||:|||||||||| ||| orf49-1 LEGTEFKTTLSGADIQAGVGEKARADAXIILKGIVNRIQTEEKLESNSTVWQKQAGSGST orf49a.pep IETLKLPSFESPTPPKLSAPGGYIVDIPKGNLKTEIEKLSKQPEYAYLKQLQVAKNINWN :|||||||||:|: |||:||||||:||||||||||||||:||||||||||||::|::||| orf49-1 VETLKLPSFEGPALPKLTAPGGYIADIPKGNLKTEIEKLAKQPEYAYLKQLQTVKDVNWN orf49a.pep QVQLAYDRWDYKQEGLTEAGAAIIALAVTVVTSGAGTGAVLGLNGAXAAATDAAFASLAS |||||||:||||||||| |||||||||||||||||||||||||||| ||||||||||||| orf49-1 QVQLAYDKWDYKQEGLTGAGAAIIALAVTVVTSGAGTGAVLGLNGAAAAATDAAFASLAS orf49a.pep QASVSFINNKGDVGKTLKELGRSSTVKNLVVAAATAGVADKIGASALXNVSDKQWINNLT |||||||||||::|:||||||||||||||:||:|||||||||||||| |||||||||||| orf49-1 QASVSFINNKGNIGNTLKELGRSSTVKNLMVAVATAGVADKIGASALNNVSDKQWINNLT orf49a.pep VNLANAGSAALINTAVNGGSLKDXLEANILAALVNTAHGEAASKIKQLDQHYIVHKIAHA ||||||||||||||||||||||| |||||||||||||||||||||||||||||:|||||| orf49-1 VNLANAGSAALINTAVNGGSLKDNLEANILAALVNTAHGEAASKIKQLDQHYIAHKIAHA orf49a.pep IAGCAAAAANKGKCQDGAIGAAVGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVS ||||||||||||||||||||||||||:||:| :|::| :|::|:| :|:| :||:||:|: orf49-1 IAGCAAAAANKGKCQDGAIGAAVGEILGETLLDGRDPGSLNVKDRAKIIAKAKLAAGAVA orf49a.pep GVVGGDVNAAANAAEVAVKNNQLSDXEGREFDNEMTACAKQNXPQLCRKNTVKKYQNVAD :: |||::||||| |||:||:|:| : | :::::: | orf49-1 ALSKGDVSTAANAAAVAVENNSLNDIQDRLLSGNYALCMSAGGAESFCESYRPLGLPHFV orf49a.pep KRLAASIAICTDISRSTECRTIRKQHLIDSRSLHSSWEAGLIGKDDEWYKLFSKSYTQAD orf49-1 SVSGEMKLPNKFGNRMVNGKLIINTRNGNVYFSVGKIWSTVKSTKSNISGVSVGWVLNVS - The complete length ORF49a nucleotide sequence <SEQ ID 21> is:
1 NTGCAACTGC TGGCAGAAGA AGGCATCCAC AAGCACGAGT TGGATGTCCA 51 AAAAAGCCGC CGCTTTATCG GCATCAAGGT AGGTNAGAGC AATTACAGTA 101 AAAACGAACT GAACGAAACC AAATTGCCTG TCCGCGTCGT CGCCCAAANT 151 GCAGCCACCC GTTCAGGCTG GGATACCGTG CTCGAAGGTA CCGAATTCAA 201 AACCACGCTG GCCGGTGCCG ACATTCAGGC AGGTGTANGC GAAAAAGCCC 251 GTGTCGATGC GAAAATTATC CTCAAAGGCA TTGTGAACCG TATCCAGTCG 301 GAAGAAAAAT TAGAAACCAA CTCAACCGTA TGGCAGAAAC AGGCCGGACG 351 CGGCAGCACT ATCGAAACGC TAAAACTGCC CAGCTTCGAA AGCCCTACTC 401 CGCCCAAATT GTCCGCACCC GGCGGNTATA TCGTCGACAT TCCGAAAGGC 451 AATCTGAAAA CCGAAATCGA AAAGCTGTCC AAACAGCCCG AGTATGCCTA 501 TCTGAAACAG CTCCAAGTAG CGAAAAACAT CAACTGGAAT CAGGTGCAGC 551 TTGCTTACGA CAGATGGGAC TACAAACAGG AGGGCTTAAC CGAAGCAGGT 601 GCGGCGATTA TCGCACTGGC CGTTACCGTG GTCACCTCAG GCGCAGGAAC 651 CGGAGCCGTA TTGGGATTAA ACGGTGCGNC CGCCGCCGCA ACCGATGCAG 701 CATTCGCCTC TTTGGCCAGC CAGGCTTCCG TATCGTTCAT CAACAACAAA 751 GGCGATGTCG GCAAAACCCT GAAAGAGCTG GGCAGAAGCA GCACGGTGAA 801 AAATCTGGTG GTTGCCGCCG CTACCGCAGG CGTAGCCGAC AAAATCGGCG 851 CTTCGGCACT GANCAATGTC AGCGATAAGC AGTGGATCAA CAACCTGACC 901 GTCAACCTAG CCAATGCGGG CAGTGCCGCA CTGATTAATA CCGCTGTCAA 951 CGGCGGCAGC CTGAAAGACA NTCTGGAAGC GAATATCCTT GCGGCTTTGG 1001 TCAATACCGC GCATGGAGAA GCAGCCAGTA AAATCAAACA GTTGGATCAG 1051 CACTACATAG TCCACAAGAT TGCCCATGCC ATAGCGGGCT GTGCGGCAGC 1101 GGCGGCGAAT AAGGGCAAGT GTCAGGATGG TGCGATAGGT GCGGCTGTGG 1151 GCGAGATAGT CGGGGAGGCT TTGACAAACG GCAAAAATCC TGACACTTTG 1201 ACAGCTAAAG AACGCGAACA GATTTTGGCA TACAGCAAAC TGGTTGCCGG 1251 TACGGTAAGC GGTGTGGTCG GCGGCGATGT AAATGCGGCG GCGAATGCGG 1301 CTGAGGTAGC GGTGAAAAAT AATCAGCTTA GCGACTAAGA GGGTAGAGAA 1351 TTTGATAACG AAATGACTGC ATGCGCCAAA CAGAATANTC CTCAACTGTG 1401 CAGAAAAAAT ACTGTAAAAA AGTATCAAAA TGTTGCTGAT AAAAGACTTG 1451 CTGCTTCGAT TGCAATATGT ACGGATATAT CCCGTAGTAC TGAATGTAGA 1501 ACAATCAGAA AACAACATTT GATCGATAGT AGAAGCCTTC ATTCATCTTG 1551 GGAAGCAGGT CTAATTGGTA AAGATGATGA ATGGTATAAA TTATTCAGCA 1601 AATCTTACAC CCAAGCAGAT TTGGCTTTAC AGTCTTATCA TTTGAATACT 1651 GCTGCTAAAT CTTGGCTTCA ATCGGGCAAT ACAAAGCCTT TATCCGAATG 1701 GATGTCCGAC CAAGGTTATA CACTTATTTC AGGAGTTAAT CCTAGATTCA 1751 TTCCAATACC AAGAGGGITF GTAAAACAAA ATACACCTAT TACTAATGTC 1801 AAATACCCGG AAGGCATCAG TTTCGATACA AACCTANAAA GACATCTGGC 1851 AAATGCTGAT GGTTTTAGTC AAGAACAGGG CATTAAAGGA GCCCATAACC 1901 GCACCAATNT TATGGCAGAA CTAAATTCAC GAGGAGGANG NGTAAAATCT 1951 GAAACCCANA CTGATATTGA AGGCATTACC CGAATTAAAT ATGAGATTCC 2001 TACACTAGAC AGGACAGGTA AACCTGATGG TGGATTTAAG GAAATTTCAA 2051 GTATAAAAAC TGTTTATAAT CCTAAAAANT TTTNNGATGA TAAAATACTT 2101 CAAATGGCTC AANATGCTGN TTCACAAGGA TATTCAAAAG CCTCTAAAAT 2151 TGCTCAAAAT GAAAGAACTA AATCAATATC GGAAAGAAAA AATGTCATTC 2201 AATTCTCAGA AACCTTTGAC GGAATCAAAT TTAGANNNTA TNTNGATGTA 2251 AATACAGGAA GAATTACAAA CATTCACCCA GAATAATTTA A - This encodes a protein having amino acid sequence <SEQ ID 22>:
1 XQLLAEEGIH KHELDVQKSR RFIGIKVGXS NYSKNELNET KLPVRVVAQX 51 AATRSGWDTV LEGTEFKTTL AGADIQAGVX EKARVOAKII LKGIVNRIQS 101 EEKLETNSTV WQKQAGRGST IETLKLPSFE SPTPPKLSAP GGYIVDIPKG 151 NLKTEIEKLS KQPEYAYLKQ LQVAKNINWN QVQLAYDRWD YKQEGLTEAG 201 AAIIALAVTV VTSGAGTGAV LGLNGAXAAA TORAFASLAS QASVSFINNK 251 GDVGKTLKEL GRSSTVKNLV VAAATAGVAD KIGASALXNV SDKQNINNLT 301 VNLANAGSAA LINTAVNGGS LKDXLEANIL AALVNTAHGE AASKIKQLDQ 351 HYIVHKIAHA IAGCAAAAAN KGKCQDGAIG AAVGEIVGEA LTNGKNPDTL 401 TAKEREQILA YSKLVAGTVS GVVGGDVNAA ANAAEVAVKN NQLSDXEGRE 451 FDWEHTACAK QNXPQLCRXN TVKKYQNVAD KRLAASIAIC TDISRSTECR 501 TIRKQHLIDS RSLHSSWEAG LIGKDDEWYK LFSKSYTQAD LALOSYHLNT 551 AAKSWLQSGN TKPLSEWNSD QGYTLISGVN PRFIPIPRGF VKQNTPITNV 601 KYPEGISFDT NLXRHLATAD GFSQEQGIKG AHNRTNXMAE LNSRGGXVKS 651 ETXTDIEGIT RIKYEIPTLD RTGKPDGGFK EISSIKTVYN FKXFKDDKIL 701 QMAQXAXSQG YSKASKIAQN ERTKSISERK NVIQFSETFD GIKFRXYXDV 751 NTGRITNIHP E - Based on the presence of a putative transmembrane domain, it is predicted that these proteins from N. meningitidis, and their epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis SEQ ID 23>
1 ..CGGATCGTTG TAGGTTTGCG GATTTCTTGC GCCGTAGTCA CCGTAGTCCC 51 AAGTATAACC CAAGGCTTTG TCTTCGCCTT TCATTCCGAT AAGGGATATG 101 ACGCTTTGGT CGGTATAGCC GTCTTGGGAA CCTTTGTCCA CCCAACGCAT 151 ATCTGCCTGC GGATTCTCAT TGCCGCTTCT TGGCTGCTGA TTTTTCTGCC 201 TTCGCGTTTT TCAACTTCGC GCTTGAGGGC TTCGGCATAT TTGTCGGCCA 251 ACGCCATTTC TTTCGGATGC AGCTGCCTAT TGTTCCAATC TACATTCGCA 301 CCCACCACAG CACCACCACT ACCACCAGTT GCATAG - This corresponds to the amino acid sequence <SEQ ID 24; ORF50>:
1 ..RIVVGLRISC AVVTVVPSIT QGFVFAFHSD KGYDALVGIA VLGTFVHPTH 51 ICLRILIAAS WLLIFLPSRF STSRLRASAY LSANAISFGC SCLLFQSTFA 101 PTTAPPLPPV A* - Computer analysis predicts two transmembrane domains and also indicates that ORF50 has no significant amino acid homology with known proteins.
- Based on the presence of a putative transmembrane domain, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <
SEQ ID 25>1 ..AAGTTTGACT TTACCTGGTT TATTCCGGCG GTAATCAAAT ACCGCCGGTT 51 GTTTTTTGAA GTATTGGTGG TGTCGGTGGT GTTGCAGCTG TTTGCGCTGA 101 TTACGCCTCT GTTTTTCCAA GTGGTGATGG ACAAGGTGCT GGTACATCGG 151 GGATTCTCTA CTTTGGATGT GGTGTCGGTG GCTTTGTTGG TGGTGTCGCT 201 GTTTGAGATT GTGTTGGGCG GTTTGCGGAC GTATCTGTTT GCACATACGA 251 CTTCACGTAT TGATGTGGAA TTGGGCGCGC GTTTGTTCCG GCATCTGCTT 301 TCCCTGCCTT TATCCTATTT CGAGCACAGA CGAGTGGGTG ATACGGTGGC 351 TCGGGTGCGG GAATTGGAGC AGATTCGCAA TTTCTTGACC GGTCAGGCGC 401 TGACTTCGGT GTTGGATTTG GCGTTTTCGT TTATCTTTCT GGCGGTGATG 451 TGGTATTACA GCTCCACTCT GACTTGGGTG GTATTGGCTT CGTTG..... // 1451 .......... .......... .......... .......... .......... 1501 .......... .......... .......... .......... ..ATTTGCGC 1551 CAACCGGACG GTGCTGATTA TCGCCCACCG TCTGTCCACT GTTAAAACGG 1601 CACACCGGAT CATTGCCATG GATAAAGGCA GGATTGTGGA AGCGGGAACA 1651 CAGCAGGAAT TGCTGGCGAA CG..AACGGA TATTACCGCT ATCTGTATGA 1701 TTTACAGAAC GGGTAG - This corresponds to the amino acid sequence <SEQ ID 26; ORF39>:
1 ..KFDFTWFIPA VIKYRRLFFE VLVVSVVLQL FALITPLFFQ VVMDKVLVHR 51 GFSTLDVVSV ALLVVSLFEI VLGGLRTYLF AHTTSRIDVE LGARLFRHLL 101 SLPLSYFEHP RVGDTVARVR ELEQIRNFLT GQALTSVLDL AFSFIFLAVM 151 WYYSSTLTWV VLASL..... .......... .......... .......... // 501 .......... ....ICANRT VLIIAHRLST VKTAHRIIAH DKGRIVEAGT 551 QQELLANXNG YYRYLYDLQN G* - Further work revealed the complete nucleotide sequence <SEQ ID 27>:
1 ATGTCTATCG TATCCGCACC GCTCCCCGCC CTTTCCGCCC TCATCATCCT 51 CGCCCATTAC CACGGCATTG CCGCCAATCC TGCCGATATA CAGCATGAAT 101 TTTGTACTTC CGCACAGAGC GATTTAAATG AAACGCAATG GCTGTTAGCC 151 GCCAAATCTT TGGGATTGAA GGCAAAGGTA GTCCGCCAGC CTATTAAACG 201 TTTGGCTATG GCGACTTTAC CCGCATTGGT ATGGTGTGAT GACGGCAACC 251 ATTTCATTTT GGCCAAAACA GACGGTGAGG GTGAGCATGC CCAATTTTFG 301 ATACAGGATT TGGTTACGAA TAAGTCTGCG GTATTGTCTT TTGCCGAATT 351 TTCTAACAGA TATTCGGGCA AACTGATATT GGTTGCTTCC CGCGCTTCGG 401 TATTGGGCAG TTTGGCAAAG TTTGACTTTA CCTGGTTTAT TCCGGCGGTA 451 ATCAAATACC GCCGGTTGTT TTTTGAAGTA TTGGTGGTGT CGGTGGTGTT 501 GCAGCTGTTT GCGCTGATTA CGCCTCTGTT TTTCCAAGTG GTGATGGACA 551 AGGTGCTGGT ACATCGGGGA TTCTCTACTT TGGATGTGGT GTCGGTGGCT 601 TTGTTGGTGG TGTCGCTGTT TGAGATTGTG TTGGGCGGTT TGCGGACGTA 651 TCTGTTTGCA CATACGACTT CACGTATTGA TGTGGAATTG GGCGCGCGTT 701 TGTTCCGGCA TCTGCTTTCC CTGCCTTTAT CCTATTTCGA GCACAGACGA 751 GTGGGTGATA CGGTGGCTCG GGTGCGGGAA TTGGAGCAGA TTCGCAATTT 801 CTTGACCGGT CAGGCGCTGA CTTCGGTGTT GGATTTGGCG TTTTCGTTTA 951 TCTTTCTGGC GGTGATGTGG TATTACAGCT CCACTCTGAC TTGGGTGGTA 901 TTGGCTTCGT TGCCTGCCTA TGCGTTTTGG TCGGCATTTA TCAGTCCGAT 951 ACTGCGGACG CGTCTGAACG ATAAGTTCGC GCGCAATGCA GACAACCAGT 1001 CGTTTTTAGT AGAAAGCATC ACTGCGGTGG GTACGGTAAA GGCGATGGCG 1051 GTGGAGCCGC AGATGACGCA GCGTTGGGAC AATCAGTTGG CGGCTTATGT 1101 GGCTTCGGGA TTTCGGGTAA CGAAGTTGGC GGTGGTCGGC CAGCAGGGGG 1151 TGCAGCTGAT TCAGAAGCTG GTGACGGTGG CGACGTTGTG GATTGGCGCA 1201 CGGCTGGTAA TTGAGAGCAA GCTGACGGTG GGGCAGCTGA TTGCGTTTAA 1251 TATGCTCTCG GGACACGTGG CGGCGCCTGT TATCCGTTTG GCGCAGTTGT 1301 GGCAGGATTT CCAGCAGGTG GGGATTTCGG TGGCGCGTTT GGGGGATATT 1351 CTGAATGCGC CGACCGAGAA TGCGTCTTCG CATTTGGCTT TGCCCGATAT 1401 CCGGGGGGAG ATTACGTTCG AACATGTCGA TTTCCGCTAT AAGGCGGACG 1451 GCAGGCTGAT TTTGCAGGAT TTGAACCTGC GGATTCCGGC GGGGGAAGTG 1501 CTGGGGATTG TGGGACGTTC GGGGTCGGGC AAATCCACAC TCACCAAATT 1551 GGTGCAGCGT CTGTATGTAC CGGAGCAGGG ACGGGTGTTG GTGGACGGCA 1601 ACGATTTGGC TTTGGCCGCT CCTGCCTGGC TGCGGCGGCA GGTCGGCGTG 1651 GTCTTGCAGG AGAATGTGCT GCTCAACCGC AGCATACGCG ACAATATCGC 1701 GCTGACGGAT ACGGGTATGC CGCTGGAACG CATTATCGAA GCAGCCAAAC 1751 TGGCGGGCGC ACACGAGTTT ATTATGGAGC TGCCGGAAGG CTACGGCACC 1801 GTGGTGGGCG AACAAGGGGC CGGCTTGTCG GGCGGACAGC GGCAGCGTAT 1951 TGCGATTGCC CGCGCGTTAA TCACCAATCC GCGCATTCTG ATTTTTGATG 1901 AAGCCACCAG CGCGCTGGAT TATGAAAGTG AACGAGCGAT TATGCAGAAC 1951 ATGCAGGCCA TTTGCGCCAA CCGGACGGTG CTGATTATCG CCCACCGTCT 2001 GTCCACTGTT AAAACGGCAC ACCGGATCAT TGCCATGGAT AAAGGCAGGA 2051 TTGTGGAAGC GGGAACACAG CAGGAATTGC TGGCGAAGCC GAACGGATAT 2101 TACCGCTATC TGTATGATTT ACAGAACGGG TAG - This corresponds to the amino acid sequence <SEQ ID 28; ORF39-1>:
1 MSIVSAPLPA LSALIILAMY HGIAANPADI QHEFCTSAQS DLNETQWLLA 51 AKSLGLKAKV VRQPIKRLAM ATLPALVWCD DGNHFILAKT DGEGEHAQFL 101 IQDLVTNKSA VLSFAEFSNR YSGKLILVAS RASVLGSLAK FDFTWFIPAV 151 IKYRRLFFEV LVVSVVLQLF ALITPLFFQV VMDKVLVHRG FSTLDVVSVA 201 LLVVSLFEIV LGGLRTYLFA HTTSRIDVEL GARLFRHLLS LPLSYFEHPA 251 VGDTVARVRE LEQIRNFLTG QALTSVLDLA FSFIFLAVMW YYSSTLTWVV 301 LASLPAYAFW SAFISPILRT RLNDKFAPNA DNQSFLVESI TAVGTVKAMA 351 VEPQHTQRWD NQLAAYVASG FRVTKLAVVG QQGVQLIQKL VTVATLWIGA 401 RLVIESRLTV GQLIAFNMLS GQVAAPVIRL AQLWQDFQQV GISVARLGDI 451 VVAPTENASS HLALPDIRGE ITFEHVDFRY KADGRLILQD LNLRIRAGEV 501 LGIVGRSGSG KSTLTKLVQR LYVPEQGRVL VDGNDLALAA PAWLRRQVGV 551 VLOENVLLNR SIRDNIALTD TGNPLERIIE AAKLAGAHEF IMELPEGYGT 601 VVGEQGAGLS GGQRQRIAIA RALITNPRIL IFDEATSALD YESERAINQN 651 MQAICANRTV LIIAHRLSTV KTAHRIIAND KGRIVEAGTQ QELLAKPNGY 701 YRYLYDLQNG * - Computer analysis of this amino acid sequence gave the following results:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF39 shows 100% identity over a 165 aa overlap with an ORF (ORF39a) from strain A of N. meningitidis:
10 20 30 orf39.pep KFDFTWFIPAVIKYRRLFFEVLVVSVVLQL |||||||||||||||||||||||||||||| orf39a AVLSFAEFSNRYSGKLILVASRASVLGSLAKFDFTWFIPAVIKYRRLFFEVLVVSVVLQL 110 120 130 140 150 160 40 50 60 70 80 90 orf39.pep FALITPLFFQVVMDKVLVHRGFSTLDVVSVALLVVSLFEIVLGGLRTYLFAHTTSRIDVE |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a FALITPLFFQVVMDKVLVHRGFSTLDVVSVALLVVSLFEIVLGGLRTYLFAHTTSRIDVE 170 180 190 200 210 220 100 110 120 130 140 150 orf39.pep LGARLFRHLLSLPLSYFEHRRVGDTVARVRELEQIRNFLTGQALTSVLDLAFSFIFLAVM |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a LGARLFRHLLSLPLSYFEHRRVGDTVARVRELEQIRNFLTGQALTSVLDLAFSFIFLAVM 230 240 250 260 270 280 160 170 180 190 200 210 orf39.pep WYYSSTLTWVVLASLXXXXXXXXXXXXXXXXXXXXXXXXXXXXICANRTVLIIAHRLSTV ||||||||||||||| orf39a WYYSSTLTWVVLASLPAYAFWSAFISPILRTRLNDKFARNADNQSFLVESITAVGTVKAM 290 300 310 320 330 340 - ORF39-1 and ORF39a show 99.4% identity in 710 aa overlap:
orf39-1.pep MSIVSAPLPALSALIILAHYHGIAANPADIQHEFCTSAQSDLNETQWLLAAKSLGLKAKV |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a MSIVSAPLPALSALIILAHYHGIAANPADIQHEFCTSAQSDLNETQWLLAAKSLGLKAKV orf39-1.pep VRQPIKRLAMATLPALVWCDDGNHFILAKTDGEGEHAQFLIQDLVTNKSAVLSFAEFSNR |||||||||||||||||||||||||||||||| |||||:|||||:||||||||||||||| orf39a VRQPIKRLAMATLPALVWCDDGNHFILAKTDGGGEHAQYLIQDLTTNKSAVLSFAEFSNR orf39-1.pep YSGKLILVASRASVLGSLAKFDFTWFIPAVIKYRRLFFEVLVVSVVLQLFALITPLFFQV |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a YSGKLILVASRASVLGSLAKFDFTWFIPAVIKYRRLFFEVLVVSVVLQLFALITPLFFQV orf39-1.pep VMDKVLVHRGFSTLDVVSVALLVVSLFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLS |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a VMDKVLVHRGFSTLDVVSVALLVVSLFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLS orf39-1.pep LPLSYFEHRRVGDTVARVRELEQIRNFLTGQALTSVLDLAFSFIFLAVMWYYSSTLTWVV |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a LPLSYFEHRRVGDTVARVRELEQIRNFLTGQALTSVLDLAFSFIFLAVMWYYSSTLTWVV orf39-1.pep LASLPAYAFWSAFISPILRTRLNDKFARNADNQSFLVESITAVGTVKAMAVEPQMTQRWD |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a LASLPAYAFWSAFISPILRTRLNDKFARNADNQSFLVESITAVGTVKAMAVEPQMTQRWD orf39-1.pep NQLAAQVASGFRVTKLAVVGQQGVQLIQKLVTVATLWIGARLVIESKLTVGQLIAFNMLS |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a NQLAAQVASGFRVTKLAVVGQQGVQLIQKLVTVATLWIGARLVIESKLTVGQLIAFNMLS orf39-1.pep GQVAAPVIRLAQLWQDFQQVGISVARLGDILNAPTENASSHLALPDIRGEITFEHVDFRY |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a GQVAAPVIRLAQLWQDFQQVGISVARLGDILNAPTENASSHLALPDIRGEITFEHVDFRY orf39-1.pep KADGRLILQDLNLRIRAGEVLGIVGRSGSGKSTLTKLVQRLYVPEQGRVLVDGNDLALAA |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a KADGRLILQDLNLRIRAGEVLGIVGRSGSGKSTLTKLVQRLYVPEQGRVLVDGNDLALAA orf39-1.pep PAWLRRQVGVVLQENVLLNRSIRDNIALTDTGMPLERIIEAAKLAGAHEFIHELPEGYGT |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a PAWLRRQVGVVLQENVLLNRSIRDNIALTDTGMPLERIIEAAKLAGAHEFIHELPEGYGT orf39-1.pep VVGEQGAGLSGGQRQRIAIARALITNPRILIFDEATSALDYESERAIMQNMQAICANRTV |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a VVGEQGAGLSGGQRQRIAIARALITNPRILIFDEATSALDYESERAIMQNMQAICANRTV orf39-1.pep LIIAHRLSTVKTAHRIIAMDKGRIVEAGTQQELLAKPNGYYRYLYDLQNGX ||||||||||||||||||||||||||||||||||||||||||||||||||| orf39a LIIAHRLSTVKTAHRIIAMDKGRIVEAGTQQELLAKPNGYYRYLYDLQNGX - The complete length ORF39a nucleotide sequence <SEQ ID 29> is:
1 ATGTCTATCG TATCCGCACC GCTCCCCGCC CTTTCCGCCC TCATCATCCT 51 CGCCCATYAC CACGGCATTG CCGCCAATCC TGCCGATATA CAGCATGAAT 101 TTTGTACTTC CGCACAGAGC GATTTAAATG AAACGCAATG GCTGTTAGCC 151 GCCAAATCTT TGGGATTGAA GGCAAAGGTA GTCCGCCAGC CTATTAAACG 201 TTTGGCTATG GCGACTTTAC CCGCATTGGT ATGGTGTGAT GACGGCAACC 251 ATTTTATTTT GGCTAAAACA GACGGTGGGG GTGAGCATGC CCAATATCTA 301 ATACAGGATT TAACTACGAA TAAGTCTGCG GTATTGTCTT TTGCCGAATT 351 TTCTAACAGA TATTCGGGCA AACTGATATT GGTTGCTTCC CGCGCTTCGG 401 TATTGGGCAG TTTGGCAAAG TTTGACTTTA CCTGGTTTAT TCCGGCGGTA 451 ATCAAATACC GCCGGTTGTT TTTTGAAGTA TTGGTGGTGT CGGTGGTGTT 501 GCAGCTGTTT GCGCTGATTA CGCCTCTGTT TTTCCAAGTG GTGATGGACA 551 AGGTGCTGGT ACATCGGGGA TTCTCTATTT TGGATGTGGT GTCGGTGGCT 601 TTGTTGGTGG TGTCGCTGTT TGAGATTGTG TTGGGCGGTT TGCGGACGTA 651 TCTGTTTGCA CATACGACTT CACGTATTGA TGTGGAATTG GGCGCGCGTT 701 TGTTCCGGCA TCTGCTTTCC CTGCCTTTAT CCTATTTCGA GCACAGACGA 751 GTGGGTGATA CGGTGGCTCG GGTGCGGGAA TTGGAGCAGA TTCGCAATTT 801 CTTGACCGGT CAGGCGCTGA CTTCGGTGTT GGATTTGGCG TTTTCGTTTA 951 TCTTTCTGGC GGTGATGTGG TATTACAGCT CCACTCTGAC TTGGGTGGTA 901 TTGGCTTCGT TGCCTGCCTA TGCGTTTTGG TCGGCATTTA TCAGTCCGAT 951 ACTGCGGACG CGTCTGAACG ATAAGTTCGC GCGCAATGCA GACAACCAGT 1001 CGTTTTTAGT AGAAAGCATC ACTGCGGTGG GTACGGTAAA GGCGATGGCG 1051 GTGGAGCCGC AGATGACGCA GCGTTGGGAC AATCAGTTGG CGGCTTATGT 1101 GGCTTCGGGA TTTCGGGTAA CGAAGTTGGC GGTGGTCGGC CAGCAGGGGG 1151 TGCAGCTGAT TCAGAAGCTG GTGACGGTGG CGACGTTGTG GATTGGCGCA 1201 CGGCTGGTAA TTGAGAGCAA GCTGACGGTG GGGCAGCTGA TTGCGTTTAA 1251 TATGCTCTCG GGACAGGTGG CGGCGCCTGT TATCCGTTTG GCGCAGTTGT 1301 GGCAGGATTT CCAGCAGGTG GGGATTTCGG TGGCGCGTTT CGGGGATATT 1351 CTGAATGCGC CGACCGAGAA TGCGTCTTCG CATTTGGCTT TGCCCGATAT 1401 CCGGGGGGAG ATTACGTTCG AACATGTCGA TTTCCGCTAT AAGGCGGACG 1451 GCAGGCTGAT TTTGCAGGAT TTGAACCTGC GGATTCGGGC GGGGGAAGTG 1501 CTGGGGATTG TGGGACGTTC GGGGTCGGGC AAATCCACAC TCACCAAATT 1551 GGTGCAGCGT CTGTATGTAC CGGCGCAGGG ACGGGTGTTG GTGGACGGCA 1601 ACGATTTGGC TTTGGCCGCT CCTGCTTGGC TGCGGCGGCA GGTCGGCGTG 1651 GTCTTGCAGG AGAATGTGCT GCTCAACCGC AGCATACGCG ACAATATCGC 1701 GCTGACGGAT ACGGGTATGC CGCTGGAACG CATTATCGAA GCAGCCAAAC 1751 TGGCGGGCGC ACACGAGTTT ATTATGGAGC TGCCGGAAGG CTACGGCACC 1801 GTGGTGGGCG AACAAGGGGC CGGCTTGTCG GGCGGACAGC GGCAGCGTAT 1851 TGCGATTGCC CGCGCGTTAA TCACCAATCC GCGCATTCTG ATTTTTGATG 1901 AAGCCACCAG CGCGCTGGAT TATGAAAGTG AACGAGCGAT TATGCAGAAC 1951 ATGCAGGCCA TTTGCGCCAA CCGGACGGTG CTGATTATCG CCCACCGTCT 2001 GTCCACTGTT AAAACGGCAC ACCGGATCAT TGCCATGGAT AAAGGCAGGA 2051 TTGTGGAAGC GGGAACACAG CAGGAATTGC TGGCGAAGCC GAACGGATAT 2101 TACCGCTATC TGTATGATTT ACAGAACGGG TAG - This encodes a protein having amino acid sequence <
SEQ ID 30>:1 MSIVSAPLPA LSALIILAHY HGIAANPADI QHEFCTSAQS DLNETQWLLA 51 AKSLGLKAKV VRQPIKRLAN ATLPALVWCD DGNHFILAKT DGGGEHAQYL 101 IQDLTTNKSA VLSFAEFSNR YSGKLILVAS RASVIASLAX FDFTWFIPAV 151 IKYRRLFFEV LVVSVVLQLF ALITPLFFQV VNDKVLVHRG FSTLDVVSVA 201 LLVVSLFEIV LGGLRTYLFA HTTSRIDVEL GARLFRHLLS LPLSYFEHRR 251 VGDTVARVRE LEQIRNFLTG QALTSVLDLA FSFIFLAVMW YYSSTLTWVV 301 LASLPAYAFW SAFISPILRT RLNDKFARNA ONQSFLVESI TAVGTVKAMA 351 VEPQNTQRWD NQLAAYVASG FRVTKLAVVG QQGVQLIQKL VTVATLWIGA 401 RLVIESKLTV GQLIAFNHLS GQVAAPVIRL AQLWQOFQQV GISVARLGDI 451 LNAPTENASS HLALPDIRGE ITFEHVDFRY KADGRLILQD LNLRIRAGEV 501 LGIVGRSGSG KSTLTKLVQR LYVPAQGRVL VDGNDLALAA PAWLREQVGV 551 VLQENVLLNR SIRDNIALTD TGMPLERIIE AAKLAGAHEF IHPLPEGYGT 601 VVGEQGAGLS GGQRQRIAIA RALITNPRIL IFDEATSALD YESERAIMQN 651 NQAICANRTV LIIAHRLSTV KTAMRIIAMD KGRIVEAGTQ QELLAKPNGY 701 YRYLYOLQNG * - ORF39a is homologous to a cytolysin from A. pleuropneumoniae:
sp|P26760|RT1B_ACTPL RTX-I TOXIN DETERMINANT B (TOXIN RTX-I SECRETION ATP- BINDING PROTEIN) (APX-IB) (HLY-IB) (CYTOLYSIN IB) (CLY-IB) >gi|97137|pir||D43599 cytolysin IB - Actinobacillus pleuropneumoniae (serotype 9) >gi|36944 (X61112) ClyI-B protein [Actinobacillus pleuropneumoniae] Length = 707 Score = 931 bits (2379), Expect =0.0 Identities = 472/690 (68%), Positives = 540/690 (77%), Gaps = 3/690 (0%) Query: 20 YHGIAANPADIQHEFCTSAQSDLNETQWXXXXXXXXXXXXVVRQPIKRLAMATLPALVWC 79 YH IA NP +++H+F + L+ T W V++ I RLA LPALVW Sbjct: 20 YHNIAVNPEELKHKFDLEGKG-LDLTAWLLAAKSLELKAKQVKKAIDRLAFIALPALVWR 78 Query: 80 DDGNHFILAKTDGGGEHAQYLIQDLTTNKSAVLSFAEFSNRYSGKLILVASRASVLGSLA 139 +DG HFIL K D E +YLI DL T+ +L AEF + Y GKLILVASRAS++G LA Sbjct: 79 EDGKHFILTKIDN--EAKKYLIFDLETHNPRILEQAEFESLYQGKLILVASRASIVGKLA 136 Query: 140 KFDFTWFIPAVIKYRRXXXXXXXXXXXXXXXXXITPLFFQVVMDKVLVHRGFXXXXXXXX 199 KFDFTWFIPAVIKYR+ ITPLFFQVVMDKVLVHRGF Sbjct: 137 KFDFTWFIPAVIKYRKIFIETLIVSIFLQIFALITPLFFQVVMDKVLVHRGFSTLNVITV 196 Query: 200 XXXXXXXFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLSLPLSYFEHRRVGDTVARVR 259 FEIVL GLRTY+FAH+TSRIDVELGARLFRHLL+LP+SYFE+RRVGDTVARVR Sbjct: 197 ALAIVVLFEIVLNGLRTYIFAHSTSRIDVELGARLFRHLLALPISYFENRRVGDTVARVR 256 Query: 260 ELEQIRNFLTGQALTSVLDLAFSFIFLAVMWYYSSTLTWVVLASLPAYAFWSAFISPILR 319 EL+QIRNFLTGQALTSVLDL FSFIF AVMWYYS LT V+L SLP Y WS FISPILR Sbjct: 257 ELDQIRNFLTGQALTSVLDIMFSFIFFAVMWYYSPKLTLVILGSLPFYNGWSIFISPILR 316 Query: 320 TRLNDKFARNADNQSFLVESITAVGTVKAMAVEPQNTQRWDNQLAAYVASGFRVTKLAVV 379 RL++KFAR ADNQSFLVES+TA+ T+KA+AV PQMT WD QLA+YV++GFRVT LA + Sbjct: 317 RRLDEKFARGADNQSFLVESVTAINTIKALAVTPQMTNTWDKQLASYVSAGFRVTTLATI 376 Query: 380 GQQGVQLIQKLVTVATLWIGARLVIESKLTVGOLIAFNNLSGQVAAPVIRLAQLWQDFQQ 439 GQQGVQ IQK+V V TLW+GA LVI L++GQLIAFNNLSGQV APVIRLAQLWQDFQQ Sbjct: 377 GQQGVQFIQKVVNVITLWLGAMLVISGDLSIGQLIAFNNLSGQVIAPVIRLAQLWQDFQQ 436 Query: 440 VGISVAPLGDILNAPTENASSHLALPDIRGEITFEHVDFRYKADGRLILQDLNLRIRAGE 499 VGISV RLGD+LN+PTE+ LALP+I+G+ITF ++ FRYX D +IL D+NL I+ GE Sbjct: 437 VGISVTRLGDVLNSPTESYQGKLALPEIKGDITFRNIRFRYXPDAPVILNDVNLSIQQGE 496 Query: 500 VLGIVGRSGSGKSTLTKLVQRLYVPAOGRVLVDGNDLALAAPAWLRRQVGVVLQENVLLN 559 V+GIVGRSGSGKSTLTKL+QR Y+P G+VL+DG+DLALA P WLRRQVGVVLQ+NVLLN Sbjct: 497 VIGIVGRSGSGKSTLTKLIQRFYIPENGQVLIDGHDLALADPNWLRRQVGVVLQDNVLLN 556 Query: 560 RSIRDNIALTDTGMPLERIIEAAKLAGAIIEFINELPEGYGTVVGEQGNLSGGQRQRIAI 619 RSIRDNIAL D GMP+E+I+ AAKLAGAHEFI EL EGY T+VGEQGAGLSGGQRQRIAI Sbjct: 557 RSIRDNIALADPGMPMEKIVHAAKLAGAHEFISELREGYNTIVGEOGAGLSGGQRQRIAI 616 Query: 620 ARALITNPRILIFDEATSALDYESERAIMQNMQAICANRTVLIIAHRLSTVKTAHRIIAM 679 ARAL+ NP+ILIFDEATSALDYESE IM+NM IC RTV+IIAHRLSTVK A RII M Sbjct: 617 ARALVNNPKILIFDEATSALDYESEHIIMRNMHQICKGRTVIIIAHRLSTVKNADRIIVM 676 Query: 680 DKGRIVEAGTQQELLAKPNGYYRYLYDLQN 709 +KG+IVE G +ELLA PNG Y YL+ LQ+ Sbjct: 677 EKGQIVEQGKHKELLADPNGLYHYLHQLQS 706
Homology with the HlyB Leucotoxin Secretion ATP-Binding Protein of Haemophilus actinomycetemcomitans (Accession Number X53955) - ORF39 and HlyB protein show 71% and 69% amino acid identity in 167 and 55 overlap at the N- and C-terminal regions, respectively:
Orf39 1 KFDFTWFIPAVIKYRRXXXXXXXXXXXXXXXXXITPLFFQVVMDKVLVHRGFXXXXXXXX 60KFDFTWFIPAVIKYR+ ITPLFFQVVMDKVLVHRGF HlyB 137 KFDFTWFIPAVIKYRKIFIETLIVSIFLQIFALITPLFFQVVMDKVLVHRGFSTLNVITV 196 Orf39 61 XXXXXXXFEIVLGGLRTYLFAHTTSRIDVELGARLFRHLLSLPLSYFEHRRVGDTVARVR 120 FEI+LGGLRTY+FAH+TSRIDVELGARLFMLL+LP+SYFE RRVGDTVARVR HlyB 197 ALAIVVLFEIILGGLRTYVFAHSTSRIDVELGARLFRHLLALPISYFEARRVGDTVARVR 256 Orf39 121 ELEQIRNFLTGQALTSVLDLAFSFIFLAVMWYYSSTLTWVVLASLIC 167 EL+QIRNFLTGQALTS+LDL FSFIF AVMWYYS LT VVL SL C HlyB 257 ELDQIRNFLTGQALTSILDLLFSFIFFAVMWYYSPKLTLVVLGSLPC 303 // Orf39 166 ICANRTVLIIAHRLSTVKTAHRIIAMDKGRIVEAGTQQELLANXNGYYRYLYDLQ 220 IC NRTVLIIAHRLSTVK A RII MDKG I+E G QELL + G Y YL+ LQ HlyB 651 ICQNRTVLIIAHRLSTVKNADRIIVMDKGEIIEQGKHQELLKDEKGLYSYLHQLQ 705 - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <SEQ ID 31>
1 ATGAAATACT TGATCCGCAC CGCCTTACTC GCAGTCGCAG CCGCCGGCAT 51 CTACGCCTGC CAACCGCAAT CCGAAGCCGC AGTGCAAGTC AAGGCTGAAA 101 ACAGCCTGAC CGCTATGCGC TTAGCCGTCG CCGACAAACA GGCAGAGATT 151 GACGGGTTGA ACGCCCAAAk sGACGCCGAA ATCAGA... - This corresponds to the amino acid sequence SEQ ID 32; ORF52>:
1 MKYLIRTALL AVAAAGIYAC QPQSEAAVQV KAZNSLTANR LAVADKQAEI 51 DGLNAQXDAE IR.. - Further work revealed the complete nucleotide sequence <SEQ ID 33>:
1 ATGAAATACT TGATCCGCAC CGCCTTACTC GCAGTCGCAG CCGCCGGCAT 51 CTACGCCTGC CAACCGCAAT CCGAAGCCGC AGTGCAAGTC AAGGCTGAAA 101 ACAGCCTGAC CGCTATGCGC TTAGCCGTCG CCGACAAACA GGCAGAGATT 151 GACGGGTTGA ACGCCCAAAT CGACGCCGAA ATCAGACAAC GCGAAGCCGA 201 AGAATTGAAA GACTACCGAT GGATACACGG CGACGCGGAA GTGCCGGAGC 251 TGGAAAAATG A - This corresponds to the amino acid sequence <SEQ ID 34; ORF52-1>:
1 MKYLIRTALL AVAAAGIYAC QPQSEAAVQV KAENSLTAMR LAVADKQAEI 51 DGLNAQIDAE IRQREAEELK DThWIHGDAE VPELEK - Computer analysis of this amino acid sequence predicts a prokaryotic membrane lipoprotein lipid attachment site (underlined).
- ORF52-1 (7 kDa) was cloned in the pGex vectors and expressed in E. coli, as described above. The products of protein expression and purification were analyzed by SDS-PAGE.
FIG. 4A shows the results of affinity purification of the GST-fusion.FIG. 4B shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF52-1. - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following DNA sequence was identified in N. meningitidis <
SEQ ID 35>1 ATGGTTATCG GAATATTACT CGCATCAAGC AAGCATGCTC TTGTCATTAC 51 TCTATTGTTA AATCCCGTCT TCCATGCATC CAGTTGCGTA TCGCGTTSGG 101 CAATACGGAA TAAAATCTGC TGTTCTGCTT TGGCTAAATT TGCCAAATTG 151 TTTATTGTTT CTTTAGGAGC AGCTTGCTTA GCCGCCTTCG CTTTCGACAA 201 CGCCCCCACA GGCGCTTCCC AAGCGTTGCC TTCCGTTACC GCACCCGTGG 251 CGATTCCCGC GCCCGCTTCG GCAGCCTGA - This corresponds to the amino acid sequence <SEQ ID 36; ORF56>:
1 MVIGILLASS KHALVITLLL NPVFHASSCV SRXAIRNKIC CSALAKFAKL 51 FIVSLGAACL AAFAFDNAPT GASQALPTVT APVAIPAPAS AA* - Further work revealed the complete nucleotide sequence <SEQ ID 37>:
1 ATGGCTTGTA CAGGTTTGAT GGTTTTTCCG TTAATGGTYA TCGGAATATT 51 ACTTGCATCA AGCAAGCCTG CTCCTTTCCT TACTCTATTG TTAAATCCCG 101 TCTTCCATGC ATCCAGTTGC GTATCGCGTT GGGCAATACG GAATAAAATC 151 TGCTGTTCTG CTTTGGCTAA ATTTGCCAAA TTGTTTATTG TTTCTTTAGG 201 AGCAGCTTGC TTAGCCGCCT TCGCTTTCGA CAACGCCCCC ACAGGCGCTT 251 CCCAAGCGTT GCCTACCGTT ACCGCACCCG TGGCGATTCC CGCGCCCGCT 301 TCGGCAGCCT GA - This corresponds to the amino acid sequence <SEQ ID 38; ORF56-1>:
1 MACTGLMVFP LNVZGILLAS SKPAPFLTLL LNPVFHASSC VSRWAIRNKI 51 CCSALAKFAK LFIVSLGAAC LAAFAFDNAP TGASQALPTV TAPVAIPAPA 101 SAA* - Computer analysis of this amino acid sequence predicts a leader peptide (underlined) and suggests that ORF56 might be a membrane or periplasmic protein.
- Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <SEQ ID 39>
1 ATGTTCAGTA TTTTAAATGT GTTTCTTCAT TGTATTCTGG CTTGTGTAGT 51 CTCTGGTGAG ACGCCTACTA TATTTGGTAT CCTTGCTCTT TTTTACTTAT 101 TGTATCTTTC TTATCTTGCT GTTTTTAAGA TTTTCTTTTC TTTTTTCTTA 151 GACAGAGTTT CACTCCGGTC TCCCAGGCTG GAGTGCAAAT GGCATGACCC 201 TTTGGCTCAC TGGCTCACGG CCACTTCTGC TATTCTGCCG CCTCAGCCTC 251 CAGGG... - This corresponds to the amino acid sequence <
SEQ ID 40; ORF63>:1 MFSILNVFLR CILACVVSGE TPTIFGILAL FYLLYLSYLA VFKIFFSFFL 51 DRVSLRSPRL ECKWNDPLAH WLTATSAILP PQPPG... - Computer analysis of this amino acid sequence predicts a transmembrane region.
- Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <SEQ ID 41>
1 ..GTGCGGACGT GGTTGGTTTT TTGGTTGCAG CGTTTGAAAT ACCCGTTGTT 51 GCTTTGGATT GCGGATATGT TGCTGTACCG GTTGTTGGGC GGCGCGGAAA 101 TCGAATGCGG CCGTTGCCCT GTGCCGCCGA TGACGGATTG GCAGCATTTT 151 TTGCCGGCGA TGGGAACGGT GTCGGCTTGG GTGGCGGTGA TTTGGGCATA 201 CCTGATGATT GAAAGTGAAA AAAACGGAAG ATATTGA - This corresponds to the amino acid sequence <SEQ ID 42; ORF69>:
1 ..VRTWLVFWLQ RLKYPLLLWI ADNLLYRLLG GAE1ECGRCP VPPMTDWQHF 51 LPANGTVSAW VAVIWAYLMI ESEKNGRY* - Computer analysis of this amino acid sequence predicts a transmembrane region.
- A corresponding ORF from strain A of N. meningitidis was also identified:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF69 shows 96.2% identity over a 78 aa overlap with an ORF (ORF69a) from strain A of N. meningitidis:
10 20 30 40 50 60 orf69.pep VRTWLVFWLQRLKYPLLLWIADMLLYRLLGGAEIECGRCPVPPMTDWQHFLPAMGTVSAW |||||||||||||||||| |||||||||||||||||||||||||||||||||:||||:|| orf69a VRTWLVFWLQRLKYPLLLCIADMLLYRLLGGAEIECGRCPVPPMTDWQHFLPTMGTVAAW 10 20 30 40 50 60 70 79 orf69.pep VAVIWAYLMIESEKNGRYX ||||||||||||||||||| orf69a VAVIWAYLMIESEKNGRYX 70 79 - The ORF69a nucleotide sequence <SEQ ID 43> is:
1 GTGCGGACGT GGTTGGTTTT TTGGTTGCAG CGTTTGAAAT ACCCGTTGTT 51 GCTTTGTATT GCGGATATGC TGCTGTACCG GTTGTTGGGC GGCGCGGAAA 101 TCGAATGCGG CCGTTGCCCT GTACCGCCGA TGACGGATTG GCAGCATTTT 151 TTGCCGACGA TGGGAACGGT GGCGGCTTGG GTGGCGGTGA TTTGGGCATA 201 CCTGATGATT GAAAGTGAAA AAAACGGAAG ATATTGA - This encodes a protein having amino acid sequence <SEQ ID 44>:
1 VRTWLVFWLQ RLKYPLLLCI ADMLLYRLLG GAEIECGRCP VPPNTDWQHF 51 LPTMGTVAAW VAVIWAYLMI ESEKNGRY* - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following DNA sequence was identified in N. meningitidis <
SEQ ID 45>1 ATGTTTCAAA ATTTTGATTT GGGCGTGTTC CTGCTTGCCG TCCTCCCCGT 51 GCTGCCCTCC ATTACCGTCT CGCACGTGGC GCGCGGCTAT ACGGCGCGCT 101 ACTGGGGAGA CAACACTGCC GAACAATACG GCAGGCTGAC ACTGAACCCC 151 CTGCCCCATA TCGATTTGGT CGGCACAATC ATCgTACCGC TGCTTACTTT 201 GATGTTCACG CCCTTCCTGT TCGGCTGGGC GCGTCCGATT CCTATCGATT 251 CGCGCAACTT CCGCAACCCG cGCCTTGCCT GGCGTTGCGT TGCCGCGTCC 301 GGCCCGCTGT CGAATCTAGC GATGGCTGTw CTGTGGGGCG TGGTTTTGGT 351 GCTGACTCCG TATGTCGGCG GGGCGTATCA GATGCCGTTG GCTCAAATGG 401 CAAACTACGG TATTCTGATC AATGCGATTC TGTTCGCGCT CAACATCATC 451 CCCATCCTGC CTTGGGACGG CGGCATTTTC ATCGACACCT TCCTGTCGGC 501 GAAATATTCG CAAGCGTTCC GCAAAATCGA ACCTTATGGG ACGTGGATTA 551 TCCTACTGCT GATGCTGACC SGGGTTTTGG GTGCGTTTAT wGCACCGATT 601 sTGCGGmTGc GTGATTGCrT TTGTGCAGAT GTwCGTCTGA CTGGCTTTCA 651 GACGGCATAA - This corresponds to the amino acid sequence <SEQ ID 46; ORF77>:
1 MFQNFDLGVF LLAVLPVLPS ITVSNVARGY TARYWGDNTA EQYGRLTLNP 51 LPHIDLVGTI IVPLLTLMFT PFLFGWPRPI PIDSRNFRNP RLAWRCVAAS 101 GPLSNLAMAV LWGVVLVLTP YVGGAYQMPL AQMANYGILI NAILFPLNII 151 PILPWDGGIF IDTFLSAKYS QAFRKIEPYG TWIILLLMLT XVLGAFIAPI 201 XRXRDCXCAD VRLTGFQTA* - Further work revealed the complete nucleotide sequence <SEQ ID 47>:
1 ATGTTTCAAA ATTTTGATTT GGGCGTGTTT CTGCTTGCCG TCCTGCCCGT 51 GCTGCTCTCC ATTACCGTCA GGGAGGTGGC GCGCGGCTAT ACGGCGCGCT 101 ACTGGGGAGA CAACACTGCC GAACAATACG GCAGGCTGAC ACTGAACCCC 151 CTGCCCCATA TCGATTTGGT CGGCACAATC ATCGTACCGC TGCTTACTTT 201 GATGTTCACG CCCTTCCTGT TCGGCTGGGC GCGTCCGATT CCTATCGATT 251 CGCGCAACTT CCGCAACCCG CGCCTTGCCT GGCGTTGCGT TGCCGCGTCC 301 GGCCCGCTGT CGAATCTAGC GATGGCTGTT CTGTGGGGCG TGGTTTTGGT 351 GCTGACTCCG TATGTCGGCG GGGCGTATCA GATGCCGTTG GCTCAAATGG 401 CAAACTACGG TATTCTGATC AATGCGATTC TGTTCGCGCT CAACATCATC 451 CCCATCCTGC CTTGGGACGG CGGCATTTTC ATCGACACCT TCCTGTCGGC 501 GAAATATTCG CAAGCGTTCC GCAAAATCGA ACCTTATGGG ACGTGGATTA 551 TCCTACTGCT GATGCTGACC GGGGTTTTGG GTGCGTTTAT TGCACCGATT 601 GTGCGGCTGG TGATTGCGTT TGTGCAGATG TTCGTCTGA - This corresponds to the amino acid sequence <SEQ ID 48; ORF77-1>:
1 MFQNFDLGVF LLAVLPVLLS ITVREVARGY TARYWGDNTA EQYGRLTLNP 51 LPHIDLVGTI IVPLLTLMFT PFLFGWARPI PIDSRNFRNP RLAWRCVAAS 101 GPLSNLAMAV LWGVVLVLTP YVGGAYQMPL AQMANYGILI NAILFALNII 151 PILPWDGGIF IDTFLSAXYS QAYRRIEPYG TWIILLLNLT GVLGAFIAPI 201 VRLVIAFVQH FV* - Computer analysis of this amino acid sequence reveals a putative leader sequence and several transmembrane domains.
- A corresponding ORF from strain A of N. meningitidis was also identified:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF77 shows 96.5% identity over a 173 aa overlap with an ORF (ORF77a) from strain A of N. meningitidis:
10 20 30 40 50 60 ort77.pep MFQNFDLGVFLLAVLPVLPSITVSHVARGYTARYWGDNTAEQYGRLTLNPLPHIDLVGTI ||||||||||||||||||||||||||||||||| orf77a RGYTARYWGDNTAEQYGRLTLNPLPHIDLVGTI 10 20 30 70 80 90 100 110 120 orf77.pep IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAASGPLSNLAMAVLWGVVLVLTP |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf77a IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAASGPLSNLAMAVLWGVVLVLTP 40 50 60 70 80 90 130 140 150 160 170 180 orf77.pep YVGGAYQMPLAQMANYGILINAILFALNIIPILPWDGGIFIDTFLSAKYSQAFRKIEPYG |||||||||||||||| ||||||| ||||||||||||||||||||||| ||||||||||| orf77a YVGGAYQMPLAQMANYXILINAILXALNIIPILPWDGGIFIDTFLSAKXSQAFRKIEPYG 100 110 120 130 140 150 190 200 210 220 orf77.pep TWIILLLMLTGVLGAFIAPIVRLVIAFVQMFVX |||| |||||||||| |||||:||||||||||| orf77a TWIIXLLMLTGVLGAXIAPIVQLVIAFVQMFVX 160 170 180 - ORF77-1 and ORF77a show 96.8% identity in 185 aa overlap:
10 20 30 40 50 60 orf77-1.pep MFQNFDLGVFLLAVLPVLLSITVREVARGYTARYWGDNTAEQYGRLTLNPLPHIDLVGTI ||||||||||||||||||||||||||||||||| orf77a RGYTARYWGDNTAEQYGRLTLNPLPHIDLVGTI 10 20 30 70 80 90 100 110 120 orf77-1.pep IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAASGPLSNLAMAVLWGVVLVLTP |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf77a IVPLLTLMFTPFLFGWARPIPIDSRNFRNPRLAWRCVAASGPLSNLAMAVLWGVVLVLTP 40 50 60 70 80 90 130 140 150 160 170 180 orf77-1.pep YVGGAYQMPLAQMANYGILINAILFALNIIPILPWDGGIFIDTFLSAKYSQAFRKIEPYG |||||||||||||||| ||||||| ||||||||||||||||||||||| ||||||||||| orf77a YVGGAYQMPLAQMANYXILINAILXALNIIPILPWDGGIFIDTFLSAKXSQAFRKIEPYG 100 110 120 130 140 150 190 200 210 orf77-1.pep TWIILLLMLTGVLGAFIAPIVRLVIAFVQMFVX |||| |||||||||| |||||:||||||||||| orf77a TWIIXLLMLTGVLGAXIAPIVQLVIAFVQMFVX 160 170 180 - A partial ORF77a nucleotide sequence <SEQ ID 49> was identified:
1 ..CGCGGCTATA CAGCGCGCTA CTGGGGTGAC AACACTGCCG AACAATACGG 51 CAGGCTGACA CTGAACCCCC TGCCCCATAT CGATTTGGTC GGCACAATCA 101 TCGTACCGCT GCTTACTTTG ATGTTTACGC CCTTCCTGTT CGGCTGGGCG 151 CGTCCGATTC CTATCGATTC GCGCAACTTC CGCAACCCGC GCCTTGCCTG 201 GCGTTGCGTT GCCGCGTCCG GCCCGCTGTC GAATCTGGCG ATGGCTGTTC 251 TGTGGGGCGT GGTTTTGGTG CTGACTCCGT ATGTCGGTGG GGCGTATCAG 301 ATGCCGTTGG CNCAAATGGC AAACTACNNN ATTCTGATCA ATGCGATTCT 351 GTNCGCGCTC AACATCATCC CCATCCTGCC TTGGGACGGC GGCATTTTCA 401 TCGACACCTT CCTGTCGGCN AAATANTCGC AAGCGTTCCG CAAAATCGAA 451 CCTTATGGGA CGTGGATTAT CCNGCTGCTT ATGCTGACCG GGGTTTTGGG 501 TGCGTNTATT GCACCGATTG TGCAGCTGGT GATTGCGTTT GTGCAGATGT 551 TCGTCTGA - This encodes a protein having amino acid sequence <
SEQ ID 50>:1 ..RGYTARYWGD NTAEQYGRLT LNPLPHIDLV GTIIVPLLTL MFTPFLFGWA 51 RPIPIDSRNF RNPRLAWRCV AASGFLSNLA MAVLWGVVLV LTPYVGGAYQ 101 MPLAQNANYX ILINAILXAL NIIPILPWDG GIFIDTFLSA KXSQAFRKIE 151 PYGTWIIXLL MLTGVLGAXI APIVQLVIAF VQNFV* - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis SEQ ID 51>
1 ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT 51 TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT 101 ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAAATGCTG 151 GGCTACACCG CCCTCAAAAT GCCCGCCCGC GCCTACGAAC TGATTCCCCT 201 CGCCGTCCTT ATCGGCGGAC TGGTCTCCCT CAGCCAGCTT GCCGCCGGCA 251 GCGAACTGAC CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG 301 TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT 351 CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAAAGCCGAA AACATCAAAG 401 CCGCCGCCAT CAACGGCAAA ATCAACACCG GCAATACCGG CCTTTGGCTG 451 AAAGAAAAAA ACAGCGTGAT CAATGTGCGC GAAATGTTGC CCGACCAT.. - This corresponds to the amino acid sequence SEQ ID 52; ORF112>:
1 HNLISRYIIR QMAVMAVYAL LAFLALYSFF EILYETGNLG KGSYGIWEML 51 GYTALIQPAR AYELIPLAVL IGGLVSLSQL AAGSELTVIK ASGNSTKKLL 101 LILSQFGFIF AIATVPLGEW VAPTLSQKAE NIKAAAINGK ISTGNTGLWL 151 KEKNSVINVR EHLPDH... - Further work revealed further partial nucleotide sequence <SEQ ID 53>:
1 ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT 51 TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT 101 ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAAATGCTG 151 GGCTACACCG CCCTCAAAAT GCCCGCCCGC GCCTACGAAC TGATTCCCCT 201 CGCCGTCCTT ATCGGCGGAC TGGTCTCCCT CAGCCAGCTT GCCGCCGGCA 251 GCGAACTGAC CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG 301 TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT 351 CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAAAGCCGAA AACATCAAAG 401 CCGCCGCCAT CAACGGCAAA ATCAGCACCG GCAATACCGG CCTTGCTCTG 451 AAAGAAAAAA ACAGCTTAAT CAATGTGCGC GAAATGTTGC CCGACCATAC 501 GCTTTTGGGC ATCAAAATTT GGGCGCGCAA CGATAAAAAC GAATTGGCAG 551 AGGCAGTGGA AGCCGATTCC GCCGTTTTGA ACAGCGACGG CAGTTGGCAG 601 TTGAAAAACA TCCGCCGCAG CACGCTTGGC GAAGACAAAG TCGAGGTCTC 651 TATTGCGGCT GAAGAAAACT GGCCGATTTC CGTCAAACGC AACCTGATGG 701 ACGTATTGCT CGTCAAACCC GACCAAATGT CCGTCGGCGA ACTGACCACC 751 TACATCCGCC ACCTCCAAAA CAACAGCCAA AACACCCGAA TCTACGCCAT 601 CGCATGGTGG CGCAAATTGG TTTACCCCGC CGCAGCCTGG GTGATGGCGC 851 TCGTCGCCTT TGCCTTTACC CCGCAAACCA CCCGCCACGG CAATATGGGC 901 TTAAAACTCT TCGGCGGCAT CTGTSTCGGA TTGCTGTTCC ACCTTGCCGG 951 ACGGCTCTTT GGGTTTACCA GCCAACTCGG... - This corresponds to the amino acid sequence <SEQ ID 54; ORF112-1>:
1 MNLISRYIIR QMAVMAVYAL LAFLALYSFF EILYETGNLG KGSYGIWEHL 51 GYTALKMPAR AYELIPLAVL IGGLVSLSQL AAGSELTVIK ASGMSTKKLL 101 LILSQFGFIF AIATVALGEW VAPTLSQKAE NIKAAAINGK ISTGNTGLWL 151 KEKNSXINVR EHLPDHTLLG IKIWARNDKN ELAEAVEADS AVLNSDGSWQ 201 LKNIRRSTLG EDKVEVSIAA EENWPISVKR NLTDVLLVKP DQMSVGELTT 251 YIRHLONNSQ NTRIYAIAWW RKLVYPAAAW VMALVAFAFT PQTTRHGNMG 301 LKLFGGICXG LLFHLAGRLF GFTSQL... - Computer analysis of this amino acid sequence predicts two transmembrane domains.
- A corresponding ORF from strain A of N. meningitidis was also identified:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF112 shows 96.4% identity over a 166 aa overlap with an ORF (ORF112a) from strain A of N. meningitidis:
10 20 30 40 50 60 orf112.pep MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMLGYTALKMPAR |||||||||||||||||||||||||||||||||||||||||||||||| ||||||| || orf112a MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMXGYTALKMXAR 10 20 30 40 50 60 70 80 90 100 110 120 orf112.pep AYELIPLAVLIGGLVSLSQLAAGSELTVIKASGMSTKKLLLILSQFGFIFAIATVALGEW ||||:||||||||||| |||||||||:||||||||||||||||||||||||||||||||| orf112a AYELMPLAVLIGGLVSXSQLAAGSELTVIKASGMSXKKLLLILSQFGFIFAIATVALGEW 70 80 90 100 110 120 130 140 150 160 orf112.pep VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSVINVREMLPDH |||||||||||||||||||||||||||||||||||:|||||||||| orf112a VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSIINVREMLPDHTLLGIKIWARNDKN 130 140 150 160 orf112a ELAEAVEADSAVLNSDGSWQLKNIRRSTLGEDKVEVSIAAEEXWPISVKRNLMDVLLVKP 190 200 210 220 230 240 - A partial ORF112a nucleotide sequence <
SEQ ID 55> was identified:1 ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT 51 TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT 101 ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAAATGNTG 151 GGNTACACCG CCCTCAAAAT GNCCGCCCGC GCCTACGAAC TGATGCCCCT 201 CGCCGTCCTT ATCGGCGGAC TGGTCTCTNT CAGCCAGCTT GCCGCCGGCA 251 GCGAACTGAN CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG 301 TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT 351 CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAAAGCCGAA AACATCAAAG 401 CCGCGGCCAT CAACGGCAAA ATCAGTACCG GCAATACCGG CCTTTGGCTG 451 AAAGAAAAAA ACAGCATTAT CAATGTGCGC GAAATGTTGC CCGACCATAC 501 CCTGCTGGGC ATTAAAATCT GGGCCCGCAA CGATAAAAAC GAACTGGCAG 551 AGGCAGTGGA AGCCGATTCC GCCGTTTTGA ACAGCGACGG CAGTTGGCAG 601 TTGAAAAACA TCCGCCGCAG CACGCTTGGC GAAGACAAAG TCGAGGTCTC 651 TATTGCGGCT GAAGAAAANT GGCCGATTTC CGTCAAACGC AACCTGATGG 701 ACGTATTGCT CGTCAAACCC GACCAAATGT CCGTCGGCGA ACTGACCACC 751 TACATCCGCC ACCTCCAAAN NNACAGCCAA AACACCCGAA TCTACGCCAT 801 CGCATGGTGG CGCAAATTGG TTTACCCCGC CGCAGCCTGG GTGATGGCGC 851 TCGTCGCCTT TGCCTTTACC CCGCAAACCA CCCGCCACGG CAATATGGGC 901 TTAAAANTCT TCGGCGGCAT CTGTCTCGGP TTGCTGTTCC ACCTTGCCGG 951 NCGGCTCTTC NGGTTTACCA GCCAACTCTA CGGCATCCCG CCCTTCCTCG 1001 NCGGCGCACT ACCTACCATA GCCTTCGCCT TGCTCGCCGT TTGGCTGATA 1051 CGCAAACAGG AAAAACGCTA A - This encodes a protein having amino acid sequence <SEQ ID 56>:
1 MNLISRYIIR QMAVMAVYAL LAFLALYSFF EILYETGNLG KGSYGIWEMK 51 GYTALKMXAR AYELMPLAVL IGGLVSXSQ L AAGSELXVIX ASGNSTKKLL 101 LILSQFGFIF AIATVALGEV VAPTLSQKAE NIKAAAINGK ISTGNTGLWL 151 KEKNSIINVR EMLPDHTLLG IKIWAIWDKN ELAEAVFADS AVLNSDGSWQ 201 LKNIRRSTLG EDKVEVSIAA EEXWPISVKR NLMDVLLVKP DQMSVGELTT 251 YIRHLQXXSQ NTRIYAIAWW RKLVYPAAAW VMALVAFAFT PQTTRHGNMG 301 LKXFGGICLG LLFHLAGRLF XFTSQLYGIP PFLXGALPTI AFALLAVWLI 351 RKQEKR* - ORF112a and ORF112-1 show 96.3% identity in 326 aa overlap:
orf112a.pep MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMXGYTALKMXAR ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| || orf112-1 MNLISRYIIRQMAVMAVYALLAFLALYSFFEILYETGNLGKGSYGIWEMLGYTALKMXAR orf112a.pep AYEIIPLAVLIGGLVSXSQLAAGSELXVIKASGHSTKKLLLILSQFGFIFAIATVALGEW ||||:||||||||||| |||||||||:||||||||||||||||||||||||||||||||| orf112-1 AYEIIPLAVLIGGLVSLSQLAAGSELTVIKASGHSTKKLLLILSQFGFIFAIATVALGEW orf112a.pep VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSIINVREMLPDHTLLGIKIWARNDKN ||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||| orf112-1 VAPTLSQKAENIKAAAINGKISTGNTGLWLKEKNSXINVREMLPDHTLLGIKIWARNDKN orf112a.pep ELAEAVEADSAVLNSDGSWQLKNIRRSTLGEDKVEVSIAAEEXWPISVKRNLMDVLLVKP |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||| orf112-1 ELAEAVEADSAVLNSDGSWQLKNIRRSTLGEDKVEVSIAAEENWPISVKRNLMDVLLVKP orf112a.pep DQMSVGELTTYIRHLQXXSQNTRIYAIAWWRKLVYPAAAWVMALVAFAFTPQTTRHGNMG |||||||||||||||| |||||||||||||||||||||||||||||||||||||||||| orf112-1 DQMSVGELTTYIRHLQXXSQNTRIYAIAWWRKLVYPAAAWVMALVAFAFTPQTTRHGNMG orf112a.pep LKXFGGICLGLLFHLAGRLFXFTSQLYGIPPFLXGALPTIAFALLAVWLIRKQEXRX || ||||| ||||||||||| ||||| orf112-1 LKLFGGICXGLLFHLAGRLFGFTSQL - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <SEQ ID 57>
1 ..GCAGTAGCCG AAACTGCCAA CAGCCAGGGC AAAGGTAAAC AGGCAGGCAG 51 TTCGGTTTCT GTTTCACTGA AAACTTCAGG CGACCTTTGC GGCAAACTCA 101 AAACCACCCT TAAAACTTTG GTCTGCTCTT TGGTTTCCCT GAGTATGGTA 151 TTGCCTGCCC ATGCCCAAAT TACCACCGAC AAATCACCAC CTAAAAACCA 201 GCAGGTCGTT ATCCTTAAAA CCAACACTGG TGCCCCCTTG GTGAATATCC 251 AAACTCCGAA TGGACGCGGA TTGAGCCACA ACCGCTA.TA CGCATTTGAT 301 GTTGACAACA AAGGGGCAGT GTTAAACAAC GACCGTAACA ATAATCCGTT 351 TGTGGTCAAA GGCAGTGCGC AATTGATTTT GAACGAGGTA CGCGGTACGG 401 CTAGCAAACT CAACGGCATC GTTACCGTAG GCGGTCAAAA GGCCGACGTG 451 ATTATTGCCA ACCCCAACGG CATTACCGTT AATGGCGGCG GCTTTAAAAA 501 TGTCGGTCGG GGCATCTTAA CTACCGGTGC GCCCCAAATC GGCAAAGACG 551 GTGCACTGAC AGGATTTGAT GTGCGTCAAG GCACATTGGA CCGTAGTAGC 601 AGCAGGTTGG AATGATAAAG GCGGAGCmrm yTACACCGGG GTACTTGCTC 651 GTGCAGTTGC TTTGCAGGGG AAATTwmmGG GTAAA.AACT GGCGGTTTCT 701 ACCGGTCCTC AGAAAGTAGA TTACGCCAGC GGCGAAATCA GTGCAGGTAC 751 GGCAGCGGGT ACGAAACCGA cTATTGCCCT TGATACTGCC GCACTGGGCG 901 GTATGTACGC CGACAGCATC ACACTGATTG CCAATGAAAA AGGCGTAGGC 951 GTCTAA - This corresponds to the amino acid sequence <
SEQ ID 58; ORF114>:1 ..AVAETANSQG KGKQAGSSVS VSLKTSGDLC GKLKTTLKTL VCSLVSLSHV 51 LPAHAQITTD KSAPKNQQVV ILKTNTGAPL VNIQTPNGRG LSHNRXYAFD 101 VDNKGAVLNN DRNNNPFVVK GSAQLILNEV RGTASKLNGI VTVGGQKADV 151 IIANPNGITV NGGGFXNVGR GILTTGAPQI GKDGALTGFD VVKAHVTVXA 201 AGWNDKGGAX YTGVLAPAVA LQGKXXGLXL AVSTGPQKVD YASGEISAGT 251 AAGTKPTIAL DTAALGGNYA DSITLIANEX GVGV* - Further work revealed the complete nucleotide sequence SEQ ID 59>:
1 ATGAATAAAG GTTTACATCG CATTATCTTT AGTAAAAAGC ACAGCACCAT 51 GGTTGCAGTA GCCGAAACTG CCAACAGCCA GGGCAAAGGT AAACAGGCAG 101 GCAGTTCGGT TTCTGTTTCA CTGAAAACTT CAGGCGACCT TTGCGGCAAA 151 CTCAAAACCA CCCTTAAAAC TTTGGTCTGC TTTTTGGTTT CCCTGAGTAT 201 GGTATTGCCT GCCCATGCCC AAATTACCAC CGACAAATCA GCACCTAAAA 251 ACCAGCAGGT CGTTATCCTT AAAACCAACA CTGGTGCCCC CTTGGTGAAT 301 ATCCAAACTC CGAATGGACG CGGATTGAGC CACAACCGCT ATACGCAGTT 351 TGATGTTGAC AACAAAGGGG CAGTGTTAAA CAACGACCGT AACAATAATC 401 CGTTTGTGGT CAAAGGCAGT GCGCAATTGA TTTTGAACGA GGTACGCGGT 451 ACGGCTAGCA AACTCAACGG CATCGTTACC GTAGGCGGTC AAAAGGCCGA 501 CGTGATTATT GCCAACCCCA ACGGCATTAC CGTTAATGGC GGCGGCTTTA 551 AAAATGTCGG TCGGGGCATC TTAACTACCG GTGCGCCCCA AATCGGCAAA 601 GACGGTGCAC TGACAGGATT TGATGTGCGT CAAGGCACAT TGACCGTAGG 651 AGCAGCAGGT TGGAATGATA AAGGCGGAGC CGACTACACC GGGGTACTTG 701 CTCGTGCAGT TGCTTTGCAG GGGAAATTAC AGGGTAAAAA CCTGGCGGTT 751 TCThCCGGTC CTCAGAAAGT AGATTACGCC AGCGGCGAAA TCAGTGCAGG 801 TACGGCAGCG GGTACGAAAC CGACTATTGC CCTTGATACT GCCGCACTGG 951 GCGGTATGTA CGCCGACACC ATCACACTGA TTGCCAATGA AAAAGGCGTA 901 GGCGTCAAAA ATGCCGGCAC ACTCGAAGCG GCCAAGCAAT TGATTGTGAC 951 TTCGTCAGGC CGCATTGAAA ACAGCGGCCG CATCGCCACC ACTGCCGACG 1001 GCACCGAAGC TTCACCGACT TATCTCTCCA TCGAAACCAC CGAAAAAGGA 1051 GCGGCAGGCA CATTTATCTC CAATGGTGGT CGGATCGAGA GCAAAGGCTT 1101 ATTGGTTATT GAGACGGGAG AAGATATCAG CTTGCGTAAC GGAGCCGTGG 1151 TGCAGAATAA CGGCAGTCTC CCAGCTACCA CGGTATTAAA TGCTGGTCAT 1201 AATTTGGTGA TTGAGAGCAA AACTAATGTG AACAATGCCA AAGGCCCGGC 1251 TACTCTGTCG GCCGACGGCC GTACCGTCAT CAAGGAGGCC AGTATTCAGA 1301 CTGGCACTAC CGTATACAGT TCCAGCAAAG GCAACGCCGA ATTAGGCAAT 1351 AACACACGCA TTACCGGGGC AGATGTTACC GTATTATCCA ACGGCACCAT 1401 CAGCAGTTCC GCCGTAATAG ATGCCAAAGA CACCGCACAC ATCGAAGCAG 1451 GCAAACCGCT TTCTTTGGAA GCTTCAACAG TTACCTCCGA TATCCGCTTA 1501 AACGGAGGCA GTATCAAGGG CGGCAAGCAG CTTGCTTTAC TGGCAGACGA 1551 TAACATTACT GCCAAAACTA CCAATCTGAA TACTCCCGGC AATCTGTATG 1601 TTCATACAGG TAAAGATCTG AATTIGAATG TTGATAAAGA TTTGTCIGCC 1651 GCCAGCATCC ATTTGAAATC GGATAACGCT GCCCATATTA CCGGCACCAG 1701 TAAAACCCTC ACTGCCTCAA AAGACATGGG TGTGGAGGCA GGCTCGCTGA 1751 ATGTTACCAA TACCAATCTG CGTACCAACT CGGGTAATCT GCACATTCAG 1801 GCAGCCAAAG GCAATATTCA GCTTCGCAAT ACCAAGCTGA ACGCAGCCAA 1851 GGCTCTCGAA ACCACCGCAT TGCAGGGCAA TATCGTTTCA GACGGCCTTC 1901 ATGCTGTTTC TGCAGACGGT CATGTATCCT TATCGGCCAA CGGTAATGCC 1951 GACTTTACCG GTCACAATAC CCTGACAGCC AAGGCCGATG TCAATGCAGG 2001 ATCGGTTGGT AAAGGCCGTC TGAAAGCAGA CAATACCAAT ATCACTTCAT 2051 CTTCAGGAGA TATTACGTTG GTTGCCGGCA ACGGTATTCA GCTTGGTGAC 2101 GGAAAACAAC GCAATTCAAT CAACGGAAAA CACATCAGCA TCAAAAACAA 2151 CGGTGGTAAT GCCGACTTAA AAAACCTTAA CGTCCATGCC AAAAGCGGGG 2201 CATTGAACAT TCATTCCGAC CGGGCATTGA GCATAGAAAA TACCAAGCTG 2251 GAGTCTACCC ATAATACGCA TCTTAATGCA CAACACGAAG GGGTAACGCT 2301 CAACCAAGTA GATGCCTACG CACACCGTCA TCTAAGCATT ACCGGCAGCC 2351 AGATTTGGCA AAACGACAAA CTGCCTTCTG CCAACAAGCT GGTGGCTAAC 2401 GGTGTATTGG CACTCAATGC GCGCTATTCC CAAATTGCCG ACAACACCAC 2451 GCTGAGAGCG GGTGCAATCA ACCTTATTGC CGGTACCGCC CTAGTCAAGC 2501 GCGGCAACAT CAATTGGAGT ACCGTTGCGA CCAAAACTTT GGAAGATAAT 2551 GCCGAATTAA AACCATTGGC CGGACGGCTG AATATTGAAG CAGGTAGCGG 2601 CACATTAACC ATCGAACCTG CCAACCGCAT CAGTGCGCAT ACCGACCTGA 2651 GCATCAAAAC AGGCGGAAAA TTGCTGTTGT CTGCAAAAGG AGGAAATGCA 2701 GGTGCGCCTA GTGCTCAAGT TTCCTCATTG GAAGCAAAAG GCAATATCCG 2751 TCTGGTTACA GGAGAAACAG ATTTAAGAGG TTCTAAAATT ACAGCCGGTA 2801 AAAACTTGGT TGTCGCCACC ACCAAAGGCA AGTTGAATAT CGAAGCCGTA 2951 AACAACTCAT TCAGCAATTA TTTTCCTACA CAAAAAGCGG CTGAACTCAA 2901 CCAAAAATCC AAAGAATTGG AACAGCAGAT TGCGCAGTTG AAAAAAAGCT 2951 CGCCTAAAAG CAAGCTGATT CCAACCCTGC AAGAAGAACG CGACCGTCTC 3001 GCTTTCTATA TTCAAGCCAT CAACAAGGAA GTTAAAGGTA AAAAACCCAA 3051 AGGCAAAGAA TACCTGCAAG CCAAGCTTTC TGCACAAAAT ATTGACTTGA 3101 TTTCCGCACA AGGCATCGAA ATCAGCGGTT CCGATATTAC CGCTTCCAAA 3151 AAACTGAACC TTCACGCCGC AGGCGTATTG CCAAAGGCAG CAGATTCAGA 3201 GGCGGCTGCT ATTCTGATTG ACGGCATAAC CGACCAATAT GAAATTGGCA 3251 AGCCCACCTA CAAGAGTCAC TACGACAAAG CTGCTCTGAA CAAGCCTTCA 3301 CGTTTGACCG GACGTACAGG GGTAAGTATT CATGCAGCTG CGGCACTCGA 3351 TGATGCACGT ATTATTATCG GTGCATCCGA AATCAAAGCT CCCTCAGGCA 3401 GCATAGACAT CAAAGCCCAT AGTGATATTG TACTGGAGGC TGGACAAAAC 3451 GATGCCTATA CCTTCTTAAA AACCAAAGGT AAAAGCGGCA AAATCATCAG 3501 AAAAACCAAG TTTACCAGCA CCCGCGACCA CCTGATTATG CCAGCCCCCG 3551 TCGAGCTGAC CGCCAACGGC ATAACGCTTC AGGCAGGCGG CAACATCGAA 3601 GCTAATACCA CCCGCTTCAA TGCCCCTGCA GGTAAAGTTA CCCTGGTTGC 3651 GGGTGAAGAG CTGCAACTGC TGGCAGAASA AGGCATCCAC AAGCACGAGT 3701 TGGATGTCCA AAAAAGCCGC CGCTTTATCG GCATCAAGGT AGGCAAGAGC 3751 AATTACAGTA AAAACGAACT GAACGAAACC AAATTGCCTG TCCGCGTCGT 3801 CGCCCAAACT GCAGCCACCC GTTCAGGCTG GGATACAGTG CTCGAAGGTA 3051 CCGAATTCAA AACCACGCTG GCCGGTGCGG ACATTCAGGC AGGTGTAGGC 3901 GAAAAAGCCC GTGCCGATGC GAAAATTATC CTCAAAGGCA TTGTGAACCG 3951 TATCCAGTCG GAAGAAAAAT TAGAAACCAA CTCAACCGTA TGGCAGAAAC 4001 AGGCCGGACG CGGCAGCACT ATCGAAACGC TGAAACTGCC CAGCTTCGAA 4051 AGCCCTACTC CGCCCAAACT GACCGCCCCC GGTGGCTATA TCGTCGACAT 4101 TCCGAAAGGC AATTTGAAAA CCGAAATCGA AAAGCTGGCC AAACAGCCCG 4151 AGTATGCCTA TCTGAAACAG CTCCAAGTAG CGAAAAACGT CAACTGGAAC 4201 CAGGTGCAAC TGGCTTACGA TAAATGGGAC TATAAGCAGG AAGGCTTAAC 4251 CAGAGCCGGT GCAGCGATTG TTACCATAAT CGTAACCGCA CTGACTTATG 4301 GATACGGCGC AACCGCAGCG GGCGGTGTAG CCGCTTCAGG AAGTAGTACA 4351 GCCGCAGCTG CCGGAACAGC CGCCACAACG ACAGCAGCAG CTACTACCGT 4401 TTCTACAGCG ACTGCCATGC AAACCGCTGC TTTAGCCTCC TTGTATAGCC 4451 AAGCAGCTGT ATCCATCATC AATAATAAAG GTGATGTCGG CAAAGCGTTG 4501 AAAGATCTCG GCACCAGTGA TACGGTCAAG CAGATTGTCA CTTCTGCCCT 4551 GACGGCGGGT GCATTAAATC AGATGGGCGC AGATATIGCC CAATTGAACA 4601 GCAAGGTAAG AACCGAACTG TTCAGCAGTA CGGGCAATCA AACTATTGCC 4651 AACCTTGGAG GCAGATTGGC TACCAATCTC AGTAATGCAG GTATCTCAGC 4701 TGGTATCAAT ACCGCCGTCA ACGGCGGCAG CCTGAAAGAC AACTTAGGCA 4751 ATGCCGCATT AGGAGCATTG GTTAATAGCT TCCAAGGAGA AGCCGCCAGC 4801 AAAATCAAAA CAACCTTCAG CGACGATTAT GTTGCCAAAC AGTTCGCCCA 4851 CGCTTTGGCT GGGTGTGTTA GCGGATTGGT ACAAGGAAAA TGTAAAGACG 4901 GGGCAATTGG CGCAGCAGTT GGGGAAATCG TAGCCGACTC CATGCTTGGC 4951 GGCAGAAACC CTGCTACACT CAGCGATGCG GAAAAGCATA AGGTTATCAG 5001 TTACTCGAAG ATTATTGCCG GCAGCGTGGC GGCACTCAAC GGCGGCGATG 5051 TGAATACTGC GGCGAATGCG GCTGAGGTGG CGGTAGTGAA TAATGCTTTG 5101 AATTTTGACA GTACCCCTAC CAATGCGAAA AAGCATCAAC CGCAGAAGCC 5151 CGACAAAACC GCACTGGAAA AAATTATCCA AGGTATTATG CCTGCACATG 5201 CAGCAGGTGC GATGACTAAT CCGCAGGATA AGGATGCTGC CATTTGGATA 5251 AGCAATATCC GTAATGGCAT CACAGGCCCG ATTGTGATTA CCAGCTATGG 5301 GGTTTATGCT GCAGGTTGGA CAGCTCCGCT GATCGGTACA GCGGGTAAAT 5351 TAGCTATCAG CACCTGCATG GCTAATCCTT CTGGTTGTAC TGTCATGGTC 5401 ACTCAGGCTG CCGAAGCGGG CGCGGGAATC GCCACGGGTG CGGTAACGGT 5451 AGGCAACGCT TGGGAAGCGC CTGTGGGGGC GTTGTCGAAA GCGAAGGCGG 5501 CCAAGCAGGC TATACCAACC CAGACAGTTA AAGAACTTGA TGGCTTACTA 5551 CAAGAATCAA AAAATATAGG TGGTGTAAAT ACACGAATAA ATATAGCGAA 5601 TAGTACTACT CGATATACAC CAATGAGACA AACGGGACAA CCGCTATCTG 5651 CTGGCTTTGA GCATGTFCTT GAGGGGGACT TCCATAGGCC TATTGCGAAT 5701 AACCGTTCAG TTTTTACCAT CTCCCCAAAT GAATTGAAGG TTATACTTCA 5751 AAGTAATAAA GTAGTTTCTT CTCCCGTATC GATGACTCCT GATGGCCAAT 5801 ATATGCGGAC TGTCGATGTA GGAAAAGTTA TTGGTACTAC TTCTATTAAA 5651 GAAGGTGGAC AACCCACAAC TACAATTAAA GTATTTACAG ATAAGTCAGG 5901 AAATTTGATT ACTACATACC CAGTAAAAGG AAACTAA - This corresponds to the amino acid sequence <SEQ ID 60; ORF114-1>:
1 HNKGLHRIIF SXKHSTMVAV AETANSQGKG KQAGSSVSVS LKTSGDLCGK 51 LKTTLKTLVC SLVSLSHVLP AHAQITTDKS APKNQQVVIL KFNTGAPLVN 101 IQTPNGRGLS HNRYTQFDVD NKGAVLNNDR NNNPFVVKGS AQLILNEVRG 151 TASKLNGIVT VGGQKADVII ANPNGITVNG GGFKNVGRGI LTTGAPQIGK 201 DGALTGFDVR QGTLTVGAAG WNDKGGADYT GVLAAAVALQ GKLQGKLLAV 251 STGFQKVDYA SGEISAGTAA GTKPTIALDT AALGGHYADS ITLIANEKGV 301 GVKNAGTLKA AXQLIVTSSG RIENSGRIAT TADGTFASPT YLSIETTEKG 351 AAGTFISNGG RIESKGLLVI ETGEDISLRN GAVVQINGSR PATTVLNAGH 401 HLVIESKTNV NNAKGFATLS ADGRTVIKEA SIQTGTTVYS SSKGTAELGN 451 NTRZTGADVT VLSNGTISSS AVIDAKOTAN IEAGKPLSLT ASTVTSDIRL 501 NGGSIKGGKQ LALLADDNIT AXTTNLNTPG NLYVHTGKDL NIMVDKDLSA 551 ASIHLKSDNA AHITGTSKTL TASKDMGVEA GSLNVTNTNL RTNSGNLHIQ 601 AAKGNIQLRN TKLNAAKALE TTALQGNIVS OGLHAVSADG HVSLLANGNA 651 DFTGHNTLTA KADVNAGSVG KGRLKADNTN ITSSSGDITL VAGNGIQLGD 701 GKQRNSINGK HISIKNNGGN ADLIQLNVHA KSGALNIHSD RALSIENTKL 751 ESTRNTHLNA QHERVTLNQV DAYAHRHLSI TGSQIWQNOK LPSANKLVTN 801 GVLALNARYS QIADNTTLRA GAINLTAGTA LVKRGNINWS TVSTKTLEDN 851 AELKPLAGRL NIEAGSGTLT IEPANRISAH TDLSIKTGGK LLLSAKGGNA 901 GAFSAQVSSL EAKGNIRLVT GETDLRGSKI TAGKNLVVAT TKGKLNIEAV 951 NNSFSNYFPT QKAAELNQKS KELEQQIAQL KKSSPKSKLI PTLQEERDRL 1001 AFYIQAINKE VKGKKPKGKE YLQAKLSAQN IDLISAQGIE ISGSDITASK 1051 KLNLHAAGVL PKAADSEAAA ILIDGITDQY EIGKPTYKSH YOKAALNKPS 1101 RLTGRTGVSI HAAAALDDAR IIIGASEIKA FSGSIDIKAH SDIVLEAGQN 1151 DAYTFLKTKG KSGKIIRXTK FTSTRDHLIM PAPVELTANG ITLQAGGNIE 1201 ANTTRFNAPA GKVTLVAGEE LQLLAEEGIH KHELDVQKSR RFIGIKVGKS 1251 NYSKNELNET KLPVRVVAQT AATRSGWDTV LEGTEFKTTL AGADIQAGVG 1301 EKAPADAKII LKGIVNRIQS EEKLETNSTV WQKQAGRGST IETLKLPSFE 1351 SPTPPKLTAP GGYIVDIPKG NLKTEIEKLA KQPEPEYLKQ LQVAKNVNWN 1401 QVQLAYDKWD YKQEGLTRAG AAIVTIIVTA LTYGYGATAA GGVAASGSST 1451 AAAAGTAATT TAAATTVSTA TANQTAALAS LYSQAAVSII NNKGDVGKAL 1501 KDLGTSDTVK QIVISALTAG ALNQMGADIA QLNSKVRTEL FSSTGVQTIA 1551 NLGGRLATNL SNAGISAGIN TAVNGGSLKD NLGNAALGAL VNSFQGEAAS 1601 KIKTTFSDDY VAKQFAHALA GCVSGLVQGK CKDGAIGAAV GEIVADSNLG 1651 GRNPATLSDA EKHKVISYSK IIAGSVAALN GGDVNTAANA AEVAVVNNAL 1701 NFDSTPTNAK KNQPQKPDKT ALEKIIQGIM PAHAAGAMTN PQDKDAAIWI 1751 SNIRNGITGP IVITSYGVYA AGWTAPLIGT AGKLAISTCM ANPSGCTVNV 1801 TQAAEAGAGI ATGAVTVGNA WEAPVGALSK AKAAKQAIPT QTVKELDGLL 1851 QESKNIGAVN TRINIANSTT RYTPNRQTGQ PVSAGFENVL EGHFHRPIAN 1901 NRSVFTXSPN ELKVILQSNK VVSSPVSMTP DGQYNRTVDV GKVIGTTSIK 1951 EGGQPTTTIK VFTDKSGNLI TTYPVKGN* - Computer analysis of this amino acid sequence predicts a transmembrane region and also gives the following results:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF114 shows 91.9% identity over a 284 aa overlap with an ORF (ORF114a) from strain A of N. meningitidis:
10 20 30 40 orf114.pep AVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTTLKTLVC |||||||||||||||||||||||||||||||||||||||||| orf114a MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTTLKTLVC 10 20 30 40 50 60 50 60 70 80 90 100 orf114.pep SLVSLSMVLPAHAQITTDKSAPKNQQVVILKTNTGAPLVNIQTPNGRGLSHNRXYAFDVD ||||||| ||||||||||| |||||||||||||||||||||||||||| |||| orf114a SLVSLSMXXXXXXQITTDKSAPKNXQVVILKTNTGAPLVNIQTPNGRGLSHNRYTQFDVD 70 80 90 100 110 120 110 120 130 140 150 160 orf114.pep NKGAVLNNDRNNNPFVVKGSAQLILNEVRGTALKLNGIVTVGGQKADVIIANPNGITVNG |||||||||||||||:|||||||||||||||||||||||||||||||||||||||||||| orf114a NKGAVLNNDRNNNPFLVKGSAQLILNEVRGTASKLNGIVTVGGQKADVIIANPNGITVNG 130 140 150 160 170 180 170 180 190 200 210 220 orf114.pep GGFKNVGRGILTTGAPQIGKDGALTGFDVVKAHWTVXAAGWNDKGGAXYTGVLARAVALQ |||||||||||| |||||||||||||||| :: || |||||||||| |||||||||||| orf114a GGFKNVGRGILTIGAPQIGKDGALTGFDVRQGTLTVAAAGWNDKGGADYTGVLARAVALQ 190 200 210 220 230 240 230 240 250 260 270 290 orf114.pep GKXXGKXLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIANEKGV || || |||||||||||||||||||||||||||||||||||||||||||||||| |||| orf114a GKLQGKNLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIAXEKGV 250 260 270 280 290 300 orf114.pep GVX || orf114a GVKNAGTLEAAKQLIVTSSGRIENSGRIATTADGTEASPTYLXIETTEKGAXGTFISNGG 310 320 330 340 350 360 - The complete length ORF114a nucleotide sequence <SEQ ID 61> is:
1 ATGAATAAAG GTTTACATCG CATTATCTTT AGTAAAAAGC ACAGCACCAT 51 GGTTGCAGTA GCCGAAACTG CCAACAGCCA GGGCAAAGGT AAACAGGCAG 101 GCAGTTCGGT TTCTGTTTCA CTGAAAACTT CAGGCGACCT TTGCGGCAAA 151 CTCAAAACCA CCCTTAAAAC CTTGGTCTGC TCTTTGGTTT CCCTGAGTAT 201 GGNATTNCNN NNCNNTNCCC AAATTACCAC CGACAAATCA GCACCTAAAA 251 ACCANCAGGT CGTTATCCTT AAAACCAACA CTGGTGCCCC CTTGGTGAAT 301 ATCCAAACTC CGAATGGACG CGGATTGAGC CACAACCGCT ATACGCAGTT 351 TGATGTTGAC AACAAAGGGG CAGTGTTAAA CAACGACCGT AACAATAATC 401 CGTTTCTGGT CAAAGGCAGT GCGCAATTGA TTTTGAACGA GGTACGCGGT 451 ACGGCTAGCA AACTCAACGG CATCGTTACC GTAGGCGGTC AAAAGGCCGA 501 CGTGATTATT GCCAACCCCA ACGGCATTAC TGTTAATGGC GGCGGCTTTA 551 AAAATGTCGG TCGGGGCATC TTAACTATCG GTGCGCCCCA AATCGGCAAA 601 GACGGTGCAC TGACAGGATT TGATGTGCGT CAAGGCACAT TGACCGTAGG 651 AGCAGCAGGT TGGAATGATA AAGGCGGAGC CGACTACACC GGGGTACTTG 701 CTCGTGCAGT TGCTTTGCAG GGGAAATTAC AAGGTAAAAA CCTGGCGGTT 751 TCTACCGGTC CTCAGAAAGT AGATTACGCC AGCGGCGAAA TCAGTGCAGG 801 TACGGCAGCG GGTACGAAAC CGACTATTGC CCTTGATACT GCCGCACTGG 951 GCGGTATGTA CGCCGAGAAA ATCACACTGA TTGCCAATGA AAAAGGCGTA 901 GGcGTCAAAA ATGCCGGCAC ACTCGAAGCG GCCAAGCAAT TGATTGTGAC 951 TTCGTCAGGC CGCATTGAAA ACAGCGGCCG CATCGCCACC ACTGCCGACG 1001 GCACCGAAGC TTCACCGACT TATCTNNCNA TCGAAACCAC CGAAAAAGGA 1051 GCNNCAGGCA CATTTATCTC CAATGGTGGT CGGATCGAGA GCAAAGGCTT 1101 ATTGGTTATT GAGACGGGAG AAGATATCAT CTTGCGTAAC GGAGCCGTGG 1151 TGCAGAATAA CGGCAGTCGC CCAGCTACCA CGGTATTAAA TGCTGGTCAT 1201 AATTTGGTGA TTGAGAGTAA AACTAATGTG AACAATGCCA AAGGCTCGNC 1251 TAATCTGTCG GCCGGCGGTC GTACTACGAT CAATGATGCT ACTATTCAAG 1301 CGGGCAGTTC CGTGTACAGC TCCACCAAAG GCGATACTGA NTTGGGTGAA 1351 AATACCCGTA TTATTGCTGA AAACGTAACC GTATTATCTA ACGGTAGTAT 1401 TGGCAGTGCT GCTGTAATTG AGGCTAAAGA CACTGCACAC ATTGAATCGG 1451 GCAAACCGCT TTCTTTAGAA ACCTCGACCG TTGCCTCCAA CATCCGTTTG 1501 AACAACGGTA ACATTAAAGG CGGAAAGCAG CTTGCTTTAC TGGCAGACGA 1551 TAACATTACT GCCAAAACTA CCAATCTGAA TACTCCCGGC AATCTGTATG 1601 TTCATACAGG TAAAGATCTG AATTTGAATG TTGATAAAGA TTTGTCTGCC 1651 GCCAGCATCC ATTTGAAATC GGATAACGCT GCCCATATTA CCGGCACCAG 1701 TAAAACCCTC ACTGCCTCAA AAGACATGGG TGTGGAGGCA GGCTTGCTGA 1751 ATGTTACCAA TACCAATCTG CGTACCAACT CGGGTAATCT GCACATTCAG 1801 GCAGCCAAAG GCAATATTCA GCTTCGCAAT ACCAAGCTGA ACGCAGCCAA 1851 GGCTCTCGAA ACCACCGCAT TGCAGGGCAA TATCGTTTCA GACGGCCTTC 1901 ATGCTGTTTC TGCAGACGGT CATGTATCCT TATTGGCCAA CGGTAATGCC 1951 GACTTTACCG GTCACAATAC CCTGACAGCC AAGGCCGATG TCNATGCAGG 2001 ATCGGTTGGT AAAGGCCGTC TGAAAGCAGA CAATACCAAT ATCACTTCAT 2051 CTTCAGGAGA TATTACGTTG GTTGCCGNNN NCGGTATTCA GCTTGGTGAC 2101 GGAAAACAAC GCAATTCAAT CAACGGAAAA CACATCAGCA TCAAAAACAA 2151 CGGTGGTAAT GCCGACTTAA AAAACCTTAA CGTCCATGCC AAAAGCGGGG 2201 CATTGAACAT TCATTCCGAC CGGGCATTGA GCATAGAAAA TACNAAGCTG 2251 GAGTCTACCC ATAATACGCA TCTTAATGCA CAACACGAGC GGGTAACGCT 2301 CAACCAAGTA GATGCCTACG CACACCGTCA TCTAAGCATT ANCGGCAGCC 2351 AGATTTGGCA AAACGACAAA CTGCCTTCTG CCAACAAGCT GGTGGCTAAC 2401 GGTGTATTGG CAATCAATGC GCGCTATTCC CAAATTGCCG ACAACACCAC 2451 GCTGAGAGCG GGTGCAATCA ACCTTACTGC CGGTACCGCC CTAGTCAAGC 2501 GCGGCAACAT CAATTGGATT ACCGTTTCGA CCAAGACTTT GGAAGATAAT 2551 GCCGAATTAA AACCATTGGC CGGACGGCTG AATATTGAAG CAGGTAGCGG 2601 CACATTAACC ATCGAACCTG CCAACCGCAT CAGTGCGCAT ACCGACCTGA 2651 GCATCAAAAC AGGCGGAAAA TTGCTGTTGT CTGCAAAAGG AGGAAATGCA 2701 GGTGCGCNTA GTGCTCAAGT TTCCTCATTG GAAGCAAAAG GCAATATCCG 2751 TCTGGTTACA GGAGNAACAG ATTTAAGAGG TTCTAAAATT ACAGCCGGTA 2901 AAAACTTGGT TGTCGCCACC ACCAAAGGCA AGTTGAATAT CGAAGCCGTA 2951 AACAACTCAT TCAGCAATTA TTTTCNTACA CAAAAAGNGN NNGNNCTCAA 2901 CCAAAAATCC AAAGAATTGG AACAACAGAT TGCGCAGTIG AAAAAAAGCT 2951 CGCNTAAAAG CAAGCTGATT CCAACCCTGC AAGAAGAACG CGACCGTCTC 3001 GCTTTCTATA TTCAAGCCAT CAACAAGGAA GTTAAAGGTA AAAAACCCAA 3051 AGGCAAAGAA TACCTGCAAG CCAAGCTTTC TGCACAAAAT ATTGACTTGA 3101 TTTCCGCACA AGGCATCGAA ATCAGCGGTT CCGATATTAC CGCTTCCAAA 3151 AAACTGAACC TTCACGCCGC AGGCGTATTG CCAAAGGCAG CAGATTCAGA 3201 GGCGGCTGCT ATTCTGATTG ACGGCATAAC CGACCAATAT GAAATTGGCA 3251 AGCCCACCTA CAAGAGTCAC TACGACAAAG CTGCTCTGAA CAAGCCTTCA 3301 CGTTTGACCG GACGTACGGG GGTAAGTATT CATGCAGCTG CGGCACTCGA 3351 TGATGCACGT ATTATTATCG GTGCATCCGA AATCAAAGCT CCCTCAGGCA 3401 GCATAGACAT CAAAGCCCAT AGTGATATTG TACTGGAGGC TGGACAAAAC 3451 GATGCCTATA CCTTCTTAAA AACCAAAGGT AAAAGCGGCA NAATNATCAG 3501 AAAAACNAAG TTTACCAGCA CCNGCGANCA CCTGATTATG CCAGCCCCNG 3551 TCGAGCTGAC CGCCAACGGT ATCACGCTTC ACGCAGGCGG CAACATCGAA 3601 GCTAATACCA CCCGCTTCAA TGCCCCTGCA GGTAAAGTIA CCCTGGTTGC 3651 GGGTGAANAG NTGCAACTGC TGGCAGAAGA AGGCATCCAC AAGCACGAGT 3701 TGGATGTCCA AAAAAGCCGC CGCTTTATCG GCATCAAGGT AGGTNAGAGC 3751 AATTACAGTA AAAACGAACT GAACGAAACC AAATTGCCTG TCCGCGTCGT 3801 CGCCCAAAAT GCAGCCACCC GTTCAGGCTG GGAThCCGTG CTCGAAGGTA 3851 CCGAATTCAA ATCCACGCTG GCCGGTGCCG ACATTCAGGC AGGTGTANGC 3901 GAAAAAGCCC GTGTCGATGC GAAAATCATC CTCAAAGGCA TTGTGAACCG 3951 TATCCAGTCG GAAGAAAAAT TAGAAACCAA CTCAACCGTA TGGCAGAAAC 4001 AGGCCGGACG CGGCAGCACT ATCGAAACGC TAAAACTGCC CAGCTTCGAA 4051 AGCCCTACTC CGCCCAAATT GTCCGCACCC GGCGGNTATA TCGTCGACAT 4101 TCCGAAAGGC AATCTGAAAA CCGAAATCGA AAAGCTGTCC AAACAGCCCG 4151 AGTATGCCtA TCTGAAACAG CTCCAAGTAG CGAAAAACAT CAACTGGAAT 4201 CAGGTGCAGC TTGCTTACGA CAGATGGGAC TACAAACAGG AGGGCTTAAC 4251 CGAAGCAGGT GCGGCGATTA TCGCACTGGC CGTTACCGTG GTCACCTCAG 4301 GCGCAGGAAC CGGAGCCGTA TTGGGATTAA ACGGTGCGNC CGCCGCCGCA 4351 ACCGATGCAG CATTCGCCTC TTTGGCCAGC CAGGCTTCCG TATCGTTCAT 4401 CAACAACAAA GGCGATGTCG GCAAAACCCT GAAAGAGCTG GGCAGAAGCA 4451 GCACGGTGAA AAATCTGGTG GTTGCCGCCG CTACCGCAGG CGTAGCCGAC 4501 AAAATCGGCG CTTCGGCACT GANCAATGTC AGCGATAAGC AGTGGATCAA 4551 CAACCTGACC GTCAACCTAG CCAATGNCGG GCAGTGCCGC ACTGAttaa - This encodes a protein having amino acid sequence <SEQ ID 62>:
1 MNKGLHRIIF SKKHSTMVAV AETANSQGKG KQAGSSVSVS LKTSGDLCGK 51 LKTTLKTLVC SLVSLSMXXX XXXQITTDKS APIDXQVVIL KTNTGAPLVN 101 IQTPNGRGLS HNRYTQFDVD NKGAVLNNDR NNNPFLVKGS AQLILNEVRG 151 TASKLNGIVT VGGQKADVII ANPNGITVNG GGFKNVGRGI LTIGAPQIGK 201 DGALTGFDVR QGTLTVGAAG WNDKGGADYT GVLARAVALQ GKLQGKNLAV 251 STGPQKVDYA SGEISAGTAA GTKPTIALDT AALGGMYADS ITLTAXEKGV 301 GVKNAGTLEA AKQLIVTSSG RIENSGRIAT TADGTEASPT YLXIETTEKG 351 AXGTFISNGG RIESKGLLVI ETGEDIXLPA GAVVQNNGSR PATTVLNAGH 401 NLVIESKTNV NNAXGSXNLS AGGRTTINDA TIQAGSSVYS STKGDTXLGE 451 NTRIIAENVT VLSNGSIGSA AVIEAKDTAN IESGKPLSLE TSTVASNIRL 501 NNGNIKGGKQ LALLADDNIT AKTTNLNTPG NLYVHTGKDL NLNVDKDLSA 551 ASIHLKSDNA AHITGTSKTL TASKDNGVEA GLLNVTNTNL RTNSGNLHIQ 601 AAKGNZQLRH TKLNAAKALE TTALQGNIVS DGLHAVSADG HVSLLANGNA 651 DFTGHNTLTA KADVXAGSVG KGRLKADNTN ITSSSGDITL VAXXGIQLGD 701 GKQRNSINGK HISIKNNGGN ADLKNLNVHA KSGALNIHSO RALSIENTKL 751 ESTHNTHLNA QHERVTLNQV DAYAHRHLSI XGSQIWQNDK LPSANKLVAN 801 GVLAXNARYS QIADNTTLRA CAINLTAGTA LVKRGNINWS TVSTKTLEDN 851 AELKPLAGRL NIEAGSGTLT IEFANRISAH TDLSIKTGGK LLLSAXGGNA 901 GAXSAQVSSL EAKGNIRLVT GXTDLRGSKI TAGKNLVVAT TKGKLNIEAV 951 NNSFSNYFXT QKXXXLNQKS KELEOQIAQL KKSSXKSKLI PTLQEERDRL 1001 AFYIQAINKE VKGKKPKGKE YLQAXLSAQN IDLISAQGIE ISGSDITASK 1051 KLNLHAAGVL PKAADSEAAA ILIDGITOQY EIGKPTYKSH YDKAALNKPS 1101 RLTGRTGVSI HAAAALDDAR IIIGASEIKA PSGSIDIKAR SDIVLEAGQN 1151 DAYTFLXTKG KSGXXIRKTK FTSTXXHLIM PAPVELTANG ITLQAGGNIE 1201 ANTTRFHAPA GKVTLVAGEK XQLLAEEGIK KHELDVQKSR RFIGIKVGXS 1251 NYSINELNET KLPVRVVAQX AATRSGWDTV LEGTEFKTTL AGADIQAGVX 1301 EKARVQAXII LKGIVNRIQS EEKLETNSTV WQKQAGRGST IETLKLPSFE 1351 SPTPPKLSAP GGYIVDIPKG NLKTEIEKLS KQPEYAYLKQ LQVAKNINWN 1401 QVQLAYQRWD YKQEGLTEAG AAIIALAVTV VTSGAGTGAV LGLNGAXAAA 1451 TDAAFASLAS QASVSFINNK GDVGKTLKEL GRSSTVKNLV VAAATAGVAD 1501 KIGASALXNV SDKQWINNLT VNLANXGQCR TD* - ORF114-1 and ORF114a show 89.8% identity in 1564 aa overlap
orf114a.pep MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTTLKTLVC |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf114-1 MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLKTSGDLCGKLKTTLKTLVC orf114a.pep SLVSLSMXXXXXXQITTDKSAPKNXQVVILKTNTGAPLVNIQTPNGRGLSHNRYTQFDVD ||||||| ||||||||||| ||||||||||||||||||||||||||||||||||| orf114-1 SLVSLSMXXXXXXQITTDKSAPKNQQVVILKTNTGAPLVNIQTPNGRGLSHNRYTQFDVD orf114a.pep NKGAVLNNDRNNNPFLVKGSAQLILNEVRGTASKLNGIVTVGGQKADVIIANPNGITVNG |||||||||||||||:|||||||||||||||||||||||||||||||||||||||||||| orf114-1 NKGAVLNNDRNNNPFVVKGSAQLILNEVRGTASKLNGIVTVGGQKADVIIANPNGITVNG orf114a.pep GGFKNVGRGILTIGAPQIGKDGALTGFDVRQGTLTVGAAGWNDKGGADYTGVLARAVALQ |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||| orf114-1 GGFKNVGRGILTTGAPQIGKDGALTGFDVRQGTLTVGAAGWNDKGGADYTGVLARAVALQ orf114a.pep GKLQGKNLAVSTGFQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIAXEKGV ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| orf114-1 GKLOGKNLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIANEKGV orf114a.pep GVKNAGTLEAAXQLIVTSSGRIENSGRIATTADGTLASPTYLXIETTEKGAXGTFISNGG |||||||||||||||||||||||||||||||||||||||||| |||||||| |||||||| orf114-1 GVKNAGTLEAAXQLIVTSSGRIENSGRIATTADGTLASPTYLSIETTEKGAAGTFISNGG orf114a.pep RIESKGLLVIETGEDIXLRNGAVVQNNGSRPATTVLNAGHNLVIESKTNVNNAKGSXNLS |||||||||||||||| |||||||||||||||||||||||||||||||||||||| :|| orf114-1 RIESKGLLVIETGEDISLRNGAVVQNNGSRPATTVLNAGHNLVIESKTNVNNAKGPANLS orf114a.pep AGGRTTINDATIQAGSSVYSSTKGDTXLGENTRIIAENVTVLSNGSIGSAAVIEAKDTAH | |||:|::|:||:|::||||:||:: ||:|||| : :|||||||||:|:|||:|||||| orf114-1 ADGRTVIKEASIQTGTTVYSSSKGNAELGNNTRITGADVTVLSNGTISSSAVIDAKDTAH orf114a.pep IESGKPLSLETSTVASNIRLNNGNIKGGKQLALLADDNITAKTTNLNTPGNLYVHTGKDL ||:|||||||||||:|||:|:||||:|:|||||||||||||||||||||||||||||||| orf114-1 IEAGKPLSLEASTVTSDIRLNGGSIKGGKQLALLADDNITAKTTNLNTPGNLYVHTGKDL orf114a.pep NLNVDKDLSAASIHLKSDNAAHITGTSKTLTASKDMGVEAGLLNVTNTNLRTNSGNLHIQ ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| orf114-1 NLNVDKDLSAASIHLKSDNAAHITGTSKTLTASKDMGVEAGSLNVTNTNLRTNSGNLHIQ orf114a.pep AAKGNIQLRNTKLNAAKALETTALQGNIVSDGLHAVSADGHVSLLANGNADFTGHNTLTA |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf114-1 AAKGNIQLRNTKLNAAKALETTALQGNIVSDGLHAVSADGHVSLLANGNADFTGHNTLTA orf114a.pep KADVXAGSVGKGRLKADNTNITSSSGDITLVAXXGIQLGDGKQRNSINGKHISIKNNGGN |||| ||||||||||||||||||||||||||| |||||||||||||||||||||||||| orf114-1 KADVNAGSVGKGRLKADNTNITSSSGDITLVAGNGIQLGDGKQRNSINGKHISIKNNGGN orf114a.pep ADLKNLNVHAKSGALNIHSDRALSIENTKLESTHNTHLNAQHERVTLNQVDAYAHRHLSI |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf114-1 ADLKNLNVHAKSGALNIHSDRALSIENTKLESTHNTHLNAQHERVTLNQVDAYAHRHLSI orf114a.pep XGSQIWQNDKLPSANKLVANGVLAXNARYSQIADNTTLRAGAINLTAGTALVKRGNINWS :||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| orf114-1 TGSQIWQNDKLPSANKLVANGVLALNARYSQIADNTTLRAGAINLTAGTALVKRGNINWS orf114a.pep TVSTKTLEDNAELKPLAGRLNIEAGSGTLTIEPANRISAHTDLSIKTGGKLLLSAKGGNA |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf114-1 TVSTKTLEDNAELKPLAGRLNIEAGSGTLTIEPANRISAHTDLSIKTGGKLLLSAKGGNA orf114a.pep GAXSAQVSSLEAKGNIRLVTGXTDLRGSKITAGKNLVVATTKGKLNIEAVNNSFSNYFXT || |||||||||||||||||| |||||||||||||||||||||||||||||||||||| | orf114-1 GAPSAQVSSLEAKGNIRLVTGETDLRGSKITAGKNLVVATTKGKLNIEAVNNSFSNYFPT orf114a.pep QKXXXLNQKSKELEQQIAQLKKSSXKSKLIPTLQEERDRLAFYIQAINKEVKGKKPKGKE || ||||||||||||||||||| ||||||||||||||||||||||||||||||||||| orf114-1 QKAAELNQKSKELEQQIAQLKKSSPKSKLIPTLQEERDRLAFYIQAINKEVKGKKPKGKE orf114a.pep YLQAKLSAQNIDLISAQGIEISGSDITASKKLNLHAAGVLPKAADSEAAAILIDGITDQY |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf114-1 YLQAKLSAQNIDLISAQGIEISGSDITASKKLNLHAAGVLPKAADSEAAAILIDGITDQY orf114a.pep EIGKPTYKSHYDKAALNKPSRLTGRTGVSIHAAAALDDARIIIGASEIKAPSGSIDIKAH |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf114-1 EIGKPTYKSHYDKAALNKPSRLTGRTGVSIHAAAALDDARIIIGASEIKAPSGSIDIKAH orf114a.pep SDIVLEAGQNDAYTFLXTKGKSGXXIRKTKFTSTXXHLIMPAPVELTANGITLQAGGNIE |||||||||||||||| |||||| ||||||||| |||||||||||||||||||||||| orf114-1 SDIVLEAGQNDAYTFLKTKGKSGKIIRKTKFTSTRDHLIMPAPVELTANGITLQAGGNIE orf114a.pep ANTTRFNAPAGKVTLVAGEXXQLLAEEGIHKHELDVQKSRRFIGIKVGXSNYSKNELNET ||||||||||||||||||| ||||||||||||||||||||||||||| ||||||||||| orf114-1 ANTTRFNAPAGKVTLVAGEELQLLAEEGIHKHELDVQKSRRFIGIKVGKSNYSKNELNET orf114a.pep KLPVRVVAQXAATRSGWDTVLEGTEFKTTLAGADIQAGVXEKARVDAKIILKGIVNRIQS |||||||||:||||||||||||||||||||||||||||| ||||:||||||||||||||| orf114-1 KLPVRVVAQTAATRSGWDTVLEGTEFKTTLAGADIQAGVGEKARADAKIILKGIVNRIQS orf114a.pep EEKLETNSTVWQKQAGRGSTIETLKLPSFESPTPPKLSAPGGYIVDIPKGNLKTEIEKLS ||||||||||||||||||||||||||||||||||||||:||||||||||||||||||||: orf114-1 EEKLETNSTVWQKQAGRGSTIETLKLPSFESPTPPKLSTPGGYIVDIPKGNLKTEIEKLA orf114a.pep KQPEYAYLKQLQVAKNINWNQVQLAYDRWDYKQEGLTEAGAAIIALAVTVVTSGAGTGAV ||||||||||||||||:||||||||||:|||||||||:|||||::: ||::| | |: |: orf114-1 KQPEYAYLKQLQVAKNVNWNQVQLAYDKWDYKQEGLTRAGAAIVTIIVTALTYGYGATAA orf114a.pep LGLNGA--------------XAATD----------AAFASLASQASVSFINNKGDVGKTL 1477 |: :: :|||| ||:||| |||:||:|||||||||:| orf114-1 GGVAASGSSTAAAAGTAATTTAAATTVSTATAMQTAALASLYSQAAVSIINNKGDVGKAL 1500 orf114a.pep KELGRSSTVKNLVVAAATAGVADKIGA----------SALXNVSDKQWINNL----TVNL 1523 |:|| |:|||::|::| |||: :::|| : | : : :| | || ::|| orf114-1 KDLGTSDTVKQIVTSALTAGALNQMGADIAQLNSKVRTELFSSTGNQTIANLGGRLATNL 1560 orf114a.pep ANXGQCRTDX :| | orf114-1 SNAGISAGINTAVN...
Homology with pspA Putative Secreted Protein of N. meningitidis (Accession Number AF030941) - ORF114 and pspA protein show 36% aa identity in 302 aa overlap:
Orf114: 1 AVAETANSQGKGKQAGSSVSVSL----KTSGDXXXXXXXXXXXXXXXXXXXXXXXPAHAQ 56 AVAE + GK Q + SV + S PA A pspA: 19 AVAENVHRDGKSMQDSEAASVRVTGAASVSSARAAFGFRMAAFSVMLALGVAAFSPAPAS 78 Orf114: 57 -ITTDKSAPKNQQVVILKTNTGAPLVNIQTPNGRGLSHNRXYAFDVDNKGAVLNNDRNN- 114 I DKSAPKNQQ VIL+T G P VNIQTP+ +G+S NR FDVD KG +LNN R+N pspA: 79 GIIADKSAPKNQQAVILQTANGLPQVNIQTPSSQGVSVNRFKQFDVDEKGVILNNSRSNT 138 Orf114: 115 ----------NPFVVKGSAQLILNEV-RGTASKLNGIVTVGGQKADVIIANPNGITVNGG 163 NP + +G A++I+N++ S LNG + VGG++A+V++ANP+GI VNGG pspA: 139 QTQLGGWIQGNPHLARGEARVIVNQIDSSNPSLLNGYIEVGGKRAEVVVANPSGIRVNGG 198 Orf114: 164 GFKNVGRGILTTGAPQIGKDGALTGFDVVKAHWTVXAAGWNDKGGAXYTGVLARAVALQG 223 G N LT+G P + +G LTGFDV + G D A YT +L+RA + papA: 199 GLINAASVTLTSGVPVL-NNGNLTGFDVSSGKVVIGGKGL-DTSDADYTRILSRAAEINA 256 Orf114: 224 KXXGKXLAVSTGPQKVDYASGEISAGTAAGTK----PTIALDTAALGGMYADSITLIANE 279 GK + V +G K+D+ +A + PT+A+DTA LGGMYAD ITLI+ + pspA: 257 GVWGKDVKVVSGKNKLDFDGSLAKTASAPSSSDSVTPTVAIDTATLGGMYAQKITLISTD 316 Orf114: 280 KG 291 G papA: 317 NG 318 - ORF114a is also homologous to pspA:
gil2623258 (AF030941) putative secreted protein (Neisseria meningitidis) Length = 2273 Score +32 261 bits (659), Expect +32 3e−69 Identities = 203/663 (30%), Positives 314/663 (46%), Gaps 76/663 (11%) Query: 1 MNKGLHRIIFSKKHSTMVAVAETANSQGKGKQAGSSVSVSLK-----TSGDXXXXXXXXX 55 MNK +++IF+KK S M+AVAE + GK Q + SV + +S Sbjct: 1 MNKRCYKVIFNKKRSCMMAVAENVHRDGKSMQDSEAASVRVTGAASVSSARAAFGFRMAA 60 Query: 56 XXXXXXXXXXXXXXXXXXQITTKDSAPKNXQVVILKTNTGAPLVNIQTPNGRGLSHNRYT 115 I DKSAPKN Q VIL+T G P VNIQTP+ +G+S NR+ Sbjct: 61 FSVMLALGVAAFSPAPASGIIADKSAPKNQQAVILQTANGLPQVNIQTPSSQGVSVNRFK 120 Query: 116 QFDVDNKGAVLNNDRNN-----------NPFLVKGSAQLILNEV-RGTASKLNGIVTVGG 163 QFDVD KG +LNN R+N-----------NP L +G A++I+N++ S LNG + VGG Sbjct: 121 QFDVDEKGVILNNSRSNTQTQLGGWIQGNPHLARGEARVIVNQIDSSNPSLLNGYIEVGG 180 Query: 164 QKADVIIANPNGITVNGGGFKNVGRGILTIGAPQIGKDGALTGFDVRQGTLTVGAAGWND 223 ++A+V++ANP+GI VNGGG N LT G P + +G LTGFDV G + +G G D Sbjct: 181 KRAEVVVANPSGIRVNGGGLINAASVTLTSGVPVL-NNGNLTGFDVSSGKVVIGGKGL-D 238 Query: 224 KGGADYTGVLARAVALQGKLQGKNLAVSTGPQKVDYASGEISAGTAAGTK----PTIALD 279 ADYT +L+RA + + GK++ V +G K+D+ +A + PT+A+D Sbjct: 239 TSDADYTRILSRAAEINAGVWGKDVKVVSGKNKLDFDGSLAKTASAPSSSDSVTPTVAID 298 Query: 280 TAALGGMYADSITLIAXEKGVGVKNAGTLEAAK-QLIVTSSGRIENSGRIATTADGTEAS 338 TA LGGMYAD ITLI+ + G ++N G + AA + +++ G++ NSG I Sbjct: 299 TATLGGMYADKITLISTDNGAVIRNKGRIFAATGGVTLSADGKLSNSGSI-------DAA 351 Query: 339 PTYLXIETTEKGAXGTFISNGGRIESKGLLVIETGEDIXLRNGAVVQNNGSRPATTVLNA 398 + +T + + G I S V++ + I + G + GS + + Sbjct: 352 EITISAQTVD--------NRQGFIRSGKGSVLKVSDGINNQAGLI----GSAGLLDIRDT 399 Query: 399 GHNLVIESKTNVNNAKGS----XNLSAGGRTTINDATIQAGSSVYSSTKGDTXLGENTRI 454 G +S ++NN G+ ++S ++ ND + A V S + D G+ Sbjct: 400 G-----KSSLHINNTDGTIIAGKDVSLQAKSLDNDGILTAARDV-SVSLHDDFAGKRDIE 453 Query: 455 IAENVTVLSNGSIGSAAVIEAKDTAHIESGKPLSLETSTVASNIRLNNGNIKGGKQLALL 514 +T + G + + +I+A DT + + + + + + S R G L+ Sbjct: 454 AGRTLTFSTQGRLKNTRIIQAGDTVSLTAAQIDNTVSGKIQSGNRTGLNGKNGITNRGLI 513 Query: 515 ADDNIT-----AKTTNLNTPGNLYVHTGKDLNLNVDKDLSAASIHLKSDNAAHITGTSKT 569 + IT AK+ N T G +Y G + + D L+ AA Sbjct: 514 NSNGITLLQTEAKSDNAGT-GRIY---GSRVAVEADTLLNREETVNGETKAA-------V 562 Query: 570 LTASKDMGVEAGXXXXXXXXXXXXSGNLHIQAA---KGNIQLRNTKL-NAAKALETTALQ 625 + A + + + A SG+LHI +A +Q NT L N + A+E++ Sbjct: 563 IAARERLDIGAREIENREAALLSSSGDLHIGSALNGSRQVQGANTSLHNRSAAIESS--- 619 Query: 626 GNI 628 GNI Sbjct: 620 GNI 622 Score +32 37.5 bits (65), Expect = 0.53 Identities = 87/432 (20%), Positives +32 159/432 (36%), Gaps = 62/432 (14%) Query: 239 LQGKLQGKNLAVSTGPQKVDYASGEISAGTAAGTKPTIALDTAALGGMYADSITLIAXEK 298 LQG LQGKN+ + G + +G I A A K A + + S T + Sbjct: 1023 LQGDLQGKNIFAAAGSDITN--TGSIGAENALLLK--------ASNNIESRSETRSNQNE 1072 Query: 299 GVGVKNAGTLEAAKQLIVTSSGRI--ENSGRIATTADGTEASPTYLXIETTEKGAXG-TF 355 V+N G + A L +G + + I TA E T + G T Sbjct: 1073 QGSVRNIGRV-AGIYLTGRQNGSVLLDAGNNIVLTAS-----------ELTNQSEDGQTV 1120 Query: 356 ISNGGRIESKGLLVIETGEDIXLRNGAVVQNNGSRPATTVLNAGHNLVIESK-------T 408 ++ GG I S + I + V++ + +T+ G NL + +K Sbjct: 1121 LNAGGDIRSDTTGISRNQNTIFDSDNYVIRKEQNEVGSTIRTRG-NLSLNAKGDIRIPAA 1179 Query: 409 NVNNAKGSXNLSAGGRTTINDATIQAGSS--------VYSSTKGDTXLGENTRIIAENVT 460 V + +G L+AG D ++AG + Y+ G + TR + Sbjct: 1180 EVGSEQGRLKLAAG-----RDIKVEAGKAHTETEDALKYTGRSGGGIKQKMTRHLKNQNG 1234 Query: 461 VLSNGSIGSAAVIEAKDTAHIESGKPLSLETSTVASWIRLNNGNIKGGKQLALLADDNIT 520 +G++ +I +G + + T+ S NN +K + + A+ N Sbjct: 1235 QAVSGTLDGKEIILVSGRDITVTGSNIIADNHTILS--AKNNIVLKAAETRSRSAEMNKK 1292 Query: 521 AKTTNLNTPG-NLYVHTGKDLNLNVDKDLSAASIHLKSDN-------AAHITGTSKTLTA 572 K+ + + G + KD N + +S + S N H T T T+++ Sbjct: 1293 EKSGLMGSGGIGFTAGSKKDTQTNRSETVSHTESVVGSLNGNTLISAGKHYTQTGSTISS 1352 Query: 573 SK-DMGVEAGXXXXXXXXXXXXSGNLHIQAAKG-----NIQLRNTKLNAAKALETTALQG 626 + D+G+ +G + + KG ++ + NT + A A++ G Sbjct: 1353 PQGDVGISSGKISIDAAQNRYSQESKQVYEQKGVTVAISVPVVNTVMGAVDAVKAVQTVG 1412 Query: 627 NIVSDGLHAVSA 638 + ++A++A Sbjct: 1413 KSKNSRVNAMAA 1424 - Amino acids 1-1423 of ORF114-1 were cloned in the pGex vector and expressed in E. coli, as described above. GST-fusion expression was visible using SDS-PAGE, and
FIG. 5 shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF114-1. - Based on these results, including the homology with the putative secreted protein of N. meningitidis and on the presence of a transmembrane domain, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <SEQ ID 63>
1 CGCTTCATTC ATGATGAAGC AGTCGGCAGC AACATCGGCG GCGGCAAAAT 51 GATTGTTGCA GCCGGGCAGG ATATCAATGT ACGCGGCAnA AGCCTTATTT 101 CTGATAAGGG CATTGTTTTA AAAGCAGGAC ACGACATCGA TATTTCTACT 151 GCCCATAATC GCTATACCGG CAATGAATAC CACGAGAGCA wAAAwTCAGG 201 CGTCATGGGT ACTGGCGGAT TGGGCTTTAC TATCGGTAAC CGGAAAACTA 251 CCGATGACAC TGATCGTACC AATATTGTsC ATACAGGCAG CATTATAGGC 301 AGCCTGAaTG GAGACACCGT TACAGTTGCA GGAAACCGCT ACCGACAAAC 351 CGGCAGTACC GTCTCCAGCC CCGACGGGCG CAATACCGTC ACAGCCAAAw 401 GCATAGATGT AGAGTTCGCA AACAACCGGT ATGCCACTGA CTACGcCCAT 451 ACCCAGGGAA CAAAAAGGCC TTACCGTCGC CCTCAATGTC CCGGTTGTCC 501 AAGCTGCACA AAACTTCATA CAAGCAGCCC AAAATGTGGG CAAAAGTAAA 551 AATAAACGCG TTAATGCCAT GGCTGCAGCC AATGCTGCAT GGCAGAGTTA 601 TCAAGCAACC CAACAAATGC AACAATTTGC TCCAAGCAGC AGTGCGGGAC 651 AAGGTCAAAA CTACAATCAA AGCCCCAGTA TCAGTGTGTC CATTAC.TAC 701 GGCGAACAGA AAAGTCGTAA CGAGCAAAAA AGACATTACA CCGAAgCGGC 751 AgCAAGTCAA ATTATCGGCA AAGGGCAAAC CACACTTGCG GCAACAGGAA 801 GTGGGGAGCA GTCCAATATC AATATTACAG GTTCCGATGT CATCGGCCAT 951 GCAGGTACTC C.CTCATTGC AAGCAACCAT ATCAGACTCC AATCTGCCAA 901 ACAGGACGGC AGCGAGCAAA GCAAAAACAA AAGCAGTGGT TGGAATGCAG 951 GCGTACGTnn CAAAATAGGC AAcGGCATCA GGTTTGGAAT TACCGCCGGA 1001 GGAAATATCG GTAAAGGTAA AGAGCAAGGG GGAAGTACTA CCCACCGCCA 1051 CACCCATGTC GGCAGCACAA CCGGCAAAAC TACCATCCGA AGCGGCGGGG 1101 GATACCACCC TCAAAGGTGT GCAGCTCATC GGCAAAGGCA TACAGGCAGA 1151 TACGCGCAAC CTGCATATAG AAAGTGTTCA AGATACTGAA ACCTATCAGA 1201 GCAAACAGCA AAACGGCAAT GTCCAAGTTt ACTGTCGGTT ACGGATTCAG 1251 TGCAAGCGGC AGTTACCGCC AAAGCAAAGT CAAAGCAGAC CATGCCTCCG 1301 TAACCGGGCA AAgCGGTATT TATGCCGGAG AAGACGGCTA TCAAATyAAA 1351 GTyAGAGACA ACACAGACCT yAAGGGCGGT ATCATCACGT CTAGCCAAAG 1401 CGCAGAAGAT AAGGGCAAAA ACCTTTTTCA GACGGCCACC CTTACTGCCA 1451 GCGACATTCA AAACCACAGC CGCTACGAAG GCAGAAGCTT CGGCATAGGC 1501 GGCAGTTTCG ACCTGAACGG CGGCTGGGAC GGCACGGTTA CCGACAAACA 1551 AGGCAGGCCT ACCGACAGGA TAAGCCCGGC AGCCGGCTAC GGCAGCGACG 1601 GAGACAGCAA AAACAGCACC ACCCGCAGCG GCGTCAACAC CCACAACATA 1651 CACATCACCG ACGAAGCGGG ACAACTTGCC CGAACAGGCA GGACTGCAAA 1701 AGAAACCGAA GCGCGTATCT ACACCGGCAT CGACACCGAA ACTGCGGATC 1751 AACACTCAGG CCATCTGAAA AACAGCTTCG AC... - This corresponds to the amino acid sequence <SEQ ID 64; ORF116>:
1 ..RFIHDEAVGS NIGGGKNIVA AGQDINVRGX SLISDKGIVL KAGADIDIST 51 AHNRYTGNEY HESXXSGVMG TGGLGFTIGN RKTTDDTDRT NIVHTGSIIG 101 SLNGDTVTVA GNRYRQTGST VSSPEGRNTV TAKXIDVEFA NNRYATDYAH 151 TQEQKGLTVA LNVPVVQAAQ NFIQAAQNVG KSKNKRVNAM AAANAAWQSY 201 QATQQMQQFA PSSSAGQGQN YNQSPSISVS IXYGEQKSRN EQKRNYTEAA 251 ASQIIGKGQT TLAATGSGEQ SNINITGSDV IGHAGTXLIA DNHIRLQSAX 301 QDGSEQSKNK SSGWNAGVRX KIGNGIRFGI TAGGNIGKGK EQGGSTTHRH 351 THVGSTTGKT TIRSGGDTTL KGVQLIGXGI QADTRNLHIE SVQDTETYQS 401 KQQNGNVQVT VGYGFSASGS YRQSKVKADH ASVTGQSGIY AGEDGYQIKV 451 RDNTDLKGGI ITSSQSAEDK GKNLFQTATL TASDIQNHSR YEGRSFGIGG 501 SFDLNGGWDG TVTDKQGRPT DRISPAAGYG SDGDSKNSTT RSGVNTHNIH 551 ITDEAGQLAR TGRTAKETEA RIYTGIDTET ADQHSGHLKN SFD... - Computer analysis of this amino acid sequence gave the following results:
- Homology with pspA Putative Secreted Protein of N. meningitidis (Accession Number AF030941)
- ORF116 and pspA protein show 38% aa identity in 502 aa overlap:
Orf116: 6 EAVGSNIGGGKMIVAAGQDINVRGXSLISDKGIVLKAGHDIDISTAHNRYTGNEYHESXX 65 +AV + G ++I+ +G+DI V G ++I+D +L A ++I + A R E ++ PspA: 1235 QAVSGTLDGKEIILVSGRDITVTGSNIIADNHTILSAKNNIVLKAAETRSRSAEMNKKEK 1294 Orf116: 66 XXXXXXXXXXXXXXNRKXXXXXXRTNIVHTGSIIGSLNGDTVTVAGNRYRQTGSTVSSPE 125 ++K + HT S++GSLNG+T+ AG Y QTGST+SSP+ PspA: 1295 SGLMGSGGIGFTAGSKKDTQTNRSETVSHTESVVGSLNGNTLISAGKHYTQTGSTISSPQ 1354 Orf116: 126 GRNTVTAKXIDVEFANNRYATDYAHTQEQKGLTVALNVPXXXX---XXXXXXXXXXXGKS 182 G +++ I ++ A NRY+ + EQKG+TVA++VP GKS PspA: 1355 GDVGISSGKISIDAAQNRYSQESKQVYEQKGVTVAISVPVVNTVMGAVDAVKAVQTVGKS 1414 Orf116: 183 KNKRVXXXXXXXXXWQSYQATQQMQQFA--PSSSAGQGQNYNQSPSISVSIXYGEQKSRN 240 KN RV + + + A P +AGQG ISVS+ YGEQK+ + PspA: 1415 KNSRVNAMAAANALNKGVDSGVALYNAARNPKKAAGQG--------ISVSVTYGEQKNTS 1466 Orf116: 241 EQKRHYTEAAASQIIGKGQTTLAATGSGEQSNINITGSDVIGHAGTXLIADNHIRLQSAK 300 E + T+ +I G G+ +L A+G+G+ S I ITGSDV G GT L A+N +++++A+ PspA: 1467 ESRIKGTQVQEGKITGGGKVSLTASGAGKDSRITITGSDVYGGKGTRLKAENAVQIEAAR 1526 Orf116: 301 QDGSEQSKNKSSGWNAGVRXKIGNGIRFGITAXXXXXXXXXXXXSTTHRHTHVGSTTGKT 360 Q E+S+NKS+G+NAGV I GI FG TA T +R++H+GS +T PspA: 1527 QTHQERSENKSAGFNAGVAIAINKGISFGFTAGANYGKGYGNGDETAYRNSHIGSKDSQT 1586 Orf116: 361 TIRSGGDTTLKGVQLIGKGIQADTRNLHIESVQDTETYQSKQQNGNVQVTVGYGFSASGS 420 I SGGDT +KG QL GKG+ +LHIES+QDT ++ KQ+N + QVTVGYGFS GS PspA: 1587 AIESGGDTVIKGGQLKGKGVGVTAESLHIESLQDTAVFKGKQENVSAQVTVGYGFSVGGS 1646 Orf116: 421 YRQSKVKADHASVTGQSGIYAGEDGYQIKVRDNTDLKGGIITSSQSAEDKGKNLFQTATL 480 Y +SK +D+ASV QSGI+AG DGY+I+V T L G + S DK KNL +T+ + PspA: 1647 YNRSKSSSDYASVNEQSGIFAGGDGYRIRVNGKTGLVGAAVVSD---ADKSKNLLKTSEI 1703 Orf116: 481 TASDIQNHSRYEGRSFGIGGSF 502 DIQNH+ + G+ G F PspA: 1704 WHKDIQNHASAAASALGLSGGF 1725 - Based on homology with pspA, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N.
meningitidis SEQ ID 65>1 ..ACGACCGGCA GCCTCGGCGG CATACTGGCC GGCGGCGGCA CTTCCCTTGC 51 CGCACCGTAT TTGGACAAAG CGGCGGAAAA CCTCGGTCCG GCGGGCAAAG 101 CGGCGGTCAA CGCACTGGGC GGTGCGGCCA TCGGCTATGC AACTGGTGGT 151 AGTGGTGGTG CTGTGGTGGG TGCGAATGTA GATTGGAACA ATAGGCAGCT 201 GCATCCGAAA GAAATGGCGT TGGCCGACAA ATATGCCGAA GCCCTCAAGC 251 GCGAAGTTGA AAAACGCGAA GGCAGAAAAA TCAGCAGCCA AGAAGCGGCA 301 ATGAGAATCC GCAGGCAGAT ATGCGTTGGG TGGACAAAGG TTCCCAAGAC 351 GGCTATACCG ACCAAAGCGT CATATCCCTT ATCGGAATGA - This corresponds to the amino acid sequence <SEQ ID 66; ORF118>:
1 ..TTGSLGGILA GGGTSLAAPY LDKAAENLGP AGKAAVNALG GAAIGYATGG 51 SGGAVVGANV DWNNRQLHPK EMALADKYAE ALKREVEKRE GRKISSQEAA 101 MRIRRQICVG WTKVPKTAIP TKASYPLSE* - Computer analysis of this amino acid sequence reveals two putative transmembrane domains.
- Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis SEQ ID 67>
1 ..CAATGCCGTC TGAAAAGCTC ACAATYTTAC AGACGGCATT TGTTATGCAA 51 GTACATATAC AGATTCCCTA TATACTGCCC AGrkGCGTGC GTgGCTGAAG 101 ACACCCCCTA CGCTTGCTAT TTGrAACAGC TCCAAGTCAC CAAAGACGTC 151 AACTGGAACC AGGTACWACT GGCGTACGAC AAATGGGACT ATAAACAGGA 201 AGGCTTAACC GGAGCCGGAG CAGCGATTAT TGCGCTGGCT GTTACCGTGG 251 TTACTGCGGG CGCGGGAgCC GGAGCCGCAC TGGGcTTAAA CGGCGCGGCc 301 GCAGCGGCAA CCGATGCCGC ATTCGCCTCG CTGGCCAGCC AGGcTTCCGT 351 ATCGCTCATC AaCAACAAAG GCAATATCGG TAaCACCCTG AAAGAGCTGG 401 GCAGAAGCAG CACGGTGAAA AATCTGATGG TTGCCGTCGc tACCGCAgGC 451 GTagCcgaCA AAATCGGTGC TTCGGCACTG AACAATGTCA GCGATAAGCA 501 GTGGATCAAC AACCTGACCG TCAACCTGGC CAATGCGGGC AGTGCCGCAC 551 TGATTAATAC CGCTGTCAAC GGCGGCAGCc tgAAAGACAA TCTGGAAGCG 601 AATATCCTTG CGGCTTTGGT GAATACTGCG CATGGAGAAG CAGCCAGTAA 651 AATCAAACAG TTGGATCAGC ACTACATTAC CCACAAGATT GCCCaTGCCA 701 TAGCGGGCTG TGCGGcTGCG GCGGCGAATA AGGGCAAGTG TCAGGATGGT 751 GCGATAgGTG CGGCTGTGGG CGAGATAGTC GGGGAgGCTT TGACAAACGG 801 CAAAAATCCT GACACTTTGA CAGCTAAAgA ACGCGaACAG ATTTTGGCAT 851 ACAGCAAACT GGTTGCCGGT ACGGTAAGCG GTGTGGTCGG CGGCGATGTA 901 AATGCGGCGG CGAATGCGGC TGAGGTAGCG GTGAAAAATA ATCAGCTTAG 951 CGACAAAtGA - This corresponds to the amino acid sequence <SEQ ID 68; ORF41>:
1 ..QCRLKSSQFY RRHLLCKYIY RFPIYCPXAC VAEDTPYACY LXQLQVTKDV 51 HWNQVXLAYD KWDYKQEGLT GAGAAIIALA VTVVT AGAGA GAALGLNGAA 101 AAATDAAFAS LASQASVSLI NNKGNIGNTL KELGRSSTVK NU4VAVATAG 151 VADKIGASAL NNVSDKQWIN NLTVNLANAG SAALINTAVN GGSLKDNLEA 201 NILAALVNTA HGEAASKIKQ LDQHYITHKI AHAIAGCAAA AANKGKCQDG 251 AIGAAVGEIV GEALTNGKNP DTLTAKEREQ ILAYSKLVAG TVSGVVGGDV 301 NAAANAAEVA VKNNQLSDK* - Further work revealed the complete nucleotide sequence <SEQ ID 69>:
1 ATGCAAGTAA ATATTCAGAT TCCCTATATA CTGCCCAGAT GCGTGCGTGC 51 TGAAGACACC CCCTACGCTT GCTATTTGAA ACAGCTCCAA GTCACCAAAG 101 ACGTCAACTG GAACCAGGTA CAACTGGCGT ACGACAAATG GGACTATAAA 151 CAGGAAGGCT TAACCGGAGC CGGAGCAGCG ATTATTGCGC TGGCTGTTAC 201 CGTGGTTACT GCGGGCGCGG GAGCCGGAGC CGCACTGGGC TTAAACGGCG 251 CGGCCGCAGC GGCAACCGAT GCCGCATTCG CCTCGCTGGC CAGCCAGGCT 301 TCCGTATCGC TCATCAACAA CAAAGGCAAT ATCGGTAACA CCCTGAAAGA 351 GCTGGGCAGA AGCAGCACGG TGAAAAATCT GATGGTTGCC GTCGCTACCG 401 CAGGCGTAGC CGACAAAATC GGTGCTTCGG CACTGAACAA TGTCAGCGAT 451 AAGCAGTGGA TCAACAACCT GACCGTCAAC CTGGCCAATG CGGGCAGTGC 501 CGCACTGATT AATACCGCTG TCAACGGCGG CAGCCTGAAA GACAATCTGG 551 AAGCGAATAT CCTTGCGGCT TTGGTGAATA CTGCGCATGG AGAAGCAGCC 601 AGTAAAATCA AACAGTTGGA TCAGCACTAC ATTACCCACA AGATTGCCCA 651 TGCCATAGCG GGCTGTGCGG CTGCGGCGGC GAATAAGGGC AAGTGTCAGG 701 ATGGTGCGAT AGGTGCGGCT GTGGGCGAGA TAGTCGGGGA GGCTTTGACA 751 AACGGCAAAA ATCCTGACAC TTTGACAGCT AAAGAACGCG AACAGATTTT 801 GGCATACAGC AAACTGGTTG CCGGTACGGT AAGCGGTGTG GTCGGCGGCG 851 ATGTAAATGC GGCGGCGAAT GCGGCTGAGG TAGCGGTGAA AAATAATCAG 901 CTTAGCGACA AAGAGGGTAG AGAATTTGAT AACGAAATGA CTGCATGCGC 951 CAAACAGAAT AATCCTCAAC TGTGCAGAAA AAATACTGTA AAAAAGTATC 1001 AAAATGTTGC TGATAAAAGA CTTGCTGCTT CGATTGCAAT ATGTACGGAT 1051 ATATCCCGTA GTACTGAATG TAGAACAATC AGAAAACAAC ATTTGATCGA 1101 TAGTAGAAGC CTTCATTCAT CTTGGGAAGC AGGTCTAATT GGTAAAGATG 1151 ATGAATGGTA TAAATTATTC AGCAAATCTT ACACCCAAGC AGATTTGGCT 1201 TTACAGTCTT ATCATTTGAA TACTGCTGCT AAATCTTGGC TTCAATCGGG 1251 CAATACAAAG CCTTTATCCG AATGGATGTC CGACCAAGGT TATACACTTA 1301 TTTCAGGAGT TAATCCTAGA TTCATTCCAA TACCAAGAGG GTTTGTAAAA 1351 CAAAATACAC CTATTACTAA TGTCAAATAC CCGGAAGGCA TCAGTTTCGA 1401 TACAAACCTA AAAAGACATC TGGCAAATGC TGATGGTTTT AGTCAAAAAC 1451 AGGGCATTAA AGGAGCCCAT AACCGCACCA ATTTTATGGC AGAACTAAAT 1501 TCACGAGGAG GACGCGTAAA ATCTGAAACC CAAACIGATA TTGAAGGCAT 1551 TACCCGAATT AAATATGAGA TTCCTACACT AGACAGGACA GGTAAACCTG 1601 ATGGTGGATT TAAGGAAATT TCAAGTATAA AAACTGTTTA TAATCCTAAA 1651 AAATTTTCTG ATGATAAAAT ACTTCAAATG GCTCAAAATG CTGCTTCACA 1701 AGGATATTCA AAAGCCTCTA AAATTGCTCA AAATGAAAGA ACTAAATCAA 1751 TATCGGAAAG AAAAAATGTC ATTCAATTCT CAGAAACCTT TGACGGAATC 1801 AAATTTAGAT CATATTTTGA TGTAAATACA GGAAGAATTA CAAACATTCA 1851 CCCAGAATAA - This corresponds to the amino acid sequence <
SEQ ID 70; ORF41-1>:1 MQVNIQIPYI LPRCVRAEDT PYACYLKQLQ VTKDVNWNQV QLAYOKWDYK 51 QEGLTGAGAA IIALAVTVVT AGA GAGAALG LNGAAAAATD AAFASLASQA 101 SVSLINNKGN IGNTLKELGR SSTVKNLHVA VATAGVADKI GASALNNVSD 151 KQWINNLTVN LANAGSAALI NTAVNGGSLX DNLEANILAA LVNTAHGEAA 201 SKIKQLDQHY ITHKIAHAIA GCAAAAANKG KCQDGAIGAA VGEIVGEALT 251 NGKNPDTLTA KEREQILAYS KLVAGTVSGV VGGDVNAAAN AAEVAVKNNQ 301 LSDKLGREFD NEMTACAKQN NPQLCRKNTV KKYQNVADKR LAASIAICTD 351 ISRSTECRTI RKQHLIDSRS LHSSWEAGLX GKDDEWYKLF SKSYTQADLA 401 LQSYHLNTAA KSWLOSGNTK PLSEWNSDQG YTLISGVNPR FIPIPRGFVK 451 QHTFITNVKY PEGISFDTNL KRMLANADGF SQKQGIKGAH NRTNFNAELN 501 SRGGRVKSET QTDIEGITRI KYEIPTLDRT GKPDGGFKEI SSIKTVYNPK 551 KFSDDKILQH AQNAASQGYS KASKIAQNER TKSISERKNV IQFSETFDGI 601 KFRSYFDVNT GRITNIHPE* - Computer analysis of this amino acid sequence predicts a transmembrane domain, and homology with an ORF from N. meningitidis (strain A) was also found.
- ORF41 shows 92.8% identity over a 279 aa overlap with an ORF (ORF41a) from strain A of N. meningitidis:
10 20 30 40 50 60 69 orf41.pep YRRHLLCKYIYRFPIYCPXACVAEDTPYACYLXQLQVTKDVNWNQVXLAYDKWDYKQEGL 11 1111:1::11111 1111:11111111 orf41a YLKQLQVAXNINWNQVQLAYDRWDYKQEGL 10 20 30 70 80 90 100 110 120 129 orf41.pep TGAGAAIIALAVTVVTAGAGAGAALGLNGAAAAATDAAFASLASQASVSLINNKGNIGNT | ||||||||||||||:|||:||:|||||| ||||||||||||||||||:|||||::|:| orf41a TEAGAAIIALAVTVVTSGAGTGAVLGLNGAXAAATDAAFASLASQASVSFINNKGDVGKT 40 50 60 70 80 90 130 140 150 160 170 180 189 orf41.pep LKELGRSSTVKNLMVAVATAGVADKIGASALNNVSDKQWINNLTVNLANAGSAALINTAV |||||||||||||:||:|||||||||||||| |||||||||||||||||||||||||||| orf41a LKELGRSSTVKNLVVAAATAGVADKIGASALXNVSDKQWINNLTVNLANAGSAALINTAV 100 110 120 130 140 150 190 200 210 220 230 240 249 orf41.pep NGGSLKDNLEANILAALVNTAHGEAASKIKQLDQHYITHKIAHAIAGCAAAAANKGKCQD ||||||| |||||||||||||||||||||||||||||:|||||||||||||||||||||| orf41a NGGSLKDXLEANILAALVNTAHGEAASKIKQLDQHYIVHKIAHAIAGCAAAAANKGKCQD 160 170 180 190 200 210 250 260 270 280 290 300 309 orf41.pep GAIGAAVGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVSGVVGGDVNAAANAAEV |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf41a GAIGAAVGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVSGVVGGDVNAAANAAEV 220 230 240 250 260 270 310 320 orf41.pep AVKNNQLSDKX ||||||||| orf41a AVKNNQLSDXEGREFDNENTACAKQNXPQLCRXWIVKKYQNVADKRLAASIAICTDISRS 280 290 300 310 320 330 - A partial ORF41a nucleotide sequence <SEQ ID 71> is:
1 TATCTGAAAC AGCTCCAAGT AGCGAAAAAC ATCAACTGGA ATCAGGTGCA 51 GCTTGCTTAC GACAGATGGG ACTACAAACA GGAGGGCTTA ACCGAAGCAG 101 GTGCGGCGAT TATCGCACTG GCCGTTACCG TGGTCACCTC AGGCGCAGGA 151 ACCGGAGCCG TATTGGGATT AAACGGTGCG NCCGCCGCCG CAACCGATGC 201 AGCATTCGCC TCTTTGGCCA GCCAGGCTTC CGTATCGTTC ATCAACAACA 251 AAGGCGATGT CGGCAAAACC CTGAAAGAGC TGGGCAGAAG CAGCACGGTG 301 AAAAATCTGG TGGTTGCCGC CGCTACCGCA GGCGTAGCCG ACAAAATCGG 351 CGCTTCGGCA CTGANCAATG TCAGCGATAA GCAGTGGATC AACAACCTGA 401 CCGTCAACCT AGCCAATGCG GGCAGTGCCG CACTGATTAA TACCGCTGTC 451 AACGGCGGCA GCCTGAAAGA CANTCTGGAA GCGAATATCC TTGCGGCTTT 501 GGTCAATACC GCGCATGGAG AAGCAGCCAG TAAAATCAAA CAGTTGGATC 551 AGCACTACAT AGTCCACAAG ATTGCCCATG CCATAGCGGG CTGTGCGGCA 601 GCGGCGGCGA ATAAGGGCAA GTGTCAGGAT GGTGCGATAG GTGCGGCTGT 651 GGGCGAGATA GTCGGGGAGG CTTTGACAAA CGGCAAAAAT CCTGACACTT 701 TGACAGCTAA AGAACGCGAA CAGATTTTGG CATACAGCAA ACTGGTTGCC 751 GGTACGGTAA GCGGTGTGGT CGGCGGCGAT GTAAATGCGG CGGCGAATGC 801 GGCTGAGGTA GCGGTGAAAA ATAATCAGCT TAGCGACNAA GAGGGTAGAG 851 AATTTGATAA CGAAATGACT GCATGCGCCA AACAGAATAN TCCTCAACTG 901 TGCAGAAAAA ATACTGTAAA AAAGTATCAA AATGTTGCTG ATAAAAGACT 951 TGCTGCTTCG ATTGCAATAT GTACGGATAT ATCCCGTAGT ACTGAATGTA 1001 GAACAATCAG AAAACAACAT TTGATCGATA GTAGAAGCCT TCATTCATCT 1051 TGGGAAGCAG GTCTAATTGG TAAAGATGAT GAATGGTATA AATTATTCAG 1101 CAAATCTTAC ACCCAAGCAG ATTTGGCTTT ACAGTCTTAT CATTTGAATA 1151 CTGCTGCTAA ATCTTGGCTT CAATCGGGCA ATACAAAGCC TTTATCCGAA 1201 TGGATGTCCG ACCAAGGTTA TACACTTATT TCAGGAGTTA ATCCTAGATT 1251 CATTCCAATA CCAAGAGGGT TTGTAAAACA AAATACACCT ATTACTAATG 1301 TCAAATACCC GGAAGGCATC AGTTTCGATA CAAACCTANA AAGACATCTG 1351 GCAAATGCTG ATGGTTTTAG TCAAGAACAG GGCATTAAAG GAGCCCATAA 1401 CCGCACCAAT NTTATGGCAG AACTAAATTC ACGAGGAGGA NGNGTAAAAT 1451 CTGAAACCCA NACTGATATT GAAGGCATTA CCCGAATTAA ATATGATATT 1501 CCTACACTAG ACAGGACAGG TAAACCTGAT GGTGGATTTA AGGAAATTTC 1551 AAGTATAAAA ACTGTTTATA ATCCTAAAAA NTTTTNNGAT GATAAAATAC 1601 TTCAAATGGC TCAANATGCT GNTTCACAAG GATATTCAAA AGCCTCTAAA 1651 ATTGCTCAAA ATGAAAGAAC TAAATCAATA TCGGAAAGAA AAAATGTCAT 1701 TCAATTCTCA GAAACCTTTG ACGGAATCAA ATTTAGANNN TATNTNGATG 1751 TAAATACAGG AAGAATTACA AACATTCACC CAGAATAA - This encodes a protein having the partial amino acid sequence <SEQ ID 72>:
1 YLKQLQVAKN INWNQVQLAY DRWDYKQEGL TEAGAAIIAL AVTVVTSGAG 51 TGAVLGLNGA XAAATDAAFA SLASQASVSF INNKGDVGKT LKELGRSSTV 101 KNLVVAAATA GVADKIGASA LXNVSDKQWI NNLTVNLANA GSAALINTAV 151 NGGSLKDXLE ANILAALVNT AHGEAASKIK QLDQHYIVRK IAHAIAGCAA 201 AAANKGKCQD GAIGAAVGEI VGEALTNGKN PDTLTAKERE QILAYSKLVA 251 GTVSGVVGGD VNAAANAAEV AVKNNQLSDX EGREFONENT ACAKQNXPQL 301 CRKNTVKKYQ NVADKRLAAS IAICTDISRS TECRTIRKQH LIDSRSLHSS 351 WEAGLIGKDD EWYKLFSKSY TQADLALQSY BLNTAAKSWL QSGNTKPLSE 401 VNSDQGYTLI SGVNPRFIFI PRGFVKQNTP ITNVKYPEGI SFDTNLXRHL 451 ANADGFSQEQ GIKGAHNRTN XMAELNSRGG XVKSETXTDI EGITRIKYEI 501 PTLDRTGKPD GGFKEISSIK TVYNPKXFXD DKILQMAQXA XSQGYSKASK 551 IAQNERTKSI SERKNVIQFS ETFDGIKFRX YXDVNTGRIT NIHPE* - ORF41a and ORF41-1 show 94.8% identity in 595 aa overlap:
10 20 30 orf41a.pep YLKQLQVAKNINWNQVQLAYDRWDYKQEGLTEAGAA |||||||:|::||||||||||:||||||||| |||| orf41-1 MQVNIQIPYILPRCVRAEDTPYACYLKQLQVTKDVNWNQVQLAYDKWDYKQEGLTGAGAA 10 20 30 40 50 60 40 50 60 70 80 90 orf41a.pep IIALAVTVVTSGAGTGAVLGLNGAXAAATDAAFASLASQASVSFINNKGDVGKTLKELGR ||||||||||:|||:||:|||||| ||||||||||||||||||:|||||::|:||||||| orf41-1 IIALAVTVVTAGAGAGAALGLNGAAAAATDAAFASLASQASVSLINNKGNIGNTLKELGR 70 80 90 100 110 120 100 110 120 130 140 150 orf41a.pep SSTVKNLVVAAATAGVADKIGASALXNVSDKQWINNLTVNLANAGSAALINTAVNGGSLK |||||||:||:|||||||||||||| |||||||||||||||||||||||||||||||||| orf41-1 SSTVKNLMVAVATAGVADKIGASALNNVSDKQWINNLTVNLANAGSAALINTAVNGGSLK 130 140 150 160 170 180 160 170 180 190 200 210 orf41a.pep DXLEANILAALVNTAHGEAASKIKQLDQHYIVHKIAHAIAGCAAAAANKGKCQDGAIGAA | |||||||||||||||||||||||||||||:|||||||||||||||||||||||||||| orf41-1 DNLEANILAALVNTAHGEAASKIKQLDQHYITHKIAHAIAGCAAAAANKGKCQDGAIGAA 190 200 210 220 230 240 220 230 240 250 260 270 orf41a.pep VGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVSGVVGGDVNAAANAAEVAVKNNQ |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf41-1 VGEIVGEALTNGKNPDTLTAKEREQILAYSKLVAGTVSGVVGGDVNAAANAAEVAVKNNQ 250 260 270 280 290 300 280 290 300 310 320 330 orf41a.pep LSDXEGREFDNEMTACAKQNXPQLCRKNTVKKYQNVADKRLAASIAICTDISRSTECRTI ||| |||||||||||||||| ||||||||||||||||||||||||||||||||||||||| orf41-1 LSDKEGREFDNEMTACAKQNNPQLCRKNTVKKYQNVADKRLAASIAICTDISRSTECRTI 310 320 330 340 350 360 340 350 360 370 380 390 orf41a.pep RKQHLIDSRSLHSSWEAGLIGKODEWYKLFSKSYTQADLALQSYHLNTAMCSWLQSGNTK |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf41-1 RKQHLIDSRSLHSSWEAGLIGKDDEWYKLFSKSYTQADLALQSYHLNTAAXSWLOSGNTK 370 380 390 400 410 420 400 410 420 430 440 450 orf41a.pep PLSEWMSDQGYTLISGVNPRFIPIPRGFVKQNTPITNVKYPEGISFDTNLXRHLANADGF |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| orf41-1 PLSEWMSDQGYTLISGVNPRFIPIPRGFVKQNTPITNVKYPEGISFDTNLKRHLANADGF 430 440 450 460 470 480 460 470 480 490 500 510 orf41a.pep SQEQGIKGAHNRTNXMAELNSRGGXVKSETXTDIEGITRIKYEIPTLDRTGKPDGGFKEI ||:||||||||||| ||||||||| ||||| ||||||||||||||||||||||||||||| orf41-1 SQKQGIKGAHNRTNFMAELNSRGGRVKSETQTDIEGITRIKYEIPTLDRTGKPDGGFKEI 490 500 510 520 530 540 520 530 540 550 560 570 orf41a.pep SSIKTVYNPKXFXDDKILQMAQXAXSQGYSKASKIAQNERTKSISERKNVIQFSETFDGI |||||||||| | ||||||||| | ||||||||||||||||||||||||||||||||||| orf41-1 SSIKTVYNPKKFSDDKILQMAQNAASQGYSKASKIAQNERTKSISERKNVIQFSETFDGI 550 560 570 580 590 600 580 590 orf41a.pep KFRXYXDVNTGRITNIHPEX ||| | |||||||||||||| orf41-1 KFRSYFDVNTGRITNIHPEX 610 620 - Amino acids 25-619 of ORF41-1 were amplified as described above.
FIG. 6 shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF41-1. - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following DNA sequence was identified in N. meningitidis <SEQ ID 73>
1 ATGGCAATCA TTACATTGTA TTATTCTGTC AATGGTATTT TAAATGTATG 51 TGCAAAAGCA AAAAATATTC AAGTAGTTGC CAATAATAAG AATATGGTTC 101 TTTTTGGGTT TTTGGSmrGC ATCATCGGCG GTTCAACCAA TGCCATGTCT 151 CCCATATTGT TAATATTTTT GCTTAGCGAA ACAGAAAATA AAAATcgTAT 201 CGTAAAATCA AGCAATCTAT GCTATCTTTT GGCGAAAATT GTTCAAATAT 251 ATATGCTAAG AGACCAGTAT TGGTTATTAA ATAAGAGTGA ATACGdTTTA 301 ATATTTTTAC TGTCCGTATT GTCTGTTATT GGATTGTATG TTGGAATTCG 351 GTTAAGGACT AAGATTAGCC CAaATTTTTT TAAAATGTTA ATTTTTATTG 401 tTTTATTGGT ATTGGCtCTG AAAATCGGGC AttCGGGTTT AAtCAAACTT 451 TAA - This corresponds to the amino acid sequence <SEQ ID 74; ORF51>:
1 HAIITLYYSV NGILNVCAKA KNIQVVANNK NMVLFGFLXX IICGSTNANS 51 PILLIFLLSE TENKNRIVKS SNLCYLLAKI VQIYMLRDQY WLLNKSEYXL 101 IFLLSVLSVI GLYVGIRLRT KISPNFFKML IFIVLLVLAL KIGHSGLIKL 151 * - Further work revealed the complete nucleotide sequence <
SEQ ID 75>:1 ATGCAAGAAA TAATGCAATC TATCGTTTTT GTTGCTGCCG CAATACTGCA 51 CGGAATTACA GGCATGGGAT TTCCGATGCT CGGTACAACC GCATTGGCTT 101 TTATCATGCC ATTGTCTAAG GTTGTTGCCT TGGTGGCATT ACCAAGCCTG 151 TTAATGAGCT TGTTGGTTCT ATGCAGCAAT AACAAAAAGG GTTTTTGGCA 201 AGAGATTGTT TATTATTTAA AAACCTATAA ATTGCTTGCT ATCGGCAGCG 251 TCGTTGGCAG CATTTTGGGG GTGAAGTTGC TTTTGATACT TCCAGTGTCT 301 TGGCTGCTTT TACTGATGGC AATCATTACA TTGTATTATT CTGTCAATGG 351 TATTTTAAAT GTATGTGCAA AAGCAAAAAA TATTCAAGTA GTTGCCAATA 401 ATAAGAATAT GGTTCTTTTT GGGTTTTTGG CAGGCATCAT CGGCGGTTCA 451 ACCAATGCCA TGTCTCCCAT ATTGTTAATA TTTTTGCTTA GCGAAACAGA 501 AAATAAAAAT CGTATCGTAA AATCAAGCAA TCTATGCTAT CTTTTGGCGA 551 AAATTGTTCA AATATATATG CTAAGAGACC AGTATTGGTT ATTAAATAAG 601 AGTGAATACG GTTTAATATT TTTACTGTCC GTATTGTCTG TTATTGGATT 651 GTATGTTGGA ATTCGGTTAA GGACTAAGAT TAGCCCAAAT TTTTTTAAAA 701 TGTTAATTTT TATTGTTTTA TTGGTATTGG CTCTGAAAAT CGGGCATTCG 751 GGTTTAATCA AACTTTAA - This corresponds to the amino acid sequence <SEQ ID 76; ORF51-1>:
1 MQEIMQSIVF VAAAILHGIT GMGFPMLGTT ALAFIMPLSK VVALVALPSL 51 LMSLLVLCSN NKKGFWQEIV YYLKTYKLLA IGSVVGSILG VKLLLILPVS 101 WLLLLMAIIT LYYSVNGILN VCAKAKNIQV VANNKNNVLF GFLAGIIGGS 151 TNAMSPILLI FLLSETENKN RIVKSSNLCY LLAKIVQIYN LRDQYWLLNK 201 SEYGLIFLLS VLSVIGLYVG IRLRTKISPN FFKMLIFIVL LVLALKIGHS 251 GLIKL* - Computer analysis of this amino acid sequence reveals three putative transmembrane domains. A corresponding ORF from strain A of N. meningitidis was also identified:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF51 shows 96.7% identity over a 150 aa overlap with an ORF (ORF51a) from strain A of N. meningitidis:
10 20 30 orf51.pep MAIITLYYSVNGILNVCAKAKNIQVVANNK |||||||||||||||||||||||||||||| orf51a YKLLAIGSVVGSILGVKLLLILPVSWLLLLMAIITLYYSVNGILNVCAKAKNIQVVANNK 80 90 100 110 120 130 40 50 60 70 80 90 orf51.pep NMVLFGFLXXIIGGSTNAMSPILLIFLLSETENKNRIVKSSNLCYLLAKIVQIYMLRDQY |||||||| ||||||||||||||||||||||||||||:|||||||||||||||||||||| orf51a NMVLFGFLAGIIGGSTNAMSPILLIFLLSETENKNRIAKSSNLCYLLAKIVQIYMLRDQY 140 150 160 170 180 190 100 110 120 130 140 150 orf51.pep WLLNKSEYXLIFLLSVLSVIGLYVGIRLRTKISPNFFKMLIFIVLLVLALKIGHSGLIKL |||||||| ||||||||||||||||||||||||||||||||||||||||||||:|||||| orf51a WLLNKSEYGLIFLLSVLSVIGLYVGIRLRTKISPNFFKMLIFIVLLVLALKIGYSGLIKL 200 210 220 230 240 250 - ORF51-1 and ORF51a show 99.2% identity in 255 aa overlap:
orf51a.pep MQEIMQSIVFVAAAILHGITGMGFPMLGTTALAFIMPLSKVVALVALPSLLMSLLVLCSN |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf51-1 MQEIMQSIVFVAAAILHGITGMGFPMLGTTALAFIMPLSKVVALVALPSLLMSLLVLCSN orf51a.pep NKKGFWQEIVYYLKTYKLLAIGSVVGSILGVKLLLILPVSWLLLLMAIITLYYSVNGILN |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf51-1 NKKGFWQEIVYYLKTYKLLAIGSVVGSILGVKLLLILPVSWLLLLMAIITLYYSVNGILN orf51a.pep VCAKAKNIQVVANNKNMVLFGFLAGIIGGSTNAMSPILLIFLLSETENKNRIAKSSNLCY ||||||||||||||||||||||||||||||||||||||||||||||||||||:||||||| orf51-1 VCAKAKNIQVVANNKNMVLFGFLAGIIGGSTNAMSPILLIFLLSETENKNRIVKSSNLCY orf51a.pep LLAKIVQIYMLRDQYWLLNKSEYGLIFLLSVLSVIGLYVGIRLRTKISPNFFKMLIFIVL |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf51-1 LLAKIVQIYMLRDQYWLLNKSEYGLIFLLSVLSVIGLYVGIRLRTKISPNFFKMLIFIVL orf51a.pep LVLALKIGYSGLIKLX ||||||||:||||||| orf51-1 LVLALKIGHSGLIKLX - The complete length ORF51a nucleotide sequence SEQ D 77> is:
1 ATGCAAGAAA TAATGCAATC TATCGTTTTT GTTGCTGCCG CAATACTGCA 51 CGGAATTACA GGCATGGGAT TTCCGATGCT CGGTACAACC GCATTGGCTT 101 TTATCATGCC ATTGTCTAAG GTTGTTGCCT TGGTGGCATT ACCAAGCCTG 151 TTAATGAGCT TGTTGGTTCT ATGCAGCAAT AACAAAAAGG GTTTTTGGCA 201 AGAGATTGTT TATTATTTAA AAACCTATAA ATTGCTTGCT ATCGGCAGCG 251 TCGTTGGCAG CATTTTGGGG GTGAAGTTGC TTTTGATACT TCCAGTGTCT 301 TGGCTGCTTT TACTGATGGC AATCATTACA TTGTATTATT CTGTCAATGG 351 TATTTTAAAT GTATGTGCAA AAGCAAAAAA TATTCAAGTA GTTGCCAATA 401 ATAAGAATAT GGTTCTTTTT GGGTTTTTGG CAGGCATCAT CGGCGGTTCA 451 ACCAATGCCA TGTCTCCCAT ATTGTTAATA TTTTTGCTTA GCGAAACAGA 501 GAATAAAAAT CGTATCGCAA AATCAAGCAA TCTATGCTAT CTTTTGGCAA 551 AAATTGTTCA AATATATATG CTAAGAGACC AGTATTGGTT ATThAATAAG 601 AGTGAATACG GTTTAATATT TTTACTGTCC GTATTGTCTG TTATTGGATT 651 GTATGTTGGA ATTCGGTTAA GGACTAAGAT TAGCCCAAAT TTTTTTAAAA 701 TGTTAATTTT TATTGTTTTA TTGGTATTGG CTCTGAAAAT CGGGTATTCA 751 GGTTTAATCA AACTTTAA - This encodes a protein having amino acid sequence <SEQ ID 78>:
1 MQEIMQSIVF VAAAILHGIT GMGFPNLGTT ALAFIMPLSK VVALVALPSL 51 LMSLLVLCSN NKKGFWQEIV YYLKTYKLLA IGSVVGSILG VKLLLILPVS 101 WLLLLMAIIT LYYSVNGILN VCAKAKNIQV VANNKNMVLF GFLAGIIGGS 151 TNAMSFILLI FLLSETENKN RIAXSSNLCY LLAKIVQIYM LRDQYWLLNK 201 SEYGLIFLLS VLSVIGLYVG IRLRTKISPN FFKMLIFIVL LVLALKIGYS 251 GLIKL* - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <SEQ ID 79>
1 ATGAGACATA TGAAAATACA AAATTATTTA CTAGTATTTA TAGTTTTACA 51 TATAGCCTTG ATAGTAATTA ATATAGTGTT TGGTTATTTT GTTTTTCTAT 101 TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTTCT TGCTGTAAAT 151 TTATTATTTT TAGAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC 201 GATTTCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA 251 AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT 301 ACTGGGGTGA TAAAACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA 351 TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAGG GTAATTAGAG 401 AAACACCTTA TATTGATGTA GTTGCATCTG ATGTTAAAAA TAAATCCATA 451 AGATTAAGCT TGGTTTGTGG TATTCATTCA TATGCTCCAT GTGCCAATTT 501 TATAAAATTT GTCAGG.. - This corresponds to the amino acid sequence <
SEQ ID 80; ORF82>:1 MRHMKIQNYL LVFIVLHIAL IVINIVFGYF VFLFDFFAFL FFANVFLAVN 51 LLFLEKNIKN KLLFLLPISI IIWMVIHISM INIKFYKFEH QIKEQNISSI 101 TGVIKPNDSY NYVYDSNGYA KLKDWHRYGR VIRETPYIDV VASDVKNKSI 151 RLSLVCGIHS YAPCANFIKF VR.. - Further work revealed the complete nucleotide sequence SEQ ID 81>:
1 ATGAGACATA TGAAAAATAA AAATTATTTA CTAGTATTTA TAGTTTTACA 51 TATAGCCTTG ATAGTAATTA ATATAGTGTT TGGTTATTTT GTTTTTCTAT 101 TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTTCT TGCTGTAAAT 151 TTATTATTTT TAAAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC 201 GATTTCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA 251 AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT 301 ACTGGGGTGA TAAAACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA 351 TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAAG GTAATTAGAG 401 AAACACCTTA TATTGATGTA GTTGCATCTG ATGTTAAAAA TAAATCCATA 451 AGATTAAGCT TGGTTTGTGG TATFCATTCA TATGCFCCAT GTGCCAATTT 501 TATAAAATTT GCAAAAAAAC CTGTTAAAAT TTATTTTTAT AATCAACCTC 551 AAGGAGATTT TATAGATAAT GTAATATTTG AAATTAATGA TGGAAACAAA 601 AGTTTGTACT TGTTAGATAA GTATAAAACA TTTTTTCTTA TTGAAAACAG 651 TGTTTGTATC GTATTAATTA TTTTATATTT AAAATTTAAT TTGCTTTTAT 701 ATAGGACTTA CTTCAATGAG TTGGAATAG - This corresponds to the amino acid sequence <SEQ ID 82; ORF82-1>:
1 MRHMKNKNYL LVFIVLHIAL IVINIVFGYF VFLFDFFAFL FFANVFLAVN 51 LLFLEKNIKH KLLFLLPISI IIWMVIHISH INIKFYKFEH QIKEQNISSI 101 TGVIKPHDSY NYVYDSNGYA KLKDNHRYGR VIRETPYIDV VASDVKNKSI 151 RLSLVCGIHS YAPCANFIKF AKKPVKIYFY NQPQGDFIDN VIFEINDGNK 201 SLYLLDKYKT FFLIENSVCI VLIILYLKFN LLLYRTYFNE LE* - Computer analysis of this amino acid sequence reveals a predicted leader peptide.
- A corresponding ORF from strain A of N. meningitidis was also identified:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF82 shows 97.1% identity over a 172 aa overlap with an ORF (ORF82a) from strain A of N. meningitidis:
10 20 30 40 50 60 orf82 pep MRHMKIQNYLLVFIVLHIALIVINIVFGYFVFLFDFFAFLFFANVFLAVNLLFLEKNIKN ||||| :|||||||||||:||||||||||||||||||||||||||||||||||||||||| orf82a MRHMKIKNYLLVFIVLHITLIVINIVFGYFVFLFDFFAFLFFANVFLAVNLLFLEKNIKN 10 20 30 40 50 60 70 80 90 100 110 120 orf82 pep KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf82a KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKFHDSYNYVYDSNGYA 70 80 90 100 110 120 130 140 150 160 170 orf82 pep KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFVR ||||||||||||||||||||||||||||||||||||||||||||||||||:: orf82a KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKKPVKIYFY 130 140 150 160 170 orf82a.pep MRHMKNKNYLLVFIVLHITLIVINIVFGYFVFLFDFFAFLFFANVFLAVNLLFLEKNIKN ||||||||||||||||||:||||||||||||||||||||||||||||||||||||||||| orf82-1 MRHMKNKNYLLVFIVLHIALIVINIVFGYFVFLFDFFAFLFFANVFLAVNLLFLEKNIKN orf82a.pep KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf82-1 KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA orf82a.pep KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKKPVKIYFY |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf82-1 KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKKPVKIYFY orf82a.pep NQPQGDFIDNVIFEINKGKKSLYLLDKYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf82-1 NQPQGDFIDNVIFEINKGKKSLYLLDKYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE orf82a.pep LEX ||| orf82-1 LEX - ORF82a and ORF82-1 show 99.2% identity in 242 aa overlap:
orf82a.pep MRHMKNKNYLLVFIVLHITLIVINIVFGYGVFLFDFFAFLFFANVFLAVNLLFLEKNIKN ||||||||||||||||||:||||||||||||||||||||||||||||||||||||||||| orf82-1 MRHMKNKNYLLVFIVLHIALIVINIVFGYGVFLFDFFAFLFFANVFLAVNLLFLEKNIKN orf82a.pep KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf82-1 KLLFLLPISIIIWMVIHISMINIKFYKFEHQIKEQNISSITGVIKPHDSYNYVYDSNGYA orf82a.pep KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKKPVKIYFY |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| orf82-1 KLKDNHRYGRVIRETPYIDVVASDVKNKSIRLSLVCGIHSYAPCANFIKFAKKPVKIYFY orf82a.pep NQPQGDFIDNVIFEINDGKKSLYLLDKYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE ||||||||||||||||||:||||||||||||||||||||||||||||||||||||||||| orf82-1 NQPQGDFIDNVIFEINDGNKSLYLLDKYKTFFLIENSVCIVLIILYLKFNLLLYRTYFNE orf82a.pep LEX ||| orf82-1 LEX - The complete length ORF82a nucleotide sequence <SEQ D 83> is:
1 ATGAGACATA TGAAAAATAA AAATTATTTA CTAGTATTTA TAGTTTTACA 51 TATAACCTTG ATAGTAATTA ATATAGTGTT TGGTTATTTT GTTTTTCTAT 101 TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTTCT TGCTGTAAAT 151 TTATTATTTT TAGAAAAAAA CATAAAAAAC AAATTATTGT TTTTATTGCC 201 GATTTCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA 251 AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT 301 ACTGGGGTGA TAAAACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA 351 TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAGG GTAATTACAG 401 AAACACCTTA TATTGATGTA GTIGCATCTG ATGTTAAAAA TAAATCCATA 451 AGATIAAGCT TGGTTTGTGG TATTCATTCA TATGCTCCAT GTGCCAATTT 501 TATAAAATTT GCAAAAAAAC CTGTTAAAAT TTATTTTTAT AATCAACCTC 551 AAGGAGATTT TATAGATAAT GTAATATTTG AAATTAATGA TGGAAAAAAA 601 AGTTTGTACT TGTTAGATAA GTATAAAACA TTTTTTCTTA TTGAAAACAG 651 TGTTTGTATC GTATTAATTA TTTTATATTT AAAATTTAAT TTGCTTTTAT 701 ATAGGACTTA CTTCAATGAG TTGGAATAG - This encodes a protein having amino acid sequence <SEQ ID 84>:
1 MRHMKNKNYL LVFIVLHITL IVINIVFGYF VFLFDFFAFL FFANVFLAVN 51 LLFLEKNIKN KLLFLLPISI IIWMVIHISM INIKFYKFEH QIKEQNISSI 101 TGVIKPHDSY NYVYDSNGYA KLKDNHRYGR VIRETPYIDV VASDVIQKSI 151 RLSLVCGIHS YAPCANFIKF AXKPVKIYFY NQPQGDFXDN VIFEINDGKK 201 SLYLLDKYKT FFLIENSVCI VLIILYLKFN LLLYRTYFNE LE* - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- The following partial DNA sequence was identified in N. meningitidis <
SEQ ID 85>1 ..ACCCCCAACA GCGTGACCGT CTTGCCGTCT TTCGGCGGAT TCGGGCGTAC 51 CGGCGCGACC ATCAATGCAG CAGGCGGGGT CGGCATGACT GCCTTTTCGA 101 CAACCTTAAT TTCCGTAGCC GAGGGCGCGG TTGTAGAGCT GCAGGCCGTG 151 AGAGCCAAAG CCGTCAATGC AACCGCCGCT TGCATTTTTA CGGTCTTGAG 201 TAAGGACATT TTCGATTTCC TTTTTATTTT CCGTTTTCAG ACGGCTGACT 251 TCCGCCTGTA TTTTCGCCAA AGCCATGCCG ACAGCGTGCG CCTTGACTTC 301 ATATTTAAAA GCTTCCGCGC GTGCCAGTTC CAGTTCGCGC GCATAGTTTT 351 GAGCCGACAA CAGCAGGGCT TGCGCCTTGT CGCGCTCCAT CTTGTCGATG 401 ACCGCCTGCA GCTTCGCAAA TGCCGACTFG TAGCCTTGAT GGTGCGACAC 451 AGCCAAGCCC GTGCCGACAA GCGCGATAAT GGCAATCGGT TGCCAGTAAT 501 TCGCCAGCAG TTTCACGAGA TTCATTCTCG ACCTCCTGAC GCTTCACGCT 551 GA - This corresponds to the amino acid sequence <SEQ ID 86; ORF124>:
1 ..TPNSVTVLPS FGGFGRTGAT INAAGGVGMT AFSTTLISVA EGAVVELQAV 51 RAKAVNATAA CIFTVLSKDI FDFLFIFRFQ TADFRLYFRQ SHADSVRLDF 101 IFKSFRACQF QFARIVLSRQ QQGLRLVALH LVDORLQLRX CRLVALMVRH 151 SQARADKRDN GNRLPVIRQQ FHEIHSRPPD ASR* - Computer analysis of this amino acid sequence predicts a transmembrane domain.
- Further work revealed the complete nucleotide sequence SEQ ID 87>:
1 ATGACTGCCT TTTCGACAAC CTTAATTTCC GTAGCCGAGG GCGCGGTTGT 51 AGAGCTGCAG GCCGTGAGAG CCAAAGCCGT CAATGCAACC GCCGCTTGCA 101 TTTTTACGGT CTTGAGTAAG GACATTTTCG ATTTCCTTTT TATTTTCCGT 151 TTTCAGACGG CTGACTTCCG CCTGTTTTTT CGCCAAAGCC ATGCCGACAG 201 CGTGCGCCTT GACTTCATAT TTTTTAGCTT CCGcGCGTGC CAGTTCCAGT 251 TCGCGCGCAT AGTTTTGAGC CGACAACAGC AGGGCTTGCG CCTTGTCGCG 301 CTCCATCTTG TCGATGACCG CCTGCTGCTT CGCAAATGCC GACTTGTAGC 351 CTTGATGGTG CGACACAGCC AAGCCCGTGC CGACAAGCGC GATAATGGCA 401 ATCGGTTGCC AGTTATTCGC CAGCAGTTTC ACGAGATTCA TTCTCGACCT 451 CCTGACGCTT CACGCTGA - This corresponds to the amino acid sequence SEQ ID 88; ORF124-1>:
1 MTAFSTTLIS VAEGAVVELQ AVRAKAVNAT AACIFTVLSK DIFDFLFIFR 51 FQTADFRLFF RQSHADSVRL DFIFFSFRAC QFQFARIVLS RQQQGLRLVA 101 LHLVDDRLLL RKCRLVAIMV RHSQARADKR DNGNRLPVIR QQFHEIHSRP 151 PDASR* - A corresponding ORF from strain A of N. meningitidis was also identified:
- Homology with a Predicted ORF from N. meningitidis (Strain A)
- ORF124 shows 87.5% identity over a 152 aa overlap with an ORF (ORF124a) from strain A of N. meningitidis:
10 20 30 40 50 60 orf124.pep TPNSVTVLPSFGGFGRTGATINAAGGVGMTAFSTTLISVAEGAVVELQAVRAKAVNATAA |||||||||||||||:|||||| |||||:||| orf124a MTAFSTTLISVAEGALVELQAVMAKAVNTTAA 10 20 30 70 80 90 100 110 120 orf124.pep CIFTVLSKDIFDFLFIFRFQTADFRLYFRQSHADSVRLDFIFKSFRACQFQFARIVLSRQ ||||||||||||||||||||||||||:|||||||:||||||| |||: |||| :||||| orf124a CIFTVLSKDIFDFLFIFRFQTADFRLFFRQSHADGVRLDFIFFSFRTRLFQFAGVVLSRQ 40 50 60 70 80 90 130 140 150 160 170 180 orf124.pep QQGLRLVALHLVDDRLQLRKCRLVALMVRHSQARADKRDNGNRLPVIRQQFHEIHSRPPD ||||||||||:::||| ||| ||||||||| |:||||||:|||||||||||||||||||| orf124a QQGLRLVALHFLNDRLLLRKSRLVALMVRHRQTRADKRDDGNRLPVIRQQFHEIHSRPPD 100 110 120 130 140 150 orf124.pep ASRX : orf124a VX - ORF124a and ORF124-1 show 89.5% identity in 152 aa overlap:
orf124-1.pep MTAFSTTLISVAEGAVVELQAVRAKAVNATAACIFTVLSKDIFDFLFIFRFQTADFRLFF |||||||||||||||:|||||| |||||:||||||||||||||||||||||||||||||| orf124a MTAFSTTLISVAEGALVELQAVMAKAVNTTAACIFTVLSKDIFDFLFIFRFQTADFRLFF orf124-1.pep RQSHADSVRLDFIFFSFRACQFQFARIVLSRQQQGLRLVALHLVDDRLLLRKCRLVALMV ||||||:|||||||||||: |||| :|||||||||||||||:::||||||| ||||||| orf124a RQSHADGVRLDFIFFSFRTRLFQFAGVVLSRQQQGLRLVALHFLNDRLLLRKSRLVALMV orf124-1.pep RHSQARADKRDNGNRLPVIRQQFHEIHSRPPDASRX || |:||||||:||||||||||||||||||||: orf124a RHRQTRADKRDDGNRLPVIRQQFHEIHSRPPDVX - The complete length ORF124a nucleotide sequence <SEQ ID 89> is:
1 ATGACCGCCT TTTCGACAAC CTTAATTTCC GTAGCCGAGG GCGCGCTTGT 51 AGAGCTGCAA GCCGTGATGG CCAAAGCCGT CAATACAACC GCCGCCTGCA 101 TTTTTACGGT CTTGAGTAAG GACATTTTCG ATTTCCTTTT TATTTTCCGT 151 TTTCAGACGG CTGACTTCCG CCTGTTTTTT CGCCAAAGCC ATGCCGACGG 201 CGTGCGCCTT GACTTCATAT TTTTTAGCTT CCGCACGCGC CTGTTCCAGT 251 TCGCGGGCGT AGTTTTGAGC CGACAACAGC AGGGCTTGCG CCTTGTCGCG 301 CTTCATTTTC TCAATGACCG CCTGCTGCTT CGCAAAAGCC GACTTGTAGC 351 CTTGATGGTG CGACACCGCC AAACCCGTGC CGACAAGCGC GATGATGGCA 401 ATCGGTTGCC AGTTATTCGC CAGCAGTTTC ACGAGATTCA TTCTCGACCT 451 CCTGACGTTT GA - This encodes a protein having amino acid sequence <
SEQ ID 90>:1 MTAFSTTLIS VAEGALVELQ AVNAXAVNTT AACIFTVLSK DIFDFLFIFR 51 FQTADFRLFF RQSHADGVRL DFIFFSFRTR LFQFAGVVLS RQQQGLRLVA 101 LHFLNDELLL RKSRLVALHV RHRQTRADKR DDGNRLPVIR QQFHEIHSRP 151 PDV* - ORF124-1 was amplified as described above.
FIG. 7 shows plots of hydrophilicity, antigenic index, and AMPHI regions for ORF124-1. - Based on this analysis, it is predicted that this protein from N. meningitidis, and its epitopes, could be useful antigens for vaccines or diagnostics.
- Table III lists several Neisseria strains which were used to assess the conservation of the sequence of ORF 40 among different strains.
TABLE III List of Neisseria Strains Used for Gene Variability Study of ORF 40 Identification number Strains Source/reference Group B zn02_1 BZ198 R. Moxon/Seiler et al., 1996 zn03_1 NG3/88 R. Moxon/Seiler et al., 1996 zn04_1 297-0 R. Moxon/Seiler et al., 1996 zn06_1 BZ147 R. Moxon/Seiler et al., 1996 zn07_1 BZ169 R. Moxon/Seiler et al., 1996 zn08_1 528 R. Moxon/Seiler et al., 1996 zn10_1 BZ133 R. Moxon/Seiler et al., 1996 zn11_1ass NGE31 R. Moxon/Seiler et al., 1996 zn14_1 NGH38 R. Moxon/Seiler et al., 1996 zn16_1 NGH15 R. Moxon/Seiler et al., 1996 zn18_1 BZ232 R. Moxon/Seiler et al., 1996 zn19_1 BZ83 R. Moxon/Seiler et al., 1996 zn20_1 44/76 R. Moxon/Seiler et al., 1996 zn21_1 MC58 R. Moxon Group A zn22_1 205900 R. Moxon zn23_1 F6124 R. Moxon z2491_1 Z2491 R. Moxon/Maiden et al., 1998 Group C zn24_1 90/18311 R. Moxon zn25_1ass 93/4286 R. Moxon Others zn28_1ass 860800 (group Y) R. Moxon/Maiden et al., 1998 zn29_1ass E32 (group Z) R. Moxon/Maiden et al., 1998
References:
Seiler A. et al., Mol. Microbiol., 1996, 19(4): 841-856.
Maiden et al., Proc. Natl. Acad. Sci. USA, 1998, 95: 3140-3145.
- The amino acid sequences for each listed strain are as follows:
>Z2491 <SEQ ID 91> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNVSPSKADEMDETV NINAGNNIEISRNGKNIDIATSNAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV RINVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVWDGNARAGIAQAIATAGLVQAYLPGKS MMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN02_1 <SEQ ID 92> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVATAVLATLLFATVQANATDDDDLYLE PVQRTAVLSFRSDKEGTGEKEGTEDSHGGAVYFDEKRVLKAGAITLKAGDNLKIKQNTNE NTNDSSFTYSLKKDLTDLTSVETEKLSFGAAGNKVNITSDTKGLNFAKETAGTAGDPTVH LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNV DFVRTYDTVEFLSADTKTTTNVSKDNGKKTEVICIGAIVTSVIKEKDGKLVTGKGKDENG SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA TVSKODQGNITVRYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGRMDE TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG KSMMAIGGDTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN03_1 <SEQ ID 93> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVATAVLATLLFATVQASTTDDDDLYLE PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVLTAGTITLKAGDNLKIKQNTDE NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGTNGDPTVH LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNV DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKDENG SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN04_1 <SEQ ID 94> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVATAVLATLLFATVQASTTDDDDLYLE PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVLTAGTITLKAGDNLKIKQNTDE NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGTNGDPTVH LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNV DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKDENG SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN06_1 < SEQ ID 95>MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNVSPSKADEMDETV NINAGNNIEISRNGKNIDIATSNAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV RINVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVWDGNARAGIAQAIATAGLVQAYLPGKS MMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN07_1 <SEQ ID 96> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNVSPSKADEMDETV NINAGNNIEISRNGKNIDIATSNAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV RINVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVWDGNARAGIAQAIATAGLVQAYLPGKS MMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN08_1 <SEQ ID 97> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVETAVLATLLFATVQANATDTDEDDEL EPVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTLHGATVTLKAGDNLKIKQNTD ENTNASSFTYSLKKDLTDLTSVGTEELSFGANGNKVNITSDTKGLNFAKKTAGTNGDTTV HLNGIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSEN VDFVRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGEN GSSTEDGEGELVTAKEVIDAVNKAGWRMKTTANGQTGQADKFETVTSGTNVTFASGKGTT ATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNAVSPSKGKMD ETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPLTLSVDDEALNVGSKDAN KPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNHIDNVDGNARAGIAQAIATAGLVQAYLP GKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN10_1 <SEQ ID 98> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN11_1 ASS <SEQ ID 99> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVATAVLATLLFATVQASTTDDDDLYLE PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVLTAGTITLKAGDNLKIKQNTDE NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGTNGDPTVH LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNV DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKDENG SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN14_1 < SEQ ID 100>MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVETAVLATLLFATVQANATDTDEDDEL EPVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTLHGATVTLKAGDNLKIKQNTD ENTNASSFTYSLKKDLTDLTSVGTEELSFGANGNKVNITSDTKGLNFAKKTAGTNGDTTV HLNGIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSEN VDFVRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGEN GSSTEDGEGELVTAKEVIDAVNKAGWRMKTTANGQTGQADKFETVTSGTNVTFASGKGTT ATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKISGNAVSPSKGKMD ETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPLTLSVDDEALNVGSKDAN KPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNHIDNVDGNARAGIAQAIATAGLVQAYLP GKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN16_1 < SEQ ID 101>MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVATAVLATLLFATVQANATDDDDLYLE PVQRTAVVLSFRSDKEGTGEKEGTEDSNWAVYFDEKRVLKAGAITLKAGDNLKIKQNTNE NTNENTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGTNGD PTVHLNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTA SDNVDFVRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGK DENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFASGN GTTATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKG KMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDEGALNVGSK DANKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLAQA YLPGKSMMAIGGGTYRGEAGYAIGYSSISDTGNWVIKGTASGNSRGHFGASASVGYQW* >ZN18_1 < SEQ ID 102>MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVATAVLATLLFATVQASTTDDDDLYLE PVQRTAPVLSFHADSEGTGEKEVTEDSNWGVYFDKKGVLTAGTITLKAGDNLKIKQNTDE NTNDSSFTYSLKKDLTDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGTNGDPTVH LNGIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNV DFVRTYDTVEFLSADTRTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKGKDENG SSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTA TVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDE TVNINAGNNIEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDTNK PVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPG KSMMAIGGDTYRGEAGYAIGYSSISDGGNMIIKGTASGNSRGHFGASASVGYQW* >ZN19_1 < SEQ ID 103>MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKTAVLATLLFATVQASANNEEQEEDL YLDPVQRTVAVLIVNSDKEGTGEKEKVEENSDWAVYFNEKGVLTAREITLKAGDNLKIKQ NGTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNVDF VRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKDKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV NINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGDALNVGSKKDNKPVR ITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSM MAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN20_1 < SEQ ID 104>MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKTAVLATLLFATVQASANNEEQEEDL YLDPVQRTVAVLIVNSDKEGTGEKEKVEENSDWAVYFNEKGVLTAREITLKAGDNLKIKQ NGTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNVDF VRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKDKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV NINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGDALNVGSKKDNKPVR ITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSM MAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN21_1 < SEQ ID 105>MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVKTAVLATLLFATVQASANNEEQEEDL YLDPVQRTVAVLIVNSDKEGTGEKEKVEENSDWAVYFNEKGVLTAREITLKAGDNLKIKQ NGTNFTYSLKKDLTDLTSVGTEKLSFSANGNKVNITSDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLLNTGATTNVTNDNVTDDEKKRAASVKDVLNAGWNIKGVKPGTTASDNVDF VRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGKDKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV NINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGDALNVGSKKDNKPVR ITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSM MAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN22_1 <SEQ ID 106> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN23_1 <SEQ ID 107> MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN24_1 <SEQ ID 108> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVATAVLATLLSATVQANATDTDEDEEL ESVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTLHGATVTLKAGDNLKIKQSGK DFTYSLKKELKDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGTNGDPTVHLNGIG STLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDFVRT YDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSSTDE GEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFASGNGTTATVSKD DQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETVNIN AGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPVRIT NVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLAQAYLPGKSMMA IGGGTYRGEAGYAIGYSSISDTGNWVIKGTASGNSRGHFGTSASVGYQW* >ZN25_ASS <SEQ ID 109> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVATAVLATLLSATVQANATDTDEDEEL ESVVRSALVLQFMIDKEGNGEIESTGDIGWSIYYDDHNTLHGATVTLKAGDNLKIKQSGK DFTYSLKKELKDLTSVETEKLSFGANGNKVNITSDTKGLNFAKETAGTNGDPTVHLNGIG STLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDFVRT YDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSSTDE GEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFASGNGTTATVSKD DQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETVNIN AGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPVRIT NVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLAQAYLPGKSMMA IGGGTYRGEAGYAIGYSSISDTGNWVIKGTASGNSRGHFGTSASVGYQW* >ZN28_ASS < SEQ ID 110>MNKIYRIIWNSALNAWVAVSELTRNHTKRASATVKTAVLATLLFATVQANATDEDEEEEL ESVQRSVVGSIQASMEGSGELETISLSMTNDSKEFVDPYIVVTLKAGDNLKIKQNTNENT NASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTNGDTTVHLN GIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTTGQSENVDF VRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGKGKGENGSS TDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNVTFASGKGTTATV SKDDQGNITVMYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETV NINAGNNIEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVDDEGALNVGSKDANKPV RITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKS MMAIGGGYTRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* >ZN29_ASS <SEQ ID 111> MNKIYRIIWNSALNAWVVVSELTRNHTKRASATVETAVLATLLFATVQANATDTDEDDEL EPVVRTAPVLSFHSDKEGTGEKEEVGASSNLTVYFDKNRVLKAGTITLKAGDNLKIKQNT NENTNENTNASSFTYSLKKDLTGLINVETEKLSFGANGKKVNIISDTKGLNFAKETAGTN GDPTVHLNGIGSTLTDTLAGSSASHVDAGNQSTHYTRAASIKDVLNAGWNIKGVKTGSTT GQSENVDFVRTYDTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKDGKLVTGK GKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKVTFAS GNGTTATVSKDDQGNITVKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPS KGKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVVEAGALNVG SKDANKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLV QAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW * -
FIG. 8 shows the results of aligning the sequences of each of these strains. Dark shading indicates regions of homology, and gray shading indicates the conservation of amino acids with similar characteristics. As is readily discernible, there is significant conservation among the various strains of ORF 40, further confirming its utility as an antigen for both vaccines and diagnostics. - It will be appreciated that the invention has been described by means of example only, and that modifications may be made whilst remaining within the spirit and scope of the invention.
-
Scarlato, Continuation of U.S. App. Ser. No. 10/695,499, filed herewith Ruelle, U.S. Pat. No. 6,780,419 18. (New) An isolated polypeptide comprising 1. An isolated polypeptide comprising a a member selected from the group consisting of member selected from the group consisting of (a) the amino acid sequence of SEQ ID (a) the amino acid sequence of SEQ ID NO: 4; and NO: 2; (b) an immunogenic fragment of at (b) an immunogenic fragment of at least least 15 contiguous amino acids of SEQ ID 15 contiguous amino acids of SEQ ID NO: 2; NO: 4, wherein the immunogenic fragment, wherein the immunogenic fragment, when when administered to a subject in a suitable administered to a subject in a suitable composition which can include an adjuvant, or composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, a suitable carrier coupled to the polypeptide, induces an antibody or T-cell meditated induces an antibody or T-cell meditated immune response that recognizes the isolated immune response that recognizes the isolated polypeptide SEQ ID NO: 4. polypeptide SEQ ID NO: 2. 19. (New) The isolated polypeptide of claim 2. The isolated polypeptide of claim 1,18, wherein the polypeptide is according to (a). wherein the polypeptide is according to (a). 20. (New) The isolated polypeptide of claim 3. The isolated polypeptide of claim 1,18, wherein the polypeptide is according to (b). wherein the polypeptide is according to (b). 21. (New) The isolated polypeptide of claim 4. The isolated polypeptide of claim 1,18, wherein the immunogenic fragment of (b) wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of comprises at least 20 contiguous amino acids of SEQ ID NO: 4; wherein the immunogenic SEQ ID NO: 2; wherein the immunogenic fragment, when administered to a subject in a fragment, when administered to a subject in a suitable composition which can include an suitable composition which can include an adjuvant, or a suitable carrier coupled to the adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell polypeptide, induces an antibody or T-cell meditated immune response that recognizes the meditated immune response that recognizes the isolated polypeptide SEQ ID NO: 4. isolated polypeptide SEQ ID NO: 2. 22. (New) The isolated polypeptide of claim 5. The isolated polypeptide of claim 1,18, wherein the isolated polypeptide consists of wherein the isolated polypeptide consists of SEQ ID NO: 4. SEQ ID NO: 2. 23. (New) A fusion protein comprising the 6. A fusion protein comprising the isolated isolated polypeptide of claim 18. polypeptide of claim 1.24. (New) An immunogenic composition 7. An immunogenic composition comprising comprising the polypeptide of claim 18, and a the polypeptide of claim 1, and apharmaceutically acceptable carrier. pharmaceutically acceptable carrier. 25. (New) The isolated polypeptide of claim 9. The isolated polypeptide of claim 1,18, wherein the isolated polypeptide is a wherein the isolated polypeptide is a recombinant polypeptide. recombinant polypeptide. 26. (New) The isolated polypeptide of claim 10. The isolated polypeptide of claim 2, 19, wherein the isolated polypeptide is a wherein the isolated polypeptide is a recombinant polypeptide. recombinant polypeptide. 27. (New) The isolated polypeptide of claim 11. The isolated polypeptide of claim 3,20, wherein the isolated polypeptide is a wherein the isolated polypeptide is a recombinant polypeptide. recombinant polypeptide. 28. (New) An immunogenic composition 12. An immunogenic composition comprising comprising the isolated polypeptide of claim 19. the isolated polypeptide of claim 2. 29. (New) An immunogenic composition 13. An immunogenic composition comprising comprising the isolated polypeptide of claim 20.the isolated polypeptide of claim 3. 30. (New) A fusion protein comprising the 14. A fusion protein comprising the isolated isolated polypeptide of claim 19. polypeptide of claim 2. 31. (New) A fusion protein comprising the 15. A fusion protein comprising the isolated isolated polypeptide of claim 20.polypeptide of claim 3. -
Written Description Support in the Current Application Written Description (Continuation of Application Support in Application Added Claim # No. 10/695,499) No. PCT/IB99/00103 Claims 18-31 Throughout the Throughout the application and at least at application and at least at the following citations: the following citations: Page 3, lines 2-24; Page 2, line 29 to page 3, Page 31, line 7 to page 34, line 20;line 17; Page 30, line 6 to pagePage 52, lines 10-18; 33, line 11; Page 65, line 3 topage 70,Page 50, lines 12-20;line 3. Page 61, line 11 to page66, line 6. Claims 23, 30,Throughout the Throughout the and 31 application and at least at application and at least at the following citations: the following citations: Page 3, lines 24-27; Page 3, lines 21-24; Page 9, line 26 to page 10,Page 9, lines 11-18; line 4; Page 20, line 6 to pagePage 21, lines 1-22. 21, line 4. Claims 25-27 Throughout the Throughout the application and at least at application and at least at the following citations: the following citations: Page 3, lines 24-27; Page 3, lines 17-20; Page 8, line 15 to page 28,Page 8, line 1 to page 27,line 23. line 25. -
Number of Amino Acids Location in ORF40 of Location in SEQ 2 in Fragment Application No. GB 9800760.2 of ‘419 Patent 25 Residues 85-109 Residues 127-151 16 Residues 111-126 Residues 153-168 98 Residues 131-228 Residues 173-270 16 Residues 230-245 Residues 272-287 -
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/212,443 US20050287165A1 (en) | 1998-01-14 | 2005-08-24 | Meningococcal antigens |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9800760.2 | 1998-01-14 | ||
GBGB9800760.2A GB9800760D0 (en) | 1998-01-14 | 1998-01-14 | Antigens |
GBGB9819015.0A GB9819015D0 (en) | 1998-09-01 | 1998-09-01 | Antigens |
GB9819015.0 | 1998-09-01 | ||
GB9822143.5 | 1998-10-09 | ||
GBGB9822143.5A GB9822143D0 (en) | 1998-10-09 | 1998-10-09 | Antigens |
PCT/IB1999/000103 WO1999036544A2 (en) | 1998-01-14 | 1999-01-14 | Neisseria meningitidis antigens |
US09/302,626 US6709660B1 (en) | 1998-01-14 | 1999-04-30 | Meningococcal antigens |
US10/695,499 US7714121B2 (en) | 1998-01-14 | 2003-10-28 | Meningococcal antigens |
US11/212,443 US20050287165A1 (en) | 1998-01-14 | 2005-08-24 | Meningococcal antigens |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/695,499 Continuation US7714121B2 (en) | 1998-01-14 | 2003-10-28 | Meningococcal antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050287165A1 true US20050287165A1 (en) | 2005-12-29 |
Family
ID=27269171
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/302,626 Expired - Fee Related US6709660B1 (en) | 1998-01-14 | 1999-04-30 | Meningococcal antigens |
US10/695,499 Expired - Fee Related US7714121B2 (en) | 1998-01-14 | 2003-10-28 | Meningococcal antigens |
US11/212,443 Abandoned US20050287165A1 (en) | 1998-01-14 | 2005-08-24 | Meningococcal antigens |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/302,626 Expired - Fee Related US6709660B1 (en) | 1998-01-14 | 1999-04-30 | Meningococcal antigens |
US10/695,499 Expired - Fee Related US7714121B2 (en) | 1998-01-14 | 2003-10-28 | Meningococcal antigens |
Country Status (16)
Country | Link |
---|---|
US (3) | US6709660B1 (en) |
EP (3) | EP1047784B2 (en) |
JP (2) | JP4399112B2 (en) |
CN (2) | CN1224708C (en) |
AT (1) | ATE446368T1 (en) |
AU (1) | AU1979599A (en) |
BR (1) | BR9906927A (en) |
CA (1) | CA2317815A1 (en) |
CY (2) | CY1109708T1 (en) |
DE (1) | DE69941567D1 (en) |
DK (1) | DK1047784T4 (en) |
ES (1) | ES2333071T5 (en) |
HK (1) | HK1030435A1 (en) |
PT (1) | PT1047784E (en) |
SG (2) | SG152917A1 (en) |
WO (1) | WO1999036544A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265332A1 (en) * | 1998-05-13 | 2004-12-30 | Smithkline Beecham Biologicals S.A. | BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis |
US20050074458A1 (en) * | 1998-10-22 | 2005-04-07 | The University Of Montana | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
Families Citing this family (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0909323T3 (en) | 1996-01-04 | 2007-05-21 | Novartis Vaccines & Diagnostic | Helicobacter pylori bacterioferritin |
FR2751000B1 (en) * | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | SPECIFIC DNA FROM NEISSERIA MENINGITIDIS BACTERIA, PROCESSES FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS |
EP2298900A1 (en) | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
CA2317815A1 (en) * | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
EP1645631B1 (en) | 1998-05-01 | 2007-10-24 | Novartis Vaccines and Diagnostics, Inc. | Neisseria antigens and compositions |
US10967045B2 (en) | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
ATE279943T1 (en) * | 1999-02-26 | 2004-11-15 | Chiron Srl | IMPROVEMENT OF BACTERICIDAL ACTIVITY OF NEISSERIA ANTIGENS WITH OLIGONUCLEOTIDES CONTAINING CG |
AU2004240199B2 (en) * | 1999-04-30 | 2007-05-17 | Novartis Vaccines And Diagnostics S.R.L. | Conserved Neisserial antigens |
ES2477194T3 (en) | 1999-04-30 | 2014-07-16 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens conserved |
CN100338218C (en) | 1999-05-19 | 2007-09-19 | 启龙股份公司 | Combination neisserial compositions |
GB9916529D0 (en) * | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
GB9928196D0 (en) * | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
AU2006202664B2 (en) * | 1999-11-29 | 2010-02-25 | Glaxosmithkline Biologicals S.A. | Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen |
ATE460484T1 (en) | 1999-11-29 | 2010-03-15 | Novartis Vaccines & Diagnostic | 85 KDA ANTIGEN OF NEISSERIA |
DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
KR100698561B1 (en) | 2000-01-25 | 2007-03-21 | 더 유니버서티 어브 퀸슬랜드 | Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha |
BR0108711A (en) * | 2000-02-28 | 2004-06-22 | Chiron Spa | Heterologous expression of neisserial proteins |
NO20002828D0 (en) * | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof |
BRPI0112928B1 (en) | 2000-07-27 | 2017-08-29 | Children's Hospital & Research Center At Oakland | A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV |
CA2881568C (en) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from streptococcus groups a & b |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
EP1412381B1 (en) | 2001-07-27 | 2010-06-02 | Novartis Vaccines and Diagnostics S.r.l. | Antibodies against meningococcal adhesin app |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
WO2003028661A2 (en) * | 2001-10-03 | 2003-04-10 | Chiron Corporation | Adjuvanted meningococcus compositions |
US7838015B2 (en) * | 2001-10-03 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
GB0129007D0 (en) * | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
CN100515494C (en) | 2001-12-12 | 2009-07-22 | 启龙有限公司 | Immunisation against chlamydia trachomatis |
AU2003215316A1 (en) | 2002-02-20 | 2003-09-09 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
ES2575014T3 (en) * | 2002-08-02 | 2016-06-23 | Glaxosmithkline Biologicals S.A. | Neisseria vaccine compositions comprising a combination of antigens |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
DK2353608T3 (en) | 2002-10-11 | 2020-02-10 | Novartis Vaccines And Diagnostics S R L | POLYPEPTID VACCINES FOR WIDE PROTECTION AGAINST HYPERVIRULENT MENINGOCOC LINES |
MY132859A (en) | 2002-11-01 | 2007-10-31 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2004046177A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
AU2003296663A1 (en) * | 2002-12-18 | 2004-07-09 | Novartis Ag | Endothelial cell specifically binding peptides |
AU2003299994A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
EP2289546A3 (en) | 2003-01-30 | 2011-03-30 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
CA2528007C (en) | 2003-06-02 | 2012-03-27 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
PT1670506E (en) | 2003-10-02 | 2013-01-28 | Novartis Ag | Liquid vaccines for multiple meningococcal serogroups |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
JP2008508320A (en) | 2004-07-29 | 2008-03-21 | カイロン コーポレイション | Immunogenic composition against gram positive bacteria such as STREPTOCOCCUSAGALACTIAE |
EP1841784A4 (en) * | 2004-12-24 | 2009-02-25 | Sugar Industry Innovation Pty | Vacuole targeting peptide and nucleic acid |
JP4993750B2 (en) | 2005-01-27 | 2012-08-08 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | Vesicular vaccine based on GNA1870 for broad protection against diseases caused by Neisseria meningitidis |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
EP1858920B1 (en) | 2005-02-18 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
AU2006216844B2 (en) | 2005-02-18 | 2012-11-08 | Novartis Vaccines And Diagnostics S.R.L. | Immunogens from uropathogenic escherichia coli |
CN101355960A (en) | 2005-10-18 | 2009-01-28 | 诺华疫苗和诊断公司 | Mucosal and systemic immunizations with alphavirus replicon particles |
JP5215865B2 (en) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | Norovirus and sapovirus antigens |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
WO2008019162A2 (en) | 2006-01-18 | 2008-02-14 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
CA2656474A1 (en) | 2006-06-29 | 2008-01-03 | Novartis Ag | Polypeptides from neisseria meningitidis |
JP2010500399A (en) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | Immunogen from Urinary Pathogenic Escherichia coli |
AR064642A1 (en) | 2006-12-22 | 2009-04-15 | Wyeth Corp | POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
TWI561530B (en) | 2007-05-21 | 2016-12-11 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
TWI501976B (en) * | 2007-05-21 | 2015-10-01 | Alder Biopharmaceuticals Inc | Antibodies to tnf alpha and use thereof |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
CA2699513C (en) | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
ES2383231T3 (en) | 2007-10-19 | 2012-06-19 | Novartis Ag | Formulations for meningococcal vaccines |
WO2009076158A1 (en) | 2007-12-07 | 2009-06-18 | Novartis Ag | Compositions for inducing immune responses |
PL2235046T3 (en) | 2007-12-21 | 2012-12-31 | Novartis Ag | Mutant forms of streptolysin o |
EP3263591B1 (en) | 2008-02-21 | 2019-03-27 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
WO2009111337A1 (en) | 2008-03-03 | 2009-09-11 | Irm Llc | Compounds and compositions as tlr activity modulators |
JP5689064B2 (en) | 2008-10-27 | 2015-03-25 | ノバルティス アーゲー | Purification method |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
AU2009323007B2 (en) * | 2008-11-25 | 2016-01-28 | H. Lundbeck A/S. | Antagonists of IL-6 to prevent or treat thrombosis |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8425922B2 (en) | 2009-01-05 | 2013-04-23 | EpitoGenesis, Inc. | Adjuvant compositions and methods of use |
MX2011007456A (en) | 2009-01-12 | 2011-08-03 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria. |
ITMI20090946A1 (en) | 2009-05-28 | 2010-11-29 | Novartis Ag | EXPRESSION OF RECOMBINANT PROTEINS |
ES2658863T3 (en) | 2009-06-10 | 2018-03-12 | Glaxosmithkline Biologicals Sa | Vaccines containing benzonaphthyridine |
EP2443250B8 (en) | 2009-06-16 | 2016-09-21 | GlaxoSmithKline Biologicals SA | High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays |
JP2013502918A (en) | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | Hybrid polypeptide comprising Neisseria meningitidis fHBP sequence |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
JO3257B1 (en) | 2009-09-02 | 2018-09-16 | Novartis Ag | Compounds and compositions as tlr activity modulators |
CA2772916C (en) | 2009-09-02 | 2019-01-15 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
US8974799B2 (en) | 2009-09-30 | 2015-03-10 | Novartis Ag | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
MX2012004850A (en) | 2009-10-27 | 2012-05-22 | Novartis Ag | Modified meningococcal fhbp polypeptides. |
WO2011051917A1 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
EP2504031A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
JP5814933B2 (en) | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | Homogeneous suspension of immune enhancing compounds and uses thereof |
EA023725B1 (en) | 2010-03-23 | 2016-07-29 | Новартис Аг | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
ES2643498T3 (en) | 2010-04-08 | 2017-11-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Assay of B cell antigen presenting cells |
JP2013532008A (en) | 2010-05-28 | 2013-08-15 | テトリス オンライン インコーポレイテッド | Interactive hybrid asynchronous computer game infrastructure |
HUE052850T2 (en) | 2010-08-23 | 2021-05-28 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
MY166172A (en) | 2010-09-10 | 2018-06-07 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
WO2012032498A2 (en) | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
EP2723378A4 (en) | 2011-06-24 | 2015-01-28 | Epitogenesis Inc | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
JP6170932B2 (en) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | Carrier molecule comprising spr0096 antigen and spr2021 antigen |
SA115360586B1 (en) | 2012-03-09 | 2017-04-12 | فايزر انك | Neisseria meningitidis compositions and methods thereof |
BR112014021658A2 (en) | 2012-03-09 | 2017-07-11 | Pfizer | neisseria meningitidis compositions and methods thereof |
CN104602704B (en) | 2012-06-14 | 2019-08-06 | 诺华股份有限公司 | For the meningococcal vaccine of serum group X |
GB201211154D0 (en) * | 2012-06-22 | 2012-08-08 | Univ Southampton | Composition |
AR092896A1 (en) | 2012-10-03 | 2015-05-06 | Novartis Ag | IMMUNOGENIC COMPOSITIONS |
TR201807340T4 (en) | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Intradermal administration of immunological compositions comprising bell-like receptor agonists. |
CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
KR101905278B1 (en) | 2013-09-08 | 2018-10-08 | 화이자 인코포레이티드 | Neisseria meningitidis compositions and methods thereof |
BR112017017460A2 (en) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | neisseria meningitidis compositions and methods thereof |
CN106290849A (en) * | 2015-05-13 | 2017-01-04 | 上海凯创生物技术有限公司 | A kind of meningitis bacterium gold-immunochromatographyreagent reagent for assay box |
BR112018017141A2 (en) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica Gmbh | method for the immobilization of biomolecules |
US11612664B2 (en) | 2016-04-05 | 2023-03-28 | Gsk Vaccines S.R.L. | Immunogenic compositions |
IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | Neisseria meningitidis compositions and methods thereof |
BR112020001255A2 (en) | 2017-07-21 | 2020-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | immunogenic compositions of neisseria meningitidis |
IL276608B1 (en) | 2018-02-12 | 2023-12-01 | Inimmune Corp | Toll-like receptor ligands |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
IL302449A (en) | 2020-11-04 | 2023-06-01 | Eligo Bioscience | Cutibacterium acnes recombinant phages, method of production and uses thereof |
CN114015805A (en) * | 2021-10-13 | 2022-02-08 | 四川农业大学 | Fluorescent RT-RAA primer and kit for detecting Getavirus and application of fluorescent RT-RAA primer and kit |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795803A (en) * | 1984-05-02 | 1989-01-03 | Syn-Tek Ab | Adhesin antigens, antibodies and DNA fragment encoding the antigen, methods and means for diagnosis and immunization etc. |
US6197312B1 (en) * | 1997-12-12 | 2001-03-06 | The University Of Queensland | Surface antigen |
US6200578B1 (en) * | 1995-03-24 | 2001-03-13 | St. Louis University | Haemophilus adhesion proteins |
US6709660B1 (en) * | 1998-01-14 | 2004-03-23 | Chrion S.R.L. | Meningococcal antigens |
US20040092711A1 (en) * | 2000-02-28 | 2004-05-13 | Arico Maria Beatrice | Hybrid expression of neisserial proteins |
US20050222385A1 (en) * | 2001-09-06 | 2005-10-06 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US7368261B1 (en) * | 1999-04-30 | 2008-05-06 | Novartis Vaccines And Diagnostics Srl | Conserved Neisserial antigens |
US7612192B2 (en) * | 1998-10-09 | 2009-11-03 | Novartis Vaccines & Diagnostics, Inc. | Neisseria genomic sequences and methods of their use |
US7618636B1 (en) * | 1999-07-14 | 2009-11-17 | Novartis Vaccines And Diagnostics Srl | Antigenic meningococcal peptides |
Family Cites Families (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2386796A (en) | 1942-08-05 | 1945-10-16 | Bond Crown & Cork Co | Extruding device |
DE2855719A1 (en) | 1978-12-22 | 1980-07-10 | Siemens Ag | DENTAL HANDPIECE ARRANGEMENT |
US4336336A (en) | 1979-01-12 | 1982-06-22 | President And Fellows Of Harvard College | Fused gene and method of making and using same |
AU545912B2 (en) | 1980-03-10 | 1985-08-08 | Cetus Corporation | Cloned heterologous jive products in bacillies |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
ZA822855B (en) | 1981-04-29 | 1983-03-30 | Biogen Nv | Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
CA1341116C (en) | 1983-02-22 | 2000-10-17 | Rae Lyn Burke | Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein |
JPS59166086A (en) | 1983-03-09 | 1984-09-19 | Teruhiko Beppu | Novel development type plasmid and development of vitular prochymosin gene in escherichia coli using it |
US4546083A (en) | 1983-04-22 | 1985-10-08 | Stolle Research & Development Corporation | Method and device for cell culture growth |
US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
JPS59205983A (en) | 1983-04-28 | 1984-11-21 | ジエネツクス・コ−ポレイシヨン | Development of different kind gene by procaryotic microorganism |
US4663280A (en) | 1983-05-19 | 1987-05-05 | Public Health Research Institute Of The City Of New York | Expression and secretion vectors and method of constructing vectors |
IE58011B1 (en) | 1983-05-27 | 1993-06-16 | Texas A & M Univ Sys | Method for producing a recombinant baculovirus expression vector |
US4689406A (en) | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
JPS6054685A (en) | 1983-09-02 | 1985-03-29 | Suntory Ltd | Improved manifestation vector and its use |
EP0136907A3 (en) | 1983-10-03 | 1986-12-30 | Genentech, Inc. | A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom |
DK518384A (en) | 1984-01-31 | 1985-07-01 | Idaho Res Found | VECTOR FOR THE MANUFACTURE OF A GENE PRODUCT IN INSECT CELLS, PROCEDURE FOR ITS MANUFACTURING AND ITS USE |
DE3587759T2 (en) | 1984-05-11 | 1994-07-07 | Chiron Corp | Increased yeast transcription using a hybrid construction of the promoter region. |
US4880734A (en) | 1984-05-11 | 1989-11-14 | Chiron Corporation | Eukaryotic regulatable transcription |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
US4738921A (en) | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
US4745056A (en) | 1984-10-23 | 1988-05-17 | Biotechnica International, Inc. | Streptomyces secretion vector |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
US4762915A (en) | 1985-01-18 | 1988-08-09 | Liposome Technology, Inc. | Protein-liposome conjugates |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
DE3679343D1 (en) | 1985-03-28 | 1991-06-27 | Chiron Corp | EXPRESSION BY USING FUSION GENES FOR PROTEIN PRODUCTION. |
US4865974A (en) | 1985-09-20 | 1989-09-12 | Cetus Corporation | Bacterial methionine N-terminal peptidase |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
JPS6296086A (en) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | Composite plasmid |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
EP0244042B1 (en) | 1986-05-02 | 1994-08-17 | Gist-Brocades N.V. | Secretory signal selection vectors for extracellular protein synthesis in bacilli |
ATE247708T1 (en) | 1986-10-02 | 2003-09-15 | Massachusetts Inst Technology | METHOD FOR REGULATING THE METABOLIC STABILITY OF PROTEINS |
JPS63123383A (en) | 1986-11-11 | 1988-05-27 | Mitsubishi Kasei Corp | Hybrid promoter, manifestation regulating dna sequence and manifestation vector |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
CA1304020C (en) | 1987-03-23 | 1992-06-23 | Meher H. Irani | High level expression in yeast |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
DK463887D0 (en) | 1987-09-07 | 1987-09-07 | Novo Industri As | GAERLEADER |
EP0633318A1 (en) | 1987-09-11 | 1995-01-11 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
CN1074422C (en) | 1987-11-18 | 2001-11-07 | 希龙股份有限公司 | Nanbv diagnostics and vaccines |
WO1989005349A1 (en) | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
CA1340772C (en) | 1987-12-30 | 1999-09-28 | Patricia Tekamp-Olson | Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences |
US4973551A (en) | 1988-01-15 | 1990-11-27 | Merck & Co., Inc. | Vector for the expression of fusion proteins and protein immunogens |
US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
JPH03504079A (en) | 1988-03-21 | 1991-09-12 | カイロン コーポレイション | recombinant retrovirus |
US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
CA2045129A1 (en) | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
JP3140757B2 (en) | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | Packaging defective HIV provirus, cell lines and uses thereof |
US5364780A (en) | 1989-03-17 | 1994-11-15 | E. I. Du Pont De Nemours And Company | External regulation of gene expression by inducible promoters |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
AU5344190A (en) | 1989-03-21 | 1990-10-22 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
NL9021328A (en) | 1989-08-15 | 1992-06-01 | Pasminco Australia Ltd | Zinc vapour absorption in molten lead - using a cyclone contact and sepn. stage with reduced plant size |
EP0845537A1 (en) | 1989-08-18 | 1998-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
AU7007491A (en) | 1990-02-02 | 1991-08-08 | Schweiz. Serum- & Impfinstitut Bern | Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses |
ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
CU22302A1 (en) | 1990-09-07 | 1995-01-31 | Cigb | Codifying nucleotidic sequence for a protein of the external membrane of neisseria meningitidis and the use of that protein in preparing vaccines. |
EP0467714A1 (en) | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis |
AU665176B2 (en) | 1990-09-21 | 1995-12-21 | Novartis Vaccines And Diagnostics, Inc. | Packaging cells |
US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
WO1992007945A1 (en) | 1990-10-30 | 1992-05-14 | Dana Farber Cancer Institute | Cell type specific alteration of levels of gene products in neural cells |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
SE9003978D0 (en) | 1990-12-13 | 1990-12-13 | Henrik Garoff | DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION |
WO1992011033A1 (en) | 1990-12-20 | 1992-07-09 | Arch Development Corporation | Control of gene expression by ionizing radiation |
GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
ATE237694T1 (en) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT |
FR2681786A1 (en) | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS. |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
WO1993014778A1 (en) | 1992-01-23 | 1993-08-05 | Vical, Inc. | Ex vivo gene transfer |
FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | Methods and compositions for targeting specific tissue. |
WO1993025698A1 (en) | 1992-06-10 | 1993-12-23 | The United States Government As Represented By The | Vector particles resistant to inactivation by human serum |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0669987B1 (en) | 1992-09-25 | 2008-08-13 | Aventis Pharma S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
ATE307212T1 (en) | 1992-11-18 | 2005-11-15 | Arch Dev Corp | ADENOVIRUS-DIRECTED GENE TRANSFER TO THE HEART AND VASCULAR SMOOTH MUSCLE |
EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5348358A (en) | 1993-02-22 | 1994-09-20 | Selick David A | Contact lens insertion tool |
DE4311651A1 (en) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells |
JP3545403B2 (en) | 1993-04-22 | 2004-07-21 | スカイファルマ インコーポレイテッド | Cyclodextrin liposomes encapsulating pharmaceutical compounds and methods of use |
JPH09501309A (en) | 1993-05-26 | 1997-02-10 | アメリカ合衆国 | Adeno-associated viral rep protein and bacterial protein-containing fusion protein |
FR2705686B1 (en) | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
WO1995000655A1 (en) | 1993-06-24 | 1995-01-05 | Mc Master University | Adenovirus vectors for gene therapy |
CA2144040A1 (en) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Defective adenovirus vectors and use thereof in gene therapy |
US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
JPH09501564A (en) | 1993-07-27 | 1997-02-18 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | Modified DNA virus vector and use thereof |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
ATE440957T1 (en) | 1993-09-15 | 2009-09-15 | Novartis Vaccines & Diagnostic | RECOMBINANT ALPHAVIRUS VECTORS |
FR2710536B1 (en) | 1993-09-29 | 1995-12-22 | Transgene Sa | Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response. |
CA2171109A1 (en) | 1993-10-01 | 1995-04-13 | Zvi Ram | Gene therapy of the nervous system |
DE69435223D1 (en) | 1993-10-25 | 2009-09-03 | Canji Inc | Recombinant adenovirus vector and method of use |
RU2160093C2 (en) | 1993-11-16 | 2000-12-10 | Скайефарма Инк. | Vesicles with controlled active ingredient release |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
FR2712603B1 (en) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Recombinant viruses, preparation and use in gene therapy. |
WO1995015400A1 (en) * | 1993-12-03 | 1995-06-08 | The Johns Hopkins University | Genotyping by simultaneous analysis of multiple microsatellite loci |
JPH07241786A (en) | 1994-03-08 | 1995-09-19 | Fanuc Ltd | Control device for industrial robot |
US6780406B1 (en) | 1994-03-21 | 2004-08-24 | The Regents Of The University Of Michigan | Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
EP0763103A4 (en) | 1994-04-28 | 1998-07-15 | Univ Michigan | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line |
EP1881075B1 (en) | 1994-05-09 | 2013-07-24 | Oxford BioMedica (UK) Limited | Retroviral vectors having a reduced recombination rate |
FR2720408B1 (en) * | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 of Neisseria meningitidis. |
CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
FR2723588B1 (en) | 1994-08-12 | 1996-09-20 | Rhone Poulenc Rorer Sa | ADENOVIRUS COMPRISING A GENE ENCODING GLUTATHIONE PEROXYDASE |
IL117483A (en) * | 1995-03-17 | 2008-03-20 | Bernard Brodeur | Proteinase k resistant surface protein of neisseria meningitidis |
WO1996037626A1 (en) | 1995-05-22 | 1996-11-28 | Chiron Corporation | Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein |
CU22559A1 (en) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | EXPRESSION SYSTEM OF HETEROLOGICAL ANTIGENS IN E. COLI AS FUSION PROTEINS |
US5753235A (en) | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
FR2751000B1 (en) | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | SPECIFIC DNA FROM NEISSERIA MENINGITIDIS BACTERIA, PROCESSES FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9810276D0 (en) * | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
US6200576B1 (en) * | 1998-07-15 | 2001-03-13 | Development Center For Biotechnology | Swine vesicular disease virus and mutant strains and preparation process and use thereof |
US6610306B2 (en) | 1998-10-22 | 2003-08-26 | The University Of Montana | OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof |
KR100698561B1 (en) | 2000-01-25 | 2007-03-21 | 더 유니버서티 어브 퀸슬랜드 | Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US9714465B2 (en) | 2008-12-01 | 2017-07-25 | Applied Materials, Inc. | Gas distribution blocker apparatus |
-
1999
- 1999-01-14 CA CA002317815A patent/CA2317815A1/en not_active Abandoned
- 1999-01-14 EP EP99900583.8A patent/EP1047784B2/en not_active Expired - Lifetime
- 1999-01-14 JP JP2000540246A patent/JP4399112B2/en not_active Expired - Fee Related
- 1999-01-14 EP EP09075464.9A patent/EP2210945B1/en not_active Expired - Lifetime
- 1999-01-14 EP EP10182660A patent/EP2278011A3/en not_active Withdrawn
- 1999-01-14 CN CNB998038733A patent/CN1224708C/en not_active Expired - Fee Related
- 1999-01-14 ES ES99900583.8T patent/ES2333071T5/en not_active Expired - Lifetime
- 1999-01-14 BR BR9906927-0A patent/BR9906927A/en not_active Application Discontinuation
- 1999-01-14 DE DE69941567T patent/DE69941567D1/en not_active Expired - Lifetime
- 1999-01-14 SG SG200700268-6A patent/SG152917A1/en unknown
- 1999-01-14 CN CNA2003101220871A patent/CN1597694A/en active Pending
- 1999-01-14 DK DK99900583.8T patent/DK1047784T4/en active
- 1999-01-14 AU AU19795/99A patent/AU1979599A/en not_active Abandoned
- 1999-01-14 PT PT99900583T patent/PT1047784E/en unknown
- 1999-01-14 SG SG200204325A patent/SG123535A1/en unknown
- 1999-01-14 AT AT99900583T patent/ATE446368T1/en active
- 1999-01-14 WO PCT/IB1999/000103 patent/WO1999036544A2/en active Search and Examination
- 1999-04-30 US US09/302,626 patent/US6709660B1/en not_active Expired - Fee Related
-
2001
- 2001-02-26 HK HK01101385.0A patent/HK1030435A1/en not_active IP Right Cessation
-
2003
- 2003-10-28 US US10/695,499 patent/US7714121B2/en not_active Expired - Fee Related
-
2005
- 2005-08-24 US US11/212,443 patent/US20050287165A1/en not_active Abandoned
-
2009
- 2009-02-17 JP JP2009034641A patent/JP2009100781A/en not_active Withdrawn
-
2010
- 2010-01-05 CY CY20101100010T patent/CY1109708T1/en unknown
-
2013
- 2013-08-06 CY CY20131100664T patent/CY1114333T1/en unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795803A (en) * | 1984-05-02 | 1989-01-03 | Syn-Tek Ab | Adhesin antigens, antibodies and DNA fragment encoding the antigen, methods and means for diagnosis and immunization etc. |
US6200578B1 (en) * | 1995-03-24 | 2001-03-13 | St. Louis University | Haemophilus adhesion proteins |
US6197312B1 (en) * | 1997-12-12 | 2001-03-06 | The University Of Queensland | Surface antigen |
US6709660B1 (en) * | 1998-01-14 | 2004-03-23 | Chrion S.R.L. | Meningococcal antigens |
US7612192B2 (en) * | 1998-10-09 | 2009-11-03 | Novartis Vaccines & Diagnostics, Inc. | Neisseria genomic sequences and methods of their use |
US7368261B1 (en) * | 1999-04-30 | 2008-05-06 | Novartis Vaccines And Diagnostics Srl | Conserved Neisserial antigens |
US7604810B2 (en) * | 1999-04-30 | 2009-10-20 | Novartis Vaccines And Diagnostics Srl | Conserved Neisserial antigens |
US7618636B1 (en) * | 1999-07-14 | 2009-11-17 | Novartis Vaccines And Diagnostics Srl | Antigenic meningococcal peptides |
US20040092711A1 (en) * | 2000-02-28 | 2004-05-13 | Arico Maria Beatrice | Hybrid expression of neisserial proteins |
US20060051840A1 (en) * | 2000-02-28 | 2006-03-09 | Chiron Srl | Hybrid expression of neisserial proteins |
US20050222385A1 (en) * | 2001-09-06 | 2005-10-06 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265332A1 (en) * | 1998-05-13 | 2004-12-30 | Smithkline Beecham Biologicals S.A. | BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis |
US20090093622A1 (en) * | 1998-05-13 | 2009-04-09 | Jean-Louis Ruelle | BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis |
US20050074458A1 (en) * | 1998-10-22 | 2005-04-07 | The University Of Montana | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
US20070087018A1 (en) * | 1998-10-22 | 2007-04-19 | The University Of Montana | Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof |
US7662588B2 (en) | 1998-10-22 | 2010-02-16 | The University Of Montana | Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof |
US7794733B2 (en) | 1998-10-22 | 2010-09-14 | The University Of Montana | Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof |
US20100272744A1 (en) * | 1998-10-22 | 2010-10-28 | The University Of Montana | OMP85 Proteins of Neisseria Gonorrhoeae and Neisseria Meningitidis, Compositions Containing Same and Methods of Use Thereof |
Also Published As
Publication number | Publication date |
---|---|
DK1047784T3 (en) | 2009-12-21 |
SG123535A1 (en) | 2006-07-26 |
JP2002508966A (en) | 2002-03-26 |
EP2210945A3 (en) | 2010-11-17 |
EP2210945B1 (en) | 2013-06-26 |
CY1114333T1 (en) | 2016-08-31 |
JP2009100781A (en) | 2009-05-14 |
HK1030435A1 (en) | 2001-05-04 |
EP1047784A2 (en) | 2000-11-02 |
DK1047784T4 (en) | 2015-06-15 |
EP1047784B1 (en) | 2009-10-21 |
PT1047784E (en) | 2009-12-21 |
CN1597694A (en) | 2005-03-23 |
AU1979599A (en) | 1999-08-02 |
EP2278011A2 (en) | 2011-01-26 |
US6709660B1 (en) | 2004-03-23 |
SG152917A1 (en) | 2009-06-29 |
US7714121B2 (en) | 2010-05-11 |
ES2333071T5 (en) | 2015-08-17 |
ATE446368T1 (en) | 2009-11-15 |
CY1109708T1 (en) | 2014-08-13 |
CN1292820A (en) | 2001-04-25 |
JP4399112B2 (en) | 2010-01-13 |
DE69941567D1 (en) | 2009-12-03 |
EP2210945A2 (en) | 2010-07-28 |
ES2333071T3 (en) | 2010-02-16 |
EP2278011A3 (en) | 2012-03-07 |
CN1224708C (en) | 2005-10-26 |
US20040126391A1 (en) | 2004-07-01 |
CA2317815A1 (en) | 1999-07-22 |
BR9906927A (en) | 2001-11-20 |
WO1999036544A2 (en) | 1999-07-22 |
WO1999036544A3 (en) | 1999-10-14 |
EP1047784B2 (en) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6709660B1 (en) | Meningococcal antigens | |
EP1645631B1 (en) | Neisseria antigens and compositions | |
EP1185691B1 (en) | Neisseria genomic sequences and methods of their use | |
EP1900818A2 (en) | Neisserial antigens | |
EP1559795A2 (en) | Neisseria genomic sequences and methods of their use | |
US20070026021A1 (en) | Neisseria meningitidis antigens and compositions | |
AU2012203235B2 (en) | Neisseria meningitidis antigens and compositions | |
AU2006202355B2 (en) | Neisseria meningitidis antigens and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CHIRON S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCARLATO, VINCENZO;MASIGNANI, VEGA;RAPPUOLI, RINO;AND OTHERS;REEL/FRAME:019468/0861 Effective date: 19990625 Owner name: CHIRON S.R.L., ITALY Free format text: CHANGE OF NAME;ASSIGNOR:CHIRON S.P.A.;REEL/FRAME:019469/0089 Effective date: 20021212 |
|
AS | Assignment |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., ITALY Free format text: CHANGE OF NAME;ASSIGNOR:CHIRON S.R.L.;REEL/FRAME:019472/0122 Effective date: 20060428 |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS SRL;REEL/FRAME:021615/0451 Effective date: 20080930 Owner name: NOVARTIS AG,SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS SRL;REEL/FRAME:021615/0451 Effective date: 20080930 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |